Introducing PHARMAC

Part I

General Rules 6

Part II

Alimentary Tract and Metabolism 14
Blood and Blood Forming Organs 28
Cardiovascular System 39
Dermatologicals 51
Genito-Urinary System 58
Hormone Preparations 62
Infections 72
Musculoskeletal System 95
Nervous System 105
Oncology Agents and Immunosuppressants 133
Respiratory System and Allergies 175
Sensory Organs 181
Various 187
Extemporaneous Compounds (ECPs) 195
Special Foods 198
Vaccines 212

Part III

Optional Pharmaceuticals 218

Index 220
Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC’s operation are made by or under the authority of the Board. More information on the Board can be found at www.pharmac.govt.nz

The functions of PHARMAC are set out in section 48 of the Act. PHARMAC is required to perform these functions within the amount of funding provided to it and in accordance with its statement of intent and any directions given by the Minister (Section 103 of the Crown Entities Act). The Government has agreed that PHARMAC will assume responsibility for the assessment, prioritisation and procurement of medical devices on behalf of DHBs. Medical devices come within the definition of Pharmaceuticals in the Act. PHARMAC is assuming responsibility for procurement of some medical devices categories immediately, as a first step to full PHARMAC management of these categories within the Pharmaceutical Schedule.

Decision Criteria

PHARMAC takes into account the following criteria when considering amendments to the Schedule:

a) the health needs of all eligible people within New Zealand;
b) the particular health needs of Māori and Pacific peoples;
c) the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
d) the clinical benefits and risks of pharmaceuticals;
e) the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
f) the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Schedule;
g) the direct cost to health service users;
h) the Government’s priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC’s Funding Agreement, or elsewhere; and
i) such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such “other criteria” into account.

PHARMAC’s clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

Contact PTAC C/-PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON 6143, Email: PTAC@pharmac.govt.nz

PTAC Subcommittees

PTAC has subcommittees from which it can seek specialist advice in relation to funding applications. PTAC may seek advice from one or more subcommittees in relation to a funding application, or may make recommendations to PHARMAC without seeking the advice of a subcommittee:

- Analgesic Subcommittee
- Anti-Infective Subcommittee
- Cancer Treatments Subcommittee
- Cardiovascular Subcommittee
- Dermatology Subcommittee
- Diabetes Subcommittee
- Endocrinology Subcommittee
- Gastrointestinal Subcommittee
- Haematology Subcommittee
- Hospital Pharmaceuticals Subcommittee
- Immunisation Subcommittee
- Mental Health Subcommittee
- Neurological Subcommittee
- Nephrology Subcommittee
- Ophthalmology Subcommittee
- Pulmonary Arterial Hypertension Subcommittee
- Rare Disorders Subcommittee
- Reproductive and Sexual Health Subcommittee
- Respiratory Subcommittee
- Rheumatology Subcommittee
- Special Foods Subcommittee
- Tenders Subcommittee
- Transplant Immunosuppressants Subcommittee
PTAC also has a Tender Medical Evaluation Subcommittee to provide advice on clinical matters relating to PHARMAC’s annual multi-product tender and other purchasing strategies. Current membership of PTAC’s subcommittees can be found on PHARMAC’s website: http://www.pharmac.health.nz/about/committees/ptac
Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC’s ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.health.nz/tools-resources/forms/named-patient-pharmaceutical-assessment-nppa-forms, or call the Panel Coordinators at (04) 9167553 or (04) 9167521.

The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer’s price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, or other Pharmaceuticals, including Medical Devices, used in DHB Hospitals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in Section H

Section H lists Pharmaceuticals that can be used in DHB Hospitals, and is split into the following parts:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB Hospitals.
- Part II lists Hospital Pharmaceuticals that are funded for use in DHB Hospitals. These are classified based on the Anatomical Therapeutic Chemical (ATC) system used for Community Pharmaceuticals. It also provides information on any National Contracts that exist, and an indication of which products have Hospital Supply Status (HSS).
- Part III lists Optional Pharmaceuticals for which National Contracts exist, and DHB Hospitals may choose to fund. These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance Limit (DV Limit).

The index located at the back of the Section H can be used to find page numbers for generic chemical entities and product brand names, for Hospital Pharmaceuticals. The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification.

Glossary

Units of Measure

- gram .................................................. g
- kilogram ........................................... kg
- international unit ............................ iu
- microgram ....................................... mcg
- milligram ......................................... mg
- millilitre .......................................... ml
- millimole ........................................ mmol
- unit .................................................. u

Abbreviations

- application ..................................... app
- capsule .......................................... cap
- cream ............................................. crm
- dispersible .................................... disp
- effervescent ................................. eff
- emulsion ........................................ emul
- enteric coated ............................... EC
- granules ......................................... grans
- injection ......................................... inj
- linctus .......................................... linc
- liquid ............................................. liq
- lotion ............................................. lotn
- ointment ........................................ oint
- solution ......................................... soln
- suppository ................................. suppos
- tablet ............................................ tab
- tincture .......................................... tinc

HSS  Hospital Supply Status (Refer to Rule 20)
Guide to Section H listings

Example

<table>
<thead>
<tr>
<th>ANATOMICAL HEADING</th>
<th>THERAPEUTIC HEADING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHEMICAL A</strong></td>
<td>Restricted see terms below</td>
</tr>
<tr>
<td></td>
<td>Presentation A........0.00 100 Brand A</td>
</tr>
<tr>
<td></td>
<td>Restricted</td>
</tr>
<tr>
<td></td>
<td>Only for use in children under 12 years of age</td>
</tr>
<tr>
<td><strong>CHEMICAL B</strong></td>
<td>Some items restricted see terms below</td>
</tr>
<tr>
<td></td>
<td>Presentation B1........1,589.00 1 Brand B1 e.g. Brand B2</td>
</tr>
<tr>
<td></td>
<td>Presentation B2</td>
</tr>
<tr>
<td><strong>CHEMICAL C</strong></td>
<td>Restricted</td>
</tr>
<tr>
<td></td>
<td>Oncologist or haematologist</td>
</tr>
<tr>
<td></td>
<td>Presentation C........15.00 28 Brand C</td>
</tr>
<tr>
<td></td>
<td>-1% DV Limit Jan-12 to 2014</td>
</tr>
<tr>
<td></td>
<td>CHEMICAL D</td>
</tr>
<tr>
<td></td>
<td>Restricted see terms below</td>
</tr>
<tr>
<td></td>
<td>Presentation D........38.65 500 Brand D</td>
</tr>
<tr>
<td></td>
<td>-1% DV Limit Mar-13 to 2014</td>
</tr>
<tr>
<td></td>
<td>CHEMICAL E</td>
</tr>
<tr>
<td></td>
<td>Restricted</td>
</tr>
<tr>
<td></td>
<td>Limited to five weeks' treatment</td>
</tr>
<tr>
<td></td>
<td>Either:</td>
</tr>
<tr>
<td></td>
<td>1 For the prophylaxis of venous thromboembolism following a total hip replacement; or</td>
</tr>
<tr>
<td></td>
<td>2 For the prophylaxis of venous thromboembolism following a total knee replacement.</td>
</tr>
<tr>
<td></td>
<td>Presentation E</td>
</tr>
<tr>
<td></td>
<td>e.g. Brand E</td>
</tr>
</tbody>
</table>

- Item restricted (see above); Item restricted (see below)
- Products with Hospital Supply Status (HSS) are in bold
INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

INTERPRETATION AND DEFINITIONS

1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:


“Combined Pharmaceutical Budget”, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

“Community”, means any setting outside of a DHB Hospital.

“Community Pharmaceutical”, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

“Contract Manufacturer”, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

“Designated Delivery Point”, means at a DHB Hospital’s discretion:

a) a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or

b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier’s national distribution centre.

“DHB”, means an organisation established as a District Health Board by or under Section 19 of the Act.

“DHB Hospital”, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

“DV Limit”, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“DV Pharmaceutical”, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Hospital Pharmaceutical.

“Extemporaneously Compounded Product”, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

“First Transition Period”, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

“Funder”, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“Give”, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “Given” has a corresponding meaning.

“Hospital Pharmaceuticals”, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

“HSS”, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply,
as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

“Indication Restriction”, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

“Individual DV Limit”, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Local Restriction”, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

“Medical Device”, has the meaning set out in the Medicines Act 1981.

“Named Patient Pharmaceutical Assessment Advisory Panel”, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

“National Contract”, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

“National Contract Pharmaceutical”, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

“National DV Limit”, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“Optional Pharmaceuticals”, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

“PHARMAC”, means the Pharmaceutical Management Agency established by Section 46 of the Act.

“Pharmacode”, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

“Pharmaceutical”, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

“Pharmaceutical Cancer Treatment”, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

“Prescriber Restriction”, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

“Price”, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

“Restriction”, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

“Schedule”, means this Pharmaceutical Schedule and all its sections and appendices.

“Special Authority Approval”, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

“Total Market Volume”, means, for a particular Hospital Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

a) the total number of Units of the relevant Hospital Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
b) the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.
“Unapproved Indication”, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

“Unit”, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

“Unlisted Pharmaceutical”, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
   a) the singular includes the plural; and
   b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

HOSPITAL SUPPLY OF PHARMACEUTICALS

2 Hospital Pharmaceuticals

2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals except for any items specifically listed in this Section H Part II:
   a) Medical Devices;
   b) whole or fractionated blood products;
   c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
   d) disinfectants and sterilising products, except those that are to be used in or on a patient;
   e) foods and probiotics;
   f) radioactive materials;
   g) medical gases; and
   h) parenteral nutrition.

Subject to rule 2.2, the funding of pharmaceuticals identified in a)–h) above is a decision for individual DHB Hospitals.

2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.

2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

3 DHB Supply Obligations

3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.

3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.

3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.

3.4 Except where permitted in accordance with rule 11, DHBs must not Give:
   a) an Unlisted Pharmaceutical; or
   b) a Hospital Pharmaceutical outside of any relevant Restrictions.

4 Funding

4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:
   a) Pharmaceutical Cancer Treatments;
   b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
   c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's
4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

**LIMITS ON SUPPLY**

5 **Prescriber Restrictions**

5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:

a) by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;

b) in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or

c) in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).

5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:

a) the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and

b) the consultation must relate to the patient for whom the prescription is written; and

b) the consultation may be in person, by telephone, letter, facsimile or email; and

d) appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.

5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

6 **Indication Restrictions**

6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.

6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.

6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:

a) the patient has been treated with the Pharmaceutical in the Community; or

b) the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

7 **Local Restrictions**

7.1 A DHB Hospital may implement a Local Restriction, provided that:

a) in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC's decision that the Hospital Pharmaceutical must be funded;

b) it provides PHARMAC with details of each Local Restriction that it implements; and

7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

8 **Community use of Hospital Pharmaceuticals**

8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:

a) the quantity does not exceed that sufficient for up to 30 days' treatment, unless:

   i) it would be inappropriate to provide less than the amount in an original pack; or

   ii) the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and

b) the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

9 **Community use of Medical Devices**

9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.

9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:
PART I: GENERAL RULES

9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
a) that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
b) the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and
c) the Medical Device has consumable components that need to be replaced throughout its usable life; then
DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.

9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.

10 Extemporaneous Compounding

10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:
a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.

10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

EXCEPTIONS

11 Named Patient Pharmaceutical Assessment

11.1 A DHB Hospitals may only Give:
a) an Unlisted Pharmaceutical; or
b) a Hospital Pharmaceutical outside of any relevant Restrictions,
in accordance with theNamed Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.

12 Continuation

12.1 Where a patient’s clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient’s stay, where:
a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
b) interrupted or delayed treatment would have significant adverse clinical consequences; and
c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.

13 Pre-Existing Use

13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:
a) is an Unlisted Pharmaceutical; or
b) treatment of the patient would not comply with any relevant Restrictions;
the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.

13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.

14 Clinical Trials and Free Stock

14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:
14.1.1 as part of a clinical trial that has Ethics Committee approval; or
14.1.2 for on-going treatment of patients following the end of such a clinical trial.

14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.

15 Pharmaceutical Cancer Treatments in Paediatrics

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of
PART I: GENERAL RULES

16 Other Government Funding
DHB Hospitals may give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

17 Other Exceptions
17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC’s decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.

17.2 Funding approvals granted under rule 17.1 will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

NATIONAL CONTRACTING

18 Hospital Pharmaceutical Contracts
18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
   a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
   b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
   c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months’ written notice to the Pharmaceutical supplier.

18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
   a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
   b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.

18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
   a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
   b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

19 National Contract Pharmaceuticals
19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.

19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
   a) DHB Hospitals at Designated Delivery Points; and/or
   b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

20 Hospital Supply Status (HSS)
20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.

20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
   a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
   b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
   c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and
PART I: GENERAL RULES

d) must purchase the National Contract Pharmaceutical with HSS except:
   i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within
      the DV Limit, provided that (subject to rule 20.2(d)(iii) below) the DV Limit has not been exceeded
      nationally;
   ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the
       relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharma-
       ceutical during that period of non-supply (and any such month(s) included in a period of non-supply
       will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
   iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Phar-
       maceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permis-
       sion to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional
       needs require a DV Pharmaceutical.

20.3 PHARMAC may, in its discretion, for any period or part period:
   a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to deter-
      mine whether the DV Limit has been exceeded; and
   b) audit compliance by DHB Hospitals with the DV Limits and related requirements.

20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:
   a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National
      Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods;
      and
   b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-
      compliance with the DV Limit for that HSS Pharmaceutical.

20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any
       individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion,
       financial compensation from the relevant DHB or DHB Hospital:
       a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where
           PHARMAC is able to quantify this based on the information available to it); or
       b) the sum of $1,000 or $5,000 (depending on the terms of the applicable national contract applying to the HSS
           Pharmaceutical),
       whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in
       the notice from the Pharmaceutical supplier requiring such payment to be made.

21 Collection of rebates and payment of financial compensation

21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract
      Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to
      it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that
      National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB
      Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed
      between the relevant DHBs and PHARMAC.

21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each
      calendar quarter in respect of rebates received quarterly (or more often).

22 Price and Volume Data

22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements,
      any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB
      Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.

22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital
      Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year)
      on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be
      measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

MISCELLANEOUS PROVISIONS

23 Unapproved Pharmaceuticals

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981.
However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the
Schedule may:

23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or

23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication;

Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;

23.2 be aware of and comply with their obligations under the Health and Disability Commissioner’s Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and

23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.
## Part II: ALIMENTARY TRACT AND METABOLISM

### Antacids and Antiflatulents

<table>
<thead>
<tr>
<th>Antacids and Reflux Barrier Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE</strong></td>
</tr>
<tr>
<td>Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg</td>
</tr>
<tr>
<td>e.g. Mylanta</td>
</tr>
<tr>
<td>Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg per 5 ml</td>
</tr>
<tr>
<td>e.g. Mylanta</td>
</tr>
<tr>
<td>Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone 30 mg per 5 ml</td>
</tr>
<tr>
<td>e.g. Mylanta Double Strength</td>
</tr>
</tbody>
</table>

| **SIMETHICONE** |
| Oral drops 100 mg per ml |

| **SODIUM ALGINATE WITH MAGNESIUM ALGINATE** |
| Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet |
| e.g. Gaviscon Infant |

| **SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE** |
| Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg |
| e.g. Gaviscon Double Strength |

| Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml |
| ---------------------------------- | ---------------------------------- |
| ................................................................. 4.95 | 500 ml Acidex |

| **SODIUM CITRATE** |
| Oral liq 8.8% (300 mmol/l) |

### Phosphate Binding Agents

| **ALUMINIUM HYDROXIDE** |
| Tab 600 mg |

| **CALCIUM CARBONATE – Restricted** see terms below |
| $ Oral liq 250 mg per ml (100 mg elemental per ml) | .................................................... 39.00 |
| 500 ml Roxane |
| $Restricted |

Only for use in children under 12 years of age for use as a phosphate binding agent

### Antidiarrhoeals and Intestinal Anti-Inflammatory Agents

#### Antipropulsives

| **DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE** |
| Tab 2.5 mg with atropine sulphate 25 mcg |

| **LOPERAMIDE HYDROCHLORIDE** |
| Tab 2 mg |
| Cap 2 mg – 1% DV Jul-14 to 2016 | .................................................... 7.84 |
| 400 Diamide Relief |

#### Rectal and Colonic Anti-Inflammatories

| **BUDESONIDE – Restricted** see terms on the next page |
| $ Cap 3 mg |
Restricted

Crohn’s disease
Both:

1. Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and
2. Any of the following:
   2.1 Diabetes; or
   2.2 Cushingoid habitus; or
   2.3 Osteoporosis where there is significant risk of fracture; or
   2.4 Severe acne following treatment with conventional corticosteroid therapy; or
   2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
   2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
   2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies

Gut Graft versus Host disease
Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation

HYDROCORTISONE ACETATE
Rectal foam 10% (14 applications) – 1% DV Jan-13 to 2015.........................25.30 21.1 g Colifoam

MESALAZINE
Tab EC 400 mg ....................................................................................49.50 100 Asacol
Tab EC 500 mg ....................................................................................49.50 100 Asamax
Tab long-acting 500 mg ...............................................................59.05 100 Pentasa
Modifed release granules 1 g .........................................................141.72 120 g Pentasa
Suppos 500 mg ...................................................................................22.80 20 Asacol
Suppos 1 g ............................................................................................54.60 30 Pentasa
Enema 1 g per 100 ml – 1% DV Sep-12 to 2015...............................44.12 7 Pentasa

OLSALAZINE
Tab 500 mg
Cap 250 mg

SODIUM CROMOGLYcate
Cap 100 mg

SULPHASALAZINE
Tab 500 mg – 1% DV Oct-13 to 2016.................................................11.68 100 Salazopyrin
Tab EC 500 mg – 1% DV Oct-13 to 2016..........................................12.89 100 Salazopyrin EN

Local Preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE
Oint 5 mg with hydrocortisone 5 mg per g .............................................15.00 30 g Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g .....................................9.90 12 Proctosedyl

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE
Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g .................................6.35 30 g Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg ....................................2.66 12 Ultraproct
### Management of Anal Fissures

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCERCYL TRINITRATE</td>
<td>$22.00</td>
<td>30 g</td>
<td>Rectogesic</td>
</tr>
</tbody>
</table>

### Rectal Sclerosants

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OILY PHENOL [PHENOL OILY]</td>
<td>5%, 5 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antispasmodics and Other Agents Altering Gut Motility

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCOPPYRONIUM BROMIDE</td>
<td>$28.56</td>
<td>10</td>
<td>Max Health</td>
</tr>
<tr>
<td>HYOSCINE BUTYLBROMIDE</td>
<td>$1.48</td>
<td>20</td>
<td>Gastrosoothe</td>
</tr>
<tr>
<td>MEBEVERINE HYDROCHLORIDE</td>
<td>$18.00</td>
<td>90</td>
<td>Colofac</td>
</tr>
</tbody>
</table>

### Antiulcerants

### Antisecretory and Cytoprotective

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MISOPROSTOL</td>
<td>Tab 200 mcg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### H2 Antagonists

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIMETIDINE</td>
<td>Tab 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RANITIDINE</td>
<td>Tab 150 mg – 1% DV Nov-14 to 2017</td>
<td>10</td>
<td>Ranitidine Relief</td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Nov-14 to 2017</td>
<td>14.73</td>
<td>500</td>
<td>Ranitidine Relief</td>
</tr>
<tr>
<td>Oral liq 150 mg per 10 ml – 1% DV Sep-14 to 2017</td>
<td>4.92</td>
<td>300 ml</td>
<td>Peptisothe</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td>8.75</td>
<td>5</td>
<td>Zantac</td>
</tr>
</tbody>
</table>

### Proton Pump Inhibitors

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>LANSOPRAZOLE</td>
<td>Cap 15 mg – 1% DV Jan-13 to 2015</td>
<td>28</td>
<td>Solox</td>
</tr>
<tr>
<td>Cap 30 mg – 1% DV Jan-13 to 2015</td>
<td>2.32</td>
<td>28</td>
<td>Solox</td>
</tr>
<tr>
<td>OMEPRAZOLE</td>
<td>$ Tab dispersible 20 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Restricted

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omezol Relief</td>
<td>Cap 10 mg – 1% DV Jan-15 to 2017</td>
<td>2.23</td>
<td>90</td>
</tr>
<tr>
<td>Cap 20 mg – 1% DV Jan-15 to 2017</td>
<td>2.91</td>
<td>90</td>
<td>Omezol Relief</td>
</tr>
<tr>
<td>Cap 40 mg – 1% DV Jan-15 to 2017</td>
<td>4.42</td>
<td>90</td>
<td>Omezol Relief</td>
</tr>
<tr>
<td>Powder for oral liq</td>
<td>42.50</td>
<td>5 g</td>
<td>Midwest</td>
</tr>
<tr>
<td>Inj 40 mg ampoule</td>
<td>19.00</td>
<td>5</td>
<td>Dr Reddy's Omeprazole</td>
</tr>
<tr>
<td>Inj 40 mg ampoule with diluent</td>
<td>28.65</td>
<td>5</td>
<td>Dr Reddy's Omeprazole</td>
</tr>
</tbody>
</table>
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pantoprazole Actavis 20</td>
</tr>
<tr>
<td>Pantoprazole Actavis 40</td>
</tr>
</tbody>
</table>

Site Protective Agents

**BISMUTH TRIOXIDE**
- Tab 120 mg .......................................................... 32.50 112 De-Nol

**SUCRALFATE**
- Tab 1 g

Bile and Liver Therapy

**L-ORNITHINE L-ASPARTATE** – **Restricted** see terms below
- Grans for oral liquid 3 g

**RIFAXIMIN** – **Restricted** see terms below
- Tab 550 mg – 1% DV Oct-14 to 2017 .............................................. 625.00 56 Xifaxan

Diabetes

**Alpha Glucosidase Inhibitors**

**ACARBOSE**
- Tab 50 mg – 1% DV Dec-12 to 2015 .............................................. 9.82 90 Accarb
- Tab 100 mg – 1% DV Dec-12 to 2015 ......................................... 15.83 90 Accarb

**Hyperglycaemic Agents**

**DIAZOXIDE** – **Restricted** see terms below
- Cap 25 mg ............................................................... 110.00 100 Proglicem
- Cap 100 mg .......................................................... 280.00 100 Proglicem
- Oral liq 50 mg per ml ...................................................... 620.00 30 ml Proglycem

**GLUCAGON HYDROCHLORIDE**
- Inj 1 mg syringe kit .......................................................... 32.00 1 Glucagen Hypokit

**GLUCOSE [DEXTROSE]**
- Tab 1.5 g
- Tab 3.1 g
- Tab 4 g
- Gel 40%

**GLUCOSE WITH SUCROSE AND FRUCTOSE**
- Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Insulin - Intermediate-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN ASPART WITH INSULIN ASPART PROTAMINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen</td>
<td>5</td>
<td>NovoMix 30 FlexPen</td>
</tr>
<tr>
<td>INSULIN ISOPHANE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge</td>
<td>5</td>
<td>Humalog Mix 25</td>
</tr>
<tr>
<td>Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge</td>
<td>5</td>
<td>Humalog Mix 50</td>
</tr>
<tr>
<td>INSULIN NEUTRAL WITH INSULIN ISOPHANE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Insulin - Long-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN GLARGINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>5</td>
<td>Lantus SoloStar</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>5</td>
<td>Lantus</td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>1</td>
<td>Lantus</td>
</tr>
</tbody>
</table>

## Insulin - Rapid-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN ASPART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSULIN GLULISINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td>1</td>
<td>Apidra</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td>5</td>
<td>Apidra</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td>5</td>
<td>Apidra Solostar</td>
</tr>
<tr>
<td>INSULIN LISPRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Insulin - Short-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin Name</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSULIN NEUTRAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see above); ‡Item restricted (see below)

e.g. *Brand* indicates brand example only. It is not a contracted product.
Oral Hypoglycaemic Agents

GLIBENCLAMIDE
  Tab 5 mg

GLICLAZIDE
  Tab 80 mg – 1% DV Nov-14 to 2017 .................................................. 11.50  500 Glizide

GLIPIZIDE
  Tab 5 mg – 1% DV Dec-12 to 2015 .................................................. 3.00  100 Minidiab

METFORMIN
  Tab immediate-release 500 mg – 1% DV Oct-12 to 2015 ................. 12.30  1,000 Apotex
  Tab immediate-release 850 mg – 1% DV Oct-12 to 2015 ................. 10.10  500 Apotex

PIOGLITAZONE
  Tab 15 mg – 1% DV Sep-12 to 2015 ............................................... 1.50  28 Pizaccord
  Tab 30 mg – 1% DV Sep-12 to 2015 ............................................... 2.50  28 Pizaccord
  Tab 45 mg – 1% DV Sep-12 to 2015 ............................................... 3.50  28 Pizaccord

Digestives Including Enzymes

PANCREATIC ENZYME
  Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease
  Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease
  Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease
  Powder 25,000 u lipase with 30,000 u amylase and 1,400 u protease per g

URSODEOXYCHOLIC ACID – Restricted see terms below
  Cap 250 mg – 1% DV Sep-14 to 2017 ............................................. 53.40  100 Ursosan

Restricted
Alagille syndrome or progressive familial intrahepatic cholestasis
Either:
1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

Chronic severe drug induced cholestatic liver injury
All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Cirrhosis
Either:
1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 µmol/l; decompensated cirrhosis.

Pregnancy
Patient diagnosed with cholestasis of pregnancy.

Haematological transplant
Both:

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Laxatives

**Bowel-Cleansing Preparations**

<table>
<thead>
<tr>
<th>TPN Cholestasis</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both:</td>
<td>1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Liver function has not improved with modifying the TPN composition.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TPN Cholestasis</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both:</td>
<td>1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Treatment for up to 13 weeks.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Laxatives**

**Bowel-Cleansing Preparations**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE</td>
<td>Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet</td>
<td></td>
<td>e.g. PicoPrep</td>
</tr>
<tr>
<td>MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE</td>
<td>Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet</td>
<td></td>
<td>e.g. Glycoprep-C</td>
</tr>
<tr>
<td></td>
<td>Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet</td>
<td></td>
<td>e.g. Glycoprep-C</td>
</tr>
<tr>
<td>MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE</td>
<td>Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet</td>
<td></td>
<td>14.31</td>
</tr>
</tbody>
</table>

**Bulk-Forming Agents**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISPAGHULA (PSYLLIUM) HUSK</td>
<td>Powder for oral soln</td>
<td>5.51</td>
<td>500 g</td>
</tr>
<tr>
<td>STERCULIA WITH FRANGULA – Restricted: For continuation only</td>
<td>Powder for oral soln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOCUSATE SODIUM</td>
<td>Tab 50 mg – 1% DV Jan-15 to 2017</td>
<td>2.31</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Tab 120 mg – 1% DV Jan-15 to 2017</td>
<td>3.13</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Cap 50 mg – 1% DV Jan-15 to 2017</td>
<td>2.57</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Cap 120 mg – 1% DV Jan-15 to 2017</td>
<td>3.48</td>
<td>100</td>
</tr>
<tr>
<td>(Laxofast 50 Cap 50 mg to be delisted 1 January 2015)</td>
<td>(Laxofast 120 Cap 120 mg to be delisted 1 January 2015)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOCUSATE SODIUM WITH SENNOSIDES</td>
<td>Tab 50 mg with sennosides 8 mg</td>
<td>6.38</td>
<td>200</td>
</tr>
<tr>
<td>PARAFFIN</td>
<td>Oral liquid 1 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enema 133 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLOXAMER</td>
<td>Oral drops 10% – 1% DV Sep-14 to 2017</td>
<td>3.78</td>
<td>30 ml</td>
</tr>
</tbody>
</table>

*e.g. Brand* indicates brand example only. It is not a contracted product.
### Osmotic Laxatives

**GLYCEROL**
- Suppos 1.27 g
- Suppos 2.55 g
- Suppos 3.6 g – 1% DV Jan-13 to 2015 ......................................................... 6.50 20 PSM

**LACTULOSE**
- Oral liq 10 g per 15 ml ................................................................. 3.84 500 ml Laevolac

**MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE** – **Restricted** see terms below
- Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
- Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-14 to 2017 ......................................................... 7.65 30 Lax-Sachets

**SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE**
- Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Sep-13 to 2016 ......................................................... 19.95 50 Micolette

**SODIUM PHOSPHATE WITH PHOSPHORIC ACID**
- Oral liq 16.4% with phosphoric acid 25.14%
- Enema 10% with phosphoric acid 6.58% ......................................................... 2.50 1 Fleet Phosphate Enema

### Stimulant Laxatives

**BISACODYL**
- Tab 5 mg ................................................................. 4.99 200 Lax-Tabs
- Suppos 5 mg ................................................................. 3.00 6 Dulcolax
- Suppos 10 mg ................................................................. 3.00 6 Dulcolax

**DANTHRON WITH POLOXAMER** – **Restricted** see terms below
- Oral liq 25 mg with poloxamer 200 mg per 5 ml ................................................. 21.30 300 ml Pinorax
- Oral liq 75 mg with poloxamer 1 g per 5 ml ......................................................... 43.60 300 ml Pinorax Forte

**SENNOSIDES**
- Tab 7.5 mg

### Metabolic Disorder Agents

**ARGININE**
- Powder
  - Inj 600 mg per ml, 25 ml vial

**BETAIN** – **Restricted** see terms on the next page
- Powder

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

** Restricted
Metabolic disorders physician or metabolic disorders dietitian

**BIOTIN – Restricted** see terms below

- Cap 50 mg
- Cap 100 mg
- Inj 10 mg per ml, 5 ml vial

** Restricted
Metabolic disorders physician or metabolic disorders dietitian.

**HAEM ARGINATE**

- Inj 25 mg per ml, 10 ml ampoule

**IMIGLUCERASE – Restricted** see terms below

- Inj 40 iu per ml, 5 ml vial
- Inj 40 iu per ml, 10 ml vial

** Restricted
Only for use in patients with approval by the Gaucher’s Treatment Panel

**LEVOCARNITINE – Restricted** see terms below

- Cap 500 mg
- Oral soln 500 mg per 15 ml
- Inj 200 mg per ml, 5 ml vial

** Restricted
Metabolic disorders physician, metabolic disorders dietitian or neurologist

**PYRIDOXAL-5-PHOSPHATE – Restricted** see terms below

- Tab 50 mg

** Restricted
Metabolic disorders physician, metabolic disorders dietitian or neurologist

**SODIUM BENZOATE**

- Cap 500 mg
- Powder
- Soln 100 mg per ml
- Inj 20%, 10 ml ampoule

**SODIUM PHENYLButYRATE**

- Tab 500 mg
- Oral liq 250 mg per ml
- Inj 200 mg per ml, 10 ml ampoule

**TRIENTINE DIHYDROCHLORIDE**

- Cap 300 mg

### Minerals

#### Calcium

**CALCIUM CARBONATE**

- Tab 1.25 g (500 mg elemental) – 1% DV Sep-14 to 2017.................................5.38 250 Arrow-Calcium
- Tab eff 1.75 g (1 g elemental) .................................................................6.21 30 Calsource

#### Fluoride

**SODIUM FLUORIDE**

- Tab 1.1 mg (0.5 mg elemental)
### Iodine

**POTASSIUM IODATE**
- Tab 253 mcg (150 mcg elemental iodine) – 1% DV Dec-14 to 2017 ............ 3.65 90 **NeuroTabs**
- Tab 256 mcg (150 mcg elemental iodine)

**POTASSIUM IODATE WITH IODINE**
- Oral liq 10% with iodine 5%

### Iron

**FERRIC CARBOXYMALTOSE**  – **Restricted** see terms below
- Inj 50 mg per ml, 10 ml vial ................................................................. 150.00 1 **Ferinject**

**FERROUS FUMARATE**
- Tab 200 mg (65 mg elemental) .............................................................. 4.35 100 **Ferro-tab**

**FERROUS FUMARATE WITH FOLIC ACID**
- Tab 310 mg (100 mg elemental) with folic acid 350 mcg .................. 4.75 60 **Ferro-F-Tabs**

**FERROUS GLUCONATE WITH ASCORBIC ACID**
- Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg

**FERROUS SULPHATE**
- Tab long-acting 325 mg (105 mg elemental) ...................................... 2.06 30 **Ferrograd**
- Oral liq 30 mg (6 mg elemental) per ml – 1% DV Apr-14 to 2016 ............ 10.28 500 ml **Ferodan**

**FERROUS SULPHATE WITH ASCORBIC ACID**
- Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg

**FERROUS SULPHATE WITH FOLIC ACID**
- Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

**IRON POLYMALTOSE**
- Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017 ...................... 15.22 5 **Ferrum H**

**IRON SUCROSE**
- Inj 20 mg per ml, 5 ml ampoule ....................................................... 100.00 5 **Venofer**

### Magnesium

**MAGNESIUM HYDROXIDE**
- Tab 311 mg (130 mg elemental)

**MAGNESIUM OXIDE**
- Cap 663 mg (400 mg elemental)

**MAGNESIUM SULPHATE**
- Inj 0.4 mmol per ml, 250 ml bag
- Inj 2 mmol per ml, 5 ml ampoule – 1% DV Oct-14 to 2017 ................. 12.65 10 **DBL**

### Zinc

**ZINC**
- Oral liq 5 mg per 5 drops

**ZINC CHLORIDE**
- Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule
### Mouth and Throat

#### Agents Used in Mouth Ulceration

**BENZYLAMINE HYDROCHLORIDE**
- Soln 0.15%
- Spray 0.15%

**BENZYLAMINE HYDROCHLORIDE WITH CETLYPYRIDINIUM CHLORIDE**
- Lozenge 3 mg with cetlypyridinium chloride

**CARBOXYMETHYLCELLULOSE**
- Oral spray

**CHLORHEXIDINE GLUCONATE**
- Mouthwash 0.2% – 1% *DV Dec-12 to 2015*  
  Price: $2.68  
  Per: 200 ml  
  Brand: healthE

**CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE**
- Adhesive gel 8.7% with cetalkonium chloride 0.01%

**DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL**
- Lozenge 1.2 mg with amylmetacresol 0.6 mg

**SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE**
- Paste
- Powder

**TRIAMCINOLONE ACETONIDE**
- Paste 0.1%  
  Price: $4.34  
  Per: 5 g  
  Brand: Oracort

#### Oropharyngeal Anti-Infectives

**AMPHOTERICIN B**
- Lozenge 10 mg  
  Price: $5.86  
  Per: 20  
  Brand: Fungilin

**MICONAZOLE**
- Oral gel 20 mg per g – 1% *DV Feb-13 to 2015*  
  Price: $4.95  
  Per: 40 g  
  Brand: Decozol

**NYSTATIN**
- Oral liquid 100,000 u per ml  
  Price: $3.19  
  Per: 24 ml  
  Brand: Nilstat

#### Other Oral Agents

**SODIUM HYALURONATE** – *Restricted* see terms below
- Inj 20 mg per ml, 1 ml syringe  
  Price: $4.78  
  Per: 1 ml syringe  
  Brand: Nilstat

**THYMOL GLYCERIN**
- Compound, BPC

---

*Item restricted (see \(|\) above); *Item restricted (see \(\|\) below)*

\(\textit{e.g. Brand} \) indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST) $</td>
</tr>
</tbody>
</table>

### Vitamins

#### Multivitamin Preparations

**MULTIVITAMINS**

Tab (BPC cap strength)

- **Multivitamin Preparations**
  - **Multivitamins**
    - **Tab (BPC cap strength)**
      - e.g. Mvite

**Restricted**

- Patient has cystic fibrosis with pancreatic insufficiency; or
- Patient is an infant or child with liver disease or short gut syndrome.

- **Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg, thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg**
  - e.g. Paediatric Seravit

**Restricted**

- Patient has inborn errors of metabolism.
  - **Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1)**
    - e.g. Pabrinex IV
  - **Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1)**
    - e.g. Pabrinex IM
  - **Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)**
    - e.g. Pabrinex IV

**VITAMIN A WITH VITAMINS D AND C**

- **Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops**
  - e.g. Vitadol C

### Vitamin A

**RETINOL**

- **Tab 10,000 IU**
- **Cap 25,000 IU**
- **Oral liq 150,000 IU per ml**

### Vitamin B

**HYDROXOCOBALAMIN ACETATE**

- **Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-12 to 2015.................................5.10**
- **3 ABM**

Hydroxocobalamin
### ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PYRIDOXINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-15 to 2017</td>
<td>2.15</td>
<td>90 PyridoxADE</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-14 to 2017</td>
<td>11.55</td>
<td>500 Apo-Pyridoxine</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**THIAMINE HYDROCHLORIDE**
- Tab 50 mg
- Tab 100 mg
- Inj 100 mg per ml, 2 ml vial

**VITAMIN B COMPLEX**
- Tab strong, BPC

### Vitamin C

**ASCORBIC ACID**
- Tab 100 mg – 1% DV Nov-13 to 2016 .......................................................... 7.00 500 Cvite
- Tab chewable 250 mg

### Vitamin D

**ALFACALCIDOL**
- Cap 0.25 mcg ................................................................. 26.32 100 One-Alpha
- Cap 1 mcg ................................................................. 87.98 100 One-Alpha
- Oral drops 2 mcg per ml

**CALCITRIOL**
- Cap 0.25 mcg ................................................................. 3.03 30 Airflow
- Cap 0.5 mcg ................................................................. 5.62 30 Airflow
- Oral liq 1 mcg per ml
- Inj 1 mcg per ml, 1 ml ampoule

**CHOLECALCIFEROL**
- Tab 1.25 mg (50,000 iu) .......................................................... 7.76 12 Cal-d-Forte

### Vitamin E

**ALPHA TOCOPHERYL ACETATE** – **Restricted** see terms below
- Cap 100 u
- Cap 500 u
- Oral liq 156 u per ml

**Restricted**

**Cystic fibrosis**
Both:
1. Cystic fibrosis patient; and
2. Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

---

*Item restricted (see ➔ above); †Item restricted (see ➔ below)*
e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

**Osteoradionecrosis**
For the treatment of osteoradionecrosis

**Other indications**
All of the following:

1. Infant or child with liver disease or short gut syndrome; and
2. Requires vitamin supplementation; and
3. Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.
### BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

#### Antianaemics

**Hypoplastic and Haemolytic**

EPOTIN ALFA [ERYTHROPOIETIN ALFA] – Restricted see terms below

- **Inj 1,000 iu in 0.5 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $48.68 6 Eprex
- **Inj 2,000 iu in 0.5 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $120.18 6 Eprex
- **Inj 3,000 iu in 0.3 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $166.87 6 Eprex
- **Inj 4,000 iu in 0.4 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $193.13 6 Eprex
- **Inj 5,000 iu in 0.5 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $243.26 6 Eprex
- **Inj 6,000 iu in 0.6 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $291.92 6 Eprex
- **Inj 10,000 iu in 1 ml syringe** – 5% DV Mar-15 to 28 Feb 2018 .................. $395.18 6 Eprex

**Initiation - chronic renal failure**

All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin $\geq 100$ g/L; and
3. Any of the following:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate $\geq 30$ ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate $\leq 45$ ml/min; or
4. Patient is on haemodialysis or peritoneal dialysis.

**Initiation - myelodysplasia**

Re-assessment required after 2 months

All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100 g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum erythropoietin level of < 500 IU/L; and
6. The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

**Continuation - myelodysplasia**

Re-assessment required after 12 months

All of the following:
1. The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

**Initiation - all other indications**

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

*Note: Indications marked with * are Unapproved Indications.
EPOTIN BETA [ERYTHROPOIETIN BETA] – Restricted see terms below

Epotin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe ..............................................................120.18 6 NeoRecormon
- Inj 3,000 iu in 0.3 ml syringe ..............................................................166.87 6 NeoRecormon
- Inj 4,000 iu in 0.3 ml syringe ..............................................................193.13 6 NeoRecormon
- Inj 5,000 iu in 0.3 ml syringe ..............................................................243.26 6 NeoRecormon
- Inj 6,000 iu in 0.3 ml syringe ..............................................................291.92 6 NeoRecormon
- Inj 10,000 iu in 0.6 ml syringe ..............................................................395.18 6 NeoRecormon

(NeoRecormon Inj 2,000 iu in 0.3 ml syringe to be delisted 1 March 2015)
( NeoRecormon Inj 3,000 iu in 0.3 ml syringe to be delisted 1 March 2015)
( NeoRecormon Inj 4,000 iu in 0.3 ml syringe to be delisted 1 March 2015)
( NeoRecormon Inj 5,000 iu in 0.3 ml syringe to be delisted 1 March 2015)
( NeoRecormon Inj 6,000 iu in 0.3 ml syringe to be delisted 1 March 2015)
( NeoRecormon Inj 10,000 iu in 0.6 ml syringe to be delisted 1 March 2015)

Initiation - chronic renal failure

All of the following:
1 Patient in chronic renal failure; and
2 Haemoglobin ≥ 100g/L; and
3 Any of the following:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate ≤ 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate ≤ 45ml/min; or
4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 2 months

All of the following:
1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for
   myelodysplastic syndrome (WPSS); and
4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5 Patient has a serum erythropoietin level of < 500 IU/L; and
6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Continuation - myelodysplasia*

Re-assessment required after 12 months

All of the following:
1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
2 Transformation to acute myeloid leukaemia has not occurred; and
3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

*Note: Indications marked with * are Unapproved Indications.
# BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

## Megaloblastic

**FOLIC ACID**
- Tab 0.8 mg
- Tab 5 mg
- Oral liq 50 mcg per ml .......................................................... 24.00 25 ml Biomed
- Inj 5 mg per ml, 10 ml vial

### Antifibrinolitics, Haemostatics and Local Sclerosants

**APROTININ** – Restricted see terms below
- Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial
- Restricted
  Cardiac anaesthetist
  Either:
  1. Paediatric patient undergoing cardiopulmonary bypass procedure; or
  2. Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

**ELTROMBOPAG** – Restricted see terms below
- Tab 25 mg .......................................................... 1,771.00 28 Revolade
- Tab 50 mg .......................................................... 3,542.00 28 Revolade
- Restricted
  Haematologist
  **Initiation (idiopathic thrombocytopenic purpura - post-splenectomy)**
  *Re-assessment required after 6 weeks*
  All of the following:
  1. Patient has had a splenectomy; and
  2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
  3. Any of the following:
     3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
     3.2 Patient has a platelet count of ≤ 20,000 platelets per microlitre and has evidence of active bleeding; or
     3.3 Patient has a platelet count of ≤ 10,000 platelets per microlitre.
  **Initiation - (idiopathic thrombocytopenic purpura - preparation for splenectomy)**
  *Re-assessment required after 6 weeks*
  The patient requires eltrombopag treatment as preparation for splenectomy.
  **Continuation - (idiopathic thrombocytopenic purpura - post-splenectomy)**
  *Re-assessment required after 12 months*
  The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.
  Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

**FERRIC SUBSULFATE**
- Gel 25.9%
- Soln 500 ml

**POLIDOCANOL**
- Inj 0.5%, 30 ml vial

**SODIUM TETRADECYL SULPHATE**
- Inj 3%, 2 ml ampoule

**THROMBIN**
- Powder

---

† Item restricted (see ‡ above); ‡ Item restricted (see † below)

*e.g. Brand indicates brand example only. It is not a contracted product.*
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

<table>
<thead>
<tr>
<th>Tranexamic Acid</th>
<th>Tab 500 mg – 1% DV Oct-14 to 2016</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>23.00</td>
<td>Cyklokapron</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 5 ml ampoule</td>
<td>124.73</td>
<td>Cyklokapron</td>
</tr>
</tbody>
</table>

**Blood Factors**

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – Restricted see terms below**
- Inj 1 mg syringe ................................................................. 1,163.75
- Inj 2 mg syringe ................................................................. 2,327.50
- Inj 5 mg syringe ................................................................. 5,818.75
- Inj 8 mg syringe ................................................................. 9,310.00

**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**FACTOR EIGHT INHIBITORS BYPASSING AGENT – Restricted see terms below**
- Inj 500 U .............................................................................. 1,640.00
- Inj 1,000 U ........................................................................... 3,280.00

**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted see terms below**
- Inj 250 iu vial .................................................................... 225.00
- Inj 500 iu vial .................................................................... 450.00
- Inj 1,000 iu vial .................................................................. 900.00
- Inj 2,000 iu vial .................................................................. 1,800.00
- Inj 3,000 iu vial .................................................................. 2,700.00

**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**NONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted see terms below**
- Inj 250 iu vial .................................................................... 310.00
- Inj 500 iu vial .................................................................... 620.00
- Inj 1,000 iu vial .................................................................. 1,240.00
- Inj 2,000 iu vial .................................................................. 2,480.00

**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

**OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted see terms on the next page**
- Inj 250 iu vial .................................................................... 237.50
- Inj 500 iu vial .................................................................... 475.00
- Inj 1,000 iu vial .................................................................. 950.00
- Inj 1,500 iu vial .................................................................. 1,425.00
- Inj 2,000 iu vial .................................................................. 1,900.00
- Inj 3,000 iu vial .................................................................. 2,850.00

**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.
## BLOOD AND BLOOD FORMING ORGANS

### Antithrombotics

#### Anticoagulants

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIVALIRUDIN</strong> – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 250 mg vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Restricted

- When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

#### Vitamin K

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHYTOMENADIONE</strong></td>
<td>Inj 2 mg in 0.2 ml ampoule</td>
<td>8.00</td>
<td>Konakion MM</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>9.21</td>
<td>Konakion MM</td>
</tr>
</tbody>
</table>

#### Antitichrombotic

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIVALIRUDIN</strong> – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 mg vial</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Either:
  1. For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
  2. For use in patients undergoing endovascular procedures.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DABIGATRAN</strong></td>
<td>Cap 75 mg</td>
<td>148.00</td>
<td>Pradaxa</td>
</tr>
<tr>
<td></td>
<td>Cap 110 mg</td>
<td>148.00</td>
<td>Pradaxa</td>
</tr>
<tr>
<td></td>
<td>Cap 150 mg</td>
<td>148.00</td>
<td>Pradaxa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DALTEPARIN</strong></td>
<td>Inj 2,500 iu in 0.2 ml syringe</td>
<td>19.97</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 5,000 iu in 0.2 ml syringe</td>
<td>39.94</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 7,500 iu in 0.75 ml syringe</td>
<td>60.03</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 10,000 iu in 1 ml syringe</td>
<td>77.55</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 12,500 iu in 0.5 ml syringe</td>
<td>99.96</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 15,000 iu in 0.6 ml syringe</td>
<td>120.05</td>
<td>Fragmin</td>
</tr>
<tr>
<td></td>
<td>Inj 18,000 iu in 0.72 ml syringe</td>
<td>158.47</td>
<td>Fragmin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DANAPAROID</strong> – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 750 u in 0.6 ml ampoule</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEFIBROTIDE</strong> – Restricted</td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 80 mg per ml, 2.5 ml ampoule</td>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Haematologist
  Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]</strong></td>
<td>Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➫ above); Item restricted (see ➫ below)*

* e.g. *Brand* indicates brand example only. It is not a contracted product.
## BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### ENOXAPARIN
- **Inj 20 mg in 0.2 ml syringe** – 1% DV Sep-12 to 2015: $37.24 10 Clexane
- **Inj 40 mg in 0.4 ml syringe** – 1% DV Sep-12 to 2015: $49.69 10 Clexane
- **Inj 60 mg in 0.6 ml syringe** – 1% DV Sep-12 to 2015: $74.91 10 Clexane
- **Inj 80 mg in 0.8 ml syringe** – 1% DV Sep-12 to 2015: $99.86 10 Clexane
- **Inj 100 mg in 1 ml syringe** – 1% DV Sep-12 to 2015: $125.06 10 Clexane
- **Inj 120 mg in 0.8 ml syringe** – 1% DV Sep-12 to 2015: $155.40 10 Clexane
- **Inj 150 mg in 1 ml syringe** – 1% DV Sep-12 to 2015: $177.60 10 Clexane

### FONDAPARINUX SODIUM – Restricted see terms below
- **Inj 2.5 mg in 0.5 ml syringe**
- **Inj 7.5 mg in 0.6 ml syringe**

**Restricted**
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

### HEPARIN SODIUM
- **Inj 100 iu per ml, 250 ml bag**
- **Inj 1,000 iu per ml, 1 ml ampoule**: $66.80 50 Hospira
- **Inj 1,000 iu per ml, 35 ml ampoule**
- **Inj 1,000 iu per ml, 5 ml ampoule**: $61.04 50 Pfizer
- **Inj 5,000 iu in 0.2 ml ampoule**
- **Inj 5,000 iu per ml, 1 ml ampoule**: $14.20 5 Hospira
- **Inj 5,000 iu per ml, 5 ml ampoule**: $236.60 50 Pfizer

### HEPARINISED SALINE
- **Inj 10 iu per ml, 5 ml ampoule**: $39.00 50 Pfizer
- **Inj 100 iu per ml, 2 ml ampoule**
- **Inj 100 iu per ml, 5 ml ampoule**

### PHENINDIONE
- **Tab 10 mg**
- **Tab 25 mg**
- **Tab 50 mg**

### PROTAMINE SULPHATE
- **Inj 10 mg per ml, 5 ml ampoule**

### RIVAROXABAN – Restricted see terms below
- **Tab 10 mg**: $153.00 15 Xarelto

**Restricted**
Either:
1. Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or
2. Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.

### SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE
- **Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag**

### TRISODIUM CITRATE
- **Inj 4%, 5 ml ampoule**
- **Inj 46.7%, 3 ml syringe**
- **Inj 46.7%, 5 ml ampoule**

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

33
BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**WARFARIN SODIUM**

- Tab 1 mg: $6.86, 100 Marevan
- Tab 2 mg: $9.70, 100 Marevan
- Tab 5 mg: $11.75, 100 Marevan

**Antiplatelets**

**ASPIRIN**

- Tab 100 mg – 1% DV Mar-14 to 2016: $1.60, 90 Ethics Aspirin EC
- Tab Suppos 300 mg: $10.50, 990 Ethics Aspirin EC

**CLOPIDOGREL**

- Tab 75 mg – 1% DV Dec-13 to 2016: $5.48, 84 Arrow - Clopid

**DIPYRIDAMOLE**

- Tab 25 mg
  - Tab long-acting 150 mg: $11.52, 60 Pytazen SR
- Inj 5 mg per ml, 2 ml ampoule

**EPTIFIBATIDE – Restricted**

- Inj 2 mg per ml, 10 ml vial: $11.10, 1 Integrilin
- Inj 750 mcg per ml, 100 ml vial: $324.00, 1 Integrilin

**PRASUGREL – Restricted**

- Tab 5 mg: $108.00, 28 Effient
- Tab 10 mg: $120.00, 28 Effient

**TICAGRELOR – Restricted**

- Tab 90 mg: $90.00, 56 Brilinta

**TICLOPIDINE**

- Tab 250 mg

---

*Item restricted (see above); Item restricted (see below) e.g. Brand indicates brand example only. It is not a contracted product.*
## Fibrinolytic Agents

**ALTEPLASE**  
- Inj 10 mg vial  
- Inj 50 mg vial  

**TENECTEPLASE**  
- Inj 50 mg vial  

**UROKINASE**  
- Inj 10,000 iu vial  
- Inj 50,000 iu vial  
- Inj 100,000 iu vial  
- Inj 500,000 iu vial  

## Colony-Stimulating Factors

### Granulocyte Colony-Stimulating Factors

**FILGRASTIM – Restricted** see terms below  
- Inj 300 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015  
  - Per 5  
  - Zarzio  
- Inj 300 mcg in 1 ml vial  
  - Per 5  
  - Neupogen  
- Inj 480 mcg in 0.5 ml syringe – 1% DV Jan-13 to 31 Dec 2015  
  - Per 5  
  - Zarzio

**PEGFILGRASTIM – Restricted** see terms below  
- Inj 6 mg per 0.6 ml syringe  
  - Per 1  
  - Neulastim

Oncologist or haematologist  

**Colonies-Stimulating Factors**

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk \( \geq 20\% \)).  
*Febrile neutropenia risk \( \geq 20\% \) after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

### Fluids and Electrolytes

#### Intravenous Administration

**CALCIUM CHLORIDE**  
- Inj 100 mg per ml, 10 ml vial

**CALCIUM GLUCONATE**  
- Inj 10%, 10 ml ampoule  
  - Per 10  
  - Hospira

**COMPOUND ELECTROLYTES**  
- Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag  
  - Per 500 ml  
  - Baxter  
  - Per 1,000 ml  
  - Baxter

**COMPOUND ELECTROLYTES WITH GLUCOSE**  
- Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag  
  - Per 1,000 ml  
  - Baxter

Products with Hospital Supply Status (HSS) are in **bold**  
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.  

---

**Price**  
(ex man. excl. GST) $  
Per Brand or Generic Manufacturer

---

35
<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLOOD AND BLOOD FORMING ORGANS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COMPOUND SODIUM LACTATE [HARTMANN’S SOLUTION]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, bag</td>
<td>1.77</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>1.80</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td><strong>COMPOUND SODIUM LACTATE WITH GLUCOSE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag</td>
<td>5.38</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5%, bag</td>
<td>2.87</td>
<td>50 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>2.84</td>
<td>100 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>3.87</td>
<td>250 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>1.77</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>1.80</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 10%, bag</td>
<td>3.70</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>5.29</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 50%, bag</td>
<td>6.84</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 50%, 10 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>27.50</td>
<td>5</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 50%, 90 ml bottle – 1% DV Oct-14 to 2017</td>
<td>14.50</td>
<td>1</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 70%, 1,000 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 70%, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE WITH POTASSIUM CHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5% glucose with 20 mmol/l potassium chloride, bag</td>
<td>7.36</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag</td>
<td>3.45</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>4.30</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag</td>
<td>3.62</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GLUCOSE WITH SODIUM CHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj glucose 2.5% with sodium chloride 0.45%, bag</td>
<td>4.95</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj glucose 5% with sodium chloride 0.45%, bag</td>
<td>9.87</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj glucose 5% with sodium chloride 0.9%, bag</td>
<td>4.54</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj glucose 5% with sodium chloride 0.2%, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>POTASSIUM CHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 75 mg (1 mmol) per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 225 mg (3 mmol) per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price (ex man. excl. GST) $</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**POTASSIUM CHLORIDE WITH SODIUM CHLORIDE**

- Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag .........................................3.85 1,000 ml Baxter
- Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag .........................................2.59 1,000 ml Baxter
- Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag .........................................6.62 1,000 ml Baxter
- Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag
- Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, 100 ml bag

**POTASSIUM DIHYDROGEN PHOSPHATE**

- Inj 1 mmol per ml, 10 ml ampoule

**RINGER’S SOLUTION**

- Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag .................................................................5.13 1,000 ml Baxter

**SODIUM ACETATE**

- Inj 4 mmol per ml, 20 ml ampoule

**SODIUM BICARBONATE**

- Inj 8.4%, 10 ml vial
- Inj 8.4%, 50 ml vial .................................................................19.95 1 Biomed
- Inj 8.4%, 100 ml vial .................................................................20.50 1 Biomed

**SODIUM CHLORIDE**

- Inj 0.45%, bag .................................................................5.50 500 ml Baxter
- Inj 0.9%, 3 ml syringe

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]**

- Inj 1 mmol per ml, 20 ml ampoule

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

#### WATER
- **Inj, bag** ................................................................. 2.75 1,000 ml Baxter
- **Inj 5 ml ampoule** .................................................. 10.25 50 Multichem
- **Inj 10 ml ampoule** ............................................... 11.25 50 Multichem
- **Inj 20 ml ampoule** ............................................. 6.50 20 Multichem
- **Inj 250 ml bag**
- **Inj 500 ml bag**

### Oral Administration

#### CALCIUM POLYSTYRENE SULPHONATE
- **Powder** ................................................................. 169.85 300 g Calcium Resonium

#### COMPOUND ELECTROLYTES
- **Powder for oral soln**

#### COMPOUND ELECTROLYTES WITH GLUCOSE
- **Soln with electrolytes**

#### PHOSPHORUS
- **Tab eff 500 mg (16 mmol)**

#### POTASSIUM CHLORIDE
- **Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)**
- **Tab long-acting 600 mg (8 mmol) – 1% DV Oct-12 to 2015** ........................................ 7.42 200 Span-K
  - Oral liq 2 mmol per ml

#### SODIUM BICARBONATE
- **Cap 840 mg** ............................................................. 8.52 100 Sodibic

#### SODIUM CHLORIDE
- **Tab 600 mg**
- **Oral liq 2 mmol/ml**

#### SODIUM POLYSTYRENE SULPHONATE
- **Powder**

### Plasma Volume Expanders

#### GELATINE, SUCCINYLATED
- **Inj 4%, 500 ml bag** .................................................. 92.50 10 Gelafusal
  - 108.00 Gelofusine

#### HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE
- **Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag** .......... 198.00 20 Volulyte 6%

#### HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE
- **Inj 6% with sodium chloride 0.9%, 500 ml bag** ...................... 198.00 20 Voluven

---

*Item restricted (see above); ‡Item restricted (see below)*
edg. *Brand* indicates brand example only. It is not a contracted product.
## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

**CAPTOPRIL**

- Oral liq 5 mg per ml ................................................................. 94.99 95 ml *Capoten*

**CILAZAPRIL**

- Tab 0.5 mg – 1% DV Sep-13 to 2016 .................................................. 2.00 90 *Zapril*
- Tab 2.5 mg – 1% DV Sep-13 to 2016 .................................................. 4.31 90 *Zapril*
- Tab 5 mg – 1% DV Sep-13 to 2016 .................................................. 6.98 90 *Zapril*

**ENALAPRIL MALEATE**

- Tab 5 mg .................................................................................. 1.19 100 *Ethics Enalapril*
- Tab 10 mg ............................................................................... 1.47 100 *Ethics Enalapril*
- Tab 20 mg .............................................................................. 1.91 100 *Ethics Enalapril*

**Lisinopril**

- Tab 5 mg – 1% DV Jan-13 to 2015 .................................................. 3.58 90 *Arrow-Lisinopril*
- Tab 10 mg – 1% DV Jan-13 to 2015 .................................................. 4.08 90 *Arrow-Lisinopril*
- Tab 20 mg – 1% DV Jan-13 to 2015 .................................................. 4.88 90 *Arrow-Lisinopril*

**PERINDOPRIL**

- Tab 2 mg – 1% DV Oct-14 to 2017 .................................................. 3.75 30 *Apo-Perindopril*
- Tab 4 mg – 1% DV Oct-14 to 2017 .................................................. 4.80 30 *Apo-Perindopril*

**QUINAPRIL**

- Tab 5 mg – 1% DV Apr-13 to 2015 .................................................. 3.44 90 *Arrow-Quinapril 5*
- Tab 10 mg – 1% DV Apr-13 to 2015 .................................................. 4.64 90 *Arrow-Quinapril 10*
- Tab 20 mg – 1% DV Apr-13 to 2015 .................................................. 6.34 90 *Arrow-Quinapril 20*

**TRANDOLAPRIL** – Restricted: For continuation only

- Cap 1 mg
- Cap 2 mg

### ACE Inhibitors with Diuretics

**CILAZAPRIL WITH HYDROCHLOROTHIAZIDE**

- Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Mar-14 to 2016 ........ 10.72 100 *Apo-Cilazapril/Hydrochlorothiazide*

**ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE** – Restricted: For continuation only

- Tab 20 mg with hydrochlorothiazide 12.5 mg

**QUINAPRIL WITH HYDROCHLOROTHIAZIDE**

- Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 ........ 3.37 30 *Accuretic 10*
- Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Aug-12 to 2015 ........ 4.57 30 *Accuretic 20*
### Angiotensin II Antagonists

**CANDESARTAN CILEXETIL** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand or Generic Manufacturer</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg</td>
<td>$4.13</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 8 mg</td>
<td>$8.10</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 16 mg</td>
<td>$10.18</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 32 mg</td>
<td>$17.66</td>
<td>Candestar</td>
</tr>
</tbody>
</table>

**ACE inhibitor intolerance**

Either:

1. Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor);
2. Patient has a history of angioedema.

**Unsatisfactory response to ACE inhibitor**

Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

**LOSARTAN POTASSIUM**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 12.5 mg</td>
<td>$1.55</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>$2.88</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>$3.20</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>$5.22</td>
<td>Losartan Actavis</td>
</tr>
</tbody>
</table>

*(Lostaar Tab 12.5 mg to be delisted 1 January 2015)*

*(Lostaar Tab 25 mg to be delisted 1 January 2015)*

*(Lostaar Tab 50 mg to be delisted 1 January 2015)*

*(Lostaar Tab 100 mg to be delisted 1 January 2015)*

### Angiotensin II Antagonists with Diuretics

**LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg with hydrochlorothiazide 12.5 mg</td>
<td>$2.18</td>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
</tr>
</tbody>
</table>

### Alpha-Adrenoceptor Blockers

**DOXAZOSIN**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg</td>
<td>$6.75</td>
<td>Apo-Doxazosin</td>
</tr>
<tr>
<td>Tab 4 mg</td>
<td>$9.67</td>
<td>Apo-Doxazosin</td>
</tr>
</tbody>
</table>

**PHENOXYBENZAMINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 10 mg</td>
<td>$3.10</td>
<td>Apo-Doxazosin</td>
</tr>
</tbody>
</table>

**PHENTOLAMINE MESYLATE**

<table>
<thead>
<tr>
<th>Strength</th>
<th>Price per Brand</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml</td>
<td>$0.97</td>
<td>Apo-Doxazosin</td>
</tr>
</tbody>
</table>

*Item restricted (see above); ‡Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRAZOSIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>5.53</td>
<td>100</td>
<td>Apo-Prazo</td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>7.00</td>
<td>100</td>
<td>Apo-Prazosin</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>11.70</td>
<td>100</td>
<td>Apo-Prazo</td>
</tr>
</tbody>
</table>

(Apo-Prazo Tab 1 mg to be delisted 1 December 2014)
(Apo-Prazo Tab 2 mg to be delisted 1 December 2014)
(Apo-Prazo Tab 5 mg to be delisted 1 December 2014)

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TERAZOSIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Sep-13 to 2016</td>
<td>0.50</td>
<td>28</td>
<td>Arrow</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-13 to 2016</td>
<td>0.45</td>
<td>28</td>
<td>Arrow</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Sep-13 to 2016</td>
<td>0.68</td>
<td>28</td>
<td>Arrow</td>
</tr>
</tbody>
</table>

**Antiarrhythmics**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADENOSINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For use in cardiac catheterisation, electrophysiology and MRI.

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AJMALINE – Restricted</strong></td>
<td>see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cardiologist

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMIODARONE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 3 ml ampoule – 1% DV Aug-13 to 2016</td>
<td>22.80</td>
<td>6</td>
<td>Cordarone-X</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATROPINE SULPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 600 mcg per ml, 1 ml ampoule – 1% DV Jan-13 to 2015</td>
<td>71.00</td>
<td>50</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIGOXIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 62.5 mcg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mcg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 250 mcg per ml, 2 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISOPYRAMIDE PHOSPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLECAINIDE ACETATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>38.95</td>
<td>60</td>
<td>Tambocor</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>68.78</td>
<td>60</td>
<td>Tambocor</td>
</tr>
<tr>
<td>Cap long-acting 100 mg</td>
<td>38.95</td>
<td>30</td>
<td>Tambocor CR</td>
</tr>
<tr>
<td>Cap long-acting 200 mg</td>
<td>68.78</td>
<td>30</td>
<td>Tambocor CR</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 15 ml ampoule</td>
<td>52.45</td>
<td>5</td>
<td>Tambocor</td>
</tr>
</tbody>
</table>
## CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### MEXILETINE HYDROCHLORIDE
- Cap 150 mg ................................................................. 65.00 100 Mexiletine Hydrochloride USP
- Cap 250 mg ................................................................. 102.00 100 Mexiletine Hydrochloride USP

### PROPafenONE HYDROCHLORIDE
- Tab 150 mg

## Antihypotensives

**MIDODRINE** – **Restricted** see terms below
- Tab 2.5 mg
- Tab 5 mg
- **Restricted**

Patient has disabling orthostatic hypotension not due to drugs.

### Beta-Adrenoceptor Blockers

#### ATENOLOL
- Tab 50 mg – 1% DV Oct-12 to 2015 ........................................... 5.56 500 Mylan Atenolol
- Tab 100 mg – 1% DV Oct-12 to 2015 ...................................... 9.12 500 Mylan Atenolol
- Oral liq 5 mg per ml .......................................................... 21.25 300 ml Atenolol-AFT

#### BISOPROLOL
- Tab 2.5 mg ................................................................. 3.88 30 Bosvate
- Tab 5 mg ................................................................. 4.74 30 Bosvate
- Tab 10 mg ............................................................... 9.18 30 Bosvate

#### CARVEDILOL
- Tab 6.25 mg ................................................................. 21.00 30 Dilatrend
- Tab 12.5 mg ............................................................... 27.00 30 Dilatrend
- Tab 25 mg ................................................................. 33.75 30 Dilatrend

#### CELIPROLOL
- Tab 200 mg ................................................................. 19.00 180 Celol

#### ESMOLOL HYDROCHLORIDE
- Inj 10 mg per ml, 10 ml vial

#### LABETALOL
- Tab 50 mg ................................................................. 8.23 100 Hybloc
- Tab 100 mg ............................................................... 10.06 100 Hybloc
- Tab 200 mg ............................................................... 17.55 100 Hybloc
- Tab 400 mg
- Inj 5 mg per ml, 20 ml ampoule

#### METOPROLOL SUCCINATE
- Tab long-acting 23.75 mg – 1% DV Sep-12 to 2015 ............... 0.96 30 Metoprolol - AFT CR
- Tab long-acting 47.5 mg – 1% DV Sep-12 to 2015 ............... 1.41 30 Metoprolol - AFT CR
- Tab long-acting 95 mg – 1% DV Sep-12 to 2015 ............... 2.42 30 Metoprolol - AFT CR
- Tab long-acting 190 mg – 1% DV Sep-12 to 2015 ............... 4.66 30 Metoprolol - AFT CR

#### METOPROLOL TARTRATE
- Tab 50 mg – 1% DV Aug-12 to 2015 .................................... 16.00 100 Lopresor
- Tab 100 mg – 1% DV Aug-12 to 2015 ................................ 21.00 60 Lopresor
- Tab long-acting 200 mg – 1% DV Aug-12 to 2015 ............. 18.00 28 Slow-Lopresor
- Inj 1 mg per ml, 5 ml vial – 1% DV Dec-12 to 2015 ............. 24.00 5 Lopresor

---

*Item restricted (see ➔ above); †Item restricted (see ➔ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
NADOLOL
Tab 40 mg – 1% DV Apr-13 to 2015..........................15.57 100 Apo-Nadolol
Tab 80 mg – 1% DV Apr-13 to 2015..........................23.74 100 Apo-Nadolol

PINDOLOL
Tab 5 mg – 1% DV Nov-13 to 2016..........................9.72 100 Apo-Pindolol
Tab 10 mg – 1% DV Nov-13 to 2016......................15.62 100 Apo-Pindolol
Tab 15 mg – 1% DV Nov-13 to 2016......................23.46 100 Apo-Pindolol

PROPRANOLOL
Tab 10 mg ..........................................................3.65 100 Apo-Propranolol
Tab 40 mg ..........................................................4.65 100 Apo-Propranolol
Cap long-acting 160 mg .......................................8.72 100 Cardinol LA
Oral liq 4 mg per ml
Inj 1 mg per ml, 1 ml ampoule

SOTALOL
Tab 80 mg ..........................................................27.50 500 Mylan
Tab 160 mg ..........................................................10.50 100 Mylan
Inj 10 mg per ml, 4 ml ampoule .........................65.39 5 Sotacor

TIMOLOOL MALEATE
Tab 10 mg

**Calcium Channel Blockers**

**Dihydropyridine Calcium Channel Blockers**

AMLODIPINE
Tab 2.5 mg .........................................................2.45 100 Apo-Amlodipine
Tab 5 mg .........................................................2.65 100 Apo-Amlodipine
Tab 10 mg .........................................................4.15 100 Apo-Amlodipine

FELODIPINE
Tab long-acting 2.5 mg – 1% DV Sep-12 to 2015........2.90 30 Plendil ER
Tab long-acting 5 mg – 1% DV Nov-12 to 2015........3.10 30 Plendil ER
Tab long-acting 10 mg – 1% DV Nov-12 to 2015.....4.60 30 Plendil ER

ISRADIPINE
Tab 2.5 mg
Cap long-acting 2.5 mg
Cap long-acting 5 mg

NIFEDIPINE
Tab long-acting 10 mg
Tab long-acting 20 mg ...........................................9.59 100 Nyefax Retard
Tab long-acting 30 mg – 1% DV Sep-14 to 2017......3.75 30 Adefin XL
Tab long-acting 60 mg – 1% DV Sep-14 to 2017.....5.75 30 Adefin XL
Cap 5 mg

NIMODIPINE
Tab 30 mg
Inj 200 mcg per ml, 50 ml vial
## Other Calcium Channel Blockers

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DILTIAZEM HYDROCHLORIDE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 30 mg – 5% DV Sep-12 to 2015</td>
<td>100</td>
<td>4.60</td>
</tr>
<tr>
<td>Tab 60 mg – 5% DV Sep-12 to 2015</td>
<td>100</td>
<td>8.50</td>
</tr>
<tr>
<td>Cap long-acting 120 mg</td>
<td>30</td>
<td>1.91</td>
</tr>
<tr>
<td>Cap long-acting 180 mg</td>
<td>500</td>
<td>31.83</td>
</tr>
<tr>
<td>Cap long-acting 240 mg</td>
<td>30</td>
<td>10.22</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PERHEXILINE MALEATE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>100</td>
<td>62.90</td>
</tr>
<tr>
<td><strong>VERAPAMIL HYDROCHLORIDE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 40 mg</td>
<td>100</td>
<td>7.01</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Sep-14 to 2017</td>
<td>100</td>
<td>11.74</td>
</tr>
<tr>
<td>Tab long-acting 120 mg</td>
<td>250</td>
<td>15.20</td>
</tr>
<tr>
<td>Tab long-acting 240 mg</td>
<td>250</td>
<td>25.00</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 2 ml ampoule</td>
<td>5</td>
<td>7.54</td>
</tr>
</tbody>
</table>

## Centrally-Acting Agents

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLONIDINE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Patch 2.5 mg, 100 mcg per day – 1% DV Jul-14 to 2017</td>
<td>4</td>
<td>12.80</td>
</tr>
<tr>
<td>Patch 5 mg, 200 mcg per day – 1% DV Jul-14 to 2017</td>
<td>4</td>
<td>18.04</td>
</tr>
<tr>
<td>Patch 7.5 mg, 300 mcg per day – 1% DV Jul-14 to 2017</td>
<td>4</td>
<td>22.68</td>
</tr>
<tr>
<td><strong>CLONIDINE HYDROCHLORIDE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 25 mcg – 1% DV Jul-13 to 2015</td>
<td>112</td>
<td>15.09</td>
</tr>
<tr>
<td>Tab 150 mcg – 1% DV Feb-13 to 2015</td>
<td>100</td>
<td>34.32</td>
</tr>
<tr>
<td>Inj 150 mcg per ml, 1 ml ampoule – 1% DV Nov-12 to 2015</td>
<td>5</td>
<td>16.07</td>
</tr>
<tr>
<td><strong>METHYLDOPA</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 125 mg</td>
<td>100</td>
<td>14.25</td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td>100</td>
<td>15.10</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>100</td>
<td>23.15</td>
</tr>
</tbody>
</table>

## Diuretics

### Loop Diuretics

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUMETANIDE</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>100</td>
<td>16.36</td>
</tr>
<tr>
<td>Inj 500 mcg per ml, 4 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FUROSEMIDE (FRUSEMIDE)</strong></td>
<td></td>
<td>Per</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Sep-12 to 2015</td>
<td>1,000</td>
<td>10.25</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Feb-13 to 2015</td>
<td>50</td>
<td>25.00</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule</td>
<td>5</td>
<td>1.30</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➔ above); ➔Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
## Osmotic Diuretics

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MANNITOL Inj 10%, 1,000 ml bag</td>
<td>14.21</td>
<td>1,000 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>MANNITOL Inj 15%, 500 ml bag</td>
<td>9.84</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
<tr>
<td>MANNITOL Inj 20%, 500 ml bag</td>
<td>10.80</td>
<td>500 ml</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

## Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE
- Tab 5 mg with furosemide 40 mg

AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE
- Tab 5 mg with hydrochlorothiazide 50 mg

## Potassium Sparing Diuretics

AMILORIDE HYDROCHLORIDE
- Tab 5 mg ................................................................. 17.50 | 100 | Apo-Amiloride |
- Oral liq 1 mg per ml ................................. 30.00 | 25 ml | Biomed |

SPIRONOLACTONE
- Tab 25 mg – 1% DV Sep-13 to 2016 ................. 3.65 | 100 | Spiractin |
- Tab 100 mg – 1% DV Sep-13 to 2016 .............. 11.80 | 100 | Spiractin |
- Oral liq 5 mg per ml ........................................... 30.00 | 25 ml | Biomed |

## Thiazide and Related Diuretics

BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]
- Tab 2.5 mg – 1% DV Sep-14 to 2017 .................. 5.48 | 500 | Arrow-Bendrofluzaid |
- Tab 5 mg – 1% DV Sep-14 to 2017 .................. 8.95 | 500 | Arrow-Bendrofluzaid |

CHLOROTHIAZIDE
- Oral liq 50 mg per ml ........................................ 26.00 | 25 ml | Biomed |

CHLORTALIDONE [CHLORTHALIDONE]
- Tab 25 mg ...................................................... 8.00 | 50 | Hygroton |

INDAPAMIDE
- Tab 2.5 mg – 1% DV Oct-13 to 2016 ............. 2.25 | 90 | Dapa-Tabs |

METOLAZONE – Restricted see terms below

- Tab 5 mg

Either:
1. Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or
2. Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions

## Lipid-Modifying Agents

### Fibrates

BEZAFIBRATE
- Tab 200 mg – 1% DV Mar-13 to 2015 .................. 9.70 | 90 | Bezalip |
- Tab long-acting 400 mg – 1% DV Oct-12 to 2015 .... 5.70 | 30 | Bezalip Retard |
GEMFIBROZIL
Tab 600 mg – 1% DV Nov-13 to 2016 ........................................................... 17.60 60 Lipazil

HMG CoA Reductase Inhibitors (Statins)

ATORVASTATIN
Tab 10 mg – 1% DV Oct-12 to 2015 ........................................................... 2.52 90 Zarator
Tab 20 mg – 1% DV Oct-12 to 2015 ........................................................... 4.17 90 Zarator
Tab 40 mg – 1% DV Oct-12 to 2015 ........................................................... 7.32 90 Zarator
Tab 80 mg – 1% DV Oct-12 to 2015 ......................................................... 16.23 90 Zarator

PRAVASTATIN
Tab 10 mg
tab 20 mg – 1% DV Oct-14 to 2017 ........................................................... 3.45 30 Cholvastin
Tab 40 mg – 1% DV Oct-14 to 2017 ........................................................... 6.36 30 Cholvastin

SIMVASTATIN
Tab 10 mg – 1% DV Sep-14 to 2017 ........................................................... 0.95 90 Arrow-Simva
Tab 20 mg – 1% DV Sep-14 to 2017 ........................................................... 1.61 90 Arrow-Simva
Tab 40 mg – 1% DV Sep-14 to 2017 ........................................................... 2.83 90 Arrow-Simva
Tab 80 mg – 1% DV Sep-14 to 2017 ......................................................... 7.91 90 Arrow-Simva

Resins

CHOLESTYRAMINE
Powder for oral liq 4 g

COLESTIPOL HYDROCHLORIDE
Grans for oral liq 5 g

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Restricted see terms below
♀ Tab 10 mg

⇒ Restricted
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
   3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
   3.2 The patient is intolerant to both simvastatin and atorvastatin; or
   3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – Restricted see terms below
♀ Tab 10 mg with simvastatin 10 mg
♀ Tab 10 mg with simvastatin 20 mg
♀ Tab 10 mg with simvastatin 40 mg
♀ Tab 10 mg with simvastatin 80 mg

⇒ Restricted
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

e.g. Brand indicates brand example only. It is not a contracted product.
Other Lipid-Modifying Agents

<table>
<thead>
<tr>
<th>Product</th>
<th>Concentration</th>
<th>Expiry Date</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACIPIMOX</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NICOTINIC ACID</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-14 to 2017</td>
<td></td>
<td></td>
<td>3.96</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Oct-14 to 2017</td>
<td></td>
<td></td>
<td>17.37</td>
<td>Apo-Nicotinic Acid</td>
</tr>
<tr>
<td><strong>GLYCERYL TRINITRATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 600 mcg</td>
<td></td>
<td></td>
<td>8.00</td>
<td>Lycinate</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule – 1% DV Dec-12 to 2015</td>
<td></td>
<td></td>
<td>22.70</td>
<td>Nitronal</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml vial – 1% DV Dec-12 to 2015</td>
<td></td>
<td></td>
<td>86.60</td>
<td>Nitronal</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td>40.00</td>
<td>Hospira</td>
</tr>
<tr>
<td>Oral spray, 400 mcg per dose</td>
<td></td>
<td></td>
<td>4.45</td>
<td>Glytrin</td>
</tr>
<tr>
<td>Patch 25 mg, 5 mg per day – 1% DV Sep-14 to 2017</td>
<td></td>
<td></td>
<td>15.73</td>
<td>Nitroderm TTS 5</td>
</tr>
<tr>
<td>Patch 50 mg, 10 mg per day – 1% DV Sep-14 to 2017</td>
<td></td>
<td></td>
<td>18.62</td>
<td>Nitroderm TTS 10</td>
</tr>
<tr>
<td><strong>ISOSORBIDE MONONITRATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Sep-14 to 2017</td>
<td></td>
<td></td>
<td>17.10</td>
<td>Ismo-20</td>
</tr>
<tr>
<td>Tab long-acting 40 mg</td>
<td></td>
<td></td>
<td>7.50</td>
<td>Ismo 40 Retard</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td></td>
<td></td>
<td>3.94</td>
<td>Duride</td>
</tr>
</tbody>
</table>

**Nitrates**

**Other Cardiac Agents**

**LEVOSIMENDAN – Restricted** see terms below

1. Inj 2.5 mg per ml, 5 ml vial
2. Inj 2.5 mg per ml, 10 ml vial

**Heart transplant**

Either:

1. For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
2. For the treatment of heart failure following heart transplant.

**Heart failure**

cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

**Sympathomimetics**

**ADRENALINE**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 in 1,000, 1 ml ampoule</td>
<td>4.98</td>
<td>Aspen Adrenaline</td>
</tr>
<tr>
<td>Inj 1 in 1,000, 30 ml vial</td>
<td>5.25</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml ampoule</td>
<td>27.00</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1 in 10,000, 10 ml syringe</td>
<td>49.00</td>
<td>Aspen Adrenaline</td>
</tr>
</tbody>
</table>

**DOBUTAMINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 12.5 mg per ml, 20 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DOPAMINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-12 to 2015</td>
<td>69.77</td>
<td>Martindale</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

**EPHEDRINE**
- Inj 3 mg per ml, 10 ml syringe
- Inj 30 mg per ml, 1 ml ampoule

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

**ISOPRENALINE**
- Inj 200 mcg per ml, 1 ml ampoule
- Inj 200 mcg per ml, 5 ml ampoule

**METARAMINOL**
- Inj 0.5 mg per ml, 20 ml syringe
- Inj 1 mg per ml, 1 ml ampoule
- Inj 1 mg per ml, 10 ml syringe
- Inj 10 mg per ml, 1 ml ampoule

**NORADRENALINE**
- Inj 0.06 mg per ml, 100 ml bag
- Inj 0.06 mg per ml, 50 ml syringe
- Inj 0.1 mg per ml, 100 ml bag
- Inj 0.12 mg per ml, 100 ml bag
- Inj 0.12 mg per ml, 50 ml syringe
- Inj 0.16 mg per ml, 50 ml syringe
- Inj 1 mg per ml, 100 ml bag
- Inj 1 mg per ml, 2 ml ampoule

**PHENYLEPHRINE HYDROCHLORIDE**
- Inj 10 mg per ml, 1 ml vial

**Vasodilators**

**ALPROSTADIL HYDROCHLORIDE**
- Inj 500 mcg per ml, 1 ml ampoule

**AMYL NITRITE**
- Liq 98% in 3 ml capsule

**DIAZOXIDE**
- Inj 15 mg per ml, 20 ml ampoule

**HYDRALAZINE HYDROCHLORIDE**
- Tab 25 mg

 Either:
- 1 For the treatment of refractory hypertension; or
- 2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

**MILRINONE**
- Inj 1 mg per ml, 10 ml ampoule

**MINOXIDIL**
- Tab 10 mg

 Either:
- 1 For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.

**NICORANDIL**
- Tab 10 mg
- Tab 20 mg
CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

PAPAVERINE HYDROCHLORIDE

- **Inj 30 mg per ml, 1 ml vial**
  - Inj 12 mg per ml, 10 ml ampoule ................................................................. 73.12 5 Hospira

PENTOXIFYLLINE [OXPENTIFYLLINE]

- **Tab 400 mg**

SODIUM NITROPRUSSIDE

- **Inj 50 mg vial**

### Endothelin Receptor Antagonists

#### AMBRISENTAN – **Restricted** see terms below

- Tab 5 mg .............................................................................................................. 4,585.00 30 Volibris
- Tab 10 mg ......................................................................................................... 4,585.00 30 Volibris

##### Restricted

1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. In hospital stabilisations in emergency situations.

#### BOSENTAN – **Restricted** see terms below

- Tab 62.5 mg .................................................................................................... 1,500.00 60 pms-Bosentan
- Tab 125 mg .................................................................................................... 1,500.00 60 pms-Bosentan

##### Restricted

1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. In hospital stabilisation in emergency situations.

#### Phosphodiesterase Type 5 Inhibitors

#### SILDENAFIL – **Restricted** see terms below

- Tab 25 mg ...................................................................................................... 1.85 4 Silagra
- Tab 50 mg ...................................................................................................... 1.85 4 Silagra
- Tab 100 mg .................................................................................................... 7.45 4 Silagra

##### Restricted

Any of the following:

1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
3. For use in weaning patients from inhaled nitric oxide; or
4. For perioperative use in cardiac surgery patients; or
5. For use in intensive care as an alternative to nitric oxide; or
6. In-hospital stabilisation in emergency situations; or
7. All of the following:
   7.1 Patient has Raynaud’s phenomenon; and
   7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
   7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
   7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).
### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>$250.00</td>
<td>5 Ilomedin</td>
</tr>
<tr>
<td>$1,185.00</td>
<td>30 Ventavis</td>
</tr>
</tbody>
</table>

#### Prostacyclin Analogues

**ILOPROST**

- Inj 50 mcg in 0.5 ml ampoule – 1% DV **Apr-14 to 2016**...925.00
- Nebuliser soln 10 mcg per ml, 2 ml..........................1,185.00

**Restricted**

Any of the following:

1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. For diagnostic use in catheter laboratories; or
3. For use following mitral or tricuspid valve surgery; or
4. In hospital stabilisation in emergency situations.
### Anti-Infective Preparations

#### Antibacterials

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FUSIDIC ACID</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 2% – 1% DV Jan-15 to 2016</td>
<td>DP Fusidic Acid Cream</td>
<td>2.52</td>
<td>15 g</td>
<td>15 g</td>
</tr>
<tr>
<td>Oint 2% – 1% DV Sep-13 to 2016</td>
<td>Foban</td>
<td>3.25</td>
<td>15 g</td>
<td>15 g</td>
</tr>
</tbody>
</table>

*(Foban Crm 2% to be delisted 1 January 2015)*

**HYDROGEN PEROXIDE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1%</td>
<td>Crystaderm</td>
<td>8.56</td>
<td>15 g</td>
<td>15 g</td>
</tr>
<tr>
<td>Soln 3% (10 vol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MAFENIDE ACETATE** – **Restricted** see terms below

- Powder 50 g sachet

**HYDROGEN PEROXIDE**

- For the treatment of burns patients.

**MUPIROCIN**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SULPHADIAZINE SILVER**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1%</td>
<td>Flamazine</td>
<td>12.30</td>
<td>50 g</td>
<td>50 g</td>
</tr>
</tbody>
</table>

#### Antifungals

**AMOROLFINE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nail soln 5% – 1% DV Jan-15 to 2017</td>
<td>MycoNail</td>
<td>19.95</td>
<td>5 ml</td>
<td>5 ml</td>
</tr>
</tbody>
</table>

**CICLOPIROX OLAMINE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nail soln 8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Soln 1% – **Restricted**: For continuation only

**CLOTRIMAZOLE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1% – 1% DV Sep-14 to 2017</td>
<td>Clomazol</td>
<td>0.52</td>
<td>20 g</td>
<td>20 g</td>
</tr>
</tbody>
</table>

- Soln 1% – **Restricted**: For continuation only

**ECONAZOLE NITRATE**

- **Restricted**: For continuation only

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foaming soln 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**KETOCONAZOLE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shampoo 2% – 1% DV Dec-14 to 2017</td>
<td>Sebizole</td>
<td>2.99</td>
<td>100 ml</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

**METRONIDAZOLE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 0.75%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MICONAZOLE NITRATE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 2%</td>
<td>Multichem</td>
<td>0.46</td>
<td>15 g</td>
<td>15 g</td>
</tr>
</tbody>
</table>

- Lotn 2% – **Restricted**: For continuation only

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tinc 2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NYSTATIN**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100,000 u per g</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antiparasitics

**LINDANE [GAMMA BENZENE HEXACHLORIDE]**

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DERMATOLOGICALS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Price</strong> (ex man. excl. GST)</td>
<td><strong>Per</strong></td>
<td><strong>Brand or Generic Manufacturer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MALATHION [MALDISON]</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn 0.5%</td>
<td>4.20</td>
<td>30 g</td>
<td>Lyderm</td>
<td></td>
</tr>
<tr>
<td>Shampoo 1%</td>
<td>3.19</td>
<td>30 ml</td>
<td>A-Scabies</td>
<td></td>
</tr>
</tbody>
</table>

| **MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE** |
| Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2% |
| Note: Temporary listing to cover out-of-stock. |

| **PERMETHRIN** |
| Crm 5% | 4.20 | 30 g | Lyderm |
| Lotn 5% – 1% DV Sep-14 to 2017 | 3.19 | 30 ml | A-Scabies |

| **Antiacne Preparations** |
| **ADAPALENE** |
| Crm 0.1% | 1.77 | 100 g | Pharmacy Health |
| Gel 0.1% | 13.45 | 2,000 ml | PSM |

| **BENZOYL PEROXIDE** |
| Soln 5% | 18.71 | 120 | Oratane |

| **ISOTRETINOIN** |
| Cap 10 mg – 1% DV Jan-13 to 2015 | 1.77 | 100 g | Pharmacy Health |
| Cap 20 mg – 1% DV Jan-13 to 2015 | 13.45 | 2,000 ml | PSM |

| **TRETINOIN** |
| Crm 0.05% | 3.48 | 20 g | Itch-Soothe |

| **Antipruritic Preparations** |
| **CALAMINE** |
| Crm, aqueous, BP – 1% DV Mar-13 to 2015 | 1.77 | 100 g | Pharmacy Health |
| Lotn, BP – 1% DV Nov-12 to 2015 | 13.45 | 2,000 ml | PSM |

| **CROTAMITON** |
| Crm 10% – 1% DV Sep-12 to 2015 | 3.48 | 20 g | Itch-Soothe |

| **Barrier Creams and Emollients** |
| **Barrier Creams** |

| **DIMETHICONE** |
| Crm 5% tube – 1% DV Apr-14 to 2016 | 1.65 | 100 g | healthE Dimethicone 5% |
| Crm 5% pump bottle – 1% DV Apr-14 to 2016 | 4.73 | 500 ml | healthE Dimethicone 5% |

| **ZINC** |
| Crm | e.g. Zinc Cream (Orion); Zinc Cream (PSM) |
| Oint | e.g. Zinc oxide (PSM) |
| Paste |

| **ZINC AND CASTOR OIL** |
| Crm | 1.63 | 20 g | Orion |
| Oint, BP |
## Emollients

**AQUEOUS CREAM**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 100 g</td>
<td>1.23</td>
<td>AFT</td>
</tr>
<tr>
<td>Crm 500 g</td>
<td>1.96</td>
<td>AFT</td>
</tr>
</tbody>
</table>

Note: DV limit applies to the pack sizes of 100 g or less.

**CETOMACROGOL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm BP, 500 g</td>
<td>3.50</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>Crm BP, 100 g</td>
<td>1.65</td>
<td>healthE</td>
</tr>
</tbody>
</table>

**CETOMACROGOL WITH GLYCEROL**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 500 ml)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 90% with glycerol 10%</td>
<td>2.10</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td></td>
<td>2.00</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td></td>
<td>3.20</td>
<td>healthE</td>
</tr>
<tr>
<td>Crm 90% with glycerol 10%</td>
<td>4.50</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
</tr>
<tr>
<td></td>
<td>6.50</td>
<td>Pharmacy Health Sorbolene with Glycerin</td>
</tr>
</tbody>
</table>

**EMULSIFYING OINTMENT**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint BP</td>
<td>1.95</td>
<td>Jaychem</td>
</tr>
<tr>
<td>Oint BP, 500 g</td>
<td>3.04</td>
<td>AFT</td>
</tr>
</tbody>
</table>

Note: DV limit applies to pack sizes of greater than 100 g.

**GLYCEROL WITH PARAFFIN**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%</td>
<td>1.60</td>
<td>healthE Fatty Cream</td>
</tr>
</tbody>
</table>

**OIL IN WATER EMULSION**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 2% for 500 ml)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm – 1% DV Dec-12 to 2015</td>
<td>2.63</td>
<td>healthE Fatty Cream</td>
</tr>
<tr>
<td>Crm, 100 g</td>
<td>1.60</td>
<td>healthE Fatty Cream</td>
</tr>
</tbody>
</table>

**PARAFFIN**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint liquid paraffin 50% with white soft paraffin 50%</td>
<td>3.10</td>
<td>healthE</td>
</tr>
<tr>
<td>White soft – 1% DV Feb-13 to 2015</td>
<td>0.92</td>
<td>healthE</td>
</tr>
</tbody>
</table>

Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.

**PARAFFIN WITH WOOL FAT**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lotn liquid paraffin 15.9% with wool fat 0.6%</td>
<td>e.g. AlphaKeri; BK; DP; Hydroderm Lotn</td>
<td></td>
</tr>
<tr>
<td>Lotn liquid paraffin 91.7% with wool fat 3%</td>
<td>e.g. Alpha Keri Bath Oil</td>
<td></td>
</tr>
</tbody>
</table>

**UREA**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per 100 g)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 10%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WOOL FAT**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (Per Crm)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Corticosteroids

<table>
<thead>
<tr>
<th>Substance</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BETAMETHASONE DIPROPIONATE</td>
<td>Crm 0.05%</td>
<td>$3.68 30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td></td>
<td>Oint 0.05%</td>
<td>$3.68 30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE</td>
<td>Crm 0.1%</td>
<td>$3.68 30 g</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oint 0.1%</td>
<td>$3.68 30 g</td>
<td></td>
</tr>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>Crm 0.05%</td>
<td>$3.68 30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td></td>
<td>Oint 0.05%</td>
<td>$3.68 30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td>CLOBETASONE BUTYRATE</td>
<td>Crm 0.05%</td>
<td>$3.68 30 g</td>
<td></td>
</tr>
<tr>
<td>DIFLUCORTOLONE VALERATE – Restricted: For continuation only</td>
<td>Crm 0.1%</td>
<td>$3.68 30 g</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatty oint 0.1%</td>
<td>$3.68 30 g</td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE</td>
<td>Crm 1%, 100 g</td>
<td>$3.75 100 g</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td></td>
<td>Crm 1%, 500 g</td>
<td>$14.00 500 g</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td></td>
<td>Note: DV limit applies to the pack sizes of greater than 100 g.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE ACETATE</td>
<td>Crm 1%</td>
<td>$2.48 14.2 g</td>
<td>AFT</td>
</tr>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td>Crm 0.1% – 1% DV Mar-13 to 2015</td>
<td>$2.30 30 g</td>
<td>Locoid Lipocream</td>
</tr>
<tr>
<td></td>
<td>Oint 0.1% – 1% DV Mar-13 to 2015</td>
<td>$6.85 100 g</td>
<td>Locoid Lipocream</td>
</tr>
<tr>
<td></td>
<td>Milky emul 0.1% – 1% DV Mar-13 to 2015</td>
<td>$6.85 100 g</td>
<td>Locoid Crelo</td>
</tr>
<tr>
<td>HYDROCORTISONE WITH PARAFFIN AND WOOL FAT</td>
<td>Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%</td>
<td>$10.57 250 ml</td>
<td>DP Lotn HC</td>
</tr>
<tr>
<td>HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL</td>
<td>Lotn 1% with wool fat hydrous 3% and mineral oil – 1% DV Dec-14 to 2017</td>
<td>$10.57 250 ml</td>
<td>DP Lotn HC</td>
</tr>
<tr>
<td>METHYLPREDNISOLONE ACEPONATE</td>
<td>Crm 0.1%</td>
<td>$4.95 15 g</td>
<td>Advantan</td>
</tr>
<tr>
<td></td>
<td>Oint 0.1%</td>
<td>$4.95 15 g</td>
<td>Advantan</td>
</tr>
<tr>
<td>MOMETASONE FUROATE</td>
<td>Crm 0.1% – 1% DV Sep-12 to 2015</td>
<td>$1.78 15 g</td>
<td>m-Mometasone</td>
</tr>
<tr>
<td></td>
<td>Oint 0.1% – 1% DV Sep-12 to 2015</td>
<td>$3.42 45 g</td>
<td>m-Mometasone</td>
</tr>
<tr>
<td></td>
<td>Lotn 0.1%</td>
<td>$1.78 15 g</td>
<td>m-Mometasone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$3.42 45 g</td>
<td>m-Mometasone</td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE</td>
<td>Crm 0.02%</td>
<td>$6.63 100 g</td>
<td>Aristocort</td>
</tr>
<tr>
<td></td>
<td>Oint 0.02%</td>
<td>$6.69 100 g</td>
<td>Aristocort</td>
</tr>
</tbody>
</table>

*Item restricted (see ➯ above); Item restricted (see ➯ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids with Anti-Infective Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE WITH CLIQUINOL – <strong>Restricted</strong> see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% with clioquinol 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Either:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 For the treatment of intertrigo; or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 For continuation use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE WITH FUSIDIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% with fusidic acid 2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE WITH MICAZOLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1% with miconazole nitrate 2%</td>
<td>2.20</td>
<td>15 g Micreme H</td>
</tr>
<tr>
<td>HYDROCORTISONE WITH NATAMYCIN AND NEOYMYCIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>2.79</td>
<td>15 g Pimafucort</td>
</tr>
<tr>
<td>Oint 1% with natamycin 1% and neomycin sulphate 0.5%</td>
<td>2.79</td>
<td>15 g Pimafucort</td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE WITH NEOYMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gramicidin 250 mcg per g</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Psoriasis and Eczema Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACITRETIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg – 1% <strong>DV Nov-14 to 2017</strong></td>
<td>17.86</td>
<td>60 Novatretin</td>
</tr>
<tr>
<td>Cap 25 mg – 1% <strong>DV Nov-14 to 2017</strong></td>
<td>41.36</td>
<td>60 Novatretin</td>
</tr>
<tr>
<td>BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 500 mcg with calcipotriol 50 mcg per g</td>
<td>26.12</td>
<td>30 g Daivobet</td>
</tr>
<tr>
<td>Oint 500 mcg with calcipotriol 50 mcg per g</td>
<td>26.12</td>
<td>30 g Daivobet</td>
</tr>
<tr>
<td>CALCIPOTRIOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 50 mcg per g</td>
<td>45.00</td>
<td>100 g Daivonex</td>
</tr>
<tr>
<td>Oint 50 mcg per g</td>
<td>45.00</td>
<td>100 g Daivonex</td>
</tr>
<tr>
<td>Soln 50 mcg per ml</td>
<td>16.00</td>
<td>30 ml Daivonex</td>
</tr>
<tr>
<td>COAL TAR WITH SALICYLIC ACID AND SULPHUR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 12% with salicylic acid 2% and sulphur 4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COAL TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</td>
<td>3.36</td>
<td>500 ml Pinetarsol</td>
</tr>
<tr>
<td></td>
<td>5.82</td>
<td>1,000 ml Pinetarsol</td>
</tr>
<tr>
<td>METHOXSALEN [8-METHOXYPSORALEN]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn 1.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POTASSIUM PERMANGANATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Scalp Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scalp app 0.1%</td>
<td>7.75</td>
<td>100 ml Beta Scalp</td>
</tr>
</tbody>
</table>
### DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Item</th>
<th>Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>Dermol</td>
<td>$6.96</td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td>Locoid</td>
<td>$3.65</td>
<td></td>
</tr>
</tbody>
</table>

### Wart Preparations

**IMIQUIMOD – Restricted** see terms below

- Crm 5%, 250 mg sachet: $62.00
- ** Restricted

Any of the following:
1. The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
2. The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
3. The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

**Notes:**

**Superficial basal cell carcinoma**
- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.
- Every effort should be made to biopsy the lesion to confirm that it is a superficial basal cell carcinoma.

**External anogenital warts**
- Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

**PODOPHYLLOTOXIN**

- Soln 0.5%: $33.60

**SILVER NITRATE**

- Sticks with applicator

### Other Skin Preparations

**DIPHEMANIL METILSULFATE**

- Powder 2%

**SUNSCREEN, PROPRIETARY**

- Crm Lotn: $3.30
- 5.10

**Antineoplastics**

**FLUOROURACIL SODIUM**

- Crm 5% – 1% DV Feb-13 to 2015: $25.16

**METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted** see terms below

- Crm 16%

- **Restricted

Dermatologist or plastic surgeon
## Wound Management Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CALCIUM GLUCONATE</strong></td>
<td>21.00</td>
<td>1 healthE</td>
</tr>
<tr>
<td>Gel 2.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Anti-Infective Agents

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ricinoleic acid 0.75% with applicator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cmr 1% – 1% DV Oct-12 to 2015</td>
<td>1.24</td>
<td>healthE</td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lotn 1%, 200 ml</td>
<td>6.75</td>
<td>healthE</td>
</tr>
<tr>
<td>CLOTRIMAZOLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal crm 1% with applicator – 1% DV Dec-13 to 2016</td>
<td>1.45</td>
<td>Clomazol</td>
</tr>
<tr>
<td>Vaginal crm 2% with applicator – 1% DV Dec-13 to 2016</td>
<td>2.20</td>
<td>Clomazol</td>
</tr>
<tr>
<td>MICONAZOLE NITRATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal crm 2% with applicator – 1% DV Oct-14 to 2017</td>
<td>3.95</td>
<td>Micreme</td>
</tr>
<tr>
<td>NYSTATIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal crm 100,000 u per 5 g with applicator(s)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antiandrogen Oral Contraceptives

#### CYPROTERONE ACETATE WITH ETHINYLESTRADIOL

- Tab 2 mg with ethinylestradiol 35 mcg and 7 inert tablets – 1% DV Dec-14 to 2017
  - Price: 5.36
  - Brand: Ginet

### Combined Oral Contraceptives

#### ETHINYLESTRADIOL WITH DESOGESTREL

- Tab 20 mcg with desogestrel 150 mcg
- Tab 30 mcg with desogestrel 150 mcg

#### ETHINYLESTRADIOL WITH LEVONORGESTREL

- Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets
  - Price: 2.65
  - Brand: Ava 20 ED
- Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets
  - Price: 2.30
  - Brand: Ava 30 ED
- Tab 20 mcg with levonorgestrel 100 mcg
- Tab 30 mcg with levonorgestrel 150 mcg
- Tab 50 mcg with levonorgestrel 125 mcg
  - Price: 9.45
  - Brand: Microgynon 50 ED

#### ETHINYLESTRADIOL WITH NORETHISTERONE

- Tab 35 mcg with norethisterone 1 mg
- Tab 35 mcg with norethisterone 500 mcg

#### NORETHISTERONE WITH MESTRANOL

- Tab 1 mg with mestranol 50 mcg
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

### GENITO-URINARY SYSTEM

#### Contraceptive Devices

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**INTRA-UTERINE DEVICE**

- IUD 29.1 mm length × 23.2 mm width ........................................................... 31.60 1 Choice TT380 Short MiniTT380 Slimline
- IUD 33.6 mm length × 29.9 mm width ........................................................... 31.60 1 Choice TT380 Standard TT380 Slimline

(MiniTT380 Slimline IUD 29.1 mm length × 23.2 mm width to be delisted 1 April 2015)

(TT380 Slimline IUD 33.6 mm length × 29.9 mm width to be delisted 1 April 2015)

#### Emergency Contraception

**LEVONORGESTREL**

- Tab 1.5 mg – 1% DV Jul-13 to 2016 ............................................................... 3.50 1 **Postinor-1**

#### Progestogen-Only Contraceptives

**LEVONORGESTREL**

- Tab 30 mcg
- Implant 75 mg – 5% DV Oct-14 to 31 Dec 2017 ............................................... 133.65 1 **Jadelle**

- Intra-uterine system, 20 mcg per day
- **Restricted**

Obstetrician or gynaecologist

**Initiation – heavy menstrual bleeding**

All of the following:

1. The patient has a clinical diagnosis of heavy menstrual bleeding; and
2. The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
3. Any of the following:
   3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or
   3.2 Haemoglobin level < 120 g/l; or
   3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.

**Continuation – heavy menstrual bleeding**

Either:

1. Patient demonstrated clinical improvement of heavy menstrual bleeding; or
2. Previous insertion was removed or expelled within 3 months of insertion.

**Initiation – endometriosis**

The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.

**Continuation – endometriosis**

Either:

1. Patient demonstrated satisfactory management of endometriosis; or
2. Previous insertion was removed or expelled within 3 months of insertion.

Note: endometriosis is an unregistered indication.

**MEDROXYPROGESTERONE ACETATE**

- Inj 150 mg per ml, 1 ml syringe – 1% DV Sep-13 to 2016 ................................ 7.00 1 **Depo-Provera**

**NORETHISTERONE**

- Tab 350 mcg
<table>
<thead>
<tr>
<th>GENITO-URINARY SYSTEM</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Obstetric Preparations

#### Antiprogestogens

MIFEPRISTONE
Tab 200 mg

#### Oxytocics

CARBOPROST TROMETAMOL
Inj 250 mcg per ml, 1 ml ampoule

DINOPROSTONE
Pessaries 10 mg
Gel 1 mg in 2.5 ml .................................................................52.65 1 Prostin E2
Gel 2 mg in 2.5 ml .................................................................64.60 1 Prostin E2

ERGOMETRINE MALEATE
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 ................94.70 5 DBL Ergometrine

OXYTOCIN
Inj 5 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015 ............................4.75 5 Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule – 1% DV Feb-14 to 2015 ...........................5.98 5 BNM

OXYTOCIN WITH ERGOMETRINE MALEATE
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1%
DV Oct-12 to 2015 ................................................................. 11.13 5 Syntometrine

#### Tocolytics

PROGESTERONE – Restricted see terms below

- Cap 100 mg ...............................................................................16.50 30 Utrogestan

- Restricted

Obstetrician or gynaecologist
Both:
1. For the prevention of pre-term labour*; and
2. Either:
   2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks) or
   2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1).

TERBUTALINE – Restricted see terms below

- Inj 500 mcg ampoule

- Restricted

Obstetrician

#### Oestrogens

OESTRIOL
Crm 1 mg per g with applicator
Pessaries 500 mcg

---

<table>
<thead>
<tr>
<th>Item restricted (see ➤ above); ➤ Item restricted (see ➤ below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Brand indicates brand example only. It is not a contracted product.</td>
</tr>
</tbody>
</table>
## GENITO-URINARY SYSTEM

### Urologicals

#### 5-Alpha Reductase Inhibitors

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $ per Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Finpro</strong></td>
<td>1.95 28</td>
</tr>
<tr>
<td><strong>Rex Medical</strong></td>
<td>5.10 30</td>
</tr>
</tbody>
</table>

**FINASTERIDE – Restricted** see terms below

- **Tab 5 mg** – 1% DV Dec-14 to 2017 .................................................. 1.95 28
- **Tab 5 mg** – 1% DV Dec-14 to 2017 .................................................. 5.10 30

*(Rex Medical Tab 5 mg to be delisted 1 December 2014)*

- **Restricted**
  - **Both:**
    1. Patient has symptomatic benign prostatic hyperplasia; and
    2. Either:
      2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
      2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

#### Alpha-1A Adrenoceptor Blockers

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $ per Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tamsulosin-Rex</strong></td>
<td>13.51 100</td>
</tr>
</tbody>
</table>

**TAMSULOSIN – Restricted** see terms below

- **Cap 400 mcg** – 1% DV Dec-13 to 2016 ........................................ 13.51 100

- **Restricted**
  - **Both:**
    1. Patient has symptomatic benign prostatic hyperplasia; and
    2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

#### Urinary Alkalisers

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST) $ per Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biomed</strong></td>
<td>30.00 200 ml</td>
</tr>
<tr>
<td><strong>Ural</strong></td>
<td>3.93 28</td>
</tr>
</tbody>
</table>

**POTASSIUM CITRATE – Restricted** see terms below

- **Oral liq 3 mmol per ml** ............................................................. 30.00 200 ml

- **Restricted**
  - **Both:**
    1. The patient has recurrent calcium oxalate urolithiasis; and
    2. The patient has had more than two renal calculi in the two years prior to the application.

**SODIUM CITRO-TARTRATE**

- **Grans eff 4 g sachets** ............................................................... 3.93 28

#### Urinary Antispasmodics

**OXYBUTYNNIN**

- **Tab 5 mg** – 1% DV Jun-13 to 2016 ................................................. 11.20 500
- **Oral liq 5 mg per 5 ml** – 1% DV Jun-13 to 2016 ................................ 56.45 473 ml

**SOLIFENACIN SUCCINATE – Restricted** see terms below

- **Tab 5 mg** ............................................................... 56.50 30
- **Tab 10 mg** ............................................................ 56.50 30

- **Restricted**
  - **Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.**

**TOLTERODINE TARTRATE – Restricted** see terms below

- **Tab 1 mg** ............................................................... 14.56 56
- **Tab 2 mg** ............................................................... 14.56 56

- **Restricted**
  - **Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.**

---

**Products with Hospital Supply Status (HSS) are in bold**

**Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.**
## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
<th>Item restricted (see above); Item restricted (see below)</th>
</tr>
</thead>
</table>

### Anabolic Agents

**OXANDROLONE**
- Tab 2.5 mg
  - Restricted
  For the treatment of burns patients.

### Androgen Agonists and Antagonists

**CYPROTERONE ACETATE**
- Tab 50 mg – 1% DV Oct-12 to 2015 ........................................ 18.80  50  Siterone
- Tab 100 mg – 1% DV Oct-12 to 2015 .................................... 34.25  50  Siterone

**TESTOSTERONE**
- Patch 2.5 mg per day ..................................................... 80.00  60  Androderm

**TESTOSTERONE CYPIONATE**
- Inj 100 mg per ml, 10 ml vial – 1% DV Sep-14 to 2017 ........... 76.50  1  Depo-Testosterone

**TESTOSTERONE ESTERS**
- Inj testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule

**TESTOSTERONE UNDECANOATE**
- Cap 40 mg – 1% DV Oct-12 to 2015 .................................... 31.17  60  Andriol Testocaps
- Inj 250 mg per ml, 4 ml ampoule ....................................... 86.00  1  Reandron 1000

### Calcium Homeostasis

**CALCITONIN**
- Inj 100 iu per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 ........ 121.00  5  Miacalcic

**ZOLEDRONIC ACID**
- Inj 0.8 mg per ml, 5 ml vial ............................................. 550.00  1  Zometa
  - Restricted
  For hypercalcaemia of malignancy

### Corticosteroids

**BETAMETHASONE**
- Tab 500 mcg
- Inj 4 mg per ml, 1 ml ampoule

**BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE**
- Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

**DEXAMETHASONE**
- Tab 1 mg – 1% DV Aug-12 to 2015 .................................... 5.87  100  Douglas
- Tab 4 mg – 1% DV Aug-12 to 2015 .................................... 8.16  100  Douglas
- Oral liq 1 mg per ml ..................................................... 45.00  25 ml  Biomed

**DEXAMETHASONE PHOSPHATE**
- Inj 4 mg per ml, 1 ml ampoule – 1% DV Apr-14 to 2016 .......... 25.80  10  Dexamethasone-hamein
- Inj 4 mg per ml, 2 ml ampoule – 1% DV Apr-14 to 2016 .......... 17.98  5  Dexamethasone-hamein

---

*e.g. Brand* indicates brand example only. It is not a contracted product.
## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUDROCORTISONE ACETATE</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mcg</td>
<td>14.32</td>
</tr>
<tr>
<td></td>
<td>100 Florinef</td>
</tr>
<tr>
<td>HYDROCORTISONE</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Nov-12 to 2015</td>
<td>8.10</td>
</tr>
<tr>
<td></td>
<td>100 Douglas</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Nov-12 to 2015</td>
<td>20.32</td>
</tr>
<tr>
<td></td>
<td>100 Douglas</td>
</tr>
<tr>
<td>Inj 100 mg vial – 1% DV Oct-13 to 2016</td>
<td>4.99</td>
</tr>
<tr>
<td></td>
<td>1 Solu-Cortef</td>
</tr>
<tr>
<td>METHYLPREDNISOLONE (AS SODIUM SUCCINATE)</td>
<td></td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Oct-12 to 2015</td>
<td>60.00</td>
</tr>
<tr>
<td></td>
<td>100 Medrol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-12 to 2015</td>
<td>166.52</td>
</tr>
<tr>
<td></td>
<td>20 Medrol</td>
</tr>
<tr>
<td>Inj 40 mg vial – 1% DV Oct-12 to 2015</td>
<td>7.50</td>
</tr>
<tr>
<td></td>
<td>1 Solu-Medrol</td>
</tr>
<tr>
<td>Inj 125 mg vial – 1% DV Oct-12 to 2015</td>
<td>18.50</td>
</tr>
<tr>
<td></td>
<td>1 Solu-Medrol</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Oct-12 to 2015</td>
<td>18.00</td>
</tr>
<tr>
<td></td>
<td>1 Solu-Medrol</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-12 to 2015</td>
<td>37.50</td>
</tr>
<tr>
<td></td>
<td>1 Solu-Medrol</td>
</tr>
<tr>
<td>METHYLPREDNISOLONE ACETATE</td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015</td>
<td>33.50</td>
</tr>
<tr>
<td></td>
<td>5 Depo-Medrol</td>
</tr>
<tr>
<td>METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE</td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg with lignocaine 10 mg per ml, 1 ml vial – 1% DV Oct-12 to 2015</td>
<td>7.50</td>
</tr>
<tr>
<td></td>
<td>1 Depo-Medrol with Lidocaine</td>
</tr>
<tr>
<td>PREDNISOLONE</td>
<td></td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>10.45</td>
</tr>
<tr>
<td></td>
<td>30 ml Redipred</td>
</tr>
<tr>
<td>Enema 200 mcg per ml, 100 ml</td>
<td></td>
</tr>
<tr>
<td>PREDNISONE</td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg</td>
<td>2.13</td>
</tr>
<tr>
<td></td>
<td>100 Apo-Prednisone S29</td>
</tr>
<tr>
<td></td>
<td>10.68</td>
</tr>
<tr>
<td></td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
<td>12.09</td>
</tr>
<tr>
<td></td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>11.09</td>
</tr>
<tr>
<td></td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>29.03</td>
</tr>
<tr>
<td></td>
<td>500 Apo-Prednisone</td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE</td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>21.90</td>
</tr>
<tr>
<td></td>
<td>5 Kenacort-A</td>
</tr>
<tr>
<td>Inj 40 mg per ml, 1 ml ampoule</td>
<td>53.79</td>
</tr>
<tr>
<td></td>
<td>5 Kenacort-A40</td>
</tr>
<tr>
<td>TRIAMCINOLONE HEXACETONIDE</td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 1 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

### Hormone Replacement Therapy

#### Oestrogens

**OESTRADIOL**

<table>
<thead>
<tr>
<th>Tab 1 mg</th>
<th>Tab 2 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 25 mcg per day</td>
<td>Patch 50 mcg per day</td>
</tr>
<tr>
<td>Patch 100 mcg per day</td>
<td></td>
</tr>
</tbody>
</table>

**OESTRADIOL VALERATE**

<table>
<thead>
<tr>
<th>Tab 1 mg</th>
<th>Tab 2 mg</th>
</tr>
</thead>
</table>

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
OESTROGENS (CONJUGATED EQUINE)
- Tab 300 mcg
- Tab 625 mcg

Progestogen and Oestrogen Combined Preparations

OESTRADIOl WITH NORETHISTERONE ACETATE
- Tab 1 mg with 0.5 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate
- Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)

OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
- Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
- Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

Progestogens

MEDROXYPROGESTERONE ACETATE
- Tab 2.5 mg – 1% DV Sep-13 to 2016
  - $3.09 30
  - Provera
- Tab 5 mg – 1% DV Sep-13 to 2016
  - $13.06 100
  - Provera
- Tab 10 mg – 1% DV Sep-13 to 2016
  - $6.85 30
  - Provera

Other Endocrine Agents

CABERGOLINE – Restricted see terms below
- Tab 0.5 mg – 1% DV Sep-12 to 2015
  - $6.25 2
  - $25.00 8
  - Dostinex

Restricted
Any of the following:
1. Inhibition of lactation; or
2. Patient has pathological hyperprolactinemia; or
3. Patient has acromegaly.

CLOMIPHENE CITRATE
- Tab 50 mg – 1% DV Sep-13 to 2016
  - $29.84 10
  - Serophene

DANAZOL
- Cap 100 mg
  - $68.33 100
  - Azol
- Cap 200 mg
  - $97.83 100
  - Azol

GESTRINONE
- Cap 2.5 mg

METYRAPONE
- Cap 250 mg

PENTAGASTRIN
- Inj 250 mcg per ml, 2 ml ampoule

Other Oestrogen Preparations

ETHINYLOESTRADIOL
- Tab 10 mcg
**Other Progestogen Preparations**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDROXYPROGESTERONE</td>
<td>Tab 100 mg – 1% DV Sep-13 to 2016</td>
<td>96.50</td>
<td>Provera</td>
<td></td>
</tr>
<tr>
<td>NORETHISTERONE</td>
<td>Tab 5 mg</td>
<td>26.50</td>
<td>Primolut N</td>
<td></td>
</tr>
</tbody>
</table>

**Pituitary and Hypothalamic Hormones and Analogues**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORTICOTRORELIN (OVINE)</td>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THYROTROPIN ALFA</td>
<td>Inj 900 mcg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Adrenocorticotropic Hormones**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>TETRACOSACTIDT [TETRACOSACTRIN]</td>
<td>Inj 250 mcg per ml, 1 ml ampoule</td>
<td>177.18</td>
<td>Synacthen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 1 mcg per ml, 1 ml ampoule</td>
<td>29.56</td>
<td>Synacthen Depot</td>
<td></td>
</tr>
</tbody>
</table>

**GnRH Agonists and Antagonists**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUSERELIN</td>
<td>Inj 1 mg per ml, 5.5 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GONADORELIN</td>
<td>Inj 100 mcg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOSERELIN</td>
<td>Implant 3.6 mg</td>
<td>166.20</td>
<td>Zoladex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Implant 10.8 mg</td>
<td>443.76</td>
<td>Zoladex</td>
<td></td>
</tr>
<tr>
<td>LEUPRORELIN ACETATE</td>
<td>Inj 3.75 mg syringe</td>
<td>221.60</td>
<td>Lucrin Depot PDS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 7.5 mg syringe</td>
<td>166.20</td>
<td>Eligard</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 11.25 mg syringe</td>
<td>591.68</td>
<td>Lucrin Depot PDS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 22.5 mg syringe</td>
<td>443.76</td>
<td>Eligard</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 30 mg syringe</td>
<td>1,109.40</td>
<td>Lucrin Depot PDS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 30 mg vial</td>
<td>591.68</td>
<td>Eligard</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 45 mg syringe</td>
<td>832.05</td>
<td>Eligard</td>
<td></td>
</tr>
</tbody>
</table>

**Gonadotrophins**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand</th>
<th>Expiry Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHORIOGONADOTROPIN ALFA</td>
<td>Inj 250 mcg in 0.5 ml syringe</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Growth Hormone

**SOMATROPIN – Restricted** see terms below

| Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 | $109.50 | 1 | Omnitrope |
| Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 | $219.00 | 1 | Omnitrope |
| Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017 | $328.50 | 1 | Omnitrope |

*Inj 16 iu (5.3 mg) vial*

*Inj 36 iu (12 mg) vial*

*(Any Inj 16 iu (5.3 mg) vial to be delisted 1 January 2015)*

*(Any Inj 36 iu (12 mg) vial to be delisted 1 January 2015)*

---

**Initiation - growth hormone deficiency in children**

**Endocrinologist**

**Paediatric Endocrinologist**

**Either:**

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2. All of the following:
   1.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
   1.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
   1.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
   1.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
   1.5 Appropriate imaging of the pituitary gland has been obtained.

**Continuation - growth hormone deficiency in children**

**Endocrinologist**

**Paediatric Endocrinologist**

**Re-assessment required after 12 months**

All of the following:

1. A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
2. Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
3. Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
4. No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed since starting growth hormone.

**Initiation - Turner syndrome**

**Endocrinologist**

**Paediatric Endocrinologist**

All of the following:

1. The patient has a post-natal genotype confirming Turner Syndrome; and
2. Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is < 14 years.

continued...
Continuation - Turner syndrome
Endocrinologist
Paediatric Endocrinologist
Re-assessment required after 12 months
All of the following:
1. Height velocity $\geq$ 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and
2. Height velocity is $\geq$ 2 cm per year, calculated over six months; and
3. A current bone age is $\leq$ 14 years; and
4. No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency
Endocrinologist
Paediatric Endocrinologist
All of the following:
1. The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
2. Height velocity is $< 25$th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is $<14$ years (female patients) or $<16$ years (male patients); and
4. The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency
Endocrinologist
Paediatric Endocrinologist
Re-assessment required after 12 months
All of the following:
1. Height velocity is $\geq$ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is $\geq$ 2 cm per year as calculated over six months; and
3. Current bone age is $\leq$ 14 years (female patients) or $\leq$ 16 years (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation - short stature due to chronic renal insufficiency
Endocrinologist
Paediatric Endocrinologist
Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist
All of the following:
1. The patient’s height is more than 2 standard deviations below the mean; and
2. Height velocity is $< 25$th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is $\leq$ to 14 years (female patients) or $\leq$ to 16 years (male patients); and
4. The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5. The patient is under the supervision of a specialist with expertise in renal medicine; and
6. Either:

continued...
6.1 The patient has a GFR ≤ 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or

6.2 The patient has received a renal transplant and has received < 5mg/ m² /day of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist
Paediatric Endocrinologist
Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

Re-assessment required after 12 months

All of the following:

1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and

2 Height velocity is ≥ 2 cm per year as calculated over six months; and

3 A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and

4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and

5 No malignancy has developed after growth hormone therapy was commenced; and

6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and

7 The patient has not received renal transplantation since starting growth hormone treatment; and

8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation - Prader-Willi syndrome

Endocrinologist
Paediatric Endocrinologist

All of the following:

1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and

2 The patient's height velocity is < 25th percentile for bone age adjusted for bone age/pubertal status if appropriate as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) or pubertal status over 6 to 12 months; and

3 Either:
   3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or
   3.2 The patient is aged two years or older; and

4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and

5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and

6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Continuation - Prader-Willi syndrome

Endocrinologist
Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and

continued...
continued...

2 Height velocity is \( \geq \) 2 cm per year as calculated over six months; and
3 A current bone age is \( \leq \) 14 years (female patients) or \( \leq \) 16 years (male patients); and
4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5 No malignancy has developed after growth hormone therapy was commenced; and
6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by \( \geq \) 0.5 standard deviations in the preceding 12 months.

**Initiation - adults and adolescents**

Endocrinologist
Paediatric Endocrinologist

All of the following:
1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3 The patient has severe growth hormone deficiency (see notes); and
4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA\textsuperscript{®}).

**Notes:**
For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of \( \leq \) 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test. Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of \( \leq \) 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Continuation - adults and adolescents**

Endocrinologist
Paediatric Endocrinologist

**Re-assessment required after 12 months**

Either:
1 All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA\textsuperscript{®}) score from baseline; and
   1.3 Serum IGF-I levels have increased to within \( \pm 1\text{SD} \) of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or
2 All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA\textsuperscript{®} score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within \( \pm 1\text{SD} \) of the mean of the normal range for age and sex (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.
### Thyroid and Antithyroid Preparations

<table>
<thead>
<tr>
<th><strong>CARBIMAZOLE</strong></th>
<th><strong>Price (ex man. excl. GST)</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **IODINE**       |                                |                                  |
| Soln BP 50 mg per ml |                                |                                  |

| **LEVOTHYROXINE** |                                |                                  |
| Tab 25 mcg       |                                |                                  |
| Tab 50 mcg       |                                |                                  |
| Tab 100 mcg      |                                |                                  |

<table>
<thead>
<tr>
<th><strong>LIOTHYRONINE SODIUM</strong></th>
<th><strong>Price (ex man. excl. GST)</strong></th>
<th><strong>Brand or Generic Manufacturer</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 20 mcg</td>
<td>$36.40</td>
<td>30 PTU</td>
</tr>
</tbody>
</table>

**Restricted**

For a maximum of 14 days’ treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Inj 20 mcg vial

| **POTASSIUM IODATE** |                                |                                  |
| Tab 170 mg          |                                |                                  |

| **POTASSIUM PERCHLORATE** |                                |                                  |
| Cap 200 mg           |                                |                                  |

| **PROPYLETHIOURACIL – Restricted** see terms below | **Price (ex man. excl. GST)** | **Brand or Generic Manufacturer** |
| Tab 50 mg            | $35.00                        | 100 PTU                          |

**Restricted**

Both:

1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

| **PROTIREDIN** |                                |                                  |
| Inj 100 mcg per ml, 2 ml ampoule |                                |                                  |

### Vasopressin Agents

| **ARGIPRESSIN [VASOPRESSIN]** | **Price (ex man. excl. GST)** | **Brand or Generic Manufacturer** |
| Inj 20 u per ml, 1 ml ampoule |                                |                                  |

| **DESMOPRESSIN ACETATE – Some items restricted** see terms below | **Price (ex man. excl. GST)** | **Brand or Generic Manufacturer** |
| Tab 100 mcg          | $36.40                        | 30 Minirin                       |
| Tab 200 mcg          | $93.60                        | 30 Minirin                       |
| Nasal spray 10 mcg per dose – 1% DV Sep-14 to 2017 | $22.95                        | 6 ml Desmopressin-PH&T |
| Inj 4 mcg per ml, 1 ml ampoule |                                |                                  |
| Inj 15 mcg per ml, 1 ml ampoule |                                |                                  |
| Nasal drops 100 mcg per ml |                                |                                  |

**Restricted**

Nocturnal enuresis

Either:

1. The nasal forms of desmopressin are contraindicated; or
2. An enuresis alarm is contraindicated.

Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.
### HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TERLIPRESSIN</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 0.1 mg per ml, 8.5 ml ampoule</td>
<td>450.00 5 Glypressin</td>
</tr>
<tr>
<td>Inj 1 mg vial</td>
<td>450.00 5 Glypressin</td>
</tr>
</tbody>
</table>

*(Glypressin Inj 1 mg vial to be delisted 1 December 2014)*
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Antibacterials</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aminoglycosides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AMIKACIN</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 5 mg per ml, 10 ml syringe</td>
<td>$176.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td>† Inj 5 mg per ml, 5 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 250 mg per ml, 2 ml vial – 1% DV Oct-14 to 2017</td>
<td>$431.20</td>
<td>5 DBL Amikacin</td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease physician, clinical microbiologist or respiratory physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GENTAMICIN SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td>$8.56</td>
<td>5 Hospira</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015</td>
<td>$6.50</td>
<td>10 Pfizer</td>
</tr>
<tr>
<td><strong>PAROMOMYCIN</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 250 mg</td>
<td>$126.00</td>
<td>16 Humatin</td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease physician or clinical microbiologist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STREPTOMYCIN SULPHATE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 400 mg per ml, 2.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease physician, clinical microbiologist or respiratory physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOBRAMYCIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 40 mg per ml, 2 ml vial</td>
<td>$29.32</td>
<td>5 DBL Tobramycin</td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease physician, clinical microbiologist or respiratory physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Inj 100 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious disease physician, clinical microbiologist or respiratory physician</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Solution for inhalation 60 mg per ml, 5 ml</td>
<td>$2,200.00</td>
<td>56 dose TOBI</td>
</tr>
<tr>
<td>→ Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient has cystic fibrosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Carbapenems**

| **ERTAPENEM** – Restricted see terms below | | |
| † Inj 1 g vial | $70.00 | 1 Invanz |
| → Restricted | | |
| Infectious disease physician or clinical microbiologist | | |
| **IMIPENEM WITH CILASTATIN** – Restricted see terms below | | |
| † Inj 500 mg with 500 mg cilastatin vial | $18.37 | 1 Primaxin |
| → Restricted | | |
| Infectious disease physician or clinical microbiologist | | |
| **MEROPENEM** – Restricted see terms below | | |
| † Inj 500 mg vial – 1% DV Oct-14 to 2017 | $35.22 | 10 DBL Meropenem |
| † Inj 1 g vial – 1% DV Oct-14 to 2017 | | |
| → Restricted | | |
| Infectious disease physician or clinical microbiologist | | |

† Item restricted (see → above); † Item restricted (see † below)
e.g. Brand indicates brand example only. It is not a contracted product.
### INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CEFALEXIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFAZOLIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-14 to 2017</td>
<td>3.99</td>
<td>5</td>
<td>AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-14 to 2017</td>
<td>3.38</td>
<td>5</td>
<td>AFT</td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins - 1st Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFALEXIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Oct-13 to 2016</td>
<td>5.70</td>
<td>20</td>
<td>Cefalexin ABM</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-13 to 2016</td>
<td>8.50</td>
<td>100 ml</td>
<td>Cefalexin Sandoz</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-13 to 2016</td>
<td>11.50</td>
<td>100 ml</td>
<td>Cefalexin Sandoz</td>
</tr>
<tr>
<td><strong>CEFAZOLIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-14 to 2017</td>
<td>3.99</td>
<td>5</td>
<td>AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-14 to 2017</td>
<td>3.38</td>
<td>5</td>
<td>AFT</td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins - 2nd Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFACLOR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Dec-13 to 2016</td>
<td>26.00</td>
<td>100</td>
<td>Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Dec-13 to 2016</td>
<td>3.53</td>
<td>100 ml</td>
<td>Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td><strong>CEFOXITIN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>55.00</td>
<td>5</td>
<td>Hospira</td>
</tr>
<tr>
<td><strong>CEFUROXIME</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg</td>
<td>29.40</td>
<td>50</td>
<td>Zinnat</td>
</tr>
<tr>
<td>Inj 750 mg vial – 1% DV Nov-14 to 2017</td>
<td>3.70</td>
<td>5</td>
<td>Zinacef</td>
</tr>
<tr>
<td>Inj 1.5 g vial – 1% DV Nov-14 to 2017</td>
<td>1.30</td>
<td>1</td>
<td>Zinacef</td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins - 3rd Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFOTAXIME</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial</td>
<td>1.90</td>
<td>1</td>
<td>Cefotaxime Sandoz</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-14 to 2017</td>
<td>17.10</td>
<td>10</td>
<td>DBL Cefotaxime</td>
</tr>
<tr>
<td><strong>CEFTAZIDIME – Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Jan-15 to 2017</td>
<td>5.30</td>
<td>1</td>
<td>Fortum</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Jan-15 to 2017</td>
<td>1.55</td>
<td>1</td>
<td>DBL Ceftazidime</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Jan-15 to 2017</td>
<td>3.34</td>
<td>1</td>
<td>Fortum</td>
</tr>
<tr>
<td>6.49</td>
<td></td>
<td></td>
<td>DBL Ceftazidime</td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins - 4th Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFTRIAXONE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(DBL Ceftazidime Inj 1 g vial to be delisted 1 January 2015)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(DBL Ceftazidime Inj 2 g vial to be delisted 1 January 2015)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFTRIAXONE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Mar-14 to 2016</td>
<td>1.50</td>
<td>1</td>
<td>Ceftriaxone-AFT</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Mar-14 to 2016</td>
<td>5.22</td>
<td>5</td>
<td>Ceftriaxone-AFT</td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Mar-14 to 2016</td>
<td>2.75</td>
<td>1</td>
<td>Ceftriaxone-AFT</td>
</tr>
<tr>
<td><strong>Cephalosporins and Cephamycins - 4th Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CEFEPIME – Restricted</strong> see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>8.80</td>
<td>1</td>
<td>DBL Cefepime</td>
</tr>
<tr>
<td>Inj 2 g vial</td>
<td>17.60</td>
<td>1</td>
<td>DBL Cefepime</td>
</tr>
</tbody>
</table>

- **Restricted**
- Infectious disease physician, clinical microbiologist or respiratory physician

---

*Products with Hospital Supply Status (HSS) are in bold*

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
Cephalosporins and Cephamycins - 5th Generation

CEFTAROLINE FOSAMIL – Restricted see terms below

- Inj 600 mg vial ......................................................... 1,450.00 10 Zinforo

Restricted
Infectious disease physician or clinical microbiologist
Multi-resistant organism salvage therapy
Either:
1. for patients where alternative therapies have failed; or
2. for patients who have a contraindication or hypersensitivity to standard current therapies.

Macrolides

AZITHROMYCIN – Restricted see terms below

- Tab 250 mg ................................................................. 10.00 30 Apo-Azithromycin
- Tab 500 mg – 1% DV Feb-13 to 2015 ......................................... 1.25 2 Apo-Azithromycin
- Oral liq 40 mg per ml .................................................. 6.60 15 ml Zithromax

Restricted
Any of the following:
1. Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or
2. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms; or
3. For any other condition for five days' treatment, with review after five days.

CLARITHROMYCIN – Restricted see terms below

- Tab 250 mg – 1% DV Sep-14 to 2017 ........................................... 3.98 14 Apo-Clarithromycin
- Tab 500 mg – 1% DV Sep-14 to 2017 ......................................... 10.40 14 Apo-Clarithromycin
- Grans for oral liq 25 mg per ml ............................................... 23.12 70 ml Klacid
- Inj 500 mg vial ............................................................. 30.00 1 Klacid

Restricted
Tab 250 mg and oral liquid
Tab 250 mg and oral liquid
1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.

Tab 500 mg
Helicobacter pylori eradication.

Infusion
Infusion
1. Atypical mycobacterial infection; or
2. Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3. Community-acquired pneumonia (clarithromycin is not to be used as the first-line macrolide).

ERYTHROMYCIN (AS ETHYL SUCCINATE)

Tab 400 mg ................................................................. 16.95 100 E-Mycin
Grans for oral liq 200 mg per 5 ml ....................................... 4.35 100 ml E-Mycin
Grans for oral liq 400 mg per 5 ml ....................................... 5.85 100 ml E-Mycin

ERYTHROMYCIN (AS LACTOBIONATE)

Inj 1 g vial ................................................................. 16.00 1 Erythrocin IV

ERYTHROMYCIN (AS STEARATE) – Restricted: For continuation only

- Tab 250 mg
- Tab 500 mg

Item restricted (see above); Item restricted (see below)

e.g. Brand indicates brand example only. It is not a contracted product.
## Penicillins

### AMOXICILLIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg – 1% DV Mar-14 to 2016</td>
<td>500 Apo-Amoxi</td>
<td>16.18</td>
<td>500</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Jul-14 to 2016</td>
<td>500 Apo-Amoxi</td>
<td>20.94</td>
<td>500</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Nov-12 to 2015</td>
<td>100 ml Amoxicillin Actavis</td>
<td>0.88</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Ospamox</td>
<td>1.55</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Nov-12 to 2015</td>
<td>100 ml Amoxicillin Actavis</td>
<td>0.97</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Ospamox</td>
<td>1.10</td>
<td></td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Oct-14 to 2017</td>
<td>10 Ibamox</td>
<td>10.67</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Oct-14 to 2017</td>
<td>10 Ibamox</td>
<td>12.41</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Oct-14 to 2017</td>
<td>10 Ibamox</td>
<td>17.29</td>
<td>10</td>
</tr>
</tbody>
</table>

### AMOXICILLIN WITH CLAVULANIC ACID

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg with clavulanic acid 125 mg – 1% DV Nov-14 to 2017</td>
<td>10 Augmentin</td>
<td>1.95</td>
<td>20</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml – 1% DV Nov-12 to 2015</td>
<td>100 ml Augmentin</td>
<td>1.61</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml – 1% DV Nov-12 to 2015</td>
<td>100 ml Augmentin</td>
<td>2.19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Jan-13 to 2015</td>
<td>10 m-Amoxiclav</td>
<td>10.14</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Jan-13 to 2015</td>
<td>10 m-Amoxiclav</td>
<td>14.03</td>
<td>10</td>
</tr>
</tbody>
</table>

### BENZATHINE BENZYL PENICILLIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-12 to 2015</td>
<td>10 Bicillin LA</td>
<td>315.00</td>
<td>10</td>
</tr>
</tbody>
</table>

### BENZYL PENICILLIN SODIUM [PENICILLIN G]

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 600 mg (1 million units) vial – 1% DV Sep-14 to 2017</td>
<td>10 Sandoz</td>
<td>10.35</td>
<td>10</td>
</tr>
</tbody>
</table>

### FLUCLOxacillin

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg – 1% DV Oct-12 to 2015</td>
<td>250 Staphlex</td>
<td>22.00</td>
<td>250</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Oct-12 to 2015</td>
<td>500 Staphlex</td>
<td>74.00</td>
<td>500</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Sep-12 to 2015</td>
<td>100 ml AFT</td>
<td>2.49</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Sep-12 to 2015</td>
<td>100 ml AFT</td>
<td>3.25</td>
<td></td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-14 to 2017</td>
<td>10 Flucloxin</td>
<td>8.80</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-14 to 2017</td>
<td>10 Flucloxin</td>
<td>9.20</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-14 to 2017</td>
<td>10 Flucloxin</td>
<td>11.60</td>
<td>10</td>
</tr>
</tbody>
</table>

### PHENOXYMETHYL PENICILLIN [PENICILLIN V]

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
<td>50 Cilicaine VK</td>
<td>11.99</td>
<td>50</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td>50 Cilicaine VK</td>
<td>14.45</td>
<td>50</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Apr-14 to 2016</td>
<td>100 ml AFT</td>
<td>1.64</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Apr-14 to 2016</td>
<td>100 ml AFT</td>
<td>1.74</td>
<td></td>
</tr>
</tbody>
</table>

### PIPERACILLIN WITH TAZOBACTAM

- **Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4 g with tazobactam 0.5 g vial – 1% DV Oct-13 to 2016</td>
<td>1 Tazocin EF</td>
<td>5.84</td>
<td>1</td>
</tr>
</tbody>
</table>

**Infectious disease physician, clinical microbiologist or respiratory physician**

### PROCAINE PENICILLIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-14 to 2017</td>
<td>5 Cilicaine</td>
<td>123.50</td>
<td>5</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**TICARCILLIN WITH CLAVULANIC ACID** – Restricted see terms below

- Inj 3 g with clavulanic acid 0.1 mg vial

**Quinolones**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**CIPROFLOXACIN** – Restricted see terms below

- Tab 250 mg – 1% DV Sep-14 to 2017 .................................................. 1.75 28 Ciplox
- Tab 500 mg – 1% DV Sep-14 to 2017 .................................................. 2.00 28 Ciplox
- Tab 750 mg – 1% DV Sep-14 to 2017 .................................................. 3.75 28 Ciplox
- Oral liq 50 mg per ml
- Oral liq 100 mg per ml
- Inj 2 mg per ml, 100 ml bag ......................................................... 41.00 10 Aspen Ciprofloxacin

**MOXIFLOXACIN** – Restricted see terms below

- Tab 400 mg ................................................................. 52.00 5 Avelox
- Inj 1.6 mg per ml, 250 ml bag ..................................................... 70.00 1 Avelox IV 400

**Mycobacterium infection**

Infectious disease physician, clinical microbiologist or respiratory physician

1. Active tuberculosis, with any of the following:
   1.1 Documented resistance to one or more first-line medications; or
   1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
   1.3 Impaired visual acuity (considered to preclude ethambutol use); or
   1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
   1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications.

2. Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated

**Pneumonia**

Infectious disease physician or clinical microbiologist

1. Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
2. Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

**Penetrating eye injury**

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury

**Mycoplasma genitalium**

All of the following:

1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and
2. Has tried and failed to clear infection using azithromycin; and
3. Treatment is only for 7 days.

**NORFLOXACIN**

Tab 400 mg – 1% DV Sep-14 to 2017 .................................................. 13.50 100 Arrow-Norfloxacin

**Tetracyclines**

**DEMECLOCYCLINE HYDROCHLORIDE**

Cap 150 mg
DOXYCYCLINE

- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg – 1% DV Sep-14 to 2017 ........................................ 6.75 250 Doxine
  - Inj 5 mg per ml, 20 ml vial

MINOCYCLINE

- Cap 100 mg – **Restricted**: For continuation only

TETRACYCLINE

- Tab 250 mg
  - Cap 500 mg ................................................................. 46.00 30 Tetracyclin Wolff

TIGECYCLINE – **Restricted** see terms below

- Inj 50 mg vial
- **Restricted**
  Infectious disease physician or clinical microbiologist

**Other Antibacterials**

AZTREONAM – **Restricted** see terms below

- Inj 1 g vial ................................................................. 131.00 5 Azactam
- **Restricted**
  Infectious disease physician or clinical microbiologist

CHLORAMPHENICOL – **Restricted** see terms below

- Inj 1 g vial
- **Restricted**
  Infectious disease physician or clinical microbiologist

CLINDAMYCIN – **Restricted** see terms below

- Cap 150 mg – 1% DV Oct-13 to 2016 ........................................ 5.80 16 Clindamycin ABM
  - Oral liq 15 mg per ml
  - Inj 150 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016 ............. 100.00 10 Dalacin C
- **Restricted**
  Infectious disease physician or clinical microbiologist

COLISTIN SULPHOMETHATE [COLESTIMETHATE] – **Restricted** see terms below

- Inj 150 mg per ml, 1 ml vial ............................................... 65.00 1 Colistin-Link
- **Restricted**
  Infectious disease physician, clinical microbiologist or respiratory physician

DAPTOMYCIN – **Restricted** see terms below

- Inj 350 mg vial
- Inj 500 mg vial
- **Restricted**
  Infectious disease physician or clinical microbiologist

FOSFOMYCIN – **Restricted** see terms below

- Powder for oral solution, 3 g sachet
- **Restricted**
  Infectious disease physician or clinical microbiologist

FUSIDIC ACID – **Restricted** see terms below

- Tab 250 mg ................................................................. 34.50 12 Fucidin
- **Restricted**
  Infectious disease physician or clinical microbiologist

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### HEXAMINE HIPPURATE
- **Tab 1 g**

### LINCOMYCIN – Restricted see terms below
- **Inj 300 mg per ml, 2 ml vial**
- **Inj 2 mg per ml, 300 ml bag**

**Infectious disease physician or clinical microbiologist**

### LINEZOLID – Restricted see terms below
- **Tab 600 mg**
- **Oral liq 20 mg per ml**
- **Inj 2 mg per ml, 300 ml bag**

**Infectious disease physician or clinical microbiologist**

### NITROFURANTOIN
- **Tab 50 mg**
- **Tab 100 mg**

### PIVMECILLINAM – Restricted see terms below
- **Tab 200 mg**

**Infectious disease physician or clinical microbiologist**

### SULPHADIAZINE – Restricted see terms below
- **Tab 500 mg**

**Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist**

### TEICOPLANIN – Restricted see terms below
- **Inj 400 mg vial**

**Infectious disease physician or clinical microbiologist**

### TRIMETHOPRIM
- **Tab 100 mg**
- **Tab 300 mg**

- **9.28**

### TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]
- **Tab 80 mg with sulphamethoxazole 400 mg**
- **Oral liq 8 mg with sulphamethoxazole 40 mg per ml**
  - **2.15 100 ml Deprim**
- **Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule**

### VANCOMYCIN – Restricted see terms below
- **Inj 500 mg vial – 1% DV Oct-14 to 2017**
  - **2.64 1 Mylan**

**Infectious disease physician or clinical microbiologist**

### Antifungals

### Imidazoles

### KETOCONAZOLE
- **Tab 200 mg**

**Oncologist**

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*E.g. Brand indicates brand example only. It is not a contracted product.*
Polyene Antimycotics

AMPHOTERICIN B

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3,450.00</td>
<td>10</td>
</tr>
</tbody>
</table>

- **Restricted**
  - Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician
  - Either:
    1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
    2. Both:
      2.1 Possible invasive fungal infection; and
      2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

- **Inj 50 mg vial**

NYSTATIN

<table>
<thead>
<tr>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$17.09</td>
</tr>
</tbody>
</table>

- **Restricted**
  - Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Triazoles

FLUCONAZOLE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.49</td>
</tr>
</tbody>
</table>

- **Cap 50 mg – 1% DV Nov-14 to 2017**
- **Cap 150 mg – 1% DV Nov-14 to 2017**
- **Cap 200 mg – 1% DV Nov-14 to 2017**
- **Oral liquid 50 mg per 5 ml**
- **Inj 2 mg per ml, 50 ml vial – 1% DV Oct-13 to 2016**
- **Inj 2 mg per ml, 100 ml vial – 1% DV Oct-13 to 2016**

- **Restricted**
  - Consultant

ITRACONAZOLE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.99</td>
</tr>
</tbody>
</table>

- **Cap 100 mg – 1% DV Oct-13 to 2016**
- **Oral liquid 10 mg per ml**

- **Restricted**
  - Infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist

POSACONAZOLE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$761.13</td>
</tr>
</tbody>
</table>

- **Oral liq 40 mg per ml**

- **Restricted**
  - Infectious disease physician or haematologist

Initiation

**Re-assessment required after 6 weeks**

Both:

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
2. Patient is to be treated with high dose remission induction therapy or re-induction therapy

Continuation

**Re-assessment required after 6 weeks**

Both:

continued...
continued . . .

1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and

2 Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or
   2.2 Patient is to be treated with high dose consolidation therapy; or
   2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>$730.00</td>
<td>56 Vfend</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>$2,930.00</td>
<td>56 Vfend</td>
</tr>
<tr>
<td>Oral liq 40 mg</td>
<td>$730.00</td>
<td>70 ml Vfend</td>
</tr>
<tr>
<td>Inj 200 mg vial</td>
<td>$185.00</td>
<td>1 Vfend</td>
</tr>
</tbody>
</table>

**Restricted**

Infectious disease physician, clinical microbiologist or haematologist

Proven or probable aspergillus infection

Both:

1. Patient is immunocompromised; and
2. Patient has proven or probable invasive aspergillus infection.

Possible aspergillus infection

All of the following:

1. Patient is immunocompromised; and
2. Patient has possible invasive aspergillus infection; and
3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Resistant candidiasis infections and other moulds

All of the following:

1. Patient is immunocompromised, and
2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or
   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CASPOFUNGIN – Restricted see terms below

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg vial</td>
<td>$667.50</td>
<td>1 Cancidas</td>
</tr>
<tr>
<td>Inj 70 mg vial</td>
<td>$862.50</td>
<td>1 Cancidas</td>
</tr>
</tbody>
</table>

**Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 500 mg</td>
<td>$1.50</td>
<td>14 Dr Reddy’s Terbinafine</td>
</tr>
</tbody>
</table>

**Restricted**

Infectious disease physician or clinical microbiologist.

TERBINAFINE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>$1.50</td>
<td>14 Dr Reddy’s Terbinafine</td>
</tr>
</tbody>
</table>
## Antimycobacterials

### Antileprotics

**CLOFAZIMINE** – Restricted see terms below
- Cap 50 mg

**DAPSONE** – Restricted see terms below
- Tab 25 mg – 1% DV Sep-14 to 2017 ............................................................ 95.00 100 Dapsone
- Tab 100 mg – 1% DV Sep-14 to 2017 ......................................................... 110.00 100 Dapsone

### Antituberculotics

**CYCLOSERINE** – Restricted see terms below
- Cap 250 mg

**ETHAMBUTOL HYDROCHLORIDE** – Restricted see terms below
- Tab 100 mg ..................................................................................................... 48.01 56 Myambutol
- Tab 400 mg ..................................................................................................... 49.34 56 Myambutol

**ISONIAZID** – Restricted see terms below
- Tab 100 mg – 1% DV Mar-13 to 2015 ............................................................ 20.00 100 PSM

**ISONIAZID WITH RIFAMPICIN** – Restricted see terms below
- Tab 100 mg with rifampicin 150 mg
- Tab 150 mg with rifampicin 300 mg

**PARA-AMINOSALICYLIC ACID** – Restricted see terms below
- Grans for oral liq 4 g ..................................................................................... 280.00 30 Paser

**PROTIONAMIDE** – Restricted see terms below
- Tab 250 mg ................................................................................................... 305.00 100 Peteha

**PYRAZINAMIDE** – Restricted see terms below
- Tab 500 mg

**RIFABUTIN** – Restricted see terms on the next page
- Cap 150 mg – 1% DV Sep-13 to 2016 ............................................................ 213.19 30 Mycobutin
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**→ Restricted**

Infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist

**RIFAMPICIN** – **→ Restricted** see terms below

- Tab 600 mg – 1% DV Nov-14 to 2017 ........................................... 108.70 30 Rifadin
- Cap 150 mg – 1% DV Nov-14 to 2017 .......................................... 55.75 100 Rifadin
- Cap 300 mg – 1% DV Nov-14 to 2017 .......................................... 116.25 100 Rifadin
- Oral liq 100 mg per 5 ml – 1% DV Nov-14 to 2017 ...................... 12.00 60 ml Rifadin
- Inv 600 mg vial – 1% DV Nov-14 to 2017 ................................. 128.85 1 Rifadin

**→ Restricted**

Internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician

**Antiparasitics**

**Anthelmintics**

**ALBENDAZOLE** – **→ Restricted** see terms below

- Tab 200 mg
- Tab 400 mg

**→ Restricted**

Infectious disease physician or clinical microbiologist

**IVERMECTIN** – **→ Restricted** see terms below

- Tab 3 mg ....................................................................................... 17.20 4 Stromectol

**→ Restricted**

Infectious disease physician, clinical microbiologist or dermatologist.

**MEBENDAZOLE**

- Tab 100 mg ............................................................................... 24.19 24 De-Worm
- Oral liq 100 mg per 5 ml

**PRAZIQUANTEL**

- Tab 600 mg

**Antiprotozoals**

**ARTEMETHER WITH LUMEFANTRINE** – **→ Restricted** see terms below

- Tab 20 mg with lumefantrine 120 mg

**→ Restricted**

Infectious disease physician or clinical microbiologist

**ARTESUNATE** – **→ Restricted** see terms below

- Inv 60 mg vial

**→ Restricted**

Infectious disease physician or clinical microbiologist

**ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE** – **→ Restricted** see terms below

- Tab 62.5 mg with proguanil hydrochloride 25 mg – 1% DV Nov-14
to 2017 ................................................................................ 25.00 12 Malarone Junior
- Tab 250 mg with proguanil hydrochloride 100 mg – 1% DV Nov-14
to 2017 ................................................................................ 64.00 12 Malarone

**→ Restricted**

Infectious disease physician or clinical microbiologist

**CHLOROQUINE PHOSPHATE** – **→ Restricted** see terms below

- Tab 250 mg

**→ Restricted**

Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEFLOQUINE – Restricted see terms below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Dec-14 to 2017</td>
<td>33.48</td>
<td>8</td>
<td>Lariam</td>
</tr>
</tbody>
</table>

**METRONIDAZOLE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>10.45</td>
<td>100</td>
<td>Trichazole</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>18.15</td>
<td>100</td>
<td>Trichazole</td>
</tr>
<tr>
<td>Oral liq benzoate 200 mg per 5 ml</td>
<td>25.00</td>
<td>100 ml</td>
<td>Flagyl-S</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bag</td>
<td>2.46</td>
<td>1</td>
<td>Baxter</td>
</tr>
<tr>
<td>Suppos 500 mg</td>
<td>12.30</td>
<td>5</td>
<td>AFT</td>
</tr>
</tbody>
</table>

**NITAZOXANIDE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td>1,680.00</td>
<td>30</td>
<td>Alinia</td>
</tr>
</tbody>
</table>

**ORNIDAZOLE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td>16.50</td>
<td>10</td>
<td>Arrow-Ornidazole</td>
</tr>
</tbody>
</table>

**PENTAMIDINE ISETHIONATE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 300 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PRIMAQUINE PHOSPHATE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 7.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PYRIMETHAMINE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**QUININE DIHYDROCHLORIDE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 60 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**QUININE SULPHATE**

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 300 mg</td>
<td>54.06</td>
<td>500</td>
<td>Q 300</td>
</tr>
</tbody>
</table>

**SODIUM STIBOGLUCONATE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SPIRAMYCIN – Restricted** see terms below

<table>
<thead>
<tr>
<th>Description</th>
<th>Price (ex. man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Antiretrovirals

#### HIV Fusion Inhibitors

**ENFUVIRTIDE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Brand</th>
<th>Product</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,380.00</td>
<td>Fuzeon</td>
<td>Inj 108 mg vial × 60</td>
<td>1</td>
</tr>
</tbody>
</table>

**Restricted Initiation**

*Re-assessment required after 12 months*

All of the following:

1. confirmed HIV infection; and
2. Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
3. Either:
   3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
   3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
4. Previous treatment with 3 different antiretroviral regimens has failed; and
5. All of the following:
   5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
   5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
   5.3 Previous treatment with a protease inhibitor has failed.

**Continuation**

Patient has had at least a 10-fold reduction in viral load at 12 months

#### Non-Nucleoside Reverse Transcriptase Inhibitors

**Restricted**

**Confirmed HIV**

Both:

1. confirmed HIV infection; and
2. Any of the following:
   2.1 Symptomatic patient; or
   2.2 Patient aged 12 months and under; or
   2.3 Both:
      2.3.1 Patient aged 1 to 5 years; and
      2.3.2 Any of the following:
         2.3.2.1 CD4 counts < 1000 cells/mm³; or
         2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
         2.3.2.3 Viral load counts > 100000 copies per ml; or
   2.4 Both:
      2.4.1 Patient aged 6 years and over; and
      2.4.2 CD4 counts < 500 cells/mm³

**Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:

---

*Item restricted (see above); **Item restricted (see below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms on the preceding page

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>Stocrin 158.33</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>Stocrin 474.99</td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td>Stocrin 474.99</td>
</tr>
<tr>
<td>Oral liq 30 mg per ml</td>
<td></td>
</tr>
</tbody>
</table>

ETRAVIRINE – Restricted see terms on the preceding page

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>Intelence 770.00</td>
</tr>
</tbody>
</table>

NEVIRAPINE – Restricted see terms on the preceding page

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg – 1% DV Jan-13 to 2015</td>
<td>Nevirapine Alphapharm 95.94</td>
</tr>
<tr>
<td>Oral suspension 10 mg per ml</td>
<td>Viramune Suspension 134.55</td>
</tr>
</tbody>
</table>

Nucleoside Reverse Transcriptase Inhibitors

- Restricted

Confirmed HIV
Both:

1. Confirmed HIV infection; and
2. Any of the following:
   2.1 Symptomatic patient; or
   2.2 Patient aged 12 months and under; or
   2.3 Both:
      2.3.1 Patient aged 1 to 5 years; and
      2.3.2 Any of the following:
         2.3.2.1 CD4 counts < 1000 cells/mm$^3$; or
         2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
         2.3.2.3 Viral load counts > 100000 copies per ml; or
   2.4 Both:
      2.4.1 Patient aged 6 years and over; and
      2.4.2 CD4 counts < 500 cells/mm$^3$

Prevention of maternal transmission
Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV
Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.
**INFECTIONS - AGENTS FOR SYSTEMIC USE**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation/Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABACAVIR SULPHATE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Tab 300 mg – 1% DV Oct-14 to 2017</td>
<td>229.00</td>
<td>60</td>
<td>Ziagen</td>
</tr>
<tr>
<td>† Oral liq 20 mg per ml – 1% DV Oct-14 to 2017</td>
<td>256.31</td>
<td>240 ml</td>
<td>Ziagen</td>
</tr>
<tr>
<td>ABACAVIR SULPHATE WITH LAMIVUDINE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Tab 600 mg with lamivudine 300 mg</td>
<td>630.00</td>
<td>30</td>
<td>Kivexa</td>
</tr>
<tr>
<td>DIDANOSINE [DDI] – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 125 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg</td>
<td>1,313.19</td>
<td>30</td>
<td>Atripla</td>
</tr>
<tr>
<td>EMTRICITABINE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 200 mg</td>
<td>307.20</td>
<td>30</td>
<td>Emtriva</td>
</tr>
<tr>
<td>EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Tab 200 mg with tenofovir disoproxil fumarate 300 mg</td>
<td>838.20</td>
<td>30</td>
<td>Truvada</td>
</tr>
<tr>
<td>LAMIVUDINE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Oral liq 10 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STAVUDINE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 30 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 40 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Powder for oral soln 1 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZIDOVUDINE [AZT] – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Cap 100 mg – 1% DV Oct-13 to 2016</td>
<td>152.25</td>
<td>100</td>
<td>Retrovir</td>
</tr>
<tr>
<td>† Oral liq 10 mg per ml – 1% DV Oct-13 to 2016</td>
<td>30.45</td>
<td>200 ml</td>
<td>Retrovir</td>
</tr>
<tr>
<td>† Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017</td>
<td>750.00</td>
<td>5</td>
<td>Retrovir IV</td>
</tr>
<tr>
<td>ZIDOVUDINE [AZT] WITH LAMIVUDINE – <em>Restricted</em></td>
<td>see terms on the preceding page</td>
<td></td>
<td></td>
</tr>
<tr>
<td>† Tab 300 mg with lamivudine 150 mg – 1% DV Sep-14 to 2017</td>
<td>44.00</td>
<td>60</td>
<td>Alphapharm</td>
</tr>
</tbody>
</table>

**Protease Inhibitors**

*Restricted*

**Confirmed HIV**

Both:

1. Confirmed HIV infection; and
2. Any of the following:
   2.1 Symptomatic patient; or
   2.2 Patient aged 12 months and under; or
3. Both:
   3.1 Patient aged 1 to 5 years; and
   3.2 Any of the following:
      3.2.1 CD4 counts < 1000 cells/mm³; or
      3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
      3.2.3 Viral load counts > 100000 copies per ml; or

4. Both:
   4.1 Patient aged 6 years and over; and

continued…

---

† Item restricted (see † above); ‡ Item restricted (see ‡ below)

*e.g.* Brand indicates brand example only. It is not a contracted product.
continued...

2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ATAZANAVIR SULPHATE – Restricted see terms on the preceding page

- Cap 150 mg ................................................................. 568.34 60 Reyataz
- Cap 200 mg ................................................................. 757.79 60 Reyataz

DARUNAVIR – Restricted see terms on the preceding page

- Tab 400 mg ................................................................. 837.50 60 Prezista
- Tab 600 mg ................................................................. 1,190.00 60 Prezista

INDINAVIR – Restricted see terms on the preceding page

- Cap 200 mg
- Cap 400 mg

LOPINAVIR WITH RITONAVIR – Restricted see terms on the preceding page

- Tab 100 mg with ritonavir 25 mg ........................................ 183.75 60 Kaletra
- Tab 200 mg with ritonavir 50 mg ........................................ 735.00 120 Kaletra
- Oral liq 80 mg with ritonavir 20 mg per ml ........................ 735.00 300 ml Kaletra

RITONAVIR – Restricted see terms on the preceding page

- Tab 100 mg – 1% DV Oct-12 to 2015 .................................. 43.31 30 Norvir
- Oral liq 80 mg per ml

Strand Transfer Inhibitors

Restricted

Confirmed HIV

Both:
1. Confirmed HIV infection; and
2. Any of the following:
   2.1 Symptomatic patient; or
   2.2 Patient aged 12 months and under; or
   2.3 Both:
      2.3.1 Patient aged 1 to 5 years; and
      2.3.2 Any of the following:
         2.3.2.1 CD4 counts < 1000 cells/mm³; or
         2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
         2.3.2.3 Viral load counts > 100000 copies per ml; or
   2.4 Both:  

continued...
2.4.1 Patient aged 6 years and over; and
2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

RALTEGRAVIR POTASSIUM – Restricted see terms on the preceding page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Tab 400 mg</td>
<td>1,090.00</td>
</tr>
<tr>
<td></td>
<td>60 Isentress</td>
</tr>
</tbody>
</table>

Hepatitis B

ADEFOVIR DIPIVOXIL – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Tab 10 mg</td>
<td>670.00</td>
</tr>
<tr>
<td></td>
<td>30 Hepsera</td>
</tr>
</tbody>
</table>

Restricted
Gastroenterologist or infectious disease physician
All of the following:
1. Patient has confirmed Hepatitis B infection (HBsAg+); and

Documented resistance to lamivudine, defined as:
1. Patient has raised serum ALT (> 1 × ULN); and
2. Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
3. Detection of M204I or M204V mutation; and
4. Either:
   4.1 Both:
      4.1.1 Patient is cirrhotic; and
      4.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or
   4.2 Both:
      4.2.1 Patient is not cirrhotic; and
      4.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Tab 0.5 mg</td>
<td>400.00</td>
</tr>
<tr>
<td></td>
<td>30 Baraclude</td>
</tr>
</tbody>
</table>

Restricted
Gastroenterologist or infectious disease physician
All of the following:
1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2. Patient is Hepatitis B nucleoside analogue treatment-naive; and
3. Entecavir dose 0.5 mg/day; and
4. Either:

continued…
continued...

4.1 ALT greater than upper limit of normal; or

4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and

5 Either:

5.1 HBeAg positive; or

5.2 Patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

6 No continuing alcohol abuse or intravenous drug use; and

7 Not co-infected with HCV, HIV or HDV; and

8 Neither ALT nor AST greater than 10 times upper limit of normal; and

9 No history of hypersensitivity to entecavir; and

10 No previous documented lamivudine resistance (either clinical or genotypic).

LAMIVUDINE – Restricted see terms below

| Tab 100 mg – 1% DV Nov-14 to 2017                  | 6.00 | 28  |
| Oral liq 5 mg per ml – 1% DV Nov-14 to 2017       | 270.00 | 240 ml |

Restricted
Gastroenterologist, infectious disease specialist, paediatrician or general physician

Initiation
Re-assessment required after 12 months

Any of the following:

1 HBV DNA positive cirrhosis prior to liver transplantation; or

2 HbsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or

3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or

4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and

5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or

6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Continuation - patients who have maintained continuous treatment and response to lamivudine
Re-assessment required after 2 years

All of the following:

1 Have maintained continuous treatment with lamivudine; and

2 Most recent test result shows continuing biochemical response (normal ALT); and

3 HBV DNA <100.00 copies per ml by quantitative PCR at a reference laboratory; or

Continuation - when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine
Re-assessment required after 2 years

All of the following:

1 Lamivudine to be used in combination with adefovir dipivoxil; and

2 Patient is cirrhotic; and

Documented resistance to lamivudine, defined as:

1 Patient has raised serum ALT (> 1 × ULN); and

2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and

3 Detection of M204I or M204V mutation; or

Continuation - when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil
Re-assessment required after 2 years

All of the following:

1 Lamivudine to be used in combination with adefovir dipivoxil; and

Documented resistance to adefovir, defined as:

1 Patient has raised serum ALT (> 1 × ULN); and

2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and

3 Detection of N236T or A181T/V mutation.
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

TENOFOVIR DISOPROXIL FUMARATE – **Restricted** see terms below

- Tab 300 mg .......................... 531.00 30 Viread

**Restricted**

**Confirmed hepatitis B**

Either:

1. All of the following:
   1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
   1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
   1.3 HBV DNA greater than 20,000 IU/mL or increased ≤ 10-fold over nadir; and
   1.4 Any of the following:
      1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
      1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
      1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I/M204V or M250I/V mutation; or

2. Patient is either listed or has undergone liver transplantation for HBV; or

3. Patient has a decompensated cirrhosis with a Mayo score > 20.

**Pregnant or Breastfeeding, Active hepatitis B**

Limited to twelve months’ treatment

Both:

1. Patient is HBsAg positive and pregnant; and
2. HBV DNA > 20,000 IU/mL and ALT > ULN.

**Pregnant, prevention of vertical transmission**

Limited to six months’ treatment

Both:

1. Patient is HBsAg positive and pregnant; and
2. HBV DNA > 20 million IU/mL and ALT normal.

**Confirmed HIV**

Both:

1. Confirmed HIV infection; and
2. Any of the following:
   2.1 Symptomatic patient; or
   2.2 Patient aged 12 months and under; or
   2.3 Both:
      2.3.1 Patient aged 1 to 5 years; and
      2.3.2 Any of the following:
         2.3.2.1 CD4 counts < 1000 cells/mm³; or
         2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
         2.3.2.3 Viral load counts > 100000 copies per ml; or
   2.4 Both:
      2.4.1 Patient aged 6 years and over; and
      2.4.2 CD4 counts < 500 cells/mm³

**Prevention of maternal transmission**

Either:

1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Post-exposure prophylaxis following non-occupational exposure to HIV**

Both:

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:

continued...
2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophy-
    laxis is required.

Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

Hepatitis C

**BOCEPREVIR – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 200 mg .................................................................5,015.00</td>
<td>336 Victrelis</td>
</tr>
</tbody>
</table>

**CIDOFOVIR – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 75 mg per ml, 5 ml vial</td>
<td>14.09 Zovirax IV</td>
</tr>
</tbody>
</table>

**CIDOFOSCARNET SODIUM – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 24 mg per ml, 250 ml bottle</td>
<td>17.09 Zovirax IV</td>
</tr>
</tbody>
</table>

**GANCICLOVIR – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mg vial .................................................................380.00</td>
<td>5 Cymevene</td>
</tr>
</tbody>
</table>

Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x10^9 /l or Albumin <35 g/l.
INFECTIONS - AGENTS FOR SYSTEMIC USE

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>VALACICLOVIR – Restricted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$ Tab 500 mg</td>
<td>$102.72</td>
<td>30 Valtrex</td>
</tr>
<tr>
<td>Restricted</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

 Any of the following:
1. Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.
2. Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.
3. Patient has undergone organ transplantation.

Immunocompromised patients
Limited to 7 days treatment
Both:
1. Patient is immunocompromised; and
2. Patient has herpes zoster.

VALGANCICLOVIR – Restricted see terms below
$ Tab 450 mg $3,000.00 60 Valcyte

Transplant cytomegalovirus prophylaxis
Limited to three months’ treatment
Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Lung transplant cytomegalovirus prophylaxis
Limited to six months’ treatment
Both:
1. Patient has undergone a lung transplant; and
2. Either:
   2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
   2.2 The recipient is cytomegalovirus positive.

Cytomegalovirus in immunocompromised patients
Both:
1. Patient is immunocompromised; and
2. Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.

Influenza

OSELTAMIVIR – Restricted see terms below
$ Tab 75 mg
$ Powder for oral suspension 6 mg per ml

Restricted
Either:
1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR
$ Powder for inhalation 5 mg $37.38 20 dose Relenza Rotadisk

Restricted
Either:
1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

\[\text{Item restricted (see above); Item restricted (see below)}\]
\[e.g. \text{Brand indicates brand example only. It is not a contracted product.}\]
Immune Modulators

INTERFERON ALFA-2A
- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B
- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – Restricted see terms below
- Inj 100 mcg in 0.5 ml vial

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below
- Inj 135 mcg prefilled syringe
- Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)
- Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)
- Inj 180 mcg prefilled syringe ................................................................. 900.00 4 Pegasys
- Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) ............ 1,159.84 1 Pegasus RBV Combination Pack
- Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168) ............ 1,290.00 1 Pegasus RBV Combination Pack

Restricted
Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant
Both:
1 Any of the following:
   1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
   1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
   1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.
2 Maximum of 48 weeks therapy.

Notes:
Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – (Chronic hepatitis C - genotype 1 infection) - gastroenterologist, infectious disease physician or general physician
All of the following:
1 Patient has chronic hepatitis C, genotype 1; and
2 Patient has had previous treatment with pegylated interferon and ribavirin; and
3 Either:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; and
4 Patient is to be treated in combination with boceprevir; and
5 Maximum of 48 weeks therapy.
Infections - Agents for Systemic Use

Price

<table>
<thead>
<tr>
<th>Brand or</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
</tr>
<tr>
<td>Generic</td>
</tr>
<tr>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

Continued...

Initiation (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) - Gastroenterologist, infectious disease physician or general physician

All of the following:
1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Any of the following:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; or
   3.3 Patient received interferon treatment prior to 2004; and
4. Patient is to be treated in combination with boceprevir; and
5. Maximum of 48 weeks therapy.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Both:
1. Patient has chronic hepatitis C, genotype 2 or 3 infection; and
2. Maximum of 6 months therapy.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

All of the following:
1. Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2. Patient is Hepatitis B treatment-naive; and
3. ALT > 2 times Upper Limit of Normal; and
4. HBV DNA < 10 log10 IU/ml; and
5. Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
6. Compensated liver disease; and
7. No continuing alcohol abuse or intravenous drug use; and
8. Not co-infected with HCV, HIV or HDV; and
9. Neither ALT nor AST > 10 times upper limit of normal; and
10. No history of hypersensitivity or contraindications to pegylated interferon; and
11. Maximum of 48 weeks therapy.

Notes:

Approved dose is 180 mcg once weekly.
The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopenia, dose should be reduced in accordance with the datasheet guidelines.
Pegylated Interferon alfa-2a is not approved for use in children.
Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms below

- **Inj 10 mg per ml, 15 ml vial**
- **Inj 10 mg per ml, 1 ml ampoule**

For the diagnosis of myasthenia gravis

NEOSTIGMINE METILSULFATE

- **Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017**
  
  98.00
  
  50
  
  AstraZeneca

NEOSTIGMINE METILSULFATE WITH GLYCOPHYRRONIUM BROMIDE

- **Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – 1% DV Nov-13 to 2016**
  
  27.86
  
  10
  
  Max Health

PYRIDOSTIGMINE BROMIDE

- **Tab 60 mg**
  
  38.90
  
  100
  
  Mestinon

Antirheumatoid Agents

AURANOFIN

- **Tab 3 mg**

HYDROXYCHLOROQUINE

- **Tab 200 mg – 1% DV Nov-12 to 2015**
  
  18.00
  
  100
  
  Plaunil

LEFLUNOMIDE

- **Tab 10 mg**
  
  55.00
  
  30
  
  Arava

- **Tab 20 mg**
  
  76.00
  
  30
  
  Arava

- **Tab 100 mg**
  
  54.44
  
  3
  
  Arava

PENICILLAMINE

- **Tab 125 mg**
  
  61.93
  
  100
  
  D-Penamine

- **Tab 250 mg**
  
  98.98
  
  100
  
  D-Penamine

SODIUM AUROTHIOMALATE

- **Inj 10 mg in 0.5 ml ampoule**
- **Inj 20 mg in 0.5 ml ampoule**
- **Inj 50 mg in 0.5 ml ampoule**

Drugs Affecting Bone Metabolism

Bisphosphonates

ALENDRONATE SODIUM

- **Tab 40 mg**

  133.00
  
  30
  
  Fosamax

- **Tab 70 mg**

  12.90
  
  4
  
  Fosamax

Both:

1. Paget's disease; and
2. Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
   2.5 Preparation for orthopaedic surgery.
MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
</table>

**Restricted**

**Osteoporosis**

Any of the following:

1. History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
2. History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
3. History of two significant osteoporotic fractures demonstrated radiologically; or
4. Documented T-Score ≤ -3.0 (see Note); or
5. A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
6. Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

**Initiation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

1. The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
2. Any of the following:
   2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

**Continuation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents)

Notes:

1. BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2. Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
3. Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Restricted see terms below

| Tab 70 mg with cholecalciferol 5,600 iu | 12.90 |

4 Fosamax Plus

**Restricted**

**Osteoporosis**

Any of the following:

1. History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or

continued…
continued...  
2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or  
3 History of two significant osteoporotic fractures demonstrated radiologically; or  
4 Documented T-Score \( \leq -3.0 \) (see Note); or  
5 A 10-year risk of hip fracture \( \geq 3\% \), calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or  
6 Patient has had a Special Authority approval for zoledronic acid (osteoarthritis) or raloxifene.

**Initiation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

1. The patient is receiving systemic glucocorticosteroid therapy \( \geq 5 \text{ mg per day prednisone equivalents} \) and has already received or is expected to receive therapy for at least three months; and  
2. Any of the following:
   1. The patient has documented BMD \( \geq 1.5 \) standard deviations below the mean normal value in young adults (i.e. T-Score \( \leq -1.5 \)) (see Note); or  
   2. The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or  
   3. The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

**Continuation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

The patient is continuing systemic glucocorticosteroid therapy \( \geq 5 \text{ mg per day prednisone equivalents} \)

Notes:

1. BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2. Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \( \geq -2.5 \) and, therefore, do not require BMD measurement for treatment with bisphosphonates.
3. Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

**ETIDRONATE DISODIUM**

Tab 200 mg – 1% DV Sep-12 to 2015 ............................................................... 15.80 100 Arrow-Etidronate

**PAMIDRONATE DISODIUM**

Inj 3 mg per ml, 10 ml vial ............................................................... 6.80 1 Pamisol  
Inj 6 mg per ml, 10 ml vial ............................................................... 13.20 1 Pamisol  
Inj 9 mg per ml, 10 ml vial ............................................................... 19.20 1 Pamisol

**ZOLEDRONIC ACID – Restricted** see terms on the next page

Inj 0.05 mg per ml, 100 ml vial ............................................................... 600.00 100 ml Aclasta
MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### Restricted

**Osteogenesis imperfecta**

Patient has been diagnosed with clinical or genetic osteogenesis imperfecta.

**Osteoporosis**

Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \( \geq 2.5 \) standard deviations below the mean normal value in young adults (i.e. T-Score \( \leq -2.5 \)) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score \( \geq -3.0 \) (see Note); or
   1.5 A 10-year risk of hip fracture \( \geq 3\% \), calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and

2. The patient will not be prescribed more than one infusion in a 12-month period.

**Initiation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (\( \geq 5 \) mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD \( \geq 1.5 \) standard deviations below the mean normal value in young adults (i.e. T-Score \( \leq -1.5 \)) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and

3. The patient will not be prescribed more than one infusion in the 12-month approval period.

**Continuation - glucocorticosteroid therapy**

*Re-assessment required after 12 months*

Both:

1. The patient is continuing systemic glucocorticosteroid therapy (\( \geq 5 \) mg per day prednisone equivalents); and

2. The patient will not be prescribed more than one infusion in the 12-month approval period.

**Initiation - Paget’s disease**

*Re-assessment required after 12 months*

All of the following:

1. Paget’s disease; and

2. Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3. The patient will not be prescribed more than one infusion in the 12-month approval period.

**Continuation - Paget’s disease**

*Re-assessment required after 12 months*

Both:

1. Any of the following:

---

e.g. *Brand* indicates brand example only. It is not a contracted product.
1. The patient has relapsed (based on increases in serum alkaline phosphatase); or
2. The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
3. Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than one infusion in the 12-month approval period.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \( \leq -2.5 \) and, therefore, do not require BMD measurement for treatment with bisphosphonates.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

RALOXIFENE – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 60 mg .......................................................................................................53.76 28 Evista</td>
</tr>
</tbody>
</table>

Restricted

Any of the following:
1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \( \geq 2.5 \) standard deviations below the mean normal value in young adults (i.e. T-Score \( \leq -2.5 \)) (see Notes); or
2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
3 History of two significant osteoporotic fractures demonstrated radiologically; or
4 Documented T-Score \( \geq -3.0 \) (see Notes); or
5 A 10-year risk of hip fracture \( \geq 3\% \), calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \( \leq -2.5 \) and, therefore, do not require BMD measurement for raloxifene funding.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.00</td>
<td>Risedronate Sandoz</td>
</tr>
<tr>
<td>490.00</td>
<td>Forteo</td>
</tr>
</tbody>
</table>

**RISEDRONATE SODIUM**
Tab 35 mg .........................................................................................................4.00 4 Risedronate Sandoz

**TERIPARATIDE – Restricted** see terms below

$ Inj 250 mcg per ml, 2.4 ml cartridge .............................................................490.00 1 Forteo

**Limited to 18 months' treatment**

All of the following:
1. The patient has severe, established osteoporosis; and
2. The patient has a documented T-score less than or equal to -3.0 (see Notes); and
3. The patient has had two or more fractures due to minimal trauma; and
4. The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

**Notes:**
1. The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2. Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months’ continuous therapy.
3. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

**Enzymes**

**HYALURONIDASE**
Inj 1,500 iu ampoule

**Hyperuricaemia and Antigout**

**ALLOPURINOL**
Tab 100 mg ..........................................................15.90 1,000 Apo-Allopurinol
Tab 300 mg ..........................................................16.75 500 Apo-Allopurinol

**BENZBROMARONE – Restricted** see terms below

$ Tab 100 mg ..........................................................45.00 100 Benzbromaron AL 100

**Restricted**

Both:
1. Any of the following:
   1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
   1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
   1.3 Both:
      1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
      1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
1.4 All of the following:
   1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
   1.4.2 Allopurinol is contraindicated; and

continued…
continued...

1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
2 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm

**COLCHICINE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500 mcg 1% DV Oct-13 to 2016</td>
<td>$10.08</td>
<td>100</td>
<td>Colgout</td>
</tr>
</tbody>
</table>

**FEBUXOSTAT – Restricted** see terms below

- Tab 80 mg | $39.50 | 28 | Adenuric |
- Tab 120 mg | $39.50 | 28 | Adenuric |
- Restricted

Any of the following:

1. The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
2. The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
3. Both:
   3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
   3.2 The patient has a rate of creatinine clearance greater than or equal to 30 ml/min.

Note: Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

**PROBENECID**

- Tab 500 mg

**RASBURICASE – Restricted** see terms below

- Inj 1.5 mg vial

- Restricted

Haematologist

**Muscle Relaxants and Related Agents**

**ATRACURIUM BESYLATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 2.5 ml ampoule 1% DV Sep-12 to 2015</td>
<td>$6.13</td>
<td>5</td>
<td>Tracrium</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule 1% DV Sep-12 to 2015</td>
<td>$9.19</td>
<td>5</td>
<td>Tracrium</td>
</tr>
</tbody>
</table>

**BACLOFEN**

- Tab 10 mg 1% DV Jun-13 to 2016 | $3.85 | 100 | Pacifen |

- Oral liq 1 mg per ml

- Inj 0.05 mg per ml, 1 ml ampoule 1% DV Oct-12 to 2015 | $11.55 | 1 | Lioresal Intrathecal |

- Inj 2 mg per ml, 5 ml ampoule 1% DV Oct-12 to 2015 | $209.29 | 1 | Lioresal Intrathecal |

**CLOSTRIDIUM BOTULINUM TYPE A TOXIN**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 u vial</td>
<td>$467.50</td>
<td>1</td>
<td>Botox</td>
</tr>
<tr>
<td>Inj 500 u vial</td>
<td>$1,295.00</td>
<td>2</td>
<td>Dysport</td>
</tr>
</tbody>
</table>
### MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

#### DANTROLENE
- Cap 25 mg ................................................................. 65.00 100 Dantrium
- Cap 50 mg ................................................................. 77.00 100 Dantrium
- Inj 20 mg vial

#### MIVACURIUM CHLORIDE
- Inj 2 mg per ml, 5 ml ampoule ........................................ 33.92 5 Mivacron
- Inj 2 mg per ml, 10 ml ampoule ........................................ 67.17 5 Mivacron

#### ORPHENADRINE CITRATE
- Tab 100 mg

#### PANCURONIUM BROMIDE
- Inj 2 mg per ml, 2 ml ampoule – 1% DV Jan-13 to 2015 ............... 260.00 50 AstraZeneca

#### ROCURONIUM BROMIDE
- Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015 ................... 38.25 10 DBL Rocuronium Bromide

#### SUXAMETHONIUM CHLORIDE
- Inj 50 mg per ml, 2 ml ampoule – 1% DV Jun-14 to 2017 .............. 78.00 50 AstraZeneca

#### VECURONIUM BROMIDE
- Inj 4 mg ampoule
- Inj 10 mg vial

#### Reversers of Neuromuscular Blockade

- SUGAMMADEX – Restricted see terms below
  - $ Inj 100 mg per ml, 2 ml vial ................................................... 1,200.00 10 Bridion
  - $ Inj 100 mg per ml, 5 ml vial ................................................... 3,000.00 10 Bridion

- Non-Steroidal Anti-Inflammatory Drugs

- CELECOXIB – Restricted see terms below
  - Cap 100 mg
  - Cap 200 mg
  - Cap 400 mg

**Item restricted (see ➕ above); $Item restricted (see ➖ below)**

*E.g. Brand indicates brand example only. It is not a contracted product.*
DICLOFENAC SODIUM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
<tr>
<td>Tab EC 25 mg – 1% DV Mar-13 to 2015</td>
<td>4.00 100 Apo-Diclo</td>
</tr>
<tr>
<td>Tab 50 mg dispersible</td>
<td></td>
</tr>
<tr>
<td>Tab EC 50 mg – 1% DV Mar-13 to 2015</td>
<td>16.00 500 Diclax SR</td>
</tr>
<tr>
<td>Tab long-acting 75 mg – 1% DV Dec-12 to 2015</td>
<td>3.10 30 Diclax SR</td>
</tr>
<tr>
<td>Tab long-acting 100 mg – 1% DV Dec-12 to 2015</td>
<td>42.25 500 Diclax SR</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 3 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>13.20 5 Voltaren</td>
</tr>
<tr>
<td>Suppos 12.5 mg – 1% DV Oct-14 to 2017</td>
<td>2.04 10 Voltaren</td>
</tr>
<tr>
<td>Suppos 25 mg – 1% DV Oct-14 to 2017</td>
<td>2.44 10 Voltaren</td>
</tr>
<tr>
<td>Suppos 50 mg – 1% DV Oct-14 to 2017</td>
<td>4.22 10 Voltaren</td>
</tr>
<tr>
<td>Suppos 100 mg – 1% DV Oct-14 to 2017</td>
<td>7.00 10 Voltaren</td>
</tr>
</tbody>
</table>

ETORICOXIB – Restricted see terms below

- Tab 30 mg
- Tab 60 mg
- Tab 90 mg
- Tab 120 mg

- Restricted

For preoperative and/or postoperative use for a total of up to 8 days’ use.

IBUPROFEN

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg – Restricted: For continuation only</td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg – Restricted: For continuation only</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 800 mg ..........................................................8.12 30 Brufen SR</td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml – 1% DV Mar-14 to 2016 ....................................................1.89 200 ml Fenpaed</td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 2 ml ampoule</td>
<td></td>
</tr>
</tbody>
</table>

INDOMETHACIN

- Cap 25 mg
- Cap 50 mg
- Cap long-acting 75 mg
- Inj 1 mg vial
- Suppos 100 mg

KETOPROFEN

- Cap long-acting 200 mg ..........................................................12.07 28 Oruvail SR

MEFENAMIC ACID – Restricted: For continuation only

- Cap 250 mg

MELOXICAM – Restricted see terms below

- Tab 7.5 mg

- Restricted

Either:

1. Haemophilic arthropathy, with both of the following:
   
   1.1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
   
   1.2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or

2. For preoperative and/or postoperative use for a total of up to 8 days’ use.
## MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAPROXEN</td>
<td></td>
</tr>
<tr>
<td>Tab 250 mg – 1% DV Jan-13 to 2015</td>
<td>21.25 500 Noflam 250</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Jan-13 to 2015</td>
<td>22.25 250 Noflam 500</td>
</tr>
<tr>
<td>Tab long-acting 750 mg</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 1 g</td>
<td></td>
</tr>
<tr>
<td>PARECOXIB</td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg vial</td>
<td>100.00 10 Dynastat</td>
</tr>
<tr>
<td>SULINDAC</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
</tr>
<tr>
<td>TENOXICAM</td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jan-15 to 2016</td>
<td>3.05 20 Reutenox</td>
</tr>
<tr>
<td>Inj 20 mg vial</td>
<td>9.95 1 AFT</td>
</tr>
</tbody>
</table>

### Topical Products for Joint and Muscular Pain

<table>
<thead>
<tr>
<th>Capsaicin – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 0.025%</td>
</tr>
</tbody>
</table>

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
Agents for Parkinsonism and Related Disorders

RILUZOLE – Restricted see terms below

Initiation
Neurologist or respiratory specialist
Re-assessment required after 6 months
All of the following:
1. The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
2. The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
3. The patient has not undergone a tracheostomy; and
4. The patient has not experienced respiratory failure; and
5. Any of the following:
   5.1 The patient is ambulatory; or
   5.2 The patient is able to use upper limbs; or
   5.3 The patient is able to swallow.

Continuation
Re-assessment required after 18 months
All of the following:
1. The patient has not undergone a tracheostomy; and
2. The patient has not experienced respiratory failure; and
3. Any of the following:
   3.1 The patient is ambulatory; or
   3.2 The patient is able to use upper limb; or
   3.3 The patient is able to swallow.

TETRABENAZINE
Tab 25 mg – 1% DV Sep-13 to 2016 ...........................................................118.00 112 Motetis

Anticholinergics

BENZTROPINE MESYLATE
Tab 2 mg .................................................................7.99 60 Benztrop
Inj 1 mg per ml, 2 ml ampoule ............................................................95.00 5 Cogentin

ORPHENADRINE HYDROCHLORIDE
Tab 50 mg

PROCYCLIDINE HYDROCHLORIDE
Tab 5 mg

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE
Cap 100 mg – 1% DV Oct-14 to 2017 ....................................................38.24 60 Symmetrel

APOMORPHINE HYDROCHLORIDE
Inj 10 mg per ml, 1 ml ampoule
Inj 10 mg per ml, 2 ml ampoule ..........................................................110.00 5 Apomine

BROMOCRIPTINE
Tab 2.5 mg
Cap 5 mg
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Item</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENTACAPONE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Dec-12 to 2015</td>
<td>47.92 100 Entapone</td>
</tr>
<tr>
<td><strong>LEVODOPA WITH BENSERAZIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 50 mg with benserazide 12.5 mg</td>
<td>10.00 100 Madopar Rapid</td>
</tr>
<tr>
<td>Cap 50 mg with benserazide 12.5 mg</td>
<td>8.00 100 Madopar 62.5</td>
</tr>
<tr>
<td>Cap 100 mg with benserazide 25 mg</td>
<td>12.50 100 Madopar 125</td>
</tr>
<tr>
<td>Cap long-acting 100 mg with benserazide 25 mg</td>
<td>17.00 100 Madopar HBS</td>
</tr>
<tr>
<td>Cap 200 mg with benserazide 50 mg</td>
<td>25.00 100 Madopar 250</td>
</tr>
<tr>
<td><strong>LEVODOPA WITH CARBIDOPA</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg with carbidopa 25 mg</td>
<td>20.00 100 Sinemet</td>
</tr>
<tr>
<td>e.g. Kinson</td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 200 mg with carbidopa 50 mg</td>
<td>47.50 100 Sinemet CR</td>
</tr>
<tr>
<td>Tab 250 mg with carbidopa 25 mg</td>
<td>40.00 100 Sinemet</td>
</tr>
<tr>
<td>e.g. Sindopa</td>
<td></td>
</tr>
<tr>
<td><strong>LISURIDE HYDROGEN MALEATE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mcg</td>
<td>25.00 30 Dopergin</td>
</tr>
<tr>
<td><strong>PRAMIPEXOLE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 0.25 mg – 1% DV Oct-14 to 2016</td>
<td>7.20 100 Ramipex</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Oct-14 to 2016</td>
<td>24.39 100 Ramipex</td>
</tr>
<tr>
<td><strong>ROPINIROLE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 0.25 mg – 1% DV Mar-14 to 2016</td>
<td>2.36 100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Mar-14 to 2016</td>
<td>5.32 100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Mar-14 to 2016</td>
<td>7.72 100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-14 to 2016</td>
<td>14.48 100 Apo-Ropinirole</td>
</tr>
<tr>
<td><strong>SELEGILINE HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td></td>
</tr>
<tr>
<td><strong>TOLCAPONE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>126.20 100 Tasmar</td>
</tr>
</tbody>
</table>

### Anaesthetics

**General Anaesthetics**

<table>
<thead>
<tr>
<th>Item</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DESFLURANE</strong></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 240 ml bottle – 1% DV Dec-12 to 2015</td>
<td>1,230.00 6 Suprane</td>
</tr>
<tr>
<td><strong>DEXMEDETOMIDINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mcg per ml, 2 ml vial – 1% DV Oct-14 to 2017</td>
<td>479.85 5 Precedex</td>
</tr>
<tr>
<td><strong>ETOMIDATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>ISOFLURANE</strong></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Dec-12 to 2015</td>
<td>1,020.00 6 Aerrane</td>
</tr>
<tr>
<td><strong>KETAMINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Sep-14 to 2017</td>
<td>27.00 1 Biomed</td>
</tr>
<tr>
<td>Inj 4 mg per ml, 50 ml syringe – 1% DV Sep-14 to 2017</td>
<td>25.00 1 Biomed</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml syringe – 1% DV Sep-14 to 2017</td>
<td>14.00 1 Biomed</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial</td>
<td></td>
</tr>
<tr>
<td><strong>METHOHEXITAL SODIUM</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 50 ml vial</td>
<td></td>
</tr>
</tbody>
</table>
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.60</td>
<td>Fresofol 1%</td>
</tr>
<tr>
<td>7.60</td>
<td>Provive MCT-LCT 1%</td>
</tr>
<tr>
<td>42.00</td>
<td>Diprivan</td>
</tr>
<tr>
<td>47.00</td>
<td>Fresofol 1%</td>
</tr>
<tr>
<td>4.00</td>
<td>Provive MCT-LCT 1%</td>
</tr>
<tr>
<td>25.00</td>
<td>Diprivan</td>
</tr>
<tr>
<td>30.00</td>
<td>Fresofol 1%</td>
</tr>
<tr>
<td>1,230.00</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

#### SEVOFLURANE

Soln for inhalation 100%, 250 ml bottle – 1% DV Dec-12 to 2015

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,230.00</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

#### THIOPENTAL [THIOPENTONE] SODIUM

Inj 500 mg ampoule

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,230.00</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

### Local Anaesthetics

#### ARTICAINE HYDROCHLORIDE

Inj 1%

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>50.00</td>
<td>Marcain Isobaric</td>
</tr>
<tr>
<td>35.00</td>
<td>Marcain</td>
</tr>
<tr>
<td>28.00</td>
<td>Marcain</td>
</tr>
<tr>
<td>150.00</td>
<td>Marcain</td>
</tr>
</tbody>
</table>

#### ARTICAINE HYDROCHLORIDE WITH ADRENALINE

Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>35.00</td>
<td>Marcain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge</td>
</tr>
</tbody>
</table>

#### BENZOCAINE

Gel 20%

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>50.00</td>
<td>Marcain</td>
</tr>
</tbody>
</table>

#### BUPIVACAINE HYDROCHLORIDE

Inj 5 mg per ml, 4 ml ampoule – 1% DV Jul-14 to 2017

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>50.00</td>
<td>Marcain Isobaric</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inj 2.5 mg per ml, 20 ml ampoule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Oct-12 to 2015</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Oct-12 to 2015</td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 100 ml bag</td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 200 ml bag</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 100 ml bag – 1% DV Jul-14 to 2017</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 200 ml bag</td>
</tr>
<tr>
<td>Inj 1.25 mg per ml, 500 ml bag</td>
</tr>
</tbody>
</table>

#### BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE

Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Sep-14 to 2017

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>135.00</td>
<td>Marcain with Adrenaline</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Sep-14 to 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>115.00</td>
</tr>
</tbody>
</table>
**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUPIVACAINE HYDROCHLORIDE WITH FENTANYL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td>$210.00</td>
<td>10 Bupafen</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe</td>
<td>$210.00</td>
<td>10 Bupafen</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td>$72.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe</td>
<td>$92.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td><strong>BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5% with glucose 8%, 4 ml ampoule</td>
<td>$38.00</td>
<td>5 Marcain Heavy</td>
</tr>
<tr>
<td><strong>COCAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste 5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 15%, 2 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 4%, 2 ml syringe</td>
<td>$25.46</td>
<td>1 Biomed</td>
</tr>
<tr>
<td><strong>COCAINE HYDROCHLORIDE WITH ADRENALINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste 15% with adrenaline 0.06%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paste 25% with adrenaline 0.06%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHYL CHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spray 100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 2% – 1% DV Oct-12 to 2015</td>
<td>$3.40</td>
<td>20 ml Orion</td>
</tr>
<tr>
<td>Soln 4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spray 10% – 1% DV Sep-13 to 2016</td>
<td>$75.00</td>
<td>50 ml Xylocaine</td>
</tr>
<tr>
<td>Oral (viscous) soln 2% – 1% DV Sep-14 to 2017</td>
<td>$55.00</td>
<td>200 ml Xylocaine Viscous</td>
</tr>
<tr>
<td>Inj 1%, 20 ml ampoule, sterile pack</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2%, 20 ml ampoule, sterile pack</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1%, 5 ml ampoule – 1% DV Jul-13 to 2015</td>
<td>$8.75</td>
<td>25 Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 1%, 20 ml ampoule – 1% DV Jul-13 to 2015</td>
<td>$2.40</td>
<td>1 Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule – 1% DV Jul-13 to 2015</td>
<td>$6.90</td>
<td>25 Lidocaine-Claris</td>
</tr>
<tr>
<td>Inj 2%, 20 ml ampoule – 1% DV Jul-13 to 2015</td>
<td>$2.40</td>
<td>1 Lidocaine-Claris</td>
</tr>
<tr>
<td>Gel 2%, 10 ml urethral syringe</td>
<td>$43.26</td>
<td>10 Pfizer</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1% with adrenaline 1:100,000, 5 ml ampoule</td>
<td>$27.00</td>
<td>10 Xylocaine</td>
</tr>
<tr>
<td>Inj 1% with adrenaline 1:200,000, 20 ml vial</td>
<td>$50.00</td>
<td>5 Xylocaine</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:200,000, 20 ml vial</td>
<td>$60.00</td>
<td>5 Xylocaine</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Oct-14 to 2017</td>
<td>$17.50</td>
<td>1 Topicaine</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe</td>
<td>$43.26</td>
<td>10 Pfizer</td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal spray 5% with phenylephrine hydrochloride 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NERVOUS SYSTEM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 2.5% with prilocaine 2.5%</td>
<td>45.00 $</td>
<td>EMLA</td>
</tr>
<tr>
<td>Patch 25 mcg with prilocaine 25 mcg</td>
<td>115.00 $</td>
<td>EMLA</td>
</tr>
<tr>
<td>Crm 2.5% with prilocaine 2.5%, 5 g</td>
<td>45.00 $</td>
<td>EMLA</td>
</tr>
<tr>
<td><strong>MEPIVACAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3%, 1.8 ml dental cartridge – 1% DV Oct-14 to 2017</td>
<td>43.60 $</td>
<td>Scandonest 3%</td>
</tr>
<tr>
<td>Inj 3%, 2.2 ml dental cartridge – 1% DV Oct-14 to 2017</td>
<td>43.60 $</td>
<td>Scandonest 3%</td>
</tr>
<tr>
<td><strong>PRILOCAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5%, 50 ml vial</td>
<td>100.00 $</td>
<td>Citanest</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule</td>
<td>55.00 $</td>
<td>Citanest</td>
</tr>
<tr>
<td><strong>PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ROPIVACAINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td>75.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 20 ml ampoule</td>
<td>200.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 10 ml ampoule</td>
<td>45.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 7.5 mg per ml, 20 ml ampoule</td>
<td>84.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml ampoule</td>
<td>54.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ROPIVACAINE HYDROCHLORIDE WITH FENTANYL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
<td>198.50 $</td>
<td>Naropin</td>
</tr>
<tr>
<td>Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag</td>
<td>270.00 $</td>
<td>Naropin</td>
</tr>
<tr>
<td><strong>TETRACAINE [AMETHOCAINE] HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gel 4%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Analgesics

#### Non-Opioid Analgesics

**ASPIRIN**
- Tab EC 300 mg
- Tab dispersible 300 mg

**CAPSAICIN** – **Restricted** see terms below
- Crm 0.075% .................................................................12.50 $ | 45 g Zostrix HP
- **Restricted**
  - For post-herpetic neuralgia or diabetic peripheral neuropathy

**METHOXYFLURANE** – **Restricted** see terms below
- Soln for inhalation 99.9%, 3 ml bottle
- **Restricted**
  - Both:
    1. Patient is undergoing a painful procedure with an expected duration of less than one hour; and
    2. Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

**NEFOPAM HYDROCHLORIDE**
- Tab 30 mg
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### PARACETAMOL – Some items restricted see terms below

- **Tab soluble 500 mg**
- **Tab 500 mg**
  - Oral liq 120 mg per 5 ml – 20% DV Oct-14 to 2017 .................. 4.15 1,000 ml Paracare
  - Oral liq 250 mg per 5 ml – 20% DV Sep-14 to 2017 .................. 4.35 1,000 ml Paracare Double Strength

- **‡ Inj 10 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017 .................. 12.90 12 Perfalgan**
- **‡ Inj 10 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017 .................. 12.90 12 Perfalgan**
  - Suppos 25 mg ................................................. 56.35 20 Biomed
  - Suppos 50 mg ................................................. 56.35 20 Biomed
  - Suppos 125 mg ................................................ 7.49 20 Panadol
  - Suppos 250 mg ................................................. 14.40 20 Panadol
  - Suppos 500 mg – 1% DV Jan-13 to 2015 .................. 20.70 50 Paracare

- **⇌ Restricted**

Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

### SUCROSE

- Oral liq 25%

### Opioid Analgesics

#### ALFENTANIL

- Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Jan-15 to 2017 .................. 39.07 10 Hameln

#### CODEINE PHOSPHATE

- Tab 15 mg – 1% DV Jul-13 to 2016 ........................................ 4.75 100 PSM
- Tab 30 mg – 1% DV Jul-13 to 2016 ........................................ 5.80 100 PSM
- Tab 60 mg – 1% DV Jul-13 to 2016 ........................................ 12.50 100 PSM

#### DIHYDROCODEINE TARTRATE

- Tab long-acting 60 mg – 1% DV Sep-13 to 2016 .................. 13.64 60 DHC Continus

#### FENTANYL

- Inj 10 mcg per ml, 10 ml syringe
- Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-12 to 2015 .................. 4.50 10 Boucher and Muir
- Inj 10 mcg per ml, 50 ml bag ................................................. 210.00 10 Biomed
- Inj 10 mcg per ml, 50 ml syringe ............................................. 165.00 10 Biomed
- Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-12 to 2015 .................. 11.77 10 Boucher and Muir
- Inj 10 mcg per ml, 100 ml bag ................................................. 210.00 10 Biomed
- Inj 20 mcg per ml, 50 ml syringe ............................................. 185.00 10 Biomed
- Inj 20 mcg per ml, 100 ml bag ................................................. 185.00 10 Biomed
- Patch 12.5 mcg per hour ......................................................... 8.90 5 Mylan Fentanyl Patch
- Patch 25 mcg per hour ......................................................... 9.15 5 Mylan Fentanyl Patch
- Patch 50 mcg per hour ......................................................... 11.50 5 Mylan Fentanyl Patch
- Patch 75 mcg per hour ......................................................... 13.60 5 Mylan Fentanyl Patch
- Patch 100 mcg per hour ...................................................... 14.50 5 Mylan Fentanyl Patch

#### METHADONE HYDROCHLORIDE

- Tab 5 mg ......................................................... 1.85 10 Methatabs
- Oral liq 2 mg per ml – 1% DV Sep-12 to 2015 .................. 5.55 200 ml Biodone
- Oral liq 5 mg per ml – 1% DV Sep-12 to 2015 .................. 5.55 200 ml Biodone Forte
- Oral liq 10 mg per ml – 1% DV Sep-12 to 2015 .................. 6.55 200 ml Biodone Extra Forte
- Inj 10 mg per ml, 1 ml vial ................................................ 61.00 10 AFT

*Item restricted (see ⇆ above); ‡Item restricted (see ⇆ below)*

*example: Brand indicates brand example only. It is not a contracted product.*
### NERVOUS SYSTEM

#### MORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Oct-12 to 2015</td>
<td>$8.84 200 ml</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-12 to 2015</td>
<td>$11.62 200 ml</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Oct-12 to 2015</td>
<td>$14.65 200 ml</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Oct-12 to 2015</td>
<td>$21.55 200 ml</td>
<td>RA-Morph</td>
</tr>
</tbody>
</table>

#### MORPHINE SULPHATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 10 mg – 1% DV Sep-13 to 2016</td>
<td>$1.95 10</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg</td>
<td>$2.80 10</td>
<td>Sevedol</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg</td>
<td>$5.52 10</td>
<td>Sevedol</td>
</tr>
<tr>
<td>Tab long-acting 30 mg – 1% DV Sep-13 to 2016</td>
<td>$2.98 10</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 60 mg – 1% DV Sep-13 to 2016</td>
<td>$5.75 10</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Cap long-acting 30 mg – 1% DV Feb-14 to 2016</td>
<td>$1.70 10</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 60 mg – 1% DV Feb-14 to 2016</td>
<td>$2.50 10</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 100 mg – 1% DV Feb-14 to 2016</td>
<td>$5.40 10</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Oct-14 to 2017</td>
<td>$185.00 10</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-14 to 2017</td>
<td>$45.00 10</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-14 to 2017</td>
<td>$87.50 10</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 30 ml syringe</td>
<td>$135.00 10</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>$12.48 5</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>$9.09 5</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 mg cassette</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>$9.77 5</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>$12.43 5</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 200 mcg in 0.4 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mcg in 0.3 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### MORPHINE TARTRATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price per</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Sep-13 to 2016</td>
<td>$35.60 5</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 80 mg per ml, 5 ml ampoule – 1% DV Sep-13 to 2016</td>
<td>$107.67 5</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OXOCODONE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab controlled-release 5 mg</td>
<td>7.51</td>
<td>20 OxyContin</td>
</tr>
<tr>
<td>Tab controlled-release 10 mg – 1% DV Oct-13 to 2015</td>
<td>6.75</td>
<td>20 OxyContin ControlledRelease Tablets(BNM)</td>
</tr>
<tr>
<td>Tab controlled-release 20 mg – 1% DV Oct-13 to 2015</td>
<td>11.50</td>
<td>20 OxyContin ControlledRelease Tablets(BNM)</td>
</tr>
<tr>
<td>Tab controlled-release 40 mg – 1% DV Oct-13 to 2015</td>
<td>18.50</td>
<td>20 OxyContin ControlledRelease Tablets(BNM)</td>
</tr>
<tr>
<td>Tab controlled-release 80 mg – 1% DV Oct-13 to 2015</td>
<td>34.00</td>
<td>20 OxyContin ControlledRelease Tablets(BNM)</td>
</tr>
<tr>
<td>Cap immediate-release 5 mg</td>
<td>2.83</td>
<td>20 OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 10 mg</td>
<td>5.58</td>
<td>20 OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 20 mg</td>
<td>9.77</td>
<td>20 OxyNorm</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml</td>
<td>11.20</td>
<td>250 ml OxyNorm</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Dec-12 to 2015</td>
<td>10.08</td>
<td>5 OxyContin Orion</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule – 1% DV Dec-12 to 2015</td>
<td>19.87</td>
<td>5 OxyContin Orion</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV May-13 to 2015</td>
<td>60.00</td>
<td>5 OxyNorm</td>
</tr>
<tr>
<td><strong>PARACETAMOL WITH CODEINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab paracetamol 500 mg with codeine phosphate 8 mg</td>
<td>2.70</td>
<td>100 Paracetamol + Codeine (Relieve)</td>
</tr>
<tr>
<td><strong>PETHIDINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Mar-13 to 2015</td>
<td>3.95</td>
<td>10 PSM</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Mar-13 to 2015</td>
<td>5.80</td>
<td>10 PSM</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017</td>
<td>5.51</td>
<td>5 DBL Pethidine Hydrochloride</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017</td>
<td>5.83</td>
<td>5 DBL Pethidine Hydrochloride</td>
</tr>
<tr>
<td><strong>REMIFENTANIL HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg vial – 1% DV Nov-14 to 2017</td>
<td>10.00</td>
<td>5 Ultiva</td>
</tr>
<tr>
<td>Inj 2 mg vial – 1% DV Nov-14 to 2017</td>
<td>18.00</td>
<td>5 Ultiva</td>
</tr>
<tr>
<td><strong>TRAMADOL HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab sustained-release 100 mg – 1% DV Oct-14 to 2017</td>
<td>2.00</td>
<td>20 Tramal SR 100</td>
</tr>
<tr>
<td>Tab sustained-release 150 mg – 1% DV Oct-14 to 2017</td>
<td>3.00</td>
<td>20 Tramal SR 150</td>
</tr>
<tr>
<td>Tab sustained-release 200 mg – 1% DV Oct-14 to 2017</td>
<td>4.00</td>
<td>20 Tramal SR 200</td>
</tr>
<tr>
<td>Cap 50 mg – 1% DV Oct-14 to 2017</td>
<td>2.50</td>
<td>100 Arrow-Tramadol</td>
</tr>
<tr>
<td>Oral drops 100 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>4.50</td>
<td>5 Tramal 50</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>4.50</td>
<td>5 Tramal 100</td>
</tr>
</tbody>
</table>

*Item restricted (see above); ❗Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Antidepressants

#### Cyclic and Related Agents

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrow-Amitriptyline</td>
<td></td>
</tr>
<tr>
<td>Arrow-Amitriptyline</td>
<td></td>
</tr>
<tr>
<td>Arrow-Amitriptyline</td>
<td></td>
</tr>
</tbody>
</table>

**AMITRIPTYLINE**

- Tab 10 mg – 1% DV Sep-14 to 2017 ........................................................................ 1.68 100 Arrow-Amitriptyline
- Tab 25 mg – 1% DV Jan-15 to 2017 ........................................................................ 1.68 100 Arrow-Amitriptyline
- Tab 50 mg – 1% DV Jan-15 to 2017 ........................................................................ 1.85
- Tab 50 mg – 1% DV Jan-15 to 2017 ........................................................................ 2.82 100 Arrow-Amitriptyline
- Tab 50 mg – 1% DV Jan-15 to 2017 ........................................................................ 3.60

*(Amitrip Tab 25 mg to be delisted 1 January 2015)*

*(Amitrip Tab 50 mg to be delisted 1 January 2015)*

**CLOMIPRAMINE HYDROCHLORIDE**

- Tab 10 mg – 1% DV Jan-13 to 2015 ........................................................................ 12.60 100 Apo-Clomipramine
- Tab 25 mg – 1% DV Jan-13 to 2015 ........................................................................ 8.68 100 Apo-Clomipramine

**DOTHIEPIN HYDROCHLORIDE**

- Tab 75 mg ......................................................................................... 10.50 100 Dopress
- Cap 25 mg ......................................................................................... 6.17 100 Dopress

**DOXEPIN HYDROCHLORIDE**

- Cap 10 mg
- Cap 25 mg
- Cap 50 mg

**IMIPRAMINE HYDROCHLORIDE**

- Tab 10 mg ......................................................................................... 5.48 50 Tofranil
- Tab 25 mg ......................................................................................... 6.58 60 Tofranil

**MAPROTILINE HYDROCHLORIDE**

- Tab 25 mg
- Tab 75 mg

**MIANSERIN HYDROCHLORIDE – Restricted see terms below**

- Tab 30 mg

**NORTRIPTYLINE HYDROCHLORIDE**

- Tab 10 mg – 1% DV Jun-13 to 2016 ..................................................................... 4.00 100 Norpress
- Tab 25 mg – 1% DV Jun-13 to 2016 ..................................................................... 9.00 180 Norpress

### Monoamine-Oxidase Inhibitors - Non-Selective

**PHENELZINE SULPHATE**

- Tab 15 mg

**TRANYLCYPROMINE SULPHATE**

- Tab 10 mg

### Monoamine-Oxidase Type A Inhibitors

**MOCLOBEMIDE**

- Tab 150 mg – 1% DV Apr-13 to 2015 .......................................................... 81.83 500 Apo-Moclobemide
- Tab 300 mg – 1% DV Apr-13 to 2015 .......................................................... 29.51 100 Apo-Moclobemide

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

Other Antidepressants

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avanza</td>
<td>$8.78</td>
</tr>
<tr>
<td>Avanza</td>
<td>$13.95</td>
</tr>
<tr>
<td>Arrow-Venlafaxine XR</td>
<td>$5.06</td>
</tr>
<tr>
<td>Arrow-Venlafaxine XR</td>
<td>$6.44</td>
</tr>
<tr>
<td>Arrow-Venlafaxine XR</td>
<td>$8.86</td>
</tr>
<tr>
<td>Arrow-Venlafaxine XR</td>
<td>$14.34</td>
</tr>
<tr>
<td>Efexor XR</td>
<td>$8.68</td>
</tr>
<tr>
<td>Efexor XR</td>
<td>$12.18</td>
</tr>
<tr>
<td>Efexor XR</td>
<td>$20.16</td>
</tr>
<tr>
<td>Arrow-Citalopram</td>
<td>$2.34</td>
</tr>
<tr>
<td>Loxalate</td>
<td>$2.65</td>
</tr>
<tr>
<td>Loxalate</td>
<td>$4.20</td>
</tr>
</tbody>
</table>

MIRTAZAPINE – Restricted see terms below

- Tab 30 mg – 1% DV Sep-12 to 2015 .......................................................... 8.78 30 Avanza
- Tab 45 mg – 1% DV Sep-12 to 2015 .......................................................... 13.95 30 Avanza

Restricted
Initiation
Re-assessment required after two years

Both:
1. The patient has a severe major depressive episode; and
2. Either:
   2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
   2.2 Both:
      2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
      2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Continuation
Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

VENLAFAXINE – Some items restricted see terms below

- Tab modified release 37.5 mg ............................................................... 5.06 28 Arrow-Venlafaxine XR
- Tab modified release 75 mg ................................................................. 6.44 28 Arrow-Venlafaxine XR
- Tab modified release 150 mg ................................................................. 8.86 28 Arrow-Venlafaxine XR
- Tab modified release 225 mg ................................................................. 14.34 28 Arrow-Venlafaxine XR
- Cap modified release 37.5 mg ............................................................... 8.68 28 Efexor XR
- Cap modified release 75 mg ................................................................. 12.18 28 Efexor XR
- Cap modified release 150 mg ................................................................. 20.16 28 Efexor XR

Restricted
Initiation
Re-assessment required after two years

Both:
1. The patient has ‘treatment-resistant’ depression; and
2. Either:
   2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
   2.2 Both:
      2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and.
      2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.Continuation.

Continuation
Re-assessment required after two years

The patient has a high risk of relapse (prescriber determined)

Selective Serotonin Reuptake Inhibitors

CITALOPRAM HYDROBROMIDE

- Tab 20 mg ................................................................. 2.34 84 Arrow-Citalopram

ESCITALOPRAM

- Tab 10 mg ................................................................. 2.65 28 Loxalate
- Tab 20 mg ................................................................. 4.20 28 Loxalate

\* Item restricted (see above); \# Item restricted (see below)

e.g. Brand indicates brand example only. It is not a contracted product.
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUOXETINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab dispersible 20 mg, scored – 1% DV Apr-14 to 2016</td>
<td>$2.50</td>
<td>30</td>
<td>Arrow-Fluoxetine</td>
</tr>
<tr>
<td>Cap 20 mg – 1% DV Apr-14 to 2016</td>
<td>$1.74</td>
<td>90</td>
<td>Arrow-Fluoxetine</td>
</tr>
<tr>
<td><strong>PAROXETINE HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>$4.32</td>
<td>90</td>
<td>Loxamine</td>
</tr>
<tr>
<td><strong>SERTRALINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Sep-13 to 2016</td>
<td>$3.64</td>
<td>90</td>
<td>Arrow-Sertraline</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Sep-13 to 2016</td>
<td>$6.28</td>
<td>90</td>
<td>Arrow-Sertraline</td>
</tr>
</tbody>
</table>

### Antiepilepsy Drugs

#### Agents for the Control of Status Epilepticus

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td>$19.00</td>
<td>5</td>
<td>Rivotril</td>
</tr>
<tr>
<td><strong>DIAZEPAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 2 ml ampoule</td>
<td>$9.24</td>
<td>5</td>
<td>Hospira</td>
</tr>
<tr>
<td>Rectal tubes 5 mg</td>
<td>$25.05</td>
<td>5</td>
<td>Stesolid</td>
</tr>
<tr>
<td>Rectal tubes 10 mg</td>
<td>$30.50</td>
<td>5</td>
<td>Stesolid</td>
</tr>
<tr>
<td><strong>LORAZEPAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PARALDEHYDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PHENYTOIN SODIUM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Control of Epilepsy

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARBAMAZEPINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLOBAZAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CLONAZEPAM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral drops 2.5 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ETHOSUXIMIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GABAPENTIN – Restricted</strong> see terms below</td>
<td></td>
</tr>
<tr>
<td>✱ Tab 600 mg</td>
<td></td>
</tr>
<tr>
<td>✱ Cap 100 mg</td>
<td>7.16 100 Arrow-Gabapentin Nupentin</td>
</tr>
<tr>
<td>✱ Cap 300 mg</td>
<td>11.00 100 Arrow-Gabapentin Nupentin</td>
</tr>
<tr>
<td>✱ Cap 400 mg</td>
<td>13.75 100 Arrow-Gabapentin Nupentin</td>
</tr>
</tbody>
</table>

#### Restricted

1. For preoperative and/or postoperative use for up to a total of 8 days' use; or
2. For the pain management of burns patients with monthly review.

### Initiation - epilepsy

*Re-assessment required after 15 months*

Either:

1. Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
2. Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

### Continuation - epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

### Initiation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

*Re-assessment required after 3 months*

Either:

1. The patient has been diagnosed with neuropathic pain; or
2. Both:
   - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
   - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

### Continuation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

1. The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
2. The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Notes: Indications marked with * are Unapproved Indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

### LACOSAMIDE – Restricted see terms on the next page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>✱ Tab 50 mg</td>
<td>25.04 14 Vimpat</td>
</tr>
<tr>
<td>✱ Tab 100 mg</td>
<td>50.06 14 Vimpat</td>
</tr>
<tr>
<td></td>
<td>200.24 56 Vimpat</td>
</tr>
<tr>
<td>✱ Tab 150 mg</td>
<td>75.10 14 Vimpat</td>
</tr>
<tr>
<td></td>
<td>300.40 56 Vimpat</td>
</tr>
<tr>
<td>✱ Tab 200 mg</td>
<td>400.55 56 Vimpat</td>
</tr>
<tr>
<td>✱ Inj 10 mg per ml, 20 ml vial</td>
<td></td>
</tr>
</tbody>
</table>

---

*e.g. Brand indicates brand example only. It is not a contracted product.*
**NERVOUS SYSTEM**

**Restricted**

Initiation

*Re-assessment required after 15 months*

Both:

1. Patient has partial-onset epilepsy; and
2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

**Continuation**

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

### LAMOTRIGINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamictal</td>
<td>$24.03</td>
<td>60</td>
</tr>
<tr>
<td>Logem</td>
<td>$28.71</td>
<td>60</td>
</tr>
<tr>
<td>Mogine</td>
<td>$45.23</td>
<td>60</td>
</tr>
</tbody>
</table>

### LEVETIRACETAM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam-Rex</td>
<td>$24.03</td>
<td>60</td>
</tr>
<tr>
<td>Levetiracetam-Rex</td>
<td>$28.71</td>
<td>60</td>
</tr>
</tbody>
</table>

### PHENOBARBITONE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSM</td>
<td>$28.00</td>
<td>500</td>
</tr>
</tbody>
</table>

### PHENYTOIN

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSM</td>
<td>$29.00</td>
<td>500</td>
</tr>
</tbody>
</table>

### PHENYTOIN SODIUM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 30 mg</td>
<td>$4.53</td>
<td>60</td>
</tr>
<tr>
<td>Cap 100 mg</td>
<td>$14.92</td>
<td>60</td>
</tr>
<tr>
<td>Oral liq 6 mg per ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PRIMIDONE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>$6.74</td>
<td>30</td>
</tr>
</tbody>
</table>

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
SODIUM VALPROATE

Tab 100 mg
Tab EC 200 mg
Tab EC 500 mg
Oral liq 40 mg per ml
Inj 100 mg per ml, 4 ml vial

STIRIPENTOL – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>509.29 60</td>
<td>Diacomit</td>
</tr>
</tbody>
</table>

STIRIPENTOL – Restricted
Paediatric neurologist

Initiation
Re-assessment required after 6 months

Both:
1 Patient has confirmed diagnosis of Dravet syndrome; and
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Continuation
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>11.07 60</td>
<td>Arrow-Topiramate</td>
</tr>
<tr>
<td>18.81 60</td>
<td>Arrow-Topiramate</td>
</tr>
<tr>
<td>31.99 60</td>
<td>Arrow-Topiramate</td>
</tr>
<tr>
<td>55.19 60</td>
<td>Arrow-Topiramate</td>
</tr>
<tr>
<td>20.84 60</td>
<td>Topamax</td>
</tr>
<tr>
<td>26.04</td>
<td>Topiramate Actavis</td>
</tr>
<tr>
<td>44.26</td>
<td>Topiramate Actavis</td>
</tr>
<tr>
<td>75.25</td>
<td>Topiramate Actavis</td>
</tr>
<tr>
<td>129.85</td>
<td>Topiramate Actavis</td>
</tr>
</tbody>
</table>

VIGABATRIN – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
<tr>
<td>509.29 60</td>
<td>Diacomit</td>
</tr>
</tbody>
</table>

VIGABATRIN – Restricted

Both:
1 Either:
   1.1 Patient has infantile spasms; or
   1.2 Both:
   1.2.1 Patient has epilepsy; and
   1.2.2 Either:
   1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
   1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
2 Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

continued…

\(\text{\# Item restricted (see }\text{\# above); }\text{\$ Item restricted (see }\text{\$ below)}\)

e.g. Brand indicates brand example only. It is not a contracted product.
continued...

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields.

Notes:
“Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

### Antimigraine Preparations

#### Acute Migraine Treatment

**DIHYDROERGOTAMINE MESYLATE**  
Inj 1 mg per ml, 1 ml ampoule

**ERGOTAMINE TARTRATE WITH CAFFEINE**  
Tab 1 mg with caffeine 100 mg

**METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL**  
Tab 5 mg with paracetamol 500 mg

**RIZATRIPTAN**  
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 .................................................8.10 30 Rizamelt

**SUMATRIPTAN**  
Tab 50 mg – 1% DV Sep-13 to 2016 .................................................................29.80 100 Arrow-Sumatriptan  
Tab 100 mg – 1% DV Sep-13 to 2016 ...............................................................54.80 100 Arrow-Sumatriptan  
Inj 12 mg per ml, 0.5 ml cartridge – 1% DV Sep-13 to 2016 .............................13.80 2 Arrow-Sumatriptan

#### Prophylaxis of Migraine

**PIZOTIFEN**  
Tab 500 mcg – 1% DV Mar-13 to 2015 ...........................................................23.21 100 Sandomigran

### Antinausea and Vertigo Agents

**APREPITANT – Restricted** see terms below  
Cap 2 × 80 mg and 1 × 125 mg – 1% DV Sep-14 to 2017 ......................................100.00 3 Emend Tri-Pack  

**BETAHISTINE DIHYDROCHLORIDE**  
Tab 16 mg – 1% DV Jun-14 to 2017 .................................................................4.95 84 Vergo 16

**CYCLIZINE HYDROCHLORIDE**  
Tab 50 mg – 1% DV Sep-12 to 2015 .................................................................0.59 10 Nausicalm

**CYCLIZINE LACTATE**  
Inj 50 mg per ml, 1 ml ampoule ...............................................................14.95 5 Nausicalm

**DOMPERIDONE**  
Tab 10 mg – 1% DV Mar-13 to 2015 .................................................................3.25 100 Prokinex

**DROPERIDOL**  
Inj 2.5 mg per ml, 1 ml ampoule

**GRANISETRON**  
Tab 1 mg – 1% DV Jan-15 to 2017 .................................................................5.98 50 Granirex
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**HYOSCINE HYDROBROMIDE**

- **Inj 400 mcg per ml, 1 ml ampoule** .................................................. $6.66 5 Hospira
- **Patch 1.5 mg – 1% DV Dec-13 to 2016** ........................................... $11.95 2 Scopoderm TTS

**Restricted**

Any of the following:

1. Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
2. Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or
3. For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.

**METOCLOPRAMIDE HYDROCHLORIDE**

- **Tab 10 mg – 1% DV Sep-14 to 2017** ..................................................... $1.82 100 Metamide
- **Oral liq 5 mg per 5 ml** ................................................................. $4.50 10 Pfizer
- **Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017** .................. $5.51 50 Onrex
- **Tab dispersible 4 mg – 1% DV Oct-14 to 2017** ............................... $1.00 10 Dr Reddy’s Ondansetron
- **Tab 8 mg – 1% DV Jan-14 to 2016** ..................................................... $5.51 50 Onral
- **Tab dispersible 8 mg – 1% DV Oct-14 to 2017** ............................... $1.50 10 Ondansetron ODT-DRLA
- **Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016** .................. $1.82 5 Ondanaccord
- **Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016** .................. $2.18 5 Ondanaccord

**PROCHLORPERAZINE**

- **Tab buccal 3 mg** ................................................................. $9.75 500 Antinaus
- **Tab 5 mg – 1% DV Jun-14 to 2017** .............................................. $52.50 60 Solian
- **Inj 12.5 mg per ml, 1 ml ampoule** ..................................................
- **Suppos 25 mg** .................................................................
- **PROMETHAZINE THEOCLATE – Restricted: For continuation only**
  - **Tab 25 mg** .................................................................

**TROPISETRON**

- **Inj 1 mg per ml, 2 ml ampoule – 1% DV May-14 to 2015** .................. $8.95 1 Tropisetrone-AFT
- **Inj 1 mg per ml, 5 ml ampoule – 1% DV May-14 to 2015** ................. $13.95 1 Tropisetrone-AFT

**Antipsychotic Agents**

**General**

**AMISULPRIDE**

- **Tab 100 mg – 1% DV Jul-13 to 2016** .............................................. $6.22 30 Solian
- **Tab 200 mg – 1% DV Jul-13 to 2016** .............................................. $21.92 60 Solian
- **Tab 400 mg – 1% DV Jul-13 to 2016** .............................................. $44.52 60 Solian
- **Oral liq 100 mg per ml – 1% DV Jul-13 to 2016** ....................... $52.50 60 ml Solian
NERVOUS SYSTEM

ARIPIPRAZOLE – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abilify</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>123.54</td>
<td>30</td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>175.28</td>
<td>30</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>213.42</td>
<td>30</td>
</tr>
<tr>
<td>Tab 30 mg</td>
<td>260.07</td>
<td>30</td>
</tr>
</tbody>
</table>

**Restricted**

Both:

1. Patient is suffering from schizophrenia or related psychoses; and
2. Either:
   2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
   2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

CHLORPROMAZINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozaril</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>13.37</td>
<td>50</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>26.74</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td>6.69</td>
<td>50</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule</td>
<td>13.37</td>
<td>100</td>
</tr>
</tbody>
</table>

CLOZAPINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>8.67</td>
<td>50</td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>17.33</td>
<td>100</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>34.65</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
<td>17.33</td>
<td>100</td>
</tr>
</tbody>
</table>

HALOPERIDOL

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serenade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mcg – 1% DV Oct-13 to 2016</td>
<td>6.23</td>
<td>100</td>
</tr>
<tr>
<td>Tab 1.5 mg – 1% DV Oct-13 to 2016</td>
<td>9.43</td>
<td>100</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-13 to 2016</td>
<td>29.72</td>
<td>100</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-13 to 2016</td>
<td>23.84</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – 1% DV Oct-13 to 2016</td>
<td>21.55</td>
<td>10</td>
</tr>
</tbody>
</table>

LEVOMEPROMAZINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td>29.72</td>
<td>100</td>
</tr>
</tbody>
</table>

LITHIUM CARBONATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithicarb FC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 400 mg</td>
<td>34.30</td>
<td>500</td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-14 to 2017</td>
<td>9.42</td>
<td>100</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLANZAPINE</td>
<td>Tab 2.5 mg – 1% DV Sep-14 to 2017</td>
<td>0.75</td>
<td>Zypine</td>
</tr>
<tr>
<td></td>
<td>Tab 5 mg – 1% DV Sep-14 to 2017</td>
<td>1.65</td>
<td>Zypine</td>
</tr>
<tr>
<td></td>
<td>Tab orodispersible 5 mg – 1% DV Sep-14 to 2017</td>
<td>1.75</td>
<td>Zypine ODT</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg – 1% DV Sep-14 to 2017</td>
<td>2.55</td>
<td>Zypine</td>
</tr>
<tr>
<td></td>
<td>Tab orodispersible 10 mg – 1% DV Sep-14 to 2017</td>
<td>3.05</td>
<td>Zypine ODT</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PERICYAZINE</td>
<td>Tab 2.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QUETIAPINE</td>
<td>Tab 25 mg – 1% DV Sep-14 to 2017</td>
<td>2.10</td>
<td>Quetapel</td>
</tr>
<tr>
<td></td>
<td>Tab 100 mg – 1% DV Sep-14 to 2017</td>
<td>4.20</td>
<td>Quetapel</td>
</tr>
<tr>
<td></td>
<td>Tab 200 mg – 1% DV Sep-14 to 2017</td>
<td>7.20</td>
<td>Quetapel</td>
</tr>
<tr>
<td></td>
<td>Tab 300 mg – 1% DV Sep-14 to 2017</td>
<td>12.00</td>
<td>Quetapel</td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

Risperidone – Some items restricted see terms on the next page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>1.90</td>
<td>Actavis</td>
</tr>
<tr>
<td>2.86</td>
<td>Risperdal</td>
</tr>
<tr>
<td>3.51</td>
<td>Apo-Risperidone</td>
</tr>
<tr>
<td>6.00</td>
<td>Dr Reddy's Risperidone</td>
</tr>
<tr>
<td>60</td>
<td>Ridal</td>
</tr>
<tr>
<td>16.92</td>
<td>Risperdal Quicklet</td>
</tr>
<tr>
<td>21.42</td>
<td>Actavis</td>
</tr>
<tr>
<td>2.10</td>
<td>Risperdal</td>
</tr>
<tr>
<td>6.00</td>
<td>Apo-Risperidone</td>
</tr>
<tr>
<td>28</td>
<td>Dr Reddy's Risperidone</td>
</tr>
<tr>
<td>3.51</td>
<td>Ridal</td>
</tr>
<tr>
<td>42.84</td>
<td>Risperdal Quicklet</td>
</tr>
<tr>
<td>2.34</td>
<td>Actavis</td>
</tr>
<tr>
<td>10.00</td>
<td>Apo-Risperidone</td>
</tr>
<tr>
<td>33.84</td>
<td>Dr Reddy's Risperidone</td>
</tr>
<tr>
<td>28</td>
<td>Ridal</td>
</tr>
<tr>
<td>50.78</td>
<td>Risperdal</td>
</tr>
<tr>
<td>3.50</td>
<td>Actavis</td>
</tr>
<tr>
<td>20.00</td>
<td>Apo-Risperidone</td>
</tr>
<tr>
<td>50.78</td>
<td>Dr Reddy's Risperidone</td>
</tr>
<tr>
<td>67.68</td>
<td>Ridal</td>
</tr>
<tr>
<td>9.75</td>
<td>Risperdal</td>
</tr>
<tr>
<td>60</td>
<td>Risperon</td>
</tr>
</tbody>
</table>

Oral liq 1 mg per ml – 1% DV Sep-14 to 2017 ................................................. 9.75 30 ml

(Risperdal Tab 0.5 mg to be delisted 1 February 2015)
(Apo-Risperidone Tab 0.5 mg to be delisted 1 February 2015)
(Dr Reddy's Risperidone Tab 0.5 mg to be delisted 1 February 2015)
(Ridal Tab 0.5 mg to be delisted 1 February 2015)
(Apo-Risperidone Tab 1 mg to be delisted 1 February 2015)
(Dr Reddy's Risperidone Tab 1 mg to be delisted 1 February 2015)
(Ridal Tab 1 mg to be delisted 1 February 2015)
(Risperdal Tab 1 mg to be delisted 1 February 2015)
(Apo-Risperidone Tab 2 mg to be delisted 1 February 2015)
(Dr Reddy's Risperidone Tab 2 mg to be delisted 1 February 2015)
(Ridal Tab 2 mg to be delisted 1 February 2015)
(Risperdal Tab 2 mg to be delisted 1 February 2015)
(Apo-Risperidone Tab 3 mg to be delisted 1 February 2015)
(Dr Reddy's Risperidone Tab 3 mg to be delisted 1 February 2015)
(Ridal Tab 3 mg to be delisted 1 February 2015)
(Risperdal Tab 3 mg to be delisted 1 February 2015)
(Apo-Risperidone Tab 4 mg to be delisted 1 February 2015)
(Dr Reddy's Risperidone Tab 4 mg to be delisted 1 February 2015)
(Ridal Tab 4 mg to be delisted 1 February 2015)
(Risperdal Tab 4 mg to be delisted 1 February 2015)

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

continued...
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIPRASIDONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 20 mg</td>
<td>87.88</td>
<td>60 Zeldox</td>
</tr>
<tr>
<td>Cap 40 mg</td>
<td>164.78</td>
<td>60 Zeldox</td>
</tr>
<tr>
<td>Cap 60 mg</td>
<td>247.17</td>
<td>60 Zeldox</td>
</tr>
<tr>
<td>Cap 80 mg</td>
<td>329.56</td>
<td>60 Zeldox</td>
</tr>
<tr>
<td>Inj 20 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Restricted

**Acute situations**

Both:

1. For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
2. The patient is under direct supervision for administration of medicine.

**Chronic situations**

Both:

1. The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
2. The patient is under direct supervision for administration of medicine.

**TRIFLUOPERAZINE HYDROCHLORIDE**

- Tab 1 mg
- Tab 2 mg
- Tab 5 mg

**ZIPRASIDONE – Some items restricted** see terms below

- Cap 20 mg ................................................................. 87.88 60 Zeldox
- Cap 40 mg ................................................................. 164.78 60 Zeldox
- Cap 60 mg ................................................................. 247.17 60 Zeldox
- Cap 80 mg ................................................................. 329.56 60 Zeldox
- Inj 20 mg
- Inj 100 mg

#### Restricted

1. Patient is suffering from schizophrenia or related psychoses; and
2. Either:
   1. An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
   2. An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

**ZUCLOPENTHIXOL ACETATE**

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

**ZUCLOPENTHIXOL HYDROCHLORIDE**

- Tab 10 mg ................................................................. 31.45 100 Clopixol

### Depot Injections

**FLUPENTHIXOL DECANOATE**

- Inj 20 mg per ml, 1 ml ampoule ........................................... 13.14 5 Fluansol
- Inj 20 mg per ml, 2 ml ampoule ........................................... 20.90 5 Fluansol
- Inj 100 mg per ml, 1 ml ampoule ........................................... 40.87 5 Fluansol

**FLUPHENAZINE DECANOATE**

- Inj 12.5 mg per 0.5 ml ampoule ........................................... 17.60 5 Modecate
- Inj 25 mg per ml, 1 ml ampoule ........................................... 27.90 5 Modecate
- Inj 100 mg per ml, 1 ml ampoule ........................................... 154.50 5 Modecate

**HALOPERIDOL DECANOATE**

- Inj 50 mg per ml, 1 ml ampoule ........................................... 28.39 5 Haldol
- Inj 100 mg per ml, 1 ml ampoule ........................................... 55.90 5 Haldol Concentrate
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

OLANZAPINE – Restricted see terms below

- Inj 210 mg vial ......................................................... 280.00 1 Zyprexa Relprevv
- Inj 300 mg vial ......................................................... 460.00 1 Zyprexa Relprevv
- Inj 405 mg vial ......................................................... 560.00 1 Zyprexa Relprevv

Restricted
Initiation
Re-assessment required after 12 months
Either:
1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
2. All of the following:
   2.1 The patient has schizophrenia; and
   2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation
Re-assessment required after 12 months
The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE – Restricted see terms below

- Inj 25 mg syringe ......................................................... 194.25 1 Invega Sustenna
- Inj 50 mg syringe ......................................................... 271.95 1 Invega Sustenna
- Inj 75 mg syringe ......................................................... 357.42 1 Invega Sustenna
- Inj 100 mg syringe ....................................................... 435.12 1 Invega Sustenna
- Inj 150 mg syringe ....................................................... 435.12 1 Invega Sustenna

Restricted
Initiation
Re-assessment required after 12 months
Either:
1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1 The patient has schizophrenia or other psychotic disorder; and
   2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation
Re-assessment required after 12 months
The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE – Restricted: For continuation only

- Inj 50 mg per ml, 1 ml ampoule
- Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – Restricted see terms on the next page

- Inj 25 mg vial .............................................................. 135.98 1 Risperdal Consta
- Inj 37.5 mg vial ............................................................ 178.71 1 Risperdal Consta
- Inj 50 mg vial ............................................................... 217.56 1 Risperdal Consta

e.g. Brand indicates brand example only. It is not a contracted product.
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

---

### NERVOUS SYSTEM

#### Restricted

**Initiation**

*Re-assessment required after 12 months*

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
2. All of the following:
   1.1 The patient has schizophrenia or other psychotic disorder; and
   1.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   1.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

---

**ZUCLOPENTHIXOL DECANOATE**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>S Per Manufacturer</td>
<td></td>
</tr>
<tr>
<td>$19.80</td>
<td>5 Clopixol</td>
</tr>
</tbody>
</table>

#### Anxiolytics

**ALPRAZOLAM**

- Tab 1 mg
- Tab 250 mcg
- Tab 500 mcg

**BUSPIRONE HYDROCHLORIDE**

- Tab 5 mg ................................................................. $28.00 100 Pacific Buspirone
- Tab 10 mg ............................................................... $17.00 100 Pacific Buspirone

**CLONAZEPAM**

- Tab 500 mcg ............................................................. $6.68 100 Paxam
- Tab 2 mg ................................................................. $12.75 100 Paxam

**DIAZEPAM**

- Tab 2 mg ................................................................. $11.44 500 Arrow-Diazepam
- Tab 5 mg ................................................................. $13.71 500 Arrow-Diazepam

**LORAZEPAM**

- Tab 1 mg ................................................................. $19.82 250 Ativan
- Tab 2.5 mg ............................................................... $13.49 100 Ativan

**OXAZEPAM**

- Tab 10 mg – 1% DV Dec-14 to 2017 ..................................... $6.17 100 Ox-Pam
- Tab 15 mg – 1% DV Dec-14 to 2017 ................................... $8.53 100 Ox-Pam

#### Multiple Sclerosis Treatments

**FINGOLIMOD – Restricted** see terms below

- Cap 0.5 mg ................................................................. $2,650.00 28 Gilenya

**NATALIZUMAB – Restricted** see terms on the next page

- Inj 20 mg per ml, 15 ml vial ........................................... $1,750.00 1 Tysabri
NERVOUS SYSTEM

**Price** (ex man. excl. GST) $ Per Brand or Generic Manufacturer

### Restricted

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

### Other Multiple Sclerosis Treatments

**Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

GLATIRAMER ACETATE – **Restricted** see terms above

- **Inj 20 mg per ml, 1 ml syringe**

INTERFERON BETA-1-ALPHA – **Restricted** see terms above

- **Inj 6 million iu in 0.5 ml pen injector** ........................................................... 1,170.00 4 Avonex Pen
- **Inj 6 million iu in 0.5 ml syringe** ................................................................. 1,170.00 4 Avonex
- **Inj 6 million iu vial** ...................................................................................... 1,170.00 4 Avonex

INTERFERON BETA-1-BETA – **Restricted** see terms above

- **Inj 8 million iu per ml, 1 ml vial**

### Sedatives and Hypnotics

CHLORAL HYDRATE

- Oral liq 100 mg per ml
- Oral liq 200 mg per ml

LORMETAZEPAM – **Restricted**: For continuation only

- Tab 1 mg

MELATONIN – **Restricted** see terms below

- Tab modified-release 2 mg 
- Tab 1 mg 
- Tab 2 mg 
- Tab 3 mg 
- Cap 2 mg 
- Cap 3 mg 

**Restricted**

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

MIDAZOLAM

- Tab 7.5 mg ...................................................................................................... 40.00 100 Hypnovel
- Oral liq 2 mg per ml
- Inj 1 mg per ml, 5 ml ampoule ................................................................. 10.00 10 Pfizer
  10.75 Hypnovel
- Inj 5 mg per ml, 3 ml ampoule ............................................................... 11.90 5 Hypnovel
  Pfizer

NITRAZEPAM

- Tab 5 mg – 1% DV Dec-14 to 2017 ............................................................... 5.22 100 Nitrados

PHENOBARBITONE

- Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM

- Tab 10 mg – 1% DV Sep-14 to 2017 ....................................................... 1.27 25 Normison

*e.g. Brand* indicates brand example only. It is not a contracted product.
TRIAZOLAM – **Restricted**: For continuation only
- Tab 125 mcg
- Tab 250 mcg

ZOPICLONE
- Tab 7.5 mg ........................................................................................................1.90 30 Apo-Zopiclone

**Stimulants / ADHD Treatments**

**ATOMOXETINE – Restricted** see terms below
- Cap 10 mg .................................................................107.03 28 Strattera
- Cap 18 mg .................................................................107.03 28 Strattera
- Cap 25 mg .................................................................107.03 28 Strattera
- Cap 40 mg .................................................................107.03 28 Strattera
- Cap 60 mg .................................................................107.03 28 Strattera
- Cap 80 mg .................................................................139.11 28 Strattera
- Cap 100 mg ..............................................................139.11 28 Strattera

**Restricted**
All of the following:
1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

**CAFFEINE**
- Tab 100 mg

**DEXAMFETAMINE SULFATE – Restricted** see terms below
- Tab 5 mg – 1% DV Mar-13 to 2015 .................................................................16.50 100 PSM

**ADHD**
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

**Narcolepsy**
Neurologist or respiratory specialist
Patient suffers from narcolepsy
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**METHYLPHENIDATE HYDROCHLORIDE – Restricted** see terms below

- Tab extended-release 18 mg .......................................................... 58.96 30 Concerta
- Tab extended-release 27 mg .......................................................... 65.44 30 Concerta
- Tab extended-release 36 mg .......................................................... 71.93 30 Concerta
- Tab extended-release 54 mg .......................................................... 86.24 30 Concerta
- Tab immediate-release 5 mg ......................................................... 3.20 30 Rubifen
- Tab immediate-release 10 mg ....................................................... 3.00 30 Ritalin
- Tab immediate-release 20 mg ........................................................ 7.85 30 Rubifen
- Tab sustained-release 20 mg ....................................................... 10.95 30 Rubifen SR
  - 50.00 100 Ritalin SR
- Cap modified-release 10 mg ......................................................... 19.50 30 Ritalin SA
- Cap modified-release 20 mg ......................................................... 25.50 30 Ritalin LA
- Cap modified-release 30 mg ......................................................... 31.90 30 Ritalin LA
- Cap modified-release 40 mg ......................................................... 38.25 30 Ritalin LA

**Modafinil – Restricted** see terms below

- Tab 100 mg

**Item restricted (see above); **Item restricted (see below)

**e.g. Brand** indicates brand example only. It is not a contracted product.

### Restricted

**ADHD (immediate-release and sustained-release formulations)**

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

**Narcolepsy (immediate-release and sustained-release formulations)**

Neurologist or respiratory specialist

Patient suffers from narcolepsy

**Extended-release and modified-release formulations**

Paediatrician or psychiatrist

Both:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
2. Either:
   1. Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
   2. There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

**MODAFINIL – Restricted** see terms below

- Tab 100 mg

**Restricted**

Neurologist or respiratory specialist

All of the following:

1. The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
2. Either:
   1. The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
   2. The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
3. Either:
   1. An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
   2. Methylphenidate and dexamphetamine are contraindicated.
### Treatments for Dementia

**DONEPEZIL HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>$7.71</td>
<td>90 Donepezil-Rex</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>$14.06</td>
<td>90 Donepezil-Rex</td>
</tr>
</tbody>
</table>

**RIVASTIGMINE** – *Restricted* see terms below

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patch 4.6 mg</td>
<td>$90.00</td>
<td>30 Exelon</td>
</tr>
<tr>
<td>Patch 9.5 mg</td>
<td>$90.00</td>
<td>30 Exelon</td>
</tr>
</tbody>
</table>

*Restricted* Initiation

*Re-assessment required after 6 months*

Both:

1. The patient has been diagnosed with dementia; and
2. The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

*Continuation* *Re-assessment required after 12 months*

Both:

1. The treatment remains appropriate; and
2. The patient has demonstrated a significant and sustained benefit from treatment.

### Treatments for Substance Dependence

**BUPRENORPHINE WITH NALOXONE** – *Restricted* see terms below

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg</td>
<td>$57.40</td>
<td>28 Suboxone</td>
</tr>
<tr>
<td>Tab 8 mg</td>
<td>$166.00</td>
<td>28 Suboxone</td>
</tr>
</tbody>
</table>

*Restricted* Detoxification

All of the following:

1. Patient is opioid dependent; and
2. Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3. Prescriber works in an opioid treatment service approved by the Ministry of Health.

*Maintenance treatment*

All of the following:

1. Patient is opioid dependent; and
2. Patient will not be receiving methadone; and
3. Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4. Prescriber works in an opioid treatment service approved by the Ministry of Health.

**BUPROPION HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab modified-release 150 mg</td>
<td>$4.97</td>
<td>30 Zyban</td>
</tr>
</tbody>
</table>

**DISULFIRAM**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>$24.30</td>
<td>100 Antabuse</td>
</tr>
</tbody>
</table>

**NALTREXONE HYDROCHLORIDE** – *Restricted* see terms below

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>$76.00</td>
<td>30 Naltraccord</td>
</tr>
</tbody>
</table>

*Restricted* Alcohol dependence

Both:

1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

**Constipation**

For the treatment of opioid-induced constipation
NICOTINE – Some items restricted see terms below

Gum 2 mg – 1% DV Apr-14 to 2017 ...............................................................26.13 384 Habitrol (Classic)
   Habitrol (Fruit)
   Habitrol (Mint)

Gum 4 mg – 1% DV Apr-14 to 2017 ...............................................................30.12 384 Habitrol (Classic)
   Habitrol (Fruit)
   Habitrol (Mint)

Patch 7 mg per 24 hours – 1% DV Apr-14 to 2017 ...................................12.40 28 Habitrol

Patch 14 mg per 24 hours – 1% DV Apr-14 to 2017 .................................13.27 28 Habitrol

Patch 21 mg per 24 hours – 1% DV Apr-14 to 2017 .................................14.02 28 Habitrol

Lozenge 1 mg – 1% DV Apr-14 to 2017 .........................................................15.15 216 Habitrol

Lozenge 2 mg – 1% DV Apr-14 to 2017 .........................................................16.60 216 Habitrol

Soln for inhalation 15 mg cartridge e.g. Nicorette Inhalator

VARENICLINE – Restricted see terms below

Tab 0.5 mg × 11 and 1 mg × 14 .................................................................60.48 25 Champix

Tab 1 mg .....................................................................................................67.74 28 Champix

135.48 56 Champix

Restricted

Any of the following:

1 For perioperative use in patients who have a ‘nil by mouth’ instruction; or
2 For use within mental health inpatient units; or
3 For acute use in agitated patients who are unable to leave the hospital facilities.

VARENICLINE – Restricted see terms below

Tab 0.5 mg × 11 and 1 mg × 14 .................................................................60.48 25 Champix

Tab 1 mg .....................................................................................................67.74 28 Champix

135.48 56 Champix

Restricted

All of the following:

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3 Either:
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
4 The patient has not used funded varenicline in the last 12 months; and
5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6 The patient is not pregnant; and
7 The patient will not be prescribed more than 3 months’ funded varenicline in a 12 month period.
### Chemotherapeutic Agents

#### Alkylating Agents

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BUSULFAN</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td>59.50 100 Myleran</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 10 ml ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>CARMUSTINE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td></td>
</tr>
<tr>
<td><strong>CHLORAMBUCIL</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
</tr>
<tr>
<td><strong>CYCLOPHOSPHAMIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td>79.00 50 Endoxan</td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>158.00 100 Procytox</td>
</tr>
<tr>
<td>Inj 2 g vial</td>
<td>26.70 1 Endoxan</td>
</tr>
<tr>
<td><strong>IFOSFAMIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 1 g vial</td>
<td>96.00 1 Holoxan</td>
</tr>
<tr>
<td>Inj 2 g vial</td>
<td>180.00 1 Holoxan</td>
</tr>
<tr>
<td><strong>LOMUSTINE</strong></td>
<td></td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td>132.59 20 Ceenu</td>
</tr>
<tr>
<td>Cap 40 mg</td>
<td>399.15 20 Ceenu</td>
</tr>
<tr>
<td><strong>MELPHALAN</strong></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
</tr>
<tr>
<td><strong>THIOTEPA</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg vial</td>
<td></td>
</tr>
</tbody>
</table>

#### Anthracyclines and Other Cytotoxic Antibiotics

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BLEOMYCIN SULPHATE</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 15,000 iu (10 mg) vial</td>
<td></td>
</tr>
<tr>
<td><strong>DACTINOMYCIN [ACTINOMYCIN D]</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 0.5 mg vial</td>
<td></td>
</tr>
<tr>
<td><strong>DAUNORUBICIN</strong></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml vial – 1% DV Aug-13 to 2016</td>
<td>118.72 1 Pfizer</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td></td>
</tr>
<tr>
<td><strong>DOXORUBICIN HYDROCHLORIDE</strong></td>
<td></td>
</tr>
<tr>
<td>Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 25 ml vial – 1% DV Mar-13 to 2015</td>
<td>17.00 1 Arrow-Doxorubicin</td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 50 ml vial</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Mar-13 to 2015</td>
<td>65.00 1 Arrow-Doxorubicin</td>
</tr>
</tbody>
</table>
### Antimetabolites

#### AZACITIDINE – Restricted see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mg vial</td>
<td>605.00</td>
<td>Vidaza</td>
</tr>
</tbody>
</table>

#### Initiation

Haematologist

*Re-assessment required after 12 months*

All of the following:

1. Any of the following:
   1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
   1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
   1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
2. The patient has performance status (WHO/ECOG) grade 0-2; and
3. The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
4. The patient has an estimated life expectancy of at least 3 months.

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

#### Continuation

Haematologist

*Re-assessment required after 12 months*

Both:

1. No evidence of disease progression, and
2. The treatment remains appropriate and patient is benefitting from treatment.

#### CAPECITABINE

<table>
<thead>
<tr>
<th>Item</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 150 mg</td>
<td>30.00</td>
<td>Capecitabine Winthrop</td>
</tr>
<tr>
<td>Tab 500 mg</td>
<td>120.00</td>
<td>Capecitabine Winthrop</td>
</tr>
</tbody>
</table>
# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLADRIBINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml vial</td>
<td>5,249.72</td>
<td>Leustatin</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYTARABINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 5 ml vial – 1% DV Nov-13 to 2016</td>
<td>55.00</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 25 ml vial</td>
<td></td>
<td>1 Pfizer</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml vial – 1% DV Nov-13 to 2016</td>
<td>8.83</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 20 ml vial – 1% DV Nov-13 to 2016</td>
<td>17.65</td>
<td>Pfizer</td>
</tr>
<tr>
<td>FLUDARABINE PHOSPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jun-12 to 2015</td>
<td>433.50</td>
<td>Fludara Oral</td>
</tr>
<tr>
<td>Inj 50 mg vial</td>
<td>525.00</td>
<td>Fludarabine Ebewe</td>
</tr>
<tr>
<td>FLUOROURACIL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 100 ml vial</td>
<td>13.55</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 10 ml vial</td>
<td>26.25</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 20 ml vial</td>
<td>7.50</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 50 ml vial</td>
<td>18.00</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 100 ml vial</td>
<td>34.50</td>
<td>Fluorouracil Ebewe</td>
</tr>
<tr>
<td>GEMCITABINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017</td>
<td>8.36</td>
<td>Gemcitabine Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017</td>
<td>15.89</td>
<td>Gemcitabine Ebewe</td>
</tr>
<tr>
<td>MERCIPTOPURINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-13 to 2016</td>
<td>49.41</td>
<td>Puri-nethol</td>
</tr>
<tr>
<td>METHOTREXATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Jun-14 to 2015</td>
<td>3.82</td>
<td>Trexate</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jun-14 to 2015</td>
<td>26.25</td>
<td>Trexate</td>
</tr>
<tr>
<td>Inj 2.5 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 7.5 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.19</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 10 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.25</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 15 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.38</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 20 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.50</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 25 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.63</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 30 mg prefilled syringe – 1% DV Jan-14 to 2016</td>
<td>17.75</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016</td>
<td>20.20</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 25 mg per ml, 20 ml vial – 1% DV Sep-13 to 2016</td>
<td>27.78</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml vial</td>
<td>25.00</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 50 ml vial – 1% DV Oct-14 to 2017</td>
<td>99.99</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td>THIOGUANINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 40 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other Cytotoxic Agents

#### AMSACRINE

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 1.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### ANAGRELIDE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 0.5 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### ARSENIC TRIOXIDE

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td>4,817.00</td>
<td>AFT</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

**BORTEZOMIB – Restricted** see terms below

|$ Inj 1 mg vial ................................................................. 540.70 | 1 Velcade
|$ Inj 3.5 mg vial ............................................................. 1,892.50 | 1 Velcade

**Restricted**

Initiation - treatment naive multiple myeloma/amyloidosis

Both:
1 Either:
   1.1 The patient has treatment-naive symptomatic multiple myeloma; or
   1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initiation - relapsed/refractory multiple myeloma/amyloidosis

All of the following:
1 Either:
   1.1 The patient has relapsed or refractory multiple myeloma; or
   1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
3 The patient has not had prior publicly funded treatment with bortezomib; and
4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Continuation - relapsed/refractory multiple myeloma/amyloidosis

Both:
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:
1 A known therapeutic chemotherapy regimen and supportive treatments; or
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

**COLASPASE [L-ASPARAGINASE]**

|$ Inj 10,000 iu vial ............................................................. 102.32 | 1 Leunase

**DACARBAZINE**

|$ Inj 200 mg vial – 1% DV Oct-13 to 2016 ........................................... 51.84 | 1 Hospira

**ETOPOSIDE**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|$ Cap 50 mg ................................................................. 340.73 | 20 Vepesid
|$ Cap 100 mg .............................................................. 340.73 | 10 Vepesid
|$ Inj 20 mg per ml, 5 ml vial ........................................ 25.00 | 1 Hospira

**ETOPOSIDE (AS PHOSPHATE)**

|$ Inj 100 mg vial ............................................................ 40.00 | 1 Etopophos

**HYDROXYUREA**

|$ Cap 500 mg ................................................................. 31.76 | 100 Hydrea

**IRINOTECAN HYDROCHLORIDE**

|$ Inj 20 mg per ml, 2 ml vial – 1% DV Nov-12 to 2015 .................. 9.34 | 1 Irinotecan Actavis 40
|$ Inj 20 mg per ml, 5 ml vial – 1% DV Nov-12 to 2015 ............... 23.34 | 1 Irinotecan Actavis 100

**LENALIDOMIDE – Restricted** see terms on the next page

|$ Cap 10 mg ................................................................. 6,207.00 | 21 Revlimid
|$ Cap 25 mg ................................................................. 7,627.00 | 21 Revlimid
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**Restricted**

Initiation

Haematologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has relapsed or refractory multiple myeloma with progressive disease; and
2. Either:
   2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
   2.2 Both:
      2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
      2.2.2 The patient has experienced severe (grade ≥ 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
3. Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation

Haematologist

*Re-assessment required after 6 months*

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and patient is benefitting from treatment.

Notes: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

**PEGASPARGASE – Restricted** see terms below

| Inj 750 iu per ml, 5 ml vial | 3,005.00 | 1 Oncaspar |

**Restricted**

Newly diagnosed ALL

*Limited to 12 months' treatment*

All of the following:

1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

Relapsed ALL

*Limited to 12 months' treatment*

All of the following:

1. The patient has relapsed acute lymphoblastic leukaemia; and
2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
3. Treatment is with curative intent.

**PENTOSTATIN [DEOXYCOFORMYCIN]**

Inj 10 mg vial

**PROCARBAZINE HYDROCHLORIDE**

Cap 50 mg .................................................................498.00 50 Natulan

**TEMOZOLOMIDE – Restricted** see terms on the next page

| Cap 5 mg – 1% DV Sep-13 to 2016 | 8.00 | 5 Temaccord |
| Cap 20 mg – 1% DV Sep-13 to 2016 | 36.00 | 5 Temaccord |
| Cap 100 mg – 1% DV Sep-13 to 2016 | 175.00 | 5 Temaccord |
| Cap 250 mg – 1% DV Sep-13 to 2016 | 410.00 | 5 Temaccord |

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

**Restricted**

All of the following:

1. Either:
   1.1 Patient has newly diagnosed glioblastoma multiforme; or
   1.2 Patient has newly diagnosed anaplastic astrocytoma; and
2. Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3. Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

**THALIDOMIDE – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- Cap 50 mg ................................................................. 378.00 28 Thalomid
- Cap 100 mg .............................................................. 756.00 28 Thalomid

**Resitcted**

**Initiation**

Either:

1. The patient has multiple myeloma; or
2. The patient has systemic AL amyloidosis; or
3. The patient has erythema nodosum leprosum.

**Continuation**

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication

**TRETINOIN**

Cap 10 mg ................................................................. 435.90 100 Vesanoid

**Platinum Compounds**

**CARBOPLATIN**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- Inj 10 mg per ml, 5 ml vial ........................................... 20.00 1 Carboplatin Ebewe
- Inj 10 mg per ml, 15 ml vial – 1% DV Jan-13 to 2015 .............. 19.50 1 Carbaccord
- Inj 10 mg per ml, 45 ml vial – 1% DV Jan-13 to 2015 .............. 48.50 1 Carbaccord
- Inj 10 mg per ml, 100 ml vial ............................................... 105.00 1 Carboplatin Ebewe

**CISPLATIN**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- Inj 1 mg per ml, 50 ml vial ............................................. 15.00 1 Cisplatin Ebewe
- Inj 1 mg per ml, 100 ml vial ............................................ 21.00 1 Cisplatin Ebewe

**OXALIPLATIN**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- Inj 50 mg vial – 1% DV Aug-12 to 2015 .............................. 15.32 1 Oxaliplatin Actavis 50
- Inj 100 mg vial – 1% DV Aug-12 to 2015 .............................. 25.01 1 Oxaliplatin Actavis 100

**Protein-Tyrosine Kinase Inhibitors**

**DASATINIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- Tab 20 mg ........................................................................ 3,774.06 60 Sprycel
- Tab 50 mg ........................................................................ 6,214.20 60 Sprycel
- Tab 70 mg ........................................................................ 7,692.58 60 Sprycel
- Tab 100 mg ................................................................. 6,214.20 30 Sprycel

**Restricted**

For use in patients with approval from the CML/GIST Co-ordinator
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ERLOTINIB – **Restricted** see terms below

- **Tab 100 mg** ................................................................. 1,133.00 30 Tarceva
- **Tab 150 mg** ................................................................. 1,700.00 30 Tarceva

**Restricted**

Initiation

*Re-assessment required after 3 months*

Either:

1. All of the following:
   1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
   1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
   1.3 Either:
      1.3.1 Patient is treatment naive; or
      1.3.2 Both:
         1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
         1.3.2.2 Patient has not received prior treatment with gefitinib; and
   1.4 Erlotinib is to be given for a maximum of 3 months, or
2. The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Continuation

*Re-assessment required after 6 months*

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – **Restricted** see terms below

- **Tab 250 mg** ................................................................. 1,700.00 30 Iressa

**Restricted**

Initiation

*Re-assessment required after 3 months*

Both

1. Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.

Continuation

*Re-assessment required after 6 months*

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

- **Tab 100 mg** ................................................................. 2,400.00 60 Glivec

**Restricted**

Initiation

*Re-assessment required after 12 months*

Both:

1. Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Maximum dose of 400 mg/day.

Continuation

*Re-assessment required after 12 months*

Adequate clinical response to treatment with imatinib (prescriber determined).

- **Cap 100 mg – 1% DV Jul-14 to 2017** ................................................................. 298.90 60 Imatinib-AFT
Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

LAPATINIB – Restricted see terms below

$ Tab 250 mg ................................................................. 1,899.00 70 Tykerb

⇒ Restricted

Initiation

Re-assessment required after 12 months

Either:

1. All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or

2. All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and
   2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

All of the following:

1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3. Lapatinib not to be given in combination with trastuzumab; and
4. Lapatinib to be discontinued at disease progression.

NILOTINIB – Restricted see terms below

$ Cap 150 mg ................................................................. 4,680.00 120 Tasigna

$ Cap 200 mg ................................................................. 6,532.00 120 Tasigna

⇒ Restricted

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1. Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
2. Either:
   2.1 Patient has documented CML treatment failure* with imatinib; or
   2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

continued…
Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation
Haematologist
Re-assessment required after 6 months
All of the following:
1. Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
2. Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
3. Maximum nilotinib dose of 800 mg/day; and
4. Subsidised for use as monotherapy only.

Pazopanib – Restricted see terms below
- Tab 200 mg .................................................................1,334.70 30 Votrient
- Tab 400 mg .................................................................2,669.40 30 Votrient

Restricted
Initiation
Re-assessment required after 3 months
All of the following:
1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1 The patient is treatment naive; or
   2.2 The patient has only received prior cytokine treatment; or
   2.3 Both:
      2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
      2.3.2 The cancer did not progress whilst on sunitinib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. The patient has intermediate or poor prognosis defined as any of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
   5.2 Haemoglobin level < lower limit of normal; or
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
   5.5 Karnofsky performance score of ≤ 70; or
   5.6 ≥ 2 sites of organ metastasis.

Continuation
Re-assessment required after 3 months
Both:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

Sunitinib – Restricted see terms on the next page
- Cap 12.5 mg .................................................................2,315.38 28 Sutent
- Cap 25 mg .................................................................4,630.77 28 Sutent
- Cap 50 mg .................................................................9,261.54 28 Sutent
Restricted
Re-assessment required after 3 months

Initiation - RCC

1. The patient has metastatic renal cell carcinoma; and
2. Any of the following:
   2.1. The patient is treatment naive; or
   2.2. The patient has only received prior cytokine treatment; or
   2.3. The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
   2.4. Both:
      2.4.1. The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
      2.4.2. The cancer did not progress whilst on pazopanib; and
3. The patient has good performance status (WHO/ECOG grade 0-2); and
4. The disease is of predominant clear cell histology; and
5. The patient has intermediate or poor prognosis defined as any of the following:
   5.1. Lactate dehydrogenase level > 1.5 times upper limit of normal; or
   5.2. Haemoglobin level < lower limit of normal; or
   5.3. Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
   5.4. Interval of < 1 year from original diagnosis to the start of systemic therapy; or
   5.5. Karnofsky performance score of \( \leq 70 \); or
   5.6. \( \geq 2 \) sites of organ metastasis; and
6. Sunitinib to be used for a maximum of 2 cycles.

Continuation - RCC
Re-assessment required after 3 months

Both:
1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Initiation - GIST
Re-assessment required after 3 months

Both:
1. The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Either:
   2.1. The patient's disease has progressed following treatment with imatinib; or
   2.2. The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation - GIST
Re-assessment required after 6 months

Both:
The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:
1. Any of the following:
   1.1. The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2. The patient has had a partial response (a decrease in size of \( \geq 10\% \) or decrease in tumour density in Hounsfield Units (HU) of \( \geq 15\% \) on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3. The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

continued...
Notes: RCC - Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

GIST - It is recommended that response to treatment be assessed using Choi’s modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

### Taxanes

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOCETAXEL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml vial – 1% DV Dec-14 to 2017</td>
<td>13.70 1375.00 137.50 137.50</td>
<td>Docetaxel Sandoz DBL Docetaxel</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 8 ml vial – 1% DV Dec-14 to 2017</td>
<td>48.75 48.75 48.75 48.75</td>
<td>Docetaxel Sandoz DBL Docetaxel</td>
</tr>
</tbody>
</table>

**PACLITAXEL**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 6 mg per ml, 5 ml vial – 1% DV Sep-14 to 2017</td>
<td>45.00 45.00 45.00 45.00</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 16.7 ml vial – 1% DV Sep-14 to 2017</td>
<td>19.02 19.02 19.02 19.02</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 25 ml vial – 1% DV Sep-14 to 2017</td>
<td>26.69 26.69 26.69 26.69</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017</td>
<td>36.53 36.53 36.53 36.53</td>
<td>Paclitaxel Ebewe</td>
</tr>
<tr>
<td>Inj 6 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017</td>
<td>73.06 73.06 73.06 73.06</td>
<td>Paclitaxel Ebewe</td>
</tr>
</tbody>
</table>

### Treatment of Cytotoxic-Induced Side Effects

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CALCIUM FOLINATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 15 mg</td>
<td>82.45 82.45 82.45 82.45</td>
<td>DBL Leucovorin Calcium</td>
</tr>
<tr>
<td>Inj 3 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Oct-14 to 2017</td>
<td>18.25 18.25 18.25 18.25</td>
<td>Calcium Folate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial – 1% DV Oct-14 to 2017</td>
<td>7.33 7.33 7.33 7.33</td>
<td>Calcium Folate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 30 ml vial – 1% DV Oct-14 to 2017</td>
<td>22.51 22.51 22.51 22.51</td>
<td>Calcium Folate Ebewe</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017</td>
<td>67.51 67.51 67.51 67.51</td>
<td>Calcium Folate Ebewe</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg – 1% DV Oct-13 to 2016</td>
<td>227.50 227.50 227.50 227.50</td>
<td>Uromitexan</td>
</tr>
<tr>
<td>Tab 600 mg – 1% DV Oct-13 to 2016</td>
<td>339.50 339.50 339.50 339.50</td>
<td>Uromitexan</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-13 to 2016</td>
<td>148.05 148.05 148.05 148.05</td>
<td>Uromitexan</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-13 to 2016</td>
<td>339.90 339.90 339.90 339.90</td>
<td>Uromitexan</td>
</tr>
</tbody>
</table>

### Vinca Alkaloids

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VINBLASTINE SULPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td>137.50 137.50 137.50 137.50</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

**VINCRISTINE SULPHATE**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 1 ml vial – 1% DV Sep-13 to 2016</td>
<td>64.80 64.80 64.80 64.80</td>
<td>Hospira</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016</td>
<td>69.60 69.60 69.60 69.60</td>
<td>Hospira</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VINORELBINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml vial – 1% DV Sep-12 to 2015</td>
<td>12.85</td>
<td>1 Navelbine</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml vial – 1% DV Sep-12 to 2015</td>
<td>64.25</td>
<td>1 Navelbine</td>
</tr>
</tbody>
</table>

**Endocrine Therapy**

**BICALUTAMIDE**
- Tab 50 mg – 1% DV Sep-14 to 2017 .............................................4.90 28 Bicalaccord

**FLUTAMIDE**
- Tab 250 mg .................................................................55.00 100 Flutamin

**MEGESTROL ACETATE**
- Tab 160 mg – 1% DV Jan-13 to 2015 ..................................................51.55 30 Apo-Megestrol

**OCTREOTIDE – Some items restricted** see terms below
- Inj 50 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 ..........................13.50 5 DBL
- Inj 100 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 ......................22.40 5 DBL
- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017 .................89.40 5 DBL
- $ Inj 10 mg vial ........................................................................1,772.50 1 Sandostatin LAR
- $ Inj 20 mg vial ........................................................................2,358.75 1 Sandostatin LAR
- $ Inj 30 mg vial ........................................................................2,951.25 1 Sandostatin LAR

⇒ Restricted

Note: restriction applies only to the long-acting formulations of octreotide

**Malignant bowel obstruction**

All of the following:
1. The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2. Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3. Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications

**Initiation - acromegaly**

Re-assessment required after 3 months

Both:
1. The patient has acromegaly; and
2. Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Continuation - acromegaly**

Both:
1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Other indications**

Any of the following:
1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or

continued…

---

*⇒ Item restricted (see ⇒ above); $Item restricted (see ⇒ below)

* e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

2 Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3 Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or

4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

TAMOXIFEN CITRATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genox</td>
</tr>
</tbody>
</table>

| Tab 10 mg | 2.63 | 60 |
| Tab 20 mg | 8.75 | 30 |

Aromatase Inhibitors

ANASTROZOLE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aremed</td>
</tr>
</tbody>
</table>

| Tab 1 mg | 26.55 | 30 |

EXEMESTANE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aromasin</td>
</tr>
</tbody>
</table>

| Tab 25 mg – 1% DV Sep-14 to 2017 | 14.50 | 30 |

LETROZOLE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letraccord</td>
</tr>
</tbody>
</table>

| Tab 2.5 mg – 1% DV Oct-12 to 2015 | 4.85 | 30 |

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoral</td>
</tr>
</tbody>
</table>

| Cap 25 mg | 44.63 | 50 |
| Cap 50 mg | 88.91 | 50 |
| Cap 100 mg | 177.81 | 50 |
| Oral liq 100 mg per ml – 1% DV Oct-12 to 2015 | 198.13 | 50 ml |
| Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-12 to 2015 | 276.30 | 10 |

TACROLIMUS – Restricted see terms below

1. Cap 0.5 mg – 1% DV Nov-14 to 31 Oct 2018 | 85.60 | 100 |
2. Cap 1 mg – 1% DV Nov-14 to 31 Oct 2018 | 171.20 | 100 |
3. Cap 5 mg – 1% DV Nov-14 to 31 Oct 2018 | 428.00 | 50 |
4. Inj 5 mg per ml, 1 ml ampoule

Restricted

For use in organ transplant recipients

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Fusion Proteins

**ETANERCEPT – Restricted** see terms below

- $ Inj 25 mg vial ..................................................................................................... 949.96 4 Enbrel
- $ Inj 50 mg autoinjector .................................................................................. 1,899.92 4 Enbrel
- $ Inj 50 mg syringe ....................................................................................... 1,899.92 4 Enbrel

**Initiation - juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 4 months*

*Either:*

1. **Both:**
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2. **All of the following:**
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m\(^2\) weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 **Both:**
   2.5.1 Either:
      2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
      2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
   2.5.2 Physician's global assessment indicating severe disease.

**Continuation - juvenile idiopathic arthritis**

Rheumatologist or named specialist

*Re-assessment required after 6 months*

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. **Either:**
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

**Initiation - rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

*Either:*

1. **Both:**
   1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
continued...

1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:
2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:
2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:
2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:
2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      continued...
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

continued...

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and

2.5 Either:
   2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
   2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and

2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2 All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

continued…
2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:
   2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
   2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation - psoriatic arthritis**

**Rheumatologist**

**Re-assessment required after 6 months**

All of the following:

1 Either:
   1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Initiation - plaque psoriasis, prior TNF use**

**Dermatologist**

**Re-assessment required after 4 months**

Both:

1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
   Either:
   1.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and

2 Patient must be reassessed for continuation after 3 doses.

**Initiation - plaque psoriasis, treatment-naive**

**Dermatologist**

**Re-assessment required after 4 months**

All of the following:

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

continued…
continued . . .

3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment
courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as
assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for
severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and
scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot,
as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation - plaque psoriasis**

Dermatologist

*Re-assessment required after 6 months*

Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or
      more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or

   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of
      treatment; and
      1.2.2 Either:
          1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom
          subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as
          compared to the treatment course baseline values; or
          1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the
          skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline
          value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

**Indication - pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and
2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone,
ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Defini-
tions) and Part V (Miscellaneous Provisions) rule 5.5).

**Renewal - pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses

**Initiation - adult-onset Still’s disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both: continued . . .
continued...

1. Either:
   1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
   1.2 The patient has received an initial Special Authority approval for tocilizumab for AOSD; or

2. All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
   2.3 Patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

Continuation - adult-onset Still’s disease
Paediatric rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

Monoclonal Antibodies

ABCIXIMAB – Restricted see terms below
- Inj 2 mg per ml, 5 ml vial ........................................................................579.53 1 ReoPro

ADALIMUMAB – Restricted see terms below
- Inj 20 mg per 0.4 ml syringe ......................................................................1,799.92 2 Humira
- Inj 40 mg per 0.8 ml pen ............................................................................1,799.92 2 HumiraPen
- Inj 40 mg per 0.8 ml syringe ......................................................................1,799.92 2 Humira

Initiation - juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 4 months
Either:
   1 Either:
      1.1 Both:
         1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
         1.1.2 The patient has experienced intolerable side effects from etanercept; or
      1.2 Either:
         1.2.1 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
   2 All of the following:
      2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
      2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
      2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

Products with Hospital Supply Status (HSS) are in **bold**
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:
   2.5.1 Either:
       2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
       2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician’s global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician’s global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician’s global assessment from baseline.

Initiation - fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 4 months
All of the following:
1 Patient has confirmed Crohn’s disease; and
2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e); and
3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation - fistulising Crohn’s disease
Gastroenterologist
Re-assessment required after 6 months
Either:
1 The number of open draining fistulae have decreased from baseline by at least 50%; or
2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Crohn’s disease
Gastroenterologist
Re-assessment required after 3 months
All of the following:
1 Patient has severe active Crohn’s disease; and
2 Any of the following:
   2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

continued…
2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - Crohn’s disease
Gastroenterologist
Re-assessment required after 3 months
Both:
1 Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5 Any of the following:
      2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
      2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
      2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
   2.6 Either:
      2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
      2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.7 Either:
      ...
2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Continuation - rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:
1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3. Adalimumab to be administered at doses no greater than 50 mg every 7 days.

**Initiation - ankylosing spondylitis**

Rheumatologist

*Re-assessment required after 6 months*

Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
2. All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
2.5 Either:
   2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
   2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

continued…
Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:
1. Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:
1. Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
2. All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
2.5 Any of the following:
   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...
Continuation - psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
1 Either:
   1.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - plaque psoriasis, prior TNF use
Dermatologist
Re-assessment required after 4 months
Both:
1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from etanercept; or
   2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; and

Initiation - plaque psoriasis, treatment-naive
Dermatologist
Re-assessment required after 4 months
All of the following:
1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis
Dermatologist
Re-assessment required after 6 months
Both:
1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued...
continued...

1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre- etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Indication - pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum*; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

**Renewal - pyoderma gangrenosum**

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and

2 Patient continues to require treatment; and

3 A maximum of 4 doses

**Initiation - adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or

1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or

2 All of the following:

2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Continuation - adult-onset Still's disease**

Rheumatologist

*Re-assessment required after 6 months*

The patient has a sustained improvement in inflammatory markers and functional status.
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BASILIXIMAB – Restricted</strong> see terms below</td>
<td>$3,200.00</td>
<td>Simulect</td>
</tr>
<tr>
<td>$ Inj 20 mg vial</td>
<td>$3,200.00</td>
<td>Simulect</td>
</tr>
<tr>
<td><strong>BEVACIZUMAB – Restricted</strong> see terms below</td>
<td>$1,227.00</td>
<td>Remicade</td>
</tr>
<tr>
<td>$ Inj 25 mg per ml, 16 ml vial</td>
<td>$1,227.00</td>
<td>Remicade</td>
</tr>
<tr>
<td>$ Inj 25 mg per ml, 4 ml vial</td>
<td>$1,227.00</td>
<td>Remicade</td>
</tr>
</tbody>
</table>

**Restricted**

For use in solid organ transplants

**BEVACIZUMAB – Restricted** see terms below

**INFLIXIMAB – Restricted** see terms below

**Graft vs host disease**

*Patient has steroid-refractory acute graft vs. host disease of the gut*

**Initiation - rheumatoid arthritis**

*Rheumatologist*

*Re-assessment required after 3-4 months*

All of the following:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2. Either:
   1. The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2. Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
3. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

**Continuation - rheumatoid arthritis**

*Rheumatologist*

*Re-assessment required after 6 months*

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   1. Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2. The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3. Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

**Initiation - ankylosing spondylitis**

*Rheumatologist*

*Re-assessment required after 3 months*

Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
2. Either:
   1. The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2. Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

*continued…*
continued... 

**Continuation - ankylosing spondylitis**
Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

**Initiation - psoriatic arthritis**
Rheumatologist

*Re-assessment required after 3-4 months*

Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
2. Either:
   1. The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2. Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

**Continuation - psoriatic arthritis**
Rheumatologist

*Re-assessment required after 6 months*

Both:

1. Either:
   1. Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2. The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation - severe ocular inflammation**

*Re-assessment required after 3 doses*

Both:

1. Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
2. Either:
   1. Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
   2. Patient developed new inflammatory symptoms while receiving high dose steroids.

**Initiation - chronic ocular inflammation**

*Re-assessment required after 3 doses*

Both:

1. Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
2. Patient has tried at least two other immunomodulatory agents.

**Continuation - ocular inflammation**

Both:

1. Patient had a good clinical response to initial treatment; and
2. Either:
   1. A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
   2. Patient has Behcet's disease.

**Pulmonary sarcoidosis**

Both: 

continued...
continued…

1. Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
2. Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

**Initiation - Crohn’s disease (adults)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Patient has severe active Crohn’s disease; and
2. Any of the following:
   2.1. Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2. Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3. Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4. Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate; and
5. Patient must be reassessed for continuation after 3 months of therapy.

**Continuation - Crohn’s disease (adults)**

Gastroenterologist

*Re-assessment required after 6 months*

All of the following:

1. One of the following:
   1.1. CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2. CDAI score is 150 or less; or
   1.3. The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3. Patient must be reassessed for continuation after further 6 months.

**Initiation - Crohn’s disease (children)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Paediatric patient has severe active Crohn’s disease; and
2. Any of the following:
   2.1. Patient has a Paediatric Crohn’s Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2. Patient has extensive small intestine disease; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate; and
5. Patient must be reassessed for continuation after 3 months of therapy.

**Continuation - Crohn’s disease (children)**

Gastroenterologist

*Re-assessment required after 6 months*

All of the following:

1. One of the following:
   1.1. PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2. PCDAI score is 15 or less; or
   continued…
continued...

1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3 Patient must be reassessed for continuation after further 6 months.

Initiation - fistulising Crohn’s disease
Gastroenterologist
All of the following:
1 Patient has confirmed Crohn’s disease; and
2 Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e); and
3 Patient must be reassessed for continuation after 4 months of therapy.

Continuation - fistulising Crohn’s disease
Gastroenterologist
All of the following:
1 Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3 Patient must be reassessed for continuation after further 6 months.

Initiation - acute severe fulminant ulcerative colitis
Gastroenterologist
All of the following:
1 Patient has acute, severe fulminant ulcerative colitis; and
2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
3 Patient must be reassessed for continuation after 6 weeks of therapy.

Continuation - severe fulminant ulcerative colitis
Gastroenterologist
All of the following:
1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3 Patient must be reassessed for continuation after further 6 months.

Initiation - severe ulcerative colitis
Gastroenterologist
All of the following:
1 Patient has histologically confirmed ulcerative colitis; and
2 The Simple Clinical Colitis Activity Index (SCCAI) is \( \geq 4 \)
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and

continued...
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

**Continuation - severe ulcerative colitis**
Gastroenterologist
All of the following:
1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2 SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; and
3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation - plaque psoriasis, prior TNF use**
Dermatologist
Re-assessment required after 3 doses
Both:
1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
   2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

**Initiation - plaque psoriasis, treatment-naïve**
Dermatologist
Re-assessment required after 3 doses
All of the following:
1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, thotrexate, cyclosporin, or acitretin; and
3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation - plaque psoriasis**
Dermatologist
Re-assessment required after 3 doses
Both:
1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and continued…
continued...

1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:
  1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
  1.2.2 Either:
    1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
    1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OMALIZUMAB – Restricted see terms below

$ Inj 150 mg vial .......................................................... 500.00 1 Xolair

Omalizumab – Restricted

Initiation
Respiratory physician

Re-assessment required after 6 months
All of the following:
1 Patient is over the age of 6; and
2 Patient has a diagnosis of severe, life threatening asthma; and
3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/mL at baseline; and
5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.

Continuation
Respiratory physician

Re-assessment required after 6 months
All of the following:
1 Hospital admissions have been reduced as a result of treatment; and
2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

RANIBIZUMAB – Restricted see terms on the next page

$ Inj 10 mg per ml, 0.23 ml vial
$ Inj 10 mg per ml, 0.3 ml vial

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

Restricted

**Initiation**

*Re-assessment required after 3 doses*

Both:

1. Either
   1.1 Age-related macular degeneration; or
   1.2 Choroidal neovascular membrane; and
2. Any of the following:
   2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
   2.2 The patient has had a myocardial infarction or stroke within the last three months; or
   2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or
   2.4 The patient is of child-bearing potential and has not completed a family.

**Continuation**

Both:

1. Documented benefit after three doses must be demonstrated to continue; and
2. In the case of but previous non-response to bevacizumab, a retrial of bevacizumab is required to confirm non-response before continuing with ranibizumab.

**RITUXIMAB** – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

\[\text{Inj 10 mg per ml, 10 ml vial} \]$ $1,075.50 2 Mabthera

\[\text{Inj 10 mg per ml, 50 ml vial} \]$ $2,688.30 1 Mabthera

Restricted

**Initiation - haemophilia with inhibitors**

Haematologist

Any of the following:

1. Patient has mild congenital haemophilia complicated by inhibitors; or
2. Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
3. Patient has acquired haemophilia.

**Continuation - haemophilia with inhibitors**

Haematologist

All of the following:

1. Patient was previously treated with rituximab for haemophilia with inhibitors; and
2. An initial response lasting at least 12 months was demonstrated; and

**Initiation - post-transplant**

Both:

1. The patient has B-cell post-transplant lymphoproliferative disorder*; and
2. To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

**Continuation - post-transplant**

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has B-cell post-transplant lymphoproliferative disorder*; and
3. To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications

**Initiation - indolent, low-grade lymphomas**

Either:

1. Both:
   1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or
   1.3 Both: continued…
1.3.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
1.3.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Continuation - indolent, low-grade lymphomas

All of the following:
1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
3. To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initiation - aggressive CD20 positive NHL

Either:
1. All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or
2. Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:
1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Chronic lymphocytic leukaemia

All of the following:
1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. The patient is rituximab treatment naive; and
3. Either:
   3.1 The patient is chemotherapy treatment naive; or
   3.2 Both:
      3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
      3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
4. The patient has good performance status; and
5. The patient has good renal function (creatinine clearance $\geq$ 30 ml/min); and
6. The patient does not have chromosome 17p deletion CLL; and
7. Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
8. It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

continued...
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

**Initiation - rheumatoid arthritis - prior TNF inhibitor use**

Rheumatologist  
**Re-assessment required after 2 doses**

All of the following:

1. Both:
   1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
      1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2. Either:
   2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

3. Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Initiation - rheumatoid arthritis - TNF inhibitors contraindicated**

Rheumatologist  
**Re-assessment required after 2 doses**

All of the following:

1. Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
2. Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
3. Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
4. Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
5. Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6. Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7. Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8. Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

continued…
8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in ‘partial responders’ to rituximab
Rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Either:
1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
3 Either:
3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in ‘responders’ to rituximab
Rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Either:
1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
3 Either:
3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)
Haematologist
Limited to 4 weeks’ treatment
Both:
1 Patient has cold haemagglutinin disease*; and
2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.
Note: Indications marked with * are Unapproved Indications.

Continuation – severe cold haemagglutinin disease (CHAD)
Haematologist
Limited to 4 weeks’ treatment
Either:
1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
continued...
2 All of the following:
   2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)
Haematologist
Limited to 4 weeks’ treatment
Both:
   1 Patient has warm autoimmune haemolytic anaemia*; and
   2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to >5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are Unapproved Indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)
Haematologist
Limited to 4 weeks’ treatment
Either:
   1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
   2 All of the following:
      2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
      2.2 An initial response lasting at least 12 months was demonstrated; and
      2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – immune thrombocytopenic purpura (ITP)
Haematologist
Limited to 4 weeks’ treatment
Both:
   1 Either:
      1.1 Patient has immune thrombocytopenic purpura* with a platelet count of ≤ 20,000 platelets per microlitre; or
      1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
   2 Any of the following:
      2.1 Treatment with steroids and splenectomy have been ineffective; or
      2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
      2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are Unapproved Indications.

Continuation – immune thrombocytopenic purpura (ITP)
Haematologist
Limited to 4 weeks’ treatment
Either:
   1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
   2 All of the following:
      2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
      2.2 An initial response lasting at least 12 months was demonstrated; and

continued…
2.3 Patient now requires repeat treatment.
Note: Indications marked with * are Unapproved Indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)
Haematologist
Limited to 4 weeks' treatment
Either:
1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
2. Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are Unapproved Indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)
Haematologist
Limited to 4 weeks' treatment
All of the following:
1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2. An initial response lasting at least 12 months was demonstrated; and

Note: Indications marked with * are Unapproved Indications.

Initiation – pure red cell aplasia (PRCA)
Haematologist
Limited to 6 weeks' treatment
Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are Unapproved Indications.

Continuation – pure red cell aplasia (PRCA)
Haematologist
Limited to 6 weeks' treatment
Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are Unapproved Indications.

Initiation – ANCA associated vasculitis
Limited to 4 weeks' treatment
All of the following:
1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Either:
   2.1 Patient does not have MPO-ANCA positive vasculitis*; or
   2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis*; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m^2 of body-surface area per week for a total of 4 weeks; and
4. Any of the following:
   4.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence of disease after at least 3 months; or
   4.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or
   4.3 Cyclophosphamide and methotrexate are contraindicated; or
   4.4 Patient is a female of child-bearing potential; or
   4.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

continued...
continued... 
Note: Indications marked with * are Unapproved Indications.

**Continuation – ANCA associated vasculitis**

*Limited to 4 weeks’ treatment*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are Unapproved Indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. The patient has severe, immediately life- or organ-threatening SLE*; and
2. The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3. The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4. Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and
3. Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

**Antibody-mediated renal transplant rejection**

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection*.

Note: Indications marked with * are Unapproved Indications.

**ABO-incompatible renal transplant**

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are Unapproved Indications.

**TOCILIZUMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra</td>
<td>$220.00</td>
</tr>
<tr>
<td>Actemra</td>
<td>$550.00</td>
</tr>
<tr>
<td>Actemra</td>
<td>$1,100.00</td>
</tr>
</tbody>
</table>

*Restricted

**Initiation -Rheumatoid Arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
2. Tocilizumab is to be used as monotherapy; and
3. Either:
   3.1 Treatment with methotrexate is contraindicated; or
   3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
4. Either:

```
continued...
```
continued...

4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or

4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

5 Either:

5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or

5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

6 Either:

6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation
Rheumatologist
Re-assessment required after 6 months

Either:

1 Following 6 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initiation - systemic juvenile idiopathic arthritis
Paediatric rheumatologist
Re-assessment required after 6 months

Both:

1 Patient diagnosed with systemic juvenile idiopathic arthritis; and

2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Continuation - systemic juvenile idiopathic arthritis
Paediatric rheumatologist
Re-assessment required after 6 months

Either:

1 Following up to 6 months’ initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Initiation - adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months

Either:

1 Both:

1.1 Either:

1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or

continued...
1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or

2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease
Rheumatologist
Re-assessment required after 6 months
The patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

Early breast cancer
Limited to 12 months' treatment
All of the following:
1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
3 Any of the following:
   3.1 9 weeks’ concurrent treatment with adjuvant chemotherapy is planned; or
   3.2 12 months’ concurrent treatment with adjuvant chemotherapy is planned; or
   3.3 12 months’ sequential treatment following adjuvant chemotherapy is planned; or
   3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naive patients)
Re-assessment required after 12 months
Either:
1 All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
   1.3 Trastuzumab not to be given in combination with lapatinib; and
   1.4 Trastuzumab to be discontinued at disease progression; or
2 All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on lapatinib; and
   2.4 Trastuzumab not to be given in combination with lapatinib; and
   2.5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)
Re-assessment required after 12 months
All of the following:
1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and

continued…
continued...  

3 Any of the following:

3.1 All of the following:
   3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
   3.1.2 Trastuzumab not to be given in combination with lapatinib; and
   3.1.3 Trastuzumab to be discontinued at disease progression; or

3.2 All of the following:
   3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
   3.2.2 The cancer did not progress whilst on lapatinib; and
   3.2.3 Trastuzumab not to be given in combination with lapatinib; and
   3.2.4 Trastuzumab to be discontinued at disease progression; or

3.3 All of the following:
   3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
   3.3.2 Trastuzumab not to be given in combination with lapatinib; and
   3.3.3 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer
Re-assessment required after 12 months

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and

3 Trastuzumab not to be given in combination with lapatinib; and

4 Trastuzumab to be discontinued at disease progression.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)
Inj 50 mg per ml, 5 ml ampoule .................................................................2,351.25 5 ATGAM

ANTITHYMOCYTE GLOBULIN (RABBIT)
Inj 25 mg vial

AZATHIOPRINE
Tab 50 mg – 1% DV Jun-14 to 2016 .........................................................13.22 100 Azamun
Inj 50 mg vial ............................................................................................126.00 1 Imuran

BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below
Inj 2-8 × 10^8 CFU vial – 1% DV Sep-13 to 2016 .........................................149.37 1 OncoTICE

EVEROLIMUS – Restricted see terms below
Tab 5 mg .................................................................................................4,555.76 30 Afinitor
Tab 10 mg ...............................................................................................6,512.29 30 Afinitor

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued...

Continuation

Neurologist or oncologist

Re-assessment required after 12 months

All of the following:

1. Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
2. The treatment remains appropriate and the patient is benefiting from treatment; and
3. Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

MYCOPHENOLATE MOFETIL

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25.00</td>
<td>CellCept</td>
</tr>
<tr>
<td>$25.00</td>
<td>CellCept</td>
</tr>
<tr>
<td>$187.25</td>
<td>CellCept</td>
</tr>
<tr>
<td>$133.33</td>
<td>CellCept</td>
</tr>
</tbody>
</table>

PICIBANIL

Inj 100 mg vial

SIROLIMUS – Restricted see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$813.00</td>
<td>Rapamune</td>
</tr>
<tr>
<td>$1,626.00</td>
<td>Rapamune</td>
</tr>
<tr>
<td>$487.80</td>
<td>Rapamune</td>
</tr>
</tbody>
</table>

Restricted

For rescue therapy for an organ transplant recipient

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
# RESPIRATORY SYSTEM AND ALLERGIES

## Antiallergy Preparations

### Allergy Desensitisation

**BEE VENOM** – **Restricted** see terms below
- Inj 120 mcg vial with diluent, 6 vial
- Inj 550 mcg vial with diluent
  - Restricted

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**PAPER WASP VENOM** – **Restricted** see terms below
- Inj 550 mcg vial with diluent
  - Restricted

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**YELLOW JACKET WASP VENOM** – **Restricted** see terms below
- Inj 550 mcg vial with diluent
  - Restricted

Both:
1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

### Allergy Prophylactics

**BECLOMETHASONE DIPROPIONATE**
- Nasal spray 50 mcg per dose .........................................................4.85 200 dose Alanase
- Nasal spray 100 mcg per dose .........................................................5.75 200 dose Alanase

**BUDESONIDE**
- Nasal spray 50 mcg per dose .........................................................4.85 200 dose Butacort Aqueous
- Nasal spray 100 mcg per dose .........................................................5.75 200 dose Butacort Aqueous

**FLUTICASONE PROPIONATE**
- Nasal spray 50 mcg per dose – 1% DV Apr-13 to 2015 ......................2.30 120 dose Flixonase Hayfever & Allergy

**IPRATROPIUM BROMIDE**
- Aqueous nasal spray 0.03% – 1% DV Jan-15 to 2017 .........................3.95 15 ml Univent

**SODIUM CROMOGLYCATE**
- Nasal spray 4%

### Antihistamines

**CETIRIZINE HYDROCHLORIDE**
- Tab 10 mg .................................................................1.59 100 Zetop
- Oral liq 1 mg per ml .........................................................3.52 200 ml Cetirizine - AFT

**CHLORPHENIRAMINE MALEATE**
- Oral liq 0.4 mg per ml
- Inj 10 mg per ml, 1 ml ampoule

**CYPROHEPTADINE HYDROCHLORIDE**
- Tab 4 mg
RESPIRATORY SYSTEM AND ALLERGIES

| Item restricted (see above); Item restricted (see below) | e.g. Brand indicates brand example only. It is not a contracted product. |
### RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### Beta-Adrenoceptor Agonists

**SALBUTAMOL**
- Oral liq 400 mcg per ml – 1% DV Jan-14 to 2016..............................................2.06 150 ml Ventolin
- Inj 500 mcg per ml, 1 ml ampoule
- Aerosol inhaler, 100 mcg per dose .......................................................4.00 200 dose Salamol
- Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015........3.25 20 Asthalin
- Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Nov-12 to 2015........3.44 20 Asthalin

**TERBUTALINE SULPHATE**
- Powder for inhalation 250 mcg per dose
- Inj 0.5 mg per ml, 1 ml ampoule

#### Cough Suppressants

**PHOLCODINE**
- Oral liq 1 mg per ml

#### Decongestants

**OXYMETAZOLINE HYDROCHLORIDE**
- Aqueous nasal spray 0.25 mg per ml
- Aqueous nasal spray 0.5 mg per ml

**PSEUDOEPHEDRINE HYDROCHLORIDE**
- Tab 60 mg

**SODIUM CHLORIDE**
- Aqueous nasal spray 7.4 mg per ml

**SODIUM CHLORIDE WITH SODIUM BICARBONATE**
- Soln for nasal irrigation

**XYLOMETAZOLINE HYDROCHLORIDE**
- Aqueous nasal spray 0.05%
- Aqueous nasal spray 0.1%
- Nasal drops 0.05%
- Nasal drops 0.1%

#### Inhaled Corticosteroids

**BECLOMETHASONE DIPROPIONATE**
- Aerosol inhaler 50 mcg per dose ..............................................................8.54 200 dose Beclazone 50
- Aerosol inhaler 100 mcg per dose ............................................................9.30 200 dose Qvar
- Aerosol inhaler 250 mcg per dose ...........................................................12.50 200 dose Beclazone 100
- Aerosol inhaler 400 mcg per dose .........................................................15.50 200 dose Qvar
- Aerosol inhaler 500 mcg per dose ...........................................................22.67 200 dose Beclazone 250

**BUDESONIDE**
- Nebuliser soln 250 mcg per ml, 2 ml ampoule
- Nebuliser soln 500 mcg per ml, 2 ml ampoule
- Powder for inhalation 100 mcg per dose
- Powder for inhalation 200 mcg per dose
- Powder for inhalation 400 mcg per dose
FLUTICASONE

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$7.50</td>
<td>120 dose</td>
<td>Flixotide</td>
</tr>
<tr>
<td>$8.67</td>
<td>60 dose</td>
<td>Flixotide Accuhaler</td>
</tr>
<tr>
<td>$13.87</td>
<td>60 dose</td>
<td>Flixotide Accuhaler</td>
</tr>
<tr>
<td>$13.60</td>
<td>120 dose</td>
<td>Flixotide</td>
</tr>
<tr>
<td>$27.20</td>
<td>120 dose</td>
<td>Flixotide</td>
</tr>
<tr>
<td>$24.51</td>
<td>60 dose</td>
<td>Flixotide Accuhaler</td>
</tr>
</tbody>
</table>

Leukotriene Receptor Antagonists

MONTELUKAST – Restricted see terms below

- Tab 4 mg ................................................................. $18.48 28 Singulair
- Tab 5 mg ................................................................. $18.48 28 Singulair
- Tab 10 mg ................................................................. $18.48 28 Singulair

Restricted

Pre-school wheeze
Both:
1. To be used for the treatment of intermittent severe wheezing (possibly viral); and
2. The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Exercise-induced asthma
Both:
1. Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
2. Patient continues to receive optimal inhaled corticosteroid therapy; and
3. Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Aspirin desensitisation
Clinical immunologist or allergist
All of the following:
1. Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
2. Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter’s triad; and
3. Nasal polyposis, confirmed radiologically or surgically; and
4. Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Long-Acting Beta-Adrenoceptor Agonists

EFORMOTEROL FUMARATE

- Powder for inhalation 6 mcg per dose
- Powder for inhalation 12 mcg per dose

INDACATEROL

- Powder for inhalation 150 mcg per dose ................................................. $61.00 30 dose Onbrez Breezhaler
- Powder for inhalation 300 mcg per dose ................................................. $61.00 30 dose Onbrez Breezhaler

SALMETEROL

- Aerosol inhaler 25 mcg per dose .............................................................. $26.46 120 dose Serevent
- Powder for inhalation 50 mcg per dose ........................................................ $26.46 60 dose Serevent Accuhaler
Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL – Restricted see terms below

- Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
- Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
- Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
- Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
- Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

**Restricted**

Either:

1. All of the following:
   1.1 Patient is a child under the age of 12; and
   1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
   1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or

2. All of the following:
   2.1 Patient is over the age of 12; and
   2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
   2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

FLUTICASONE WITH SALMETEROL

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol inhaler 50 mcg with salmeterol 25 mcg</td>
<td>37.48</td>
<td>120 dose Seretide</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg with salmeterol 50 mcg</td>
<td>37.48</td>
<td>60 dose Seretide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg with salmeterol 25 mcg</td>
<td>49.69</td>
<td>120 dose Seretide</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg with salmeterol 50 mcg</td>
<td>49.69</td>
<td>60 dose Seretide Accuhaler</td>
</tr>
</tbody>
</table>

Mast Cell Stabilisers

NEDOCROMIL

- Aerosol inhaler 2 mg per dose

SODIUM CROMOGLYcate

<table>
<thead>
<tr>
<th>Powder description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for inhalation 20 mg per dose</td>
<td>14.85</td>
<td>25 ml Biomed</td>
</tr>
<tr>
<td>Aerosol inhaler 5 mg per dose</td>
<td>55.75</td>
<td>5 Biomed</td>
</tr>
</tbody>
</table>

Methylxanthines

AMINOPHYLLINE

- Inj 25 mg per ml, 10 ml ampoule – 1% DV Oct-14 to 2017 | 118.25 | 5 DBL Aminophylline |

CAFFEINE CITRATE

- Oral liq 20 mg per ml (caffeine 10 mg per ml) | 14.85 | 25 ml Biomed |
- Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule | 55.75 | 5 Biomed |

THEOPHYLLINE

- Tab long-acting 250 mg
- Oral liq 80 mg per 15 ml

Mucolytics and Expectorants

DORNASE ALFA – Restricted see terms on the next page

- Nebuliser soln 2.5 mg per 2.5 ml ampoule | 250.00 | 6 Pulmozyme |
### RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**Restricted**

Any of the following:

1. Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or
2. Significant mucus production and meets the following criteria
3. Treatment for up to four weeks for patients meeting the following:
   3.1 Patient is an in-patient; and
   3.2 The mucus production cannot be cleared by first line chest techniques; or
4. Treatment for up to three days for patients diagnosed with empyema.

### SODIUM CHLORIDE

| Nebuliser soln 7%, 90 ml bottle | .......................................................... | 23.50 | 90 ml | Biomed |

### Pulmonary Surfactants

**BERACTANT**

- Soln 200 mg per 8 ml vial .......................................................... 550.00 1 Survanta

**PORACTANT ALFA**

- Soln 120 mg per 1.5 ml vial .......................................................... 425.00 1 Curosurf
- Soln 240 mg per 3 ml vial .......................................................... 695.00 1 Curosurf

### Respiratory Stimulants

**DOXAPRAM**

- Inj 20 mg per ml, 5 ml vial

### Sclerosing Agents

**TALC**

- Powder
- Soln (slurry) 100 mg per ml, 50 ml
## Anti-Infective Preparations

### Antibacterials

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Expiry Date</th>
<th>Price ($ ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHLORAMPHENICOL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 1% – 1% DV Jan-13 to 2015</td>
<td></td>
<td></td>
<td>2.76</td>
<td>Chlorsig</td>
</tr>
<tr>
<td>Ear drops 0.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5% – 1% DV Sep-12 to 2015</td>
<td></td>
<td></td>
<td>1.20</td>
<td>Chlorafast</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CIPROFLOXACIN</strong></td>
<td>Eye drops 0.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FRAMYCETIN SULPHATE</strong></td>
<td>Ear/eye drops 0.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FUSIDIC ACID</strong></td>
<td>Eye drops 1%</td>
<td></td>
<td>4.50</td>
<td>Fucithalmic</td>
</tr>
<tr>
<td><strong>GENTAMICIN SULPHATE</strong></td>
<td>Eye drops 0.3%</td>
<td></td>
<td>11.40</td>
<td>Genoptic</td>
</tr>
<tr>
<td><strong>PROPAMIDINE ISETHIONATE</strong></td>
<td>Eye drops 0.1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SULPHACETAMIDE SODIUM</strong></td>
<td>Eye drops 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOBRAMYCIN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 0.3% – 1% DV Sep-14 to 2017</td>
<td></td>
<td></td>
<td>10.45</td>
<td>Tobrex</td>
</tr>
<tr>
<td>Eye drops 0.3% – 1% DV Sep-14 to 2017</td>
<td></td>
<td></td>
<td>11.48</td>
<td>Tobrex</td>
</tr>
</tbody>
</table>

### Antifungals

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Price ($ ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATAMYCIN</strong></td>
<td>Eye drops 5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antivirals

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Price ($ ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACICLOVIR</strong></td>
<td>Eye oint 3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Combination Preparations

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>Expiry Date</th>
<th>Price ($ ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN</strong></td>
<td>Eye/ear drops 500 mcg with framyctin sulphate 5 mg and gramicidin 50 mcg per ml</td>
<td></td>
<td></td>
<td>Maxitrol</td>
</tr>
<tr>
<td><strong>DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMIXIN B SULPHATE</strong></td>
<td>Eye oint 0.1% with neomycin sulphate 0.35% and polymixin b sulphate 6,000 u per ml – 1% DV Sep-14 to 2017</td>
<td></td>
<td>5.39</td>
<td>Maxitrol</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.1% with neomycin sulphate 0.35% and polymixin b sulphate 6,000 u per ml – 1% DV Sep-14 to 2017</td>
<td></td>
<td>4.50</td>
<td>Maxitrol</td>
</tr>
<tr>
<td><strong>DEXAMETHASONE WITH TOBRAMYCIN</strong></td>
<td>Eye drops 0.1% with tobramycin 0.3%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FLUMETASONE PIVALATE WITH CLIQUINOL</strong></td>
<td>Ear drops 0.02% with clioquinol 1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SENSORY ORGANS</td>
<td>Price (ex man. excl. GST) $</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE WITH CIPROFLOXACIN</td>
<td>ear drops 1% with ciprofloxacin 0.2%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</td>
<td>ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g</td>
<td>5.16 7.5 ml Kenacomb</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Anti-Inflammatory Preparations

#### Corticosteroids

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXAMETHASONE</td>
<td>eye oint 0.1% – 1% DV Oct-14 to 2017</td>
<td>5.86</td>
<td>Maxidex</td>
</tr>
<tr>
<td></td>
<td>eye drops 0.1% – 1% DV Oct-14 to 2017</td>
<td>4.50</td>
<td>Maxidex</td>
</tr>
<tr>
<td>FLUOROMETHOLONE</td>
<td>eye drops 0.1% – 1% DV Dec-12 to 2015</td>
<td>3.80</td>
<td>Flucon</td>
</tr>
<tr>
<td>PREDNISOLONE ACETATE</td>
<td>eye drops 0.12%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PREDNISOLONE SODIUM PHOSPHATE</td>
<td>eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Non-Steroidal Anti-Inflammatory Drugs

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>eye drops 0.1% – 1% DV Sep-14 to 2017</td>
<td>13.80</td>
<td>Voltaren Ophtha</td>
</tr>
<tr>
<td></td>
<td>eye drops 0.1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KETOROLAC TROMETAMOL</td>
<td>eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Decongestants and Antiallergics

#### Antiallergic Preparations

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEVOCABASTINE</td>
<td>eye drops 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LODOSAXamide</td>
<td>eye drops 0.1% – 1% DV Sep-14 to 2017</td>
<td>8.71</td>
<td>Lomide</td>
</tr>
<tr>
<td>OLOPATADINE</td>
<td>eye drops 0.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CROMOGLYcate</td>
<td>eye drops 2%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Decongestants

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAPHAZOLINE HYDROCHLORIDE</td>
<td>eye drops 0.1% – 1% DV Sep-14 to 2017</td>
<td>4.15</td>
<td>Naphcon Forte</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ⇨ above); ‡Item restricted (see ⇨ below)*
*E.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

### Diagnostic and Surgical Preparations

#### Diagnostic Dyes

**FLUORESCEIN SODIUM**
- Eye drops 2%, single dose
- Inj 10%, 5 ml vial ................................. 125.00 12 Fluorescite
- Ophthalmic strips 1 mg

**FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE**
- Eye drops 0.25% with lignocaine hydrochloride 4%, single dose

**LISSAMINE GREEN**
- Ophthalmic strips 1.5 mg

**ROSE BENGAL SODIUM**
- Ophthalmic strips 1%

#### Irrigation Solutions

**CALCIUM CHLORIDE WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE, SODIUM CHLORIDE AND SODIUM CITRATE**
- Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml  
  e.g. Balanced Salt Solution
- Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml  
  e.g. Balanced Salt Solution
- Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml  
  e.g. Balanced Salt Solution

#### Ocular Anaesthetics

**OXYPUBROCAINE HYDROCHLORIDE**
- Eye drops 0.4%, single dose

**PROXYMETACAINE HYDROCHLORIDE**
- Eye drops 0.5%

**TETRACAINE [AMETHOCAINE] HYDROCHLORIDE**
- Eye drops 0.5%, single dose
- Eye drops 1%, single dose

#### Viscoelastic Substances

**HYPROMELLOSE**
- Inj 2%, 1 ml syringe
- Inj 2%, 2 ml syringe
**SENSORY ORGANS**

| Item restricted (see ➡️ above); ➥ Item restricted (see ➡️ below) |
| e.g. *Brand* indicates brand example only. It is not a contracted product. |

<table>
<thead>
<tr>
<th>SODIUM HYALURONATE</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-12 to 2015</td>
<td>$50.00</td>
<td>Healon GV</td>
</tr>
<tr>
<td>Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-12 to 2015</td>
<td>$50.00</td>
<td>Healon GV</td>
</tr>
<tr>
<td>Inj 23 mg per ml, 0.6 ml syringe</td>
<td>1</td>
<td>Provisc</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-12 to 2015</td>
<td>$30.00</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SODIUM HYALURONATE WITH CHONDROITIN SULPHATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.4 ml syringe</td>
</tr>
<tr>
<td>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.55 ml syringe</td>
</tr>
<tr>
<td>Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe</td>
</tr>
</tbody>
</table>

**Other**

<table>
<thead>
<tr>
<th>DISODIUM EDETATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 150 mg per ml, 20 ml ampoule</td>
</tr>
<tr>
<td>Inj 150 mg per ml, 20 ml vial</td>
</tr>
<tr>
<td>Inj 150 mg per ml, 100 ml vial</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RIBOFLAVIN 5-PHOSPHATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln trans epithelial riboflavin</td>
</tr>
<tr>
<td>Inj 0.1%</td>
</tr>
<tr>
<td>Inj 0.1% plus 20% dextran T500</td>
</tr>
</tbody>
</table>

**Glaucoma Preparations**

**Beta Blockers**

| BETAXOLOL |
|--------------------|-----------------|-----|
| Eye drops 0.25% – 1% DV Sep-14 to 2017 | $11.80 | Betoptic S |
| Eye drops 0.5% – 1% DV Sep-14 to 2017 | $7.50 | Betoptic |

<table>
<thead>
<tr>
<th>LEVOBUNOLOL HYDROCHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 0.25%</td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIMOLOL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 0.25% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 0.25%, gel forming – 1% DV Mar-14 to 2016</td>
</tr>
<tr>
<td>Eye drops 0.5% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 0.5%, gel forming – 1% DV Mar-14 to 2016</td>
</tr>
</tbody>
</table>

**Carbonic Anhydrase Inhibitors**

<table>
<thead>
<tr>
<th>ACETAZOLAMIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Inj 500 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BRINZOLAMIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 1%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DORZOLAMIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DORZOLAMIDE WITH TIMOLOL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye drops 2% with timolol 0.5%</td>
</tr>
<tr>
<td>Miotics</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td><strong>ACETYLCHOLINE CHLORIDE</strong></td>
</tr>
<tr>
<td><strong>PILOCARPINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 2% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 2%, single dose</td>
</tr>
<tr>
<td>Eye drops 4% – 1% DV Sep-14 to 2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prostaglandin Analogues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIMATOPROST</strong></td>
</tr>
<tr>
<td>Eye drops 0.03%</td>
</tr>
<tr>
<td><strong>LATANOPROST</strong></td>
</tr>
<tr>
<td>Eye drops 0.005% – 1% DV Sep-12 to 2015</td>
</tr>
<tr>
<td><strong>TRAVOPROST</strong></td>
</tr>
<tr>
<td>Eye drops 0.004%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sympathomimetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APRACLONIDINE</strong></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
</tr>
<tr>
<td><strong>BRIMONIDINE TARTRATE</strong></td>
</tr>
<tr>
<td>Eye drops 0.2% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td><strong>BRIMONIDINE TARTRATE WITH TIMOLOL</strong></td>
</tr>
<tr>
<td>Eye drops 0.2% with timolol 0.5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mydriatics and Cycloplegics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticholinergic Agents</strong></td>
</tr>
<tr>
<td><strong>ATROPINE SULPHATE</strong></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Jul-14 to 2017</td>
</tr>
<tr>
<td><strong>CYCLOPENTOLATE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Sep-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
</tr>
<tr>
<td><strong>TROPICAMIDE</strong></td>
</tr>
<tr>
<td>Eye drops 0.5% – 1% DV Oct-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
</tr>
<tr>
<td>Eye drops 1% – 1% DV Oct-14 to 2017</td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sympathomimetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHENYLEPHRINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Eye drops 2.5%, single dose</td>
</tr>
<tr>
<td>Eye drops 10%, single dose</td>
</tr>
</tbody>
</table>
### SENSORY ORGANS

<table>
<thead>
<tr>
<th>Ocular Lubricants</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARBOMER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmic gel 0.3%, single dose</td>
<td>8.25</td>
<td>30 Poly Gel</td>
</tr>
<tr>
<td>Ophthalmic gel 0.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CARMELLOSE SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HYPROMELLOSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td>3.92</td>
<td>15 ml Methopt</td>
</tr>
<tr>
<td><strong>HYPROMELLOSE WITH DEXTRAN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.3% with dextran 0.1%</td>
<td>2.30</td>
<td>15 ml Poly-Tears</td>
</tr>
<tr>
<td>Eye drops 0.3% with dextran 0.1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MACROGOL 400 AND PROPYLENE GLYCOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose</td>
<td>4.30</td>
<td>24 Systane Unit Dose</td>
</tr>
<tr>
<td><strong>PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 42.5% with soft white paraffin 57.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PARAFFIN LIQUID WITH WOOL FAT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye oint 3% with wool fat 3% – 1% DV Jul-14 to 2017</td>
<td>3.63</td>
<td>3.5 g Poly-Visc</td>
</tr>
<tr>
<td><strong>POLYVINYL ALCOHOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1.4%</td>
<td>2.95</td>
<td>15 ml Vistil</td>
</tr>
<tr>
<td>Eye drops 3%</td>
<td>3.62</td>
<td>15 ml Liquifilm Tears</td>
</tr>
<tr>
<td><strong>POLYVINYL ALCOHOL WITH Povidone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1.4% with povidone 0.6%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RETINOL PALMITATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 138 mcg per g</td>
<td>3.80</td>
<td>5 g VitA-POS</td>
</tr>
<tr>
<td><strong>SODIUM HYALURONATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye drops 1 mg per ml</td>
<td>22.00</td>
<td>10 ml Hylo-Fresh</td>
</tr>
</tbody>
</table>

### Other Otological Preparations

<table>
<thead>
<tr>
<th>Other Otological Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETIC ACID WITH PROPYLENE GLYCOL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear drops 2.3% with propylene glycol 2.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DOUCUSATE SODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear drops 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Agents Used in the Treatment of Poisonings

#### Antidotes

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength/Formulation</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETYLHYDROXYSTEINE</td>
<td>Tab eff 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 200 mg per ml, 10 ml ampoule – 1% DV Jul-12 to 2015</td>
<td>178.00</td>
<td>10</td>
<td>Martindale Acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Inj 200 mg per ml, 30 ml vial</td>
<td>219.00</td>
<td>4</td>
<td>Acetadote</td>
</tr>
<tr>
<td>DIGOXIN IMMUNE FAB</td>
<td>Inj 38 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 40 mg vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL</td>
<td>Liq 96%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL WITH GLUCOSE</td>
<td>Inj 10% with glucose 5%, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOL, DEHYDRATED</td>
<td>Inj 100%, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 96%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLUMAZENIL</td>
<td>Inj 0.1 mg per ml, 5 ml ampoule</td>
<td>170.10</td>
<td>5</td>
<td>Anexate</td>
</tr>
<tr>
<td>HYDROXOCOBALAMIN</td>
<td>Inj 5 g vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 g vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NALOXONE HYDROCHLORIDE</td>
<td>Inj 400 mcg per ml, 1 ml ampoule</td>
<td>33.00</td>
<td>5</td>
<td>Hospira</td>
</tr>
<tr>
<td>PRALIDOXIME IODIDE</td>
<td>Inj 25 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM NITRITE</td>
<td>Inj 30 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM THIOSULFATE</td>
<td>Inj 500 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 250 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOYA OIL</td>
<td>Inj 20%, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 20%, 500 ml bottle</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Antitoxins

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Strength/Formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOTULISM ANTITOXIN</td>
<td>Inj 250 ml vial</td>
</tr>
<tr>
<td>DIPHTHERIA ANTITOXIN</td>
<td>Inj 10,000 iu vial</td>
</tr>
</tbody>
</table>
**Antivenoms**

RED BACK SPIDER ANTIVENOM  
Inj 500 u vial  
SNAKE ANTIVENOM  
Inj 50 ml vial

**Removal and Elimination**

CHARCOAL  
Oral liq 200 mg per ml ................................................................. 43.50  250 ml Carbasorb-X

**DEFERASIROX – Restricted see terms below**

- Tab 125 mg dispersible ............................................................ 276.00  28 Exjade
- Tab 250 mg dispersible ............................................................ 552.00  28 Exjade
- Tab 500 mg dispersible ............................................................ 1,105.00  28 Exjade

**DEFERIPRONE – Restricted see terms below**

- Tab 500 mg ........................................................................... 533.17  100 Ferriprox
- Oral liq 100 mg per ml ............................................................. 266.59  250 ml Ferriprox

**DESFERRIOXAMINE MESILATE**  
Inj 500 mg vial ................................................................. 99.00  10 Hospira

**DICOBALT EDETATE**  
Inj 15 mg per ml, 20 ml ampoule

**DIMERCAPROL**  
Inj 50 mg per ml, 2 ml ampoule

---

*Item restricted (see ➡️ above); $Item restricted (see ➡️ below)*  
*e.g. Brand indicates brand example only. It is not a contracted product.*
### DIMERCAPTO Succinic Acid
- **Cap 100 mg**

### SODIUM CALCIUM EDTATE
- **Inj 200 mg per ml, 2.5 ml ampoule**
- **Inj 200 mg per ml, 5 ml ampoule**

### Antiseptics and Disinfectants

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHLORHEXIDINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 4%</td>
<td>1.86</td>
<td>50 ml</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 5%</td>
<td>15.50</td>
<td>500 ml</td>
<td>healthE</td>
</tr>
<tr>
<td><strong>CHLORHEXIDINE WITH CETRIMIDE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% with cetrimide 0.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foaming soln 0.5% with cetrimide 0.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CHLORHEXIDINE WITH ETHANOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml</td>
<td>2.65</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 2% with ethanol 70%, non-staining (pink) 100 ml</td>
<td>3.54</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml</td>
<td>1.55</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 0.5% with ethanol 70%, staining (red) 100 ml</td>
<td>2.90</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 2% with ethanol 70%, staining (red) 100 ml</td>
<td>3.86</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml</td>
<td>5.45</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 0.5% with ethanol 70%, staining (red) 500 ml</td>
<td>5.90</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>Soln 2% with ethanol 70%, staining (red) 500 ml</td>
<td>9.56</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td><strong>IODINE WITH ETHANOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 1% with ethanol 70%, 100 ml</td>
<td>9.30</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td><strong>ISOPROPYL ALCOHOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 70%, 500 ml</td>
<td>5.00</td>
<td>1</td>
<td>PSM</td>
</tr>
<tr>
<td></td>
<td>5.65</td>
<td></td>
<td>healthE</td>
</tr>
<tr>
<td><strong>POVIDONE-IODINE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal tab 200 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectal administration pre-prostate biopsy.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oint 10%</td>
<td>3.27</td>
<td>25 g</td>
<td>Betadine</td>
</tr>
<tr>
<td>Soln 10%</td>
<td>2.95</td>
<td>100 ml</td>
<td>Riodine</td>
</tr>
<tr>
<td></td>
<td>6.20</td>
<td>500 ml</td>
<td>Riodine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Betadine</td>
<td></td>
</tr>
<tr>
<td>Soln 5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 7.5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pad 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swab set 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>POVIDONE-IODINE WITH ETHANOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 10% with ethanol 30%</td>
<td>10.00</td>
<td>500 ml</td>
<td>Betadine Skin Prep</td>
</tr>
<tr>
<td>Soln 10% with ethanol 70%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM HYPOCHLORITE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Contrast Media

#### Iodinated X-ray Contrast Media

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle</td>
<td>22.50</td>
<td>100 ml Gastrografin</td>
</tr>
<tr>
<td>Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle</td>
<td>80.00</td>
<td>1 Urografin</td>
</tr>
<tr>
<td>DIATRIZOATE SODIUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 370 mg per ml, 10 ml sachet</td>
<td>156.12</td>
<td>50 Ioscan</td>
</tr>
<tr>
<td>IODISED OIL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 38% w/w (480 mg per ml), 10 ml ampoule</td>
<td>143.00</td>
<td>1 Lipiodol Ultra Fluid</td>
</tr>
<tr>
<td>IODIXANOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017</td>
<td>220.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017</td>
<td>430.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017</td>
<td>220.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017</td>
<td>430.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017</td>
<td>850.00</td>
<td>10 Visipaque</td>
</tr>
<tr>
<td>IOHEXOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 240 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017</td>
<td>57.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017</td>
<td>150.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017</td>
<td>59.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017</td>
<td>75.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 75 ml bottle – 5% DV Sep-14 to 2017</td>
<td>114.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017</td>
<td>150.00</td>
<td>10 Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017</td>
<td>290.00</td>
<td>10 Omnipaque</td>
</tr>
</tbody>
</table>

*Item restricted (see above); ‸Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Non-iodinated X-ray Contrast Media

<table>
<thead>
<tr>
<th>Barium Sulfate</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARIUM SULPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet</td>
<td>507.50</td>
<td>50 E-Z-Cat Dry</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle</td>
<td>17.39</td>
<td>148 g Varibar - Thin Liquid</td>
</tr>
<tr>
<td>Oral liq 600 mg per g (60% w/w), tube</td>
<td>36.51</td>
<td>454 g E-Z-Paste</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v), bottle</td>
<td>38.40</td>
<td>240 ml Varibar - Nectar</td>
</tr>
<tr>
<td>Enema 1,250 mg per ml (125% w/v), 500 ml bag</td>
<td>282.30</td>
<td>12 Liquibar</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 250 ml bottle</td>
<td>175.00</td>
<td>24 CT Plus+</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 450 ml bottle</td>
<td>220.00</td>
<td>24 CT Plus+</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle</td>
<td>441.12</td>
<td>24 Volumen</td>
</tr>
<tr>
<td>Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle</td>
<td>140.94</td>
<td>24 Readi-CAT 2</td>
</tr>
<tr>
<td>Powder for oral soln 97.65% w/v, 300 g bottle</td>
<td>237.76</td>
<td>24 X-Opaque-HD</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle</td>
<td>52.35</td>
<td>3 Tagitol V</td>
</tr>
<tr>
<td>Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle</td>
<td>91.77</td>
<td>1 Liquibar</td>
</tr>
</tbody>
</table>

**BARIUM SULPHATE WITH SODIUM BICARBONATE**

- Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet: 102.93

**CITRIC ACID WITH SODIUM BICARBONATE**

- Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet: e.g. E-Z-GAS II

### Paramagnetic Contrast Media

<table>
<thead>
<tr>
<th>Gadobenic Acid</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 334 mg per ml, 10 ml vial</td>
<td>324.74</td>
<td>10 Multihance</td>
</tr>
<tr>
<td>Inj 334 mg per ml, 20 ml vial</td>
<td>636.28</td>
<td>10 Multihance</td>
</tr>
</tbody>
</table>

**Gadobutrol**

- Inj 1 mmol per ml, 15 ml vial
  - Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe: 180.00
  - Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe: 700.00

**Gadodiamide**

- Inj 287 mg per ml, 10 ml prefilled syringe: 200.00
- Inj 287 mg per ml, 10 ml vial: 170.00
- Inj 287 mg per ml, 5 ml vial: 120.00
- Inj 287 mg per ml, 15 ml prefilled syringe: 320.00

**Gadoteric Acid**

- Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe: 24.50
- Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle: 34.50
- Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe: 41.00
- Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe: 55.00
- Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle: 23.20
- Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle: 46.30
- Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle: 12.30

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

---

191
<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GADOXETATE DISODIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe</td>
<td>300.00</td>
<td>1 Primovist</td>
</tr>
<tr>
<td><strong>MEGLUMINE GADOPENTETATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 469 mg per ml, 10 ml prefilled syringe</td>
<td>95.00</td>
<td>5 Magnevist</td>
</tr>
<tr>
<td>Inj 469 mg per ml, 10 ml vial</td>
<td>185.00</td>
<td>10 Magnevist</td>
</tr>
<tr>
<td><strong>MEGLUMINE IOTROXATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 105 mg per ml, 100 ml bottle</td>
<td>150.00</td>
<td>100 ml Biliscopin</td>
</tr>
</tbody>
</table>

**Ultrasound Contrast Media**

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PERFLUTREN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.1 mg per ml, 1.5 ml vial – 5% DV Sep-14 to 2017</td>
<td>180.00</td>
<td>1 Definity</td>
</tr>
<tr>
<td></td>
<td>720.00</td>
<td>4 Definity</td>
</tr>
</tbody>
</table>

**Diagnostic Agents**

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ARGININE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 mg per ml, 300 ml bottle</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HISTAMINE ACID PHOSPHATE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 0.6%, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 2.5%, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebuliser soln 5%, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METHACHOLINE CHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SECRETIN PENTAHYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SINCALIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mcg per vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TUBERCULIN, PURIFIED PROTEIN DERIVATIVE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 TU per 0.1 ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Diagnostic Dyes**

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BONNEY’S BLUE DYE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INDIGO CARMINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 8 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INDOCYANINE GREEN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PATENT BLUE V</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 2.5%, 2 ml ampoule</td>
<td>440.00</td>
<td>5 Obex Medical</td>
</tr>
</tbody>
</table>
### Irrigation Solutions

**CHLORHEXIDINE**
- Irrigation soln 0.02%, bottle .......................................................... $2.92 100 ml Baxter
- Irrigation soln 0.05%, bottle .......................................................... $3.02 100 ml Baxter
- Irrigation soln 0.1%, bottle .......................................................... $3.10 100 ml Baxter
- Irrigation soln 0.5%, bottle .......................................................... $4.69 500 ml Baxter
- Irrigation soln 0.02%, 500 ml bottle
- Irrigation soln 0.1%, 30 ml ampoule

**CHLORHEXIDINE WITH CETRIMIDE**
- Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule $3.21 100 ml Baxter
- Irrigation soln 0.015% with cetrimide 0.15%, bottle ......................... $3.47 500 ml Baxter
- Irrigation soln 0.05% with cetrimide 0.5%, bottle ................................ $4.20 100 ml Baxter
- Irrigation soln 0.05% with cetrimide 0.5%, bottle .......................... $3.87 500 ml Baxter
- Irrigation soln 0.1% with cetrimide 1%, bottle ................................ $4.38 100 ml Baxter
- Irrigation soln 0.1% with cetrimide 1%, 1,000 ml bottle ............... $5.81 500 ml Baxter

**GLYCINE**
- Irrigation soln 1.5%, bottle .......................................................... $11.38 2,000 ml Baxter
- Irrigation soln 1.5%, bottle .......................................................... $14.44 3,000 ml Baxter

**SODIUM CHLORIDE**
- Irrigation soln 0.9%, 30 ml ampoule .................................................. $19.50 30 ml Pfizer
- Irrigation soln 0.9%, bottle .......................................................... $2.49 100 ml Baxter
- Irrigation soln 0.9%, 500 ml bottle .................................................. $2.88 500 ml Baxter
- Irrigation soln 0.9%, 1,000 ml bottle ............................................... $2.96 1,000 ml Baxter
- Irrigation soln 0.9%, 2,000 ml bottle ............................................... $10.00 2,000 ml Baxter
- Irrigation soln 0.9%, 3,000 ml bottle ............................................... $12.67 3,000 ml Baxter

**WATER**
- Irrigation soln, bottle ................................................................. $2.68 100 ml Baxter
- Irrigation soln, bottle ................................................................. $2.61 500 ml Baxter
- Irrigation soln, bottle ................................................................. $2.75 1,000 ml Baxter
- Irrigation soln, bottle ................................................................. $9.71 2,000 ml Baxter
- Irrigation soln, bottle ................................................................. $15.80 3,000 ml Baxter

### Surgical Preparations

**BISMUTH SUBNITRATE AND IODOFORM PARAFFIN**
- Paste

**DIMETHYL SULFOXIDE**
- Soln 50%
- Soln 99%

**PHENOL**
- Inj 6%, 10 ml ampoule

**PHENOL WITH IOXAGLIC ACID**
- Inj 12%, 10 ml ampoule

**TROMETAMOL**
- Inj 36 mg per ml, 500 ml bottle

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## Cardioplegia Solutions

### ELECTROLYTES

- **Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag**

- **Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag**

- **Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg per ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag**

- **Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag**

- **Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag**

### MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

- **Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle**

### MONOSODIUM L-ASPARTATE

- **Inj 14 mmol per 10 ml, 10 ml**

### Cold Storage Solutions

### SODIUM WITH POTASSIUM

- **Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag**

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARACHIS OIL [PEANUT OIL]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASCORBIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BENZOLIN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tincture compound BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BISMUTH SUBGALLATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BORIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARBOXYMETHYLCELLULOSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 1.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CETRIMIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLOROFORM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liq BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CITRIC ACID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLOVE OIL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COAL TAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln BP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CODEINE PHOSPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COLLODION FLEXIBLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COMPOUND HYDROXYBENZOATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYSTEAMINE HYDROCHLORIDE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DITHRANOL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price (ex man. excl. GST) $</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>GLUCOSE [DEXTROSE] Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLYCERIN WITH SODIUM SACCHARIN Suspension</td>
<td>35.50</td>
<td>473 ml</td>
</tr>
<tr>
<td>GLYCERIN WITH SUCROSE Suspension</td>
<td>35.50</td>
<td>473 ml</td>
</tr>
<tr>
<td>GLYCEROL Liq</td>
<td>19.80</td>
<td>2,000 ml</td>
</tr>
<tr>
<td>HYDROCORTISONE Powder – 1% DV Dec-14 to 2017</td>
<td>59.50</td>
<td>25 g</td>
</tr>
<tr>
<td>LACTOSE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM HYDROXIDE Paste</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MENTHOL Crystals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHADONE HYDROCHLORIDE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYL HYDROXYBENZOATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>METHYLCELLULOSE Powder Suspension</td>
<td>35.50</td>
<td>473 ml</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension</td>
<td>35.50</td>
<td>473 ml</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension</td>
<td>35.50</td>
<td>473 ml</td>
</tr>
<tr>
<td>OLIVE OIL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAFFIN Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOBARBITONE SODIUM Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHENOL Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PILOCARPINE NITRATE Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLYHEXAMETHYLENE BIGUANIDE Liq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Povidone K30 Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROPYLENE GLYCOL Liq</td>
<td>12.00</td>
<td>500 ml</td>
</tr>
</tbody>
</table>

*Item restricted (see ➔ above); Item restricted (see ➔ below)

* e.g. *Brand* indicates brand example only. It is not a contracted product.*
### Extemporaneously Compounded Preparations and Galenicals

<table>
<thead>
<tr>
<th>Product</th>
<th>Authoritative Dose</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SALICYLIC ACID</strong></td>
<td>Powder</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SILVER NITRATE</strong></td>
<td>Crystals</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM BICARBONATE</strong></td>
<td>Powder BP</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM CITRATE</strong></td>
<td>Powder</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM METABISULFITE</strong></td>
<td>Powder</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STARCH</strong></td>
<td>Powder</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SULPHUR</strong></td>
<td>Precipitated</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sublimed</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SYRUP</strong></td>
<td>Liq (pharmaceutical grade)</td>
<td>$21.75</td>
<td>2,000 ml</td>
<td>Midwest</td>
</tr>
<tr>
<td><strong>THEOBROMA OIL</strong></td>
<td>Oint</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRI-SODIUM CITRATE</strong></td>
<td>Crystals</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRICHLORACETIC ACID</strong></td>
<td>Grans</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>UREA</strong></td>
<td>Powder BP</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WOOL FAT</strong></td>
<td>Oint, anhydrous</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>XANTHAN</strong></td>
<td>Gum 1%</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZINC OXIDE</strong></td>
<td>Powder</td>
<td>$2.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Food Modules

**Carbohydrate**

- **Restricted**
- Use as an additive
  - Any of the following:
    1. Cystic fibrosis; or
    2. Chronic kidney disease; or
    3. Cancer in children; or
    4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
    5. Faltering growth in an infant/child; or
    6. Bronchopulmonary dysplasia; or
    7. Premature and post premature infant; or
    8. Inborn errors of metabolism.

- **Use as a module**
  - For use as a component in a modular formula
  
  **CARBOHYDRATE SUPPLEMENT** – **Restricted** see terms above
  - **Powder 95 g carbohydrate per 100 g, 368 g can**
  - **Powder 96 g carbohydrate per 100 g, 400 g can**

- **Fat**

  - **Restricted**
  - Use as an additive
    - Any of the following:
      1. Patient has inborn errors of metabolism; or
      2. Faltering growth in an infant/child; or
      3. Bronchopulmonary dysplasia; or
      4. Fat malabsorption; or
      5. Lymphangiectasia; or
      6. Short bowel syndrome; or
      7. Infants with necrotising enterocolitis; or
      8. Biliary atresia; or
      9. For use in a ketogenic diet; or
      10. Chyle leak; or
      11. Ascites; or
      12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

- **Use as a module**
  - For use as a component in a modular formula

  **LONG-CHAIN TRIGLYCERIDE SUPPLEMENT** – **Restricted** see terms above
  - **Liquid 50 g fat per 100 ml, 200 ml bottle**
  - **Liquid 50 g fat per 100 ml, 500 ml bottle**

  **MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT** – **Restricted** see terms above
  - **Liquid 50 g fat per 100 ml, 250 ml bottle**
  - **Liquid 95 g fat per 100 ml, 500 ml bottle**

  **WALNUT OIL** – **Restricted** see terms above
  - **Liq**
### Protein

- **Restricted**
- **Use as an additive**
  
  Either:
  
  1. Protein losing enteropathy; or
  2. High protein needs.

- **Use as a module**
  
  For use as a component in a modular formula

#### PROTEIN SUPPLEMENT – Restricted

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Promod</td>
<td>£8.95 227 g</td>
<td>Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can</td>
</tr>
<tr>
<td>Resource Beneprotein</td>
<td>£8.95 227 g</td>
<td>Powder 6 g protein per 7 g, can</td>
</tr>
<tr>
<td>e.g. Protifar</td>
<td>£8.95 227 g</td>
<td>Powder 89 g protein, &lt;1.5 g carbohydrate and 2 g fat per 100 g, 225 g can</td>
</tr>
</tbody>
</table>

#### Other Supplements

- **BREAST MILK FORTIFIER**
  
  Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
  
  Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
  
  Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet

- **CARBOHYDRATE AND FAT SUPPLEMENT – Restricted**
  
  Both:
  
  1. Infant or child aged four years or under; and
  2. Any of the following:
     
     2.1 Cystic fibrosis; or
     2.2 Cancer in children; or
     2.3 Faltering growth; or
     2.4 Bronchopulmonary dysplasia; or
     2.5 Premature and post premature infants.

- **Food/Fluid Thickeners**

  **NOTE:**
  
  While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:
  
  - use was established prior to 1 July 2013; and
  - the product has not been specifically considered and excluded by PHARMAC; and
  - use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

  PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

- **CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN**
  
  Powder

  e.g. Feed Thickener

  Karicare Aptamil
GUAR GUM
Powder

MAIZE STARCH
Powder

MALTODEXTRIN WITH XANTHAN GUM
Powder

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID
Powder

**Metabolic Products**

*Restricted*

Any of the following:

1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

**Glutaric Aciduria Type 1 Products**

**AMINO ACID FORMULA (WITHOUT LYSINE AND LOW Tryptophan)** – *Restricted* see terms above

| Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can | e.g. GA1 Anamix Infant |
| Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can | e.g. XLYS Low TRY Maxamaid |

**Homocystinuria Products**

**AMINO ACID FORMULA (WITHOUT METHIONINE)** – *Restricted* see terms above

| Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can | e.g. HCU Anamix Infant |
| Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can | e.g. XMET Maxamaid |
| Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can | e.g. XMET Maxamum |
| Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle | e.g. HCU Anamix Junior LQ |

**Isovaleric Acidemia Products**

**AMINO ACID FORMULA (WITHOUT LEUCINE)** – *Restricted* see terms above

| Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can | e.g. IVA Anamix Infant |
| Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can | e.g. XLEU Maxamaid |
| Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can | e.g. XLEU Maxamum |
### Maple Syrup Urine Disease Products

**AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted see terms on the preceding page

- **Powder** 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  
  e.g. MSUD Anamix Infant
- **Powder** 25 g protein and 51 g carbohydrate per 100 g, 500 g can  
  e.g. MSUD Maxamaid
- **Powder** 39 g protein and 34 g carbohydrate per 100 g, 500 g can  
  e.g. MSUD Maxamum
- **Liquid** 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle  
  e.g. MSUD Anamix Junior LQ

### Phenylketonuria Products

**AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – **Restricted see terms on the preceding page

- **Tab** 8.33 mg  
  e.g. Phlexy-10
- **Powder** 29 g protein, 38 g carbohydrate and 13.5 g fibre per 100 g, 29 g sachet  
  e.g. PKU Anamix Junior
- **Powder** 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can  
  e.g. PKU Anamix Infant
- **Powder** 25 g protein and 51 g carbohydrate per 100 g, 500 g can  
  e.g. XP Maxamaid
- **Powder** 39 g protein and 34 g carbohydrate per 100 g, 500 g can  
  e.g. XP Maxamum
- **Powder** 8.33 g protein and 8.8 g carbohydrate per 20 g sachet  
  e.g. Phlexy-10
- **Liquid** 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle  
  e.g. PKU Lophlex LQ 10
- **Liquid** 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle  
  e.g. PKU Lophlex LQ 20
- **Liquid** 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle  
  e.g. PKU Lophlex LQ 20
- **Liquid** 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle  
  e.g. PKU Lophlex LQ 20
- **Liquid** 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle  
  e.g. PKU Lophlex LQ 10
- **Liquid** 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle  
  e.g. PKU Lophlex LQ 20
- **Liquid** 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle  
  e.g. PKU Lophlex LQ 10
- **Liquid** 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton  
  e.g. Easiphen
Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – Restricted see terms on page 200

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  e.g. MMA/PA Anamix Infant

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  e.g. XMTVI Maxamaid

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
  e.g. XMTVI Maxamum

Protein Free Supplements

PROTEIN FREE SUPPLEMENT – Restricted see terms on page 200

Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can
  e.g. Energivit

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – Restricted see terms on page 200

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  e.g. TYR Anamix Infant

Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can
  e.g. XPHEN, TYR Maxamaid

Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet
  e.g. TYR Anamix Junior

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  e.g. TYR Anamix Junior LQ

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – Restricted see terms on page 200

Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can
  e.g. Dialamine

Powder 79 g protein per 100 g, 200 g can
  e.g. Essential Amino Acid Mix

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – Restricted see terms on page 200

Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – Restricted see terms on page 200

Liquid, 500 ml bottle

Specialised Formulas

Diabetic Products

Restricted

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days;
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued…
continued...

5 For use pre- and post-surgery; or
6 For patients being tube-fed; or
7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page

- Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle .............................................................. 7.50 1,000 ml Glucerna Select RTH (Vanilla)
- Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag e.g. Nutrison Advanced Diason

LOW-GI ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page

- Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can .............................................................. 2.10 237 ml Sustagen Diabetic (Vanilla)
- Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can .............................................................. 2.10 237 ml Resource Diabetic (Vanilla)
- Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle e.g. Diasip

Elemental and Semi-Elemental Products

- Restricted

Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED – Restricted see terms above

- Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet ..............4.50 80.4 g Vivonex TEN

AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above

- Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton e.g. Elemental 028 Extra

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted see terms above

- Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag e.g. Nutrison Advanced Peptisorb
## SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet</td>
<td>Vital HN</td>
</tr>
<tr>
<td>Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can</td>
<td>e.g. Peptamen Junior</td>
</tr>
<tr>
<td>Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can</td>
<td>e.g. MCT Pepdite; MCT Pepdite 1+</td>
</tr>
<tr>
<td>Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet</td>
<td>Alitraq</td>
</tr>
</tbody>
</table>

**PEPTIDE-BASED ORAL FEED – Restricted** see terms on the preceding page

**Fat Modified Products**

**FAT-MODIFIED FEED – Restricted** see terms below

- Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can | e.g. Monogen |

- **Restricted**

Any of the following:
1. Patient has metabolic disorders of fat metabolism; or
2. Patient has a chyle leak; or
3. Modified as a modular feed for adults.

**Hepatic Products**

**Restricted**

For children (up to 18 years) who require a liver transplant

**HEPATIC ORAL FEED – Restricted** see terms above

- Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can | Heparon Junior |

**High Calorie Products**

**Restricted**

Any of the following:
1. Patient is fluid volume or rate restricted; or
2. Patient requires low electrolyte; or
3. Both:
   3.1 Any of the following:
      3.1.1 Cystic fibrosis; or
      3.1.2 Any condition causing malabsorption; or
      3.1.3 Faltering growth in an infant/child; or
      3.1.4 Increased nutritional requirements; and
   3.2 Patient has substantially increased metabolic requirements.

**ENTERAL FEED 2 KCAL/ML – Restricted** see terms above

- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle | Nutrison Concentrated |
- Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle | TwoCal HN RTH (Vanilla) |

**ORAL FEED 2 KCAL/ML – Restricted** see terms above

- Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle | Two Cal HN |
High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms below
- Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,
  1,000 ml bag
- e.g. Nutrison Protein Plus

**Restricted**

Both:
1. The patient has a high protein requirement; and
2. Any of the following:
   2.1 Patient has liver disease; or
   2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   2.3 Patient is fluid restricted; or
   2.4 Patient’s needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms below
- Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per
  100 ml, 1,000 ml bag
- e.g. Nutrison Protein Plus Multi Fibre

**Restricted**

Both:
1. The patient has a high protein requirement; and
2. Any of the following:
   2.1 Patient has liver disease; or
   2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   2.3 Patient is fluid restricted; or
   2.4 Patient’s needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ORAL FEED 1 KCAL/ML – **Restricted** see terms below
- Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml,
  200 ml bottle
- e.g. Fortimel Regular

**Restricted**

Any of the following:
1. Decompensating liver disease without encephalopathy; or
2. Protein losing gastro-enteropathy; or
3. Patient has increased protein requirements without increased energy requirements.
Infant Formulas

AMINO ACID FORMULA – Restricted see terms below

$ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can
  e.g. Neocate

$ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can
  e.g. Neocate LCP

$ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can ..........53.00 400 g Neocate Gold (Unflavoured)

$ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can
  e.g. Neocate Advance

$ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ..........53.00 400 g Neocate Advance (Unflavoured)

$ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 g, 400 g can
  e.g. Neocate (Unflavoured)

$ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet .................6.00 48.5 g Vivonex Paediatric

Restricted
Initiation
Any of the following:
  1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
  2 History of anaphylaxis to cows' milk protein formula or dairy products; or
  3 Eosinophilic oesophagitis.

Continuation
Both:
  1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
  2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – Restricted see terms below

$ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can
  e.g. Gold Pepti Junior
  Karicare Aptamil

Restricted
Initiation - new patients
Any of the following:
  1 Both:
     1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
     1.2 Either:
        1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
        1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
  2 Severe malabsorption; or
  3 Short bowel syndrome; or
  4 Intractable diarrhoea; or
  5 Biliary atresia; or
  6 Cholestatic liver diseases causing malsorption; or
  7 Cystic fibrosis; or

continued...
continued...

8 Proven fat malabsorption; or
9 Severe intestinal motility disorders causing significant malabsorption; or
10 Intestinal failure.

**Initiation - step down from amino acid formula**

Both:
1. The infant is currently receiving funded amino acid formula; and
2. The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.

**Continuation**

Both:
1. An assessment as to whether the infant can be transitioned to a cows’ milk protein or soy infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

**FRUCTOSE-BASED FORMULA**

- Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can
  - e.g. Galactomin 19

**LACTOSE-FREE FORMULA**

- Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can
  - e.g. Karicare Aptamil Gold De-Lact
- Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can
  - e.g. S26 Lactose Free

**LOW-CALCIUM FORMULA**

- Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can
  - e.g. Locasol

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms below**

- Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 100 ml bottle
  - e.g. Infatrini
  - Restricted
  - Both:
    1. Either:
      1.1 The patient is fluid restricted; or
      1.2 The patient has increased nutritional requirements due to faltering growth; and
    2. Patient is under 18 months old and weighs less than 8kg.

**PRETERM FORMULA – Restricted see terms below**

- Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can ..........15.25 400 g S-26 Gold Premgro
- Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle ..........0.75 100 ml S26 LBW Gold RTF
- Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle
  - e.g. Pre Nan Gold RTF
- Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle
  - e.g. Karicare Aptamil Gold+Preterm
  - Restricted
  - For infants born before 33 weeks’ gestation or weighing less than 1.5 kg at birth.

**THICKENED FORMULA**

- Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can
  - e.g. Karicare Aptamil Thickened AR
## SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

### Ketogenic Diet Products

**HIGH FAT FORMULA – Restricted** see terms below

1. Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, can ...........35.50 300 g Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)

2. Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can .................................................................35.50 300 g Ketocal 3:1 (Unflavoured)

**Restricted**

For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

### Paediatric Products

**Restricted**

Both:

1. Child is aged one to ten years; and
2. Any of the following:
   1. The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2. Any condition causing malabsorption; or
   3. Faltering growth in an infant/child; or
   4. Increased nutritional requirements; or
   5. The child is being transitioned from TPN or tube feeding to oral feeding.

**PAEDIATRIC ORAL FEED – Restricted** see terms above

1. Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can .................................................................20.00 850 g Pediasure (Vanilla)

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted** see terms above

1. Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag .......................................................4.00 500 ml Nutrini Low Energy Multifibre RTH

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted** see terms above

1. Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag ........2.68 500 ml Pediasure RTH
e.g. *Nutrini RTH*

2. Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag
e.g. *Nutrini RTH*

**PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

1. Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag ...............................................................6.00 500 ml Nutrini Energy Multi Fibre
e.g. *Nutrini Energy RTH*

2. Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag
e.g. *Fortini Multifibre*

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted** see terms above

1. Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle .................................................................1.07 200 ml Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)

2. Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can ...............1.34 250 ml Pediasure (Vanilla)

**PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

1. Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle
e.g. *Fortini*

2. Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle
e.g. *Fortini Multifibre*
### Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted** see terms below

- Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle ................................................................. 6.08 500 ml Nepro HP RTH

- **Restricted**
  For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted** see terms below

- Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can
  
  
  **Restricted**
  For children (up to 18 years) with acute or chronic kidney disease

**LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML**

- Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton ...............2.67 220 ml Nepro HP (Strawberry)
  
  **Restricted**
  For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted** see terms below

- Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton ...............3.31 237 ml Novasource Renal (Vanilla)
  
  - Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle
  - Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton
  
  **Restricted**
  For patients with acute or chronic kidney disease.

### Respiratory Products

**LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted** see terms below

- Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle ......................................................... 1.66 237 ml Pulmocare (Vanilla)

- **Restricted**
  For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg

### Surgical Products

**HIGH ARGinine ORAL FEED 1.4 KCAL/ML – Restricted** see terms below

- Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton ............................................................. 4.00 237 ml Impact Advanced Recovery (Chocolate)

- **Restricted**
  Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

**PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted** see terms on the next page

- Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle ......................................................... 6.80 4 preOp

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

### Item restricted (see above); Item restricted (see below)

#### Standard Feeds

**Item restricted**

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

**Restricted**

Any of the following:

1. For patients with malnutrition, defined as any of the following:
   1.1 BMI < 18.5; or
   1.2 Greater than 10% weight loss in the last 3-6 months; or
   1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days; or
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4. For use pre- and post-surgery; or
5. For patients being tube-fed; or
6. For tube-feeding as a transition from intravenous nutrition; or
7. For any other condition that meets the community Special Authority criteria.

**ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

- Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle
  - e.g. Isosource Standard RTH

- Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag ..........7.00 1,000 ml Nutrison Energy Multi Fibre

- Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag
  - e.g. Nutrison Energy Multi Fibre

- Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can ..........1.75 250 ml Ensure Plus HN

- Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag ......7.00 1,000 ml Ensure Plus HN RTH

- Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag .................................................. 7.00 1,000 ml Jevity HiCal RTH

**ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

- Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle ..........2.65 500 ml Osmolite RTH

- Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can ..........1.24 250 ml Osmolite

- Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle ...................................................... 2.65 500 ml Jevity RTH

- Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can ......................................................... 1.32 237 ml Jevity

- Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag
  - e.g. NutrisonStdRTH; NutrisonLowSodium

- Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag
  - e.g. Nutrison Multi Fibre

**ENTERAL FEED 1.2 KCAL/ML – Restricted** see terms above

- Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag
  - e.g. Jevity Plus RTH

---

*E.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ORAL FEED – Restricted** see terms on the preceding page

| Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can | 13.00 | 850 g | Ensure (Chocolate) |
| Powder 21.9 g protein, 53.5 g carbohydrate and 14.5 g fat per 100 g, can | 3.67 | 350 g | Fortisip (Vanilla) |
| Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can | 10.22 | 900 g | Sustagen Hospital Formula (Chocolate) |

**ORAL FEED 1 KCAL/ML – Restricted** see terms on the preceding page

| Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton | 1.33 | 237 ml | Ensure Plus (Chocolate) |
| Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can | 1.33 | 237 ml | Ensure Plus (Vanilla) |
| Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton | 1.26 | 200 ml | Ensure Plus (Vanilla) |
| Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle | e.g. Fortijuce |
| Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle | e.g. Fortisip |
| Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle | e.g. Fortisip Multi Fibre |
Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms below

¶ Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe

– 1% DV Jul-14 to 2017 .......................................................... 0.00 10 Infanrix IPV

**Restricted**

Funded for any of the following:

1. A single dose for children up to the age of 7 who have completed primary immunisation; or
2. A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
3. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
4. Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUNZAE TYPE B VACCINE – **Restricted** see terms below

¶ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial – 1% DV Jul-14 to 2017 ........................................ 0.00 10 Infanrix-hexa

**Restricted**

Funded for patients meeting any of the following criteria:

1. Up to four doses for children up to the age of 10 for primary immunisation; or
2. Up to four doses (as appropriate) for children are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; renal dialysis and other severely immunosuppressive regimens; or
3. Up to five doses for children up to the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

¶ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe –

1% DV Jul-14 to 2017 .......................................................... 0.00 5 ADT Booster

**Restricted**

Any of the following:

1. For vaccination of patients aged 45 and 65 years old; or
2. For vaccination of previously unimmunised or partially immunised patients; or
3. For revaccination following immunosuppression; or
4. For boosting of patients with tetanus-prone wounds; or
5. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

BACILLUS CALMETTE-GUERIN VACCINE – **Restricted** see terms on the next page

¶ Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent – 1% DV Oct-14 to 2017 ........................................ 0.00 10 BCG Vaccine

---

¶ Item restricted (see ➤ above); ¶ Item restricted (see ➤ below)

e.g. Brand indicates brand example only. It is not a contracted product.
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**Restricted**

Any of the following:

1. Up to three doses for patients pre- and post splenectomy and patients with functional or anatomic asplenia; or
2. One dose every five years for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
3. One dose for close contacts of meningococcal cases; or
4. A maximum of two doses for bone marrow transplant patients; or
5. A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require a second dose three years after the first and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

**PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted** see terms below

- Inj 30.8 mcg in 0.5 ml syringe  – 1% DV Oct-14 to 2017 ...............................................0.00 1 Prevenar 13

**Restricted**

Any of the following:

1. A primary course of up to four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
2. Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or
3. One dose is funded for high risk children who have previously received four doses of PCV10; or
4. Up to an additional four doses (as appropriate) are funded for (re-)immunisation for patients with HIV, patients post HSCT, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis and other severely immunosuppressive regimens up to the age of 18; or
5. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

**PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted** see terms below

- Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal serotype) – 1% DV Jul-14 to 2017 ...............................................0.00 1 Pneumovax 23

**Restricted**

Either of the following:

1. Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or
2. Up to two doses are funded for high risk children to the age of 18.

**SALMONELLA TYPHI VACCINE – Restricted** see terms below

- Inj 25 mcg in 0.5 ml syringe

**Restricted**

For use during typhoid fever outbreaks

**Viral Vaccines**

**HEPATITIS A VACCINE – Restricted** see terms below

- Inj 720 ELISA units in 0.5 ml syringe  – 1% DV Jul-14 to 2017 ...............................................0.00 1 Havrix Junior
- Inj 1440 ELISA units in 1 ml syringe  – 1% DV Jul-14 to 2017 ...............................................0.00 1 Havrix

**Restricted**

Funded for patients meeting any of the following criteria:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases; or
4. One dose for any of the following on the recommendation of a local medical officer of health
   4.1 Children, aged 1–4 years inclusive who reside in Ashburton district; or
   4.2 Children, aged 1–9 years inclusive, residing in Ashburton; or

continued…
continued…

4.3 Children, aged 1–9 years inclusive, who attend a preschool or school in Ashburton; or

4.4 Children, aged older than 9 years, who attend a school with children aged 9 years old or less, in Ashburton funded for children in Ashburton.

HEPATITIS B RECOMBINANT VACCINE

ền Inj 40 mcg per 1 ml vial – 1% DV Jul-14 to 2017 .................................................0.00 1 HBvaxPRO

本網站 Restricted
Fund for any of the following criteria:

1. For dialysis patients; or
2. For liver or kidney transplant patient.

ền Inj 5 mcg in 0.5 ml vial – 1% DV Jul-14 to 2017 ..............................................0.00 1 HBvaxPRO

本網站 Restricted
Fund for any of the following criteria:

1. For household or sexual contacts of known hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following immunosuppression; or
7. For transplant patients.

ền Inj 10 mcg in 1 ml vial – 1% DV Jul-14 to 2017 .................................................0.00 1 HBvaxPRO

本網站 Restricted
Fund for any of the following criteria:

1. For household or sexual contacts of known hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. For patients following immunosuppression; or
7. For transplant patients.

HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – Restricted see terms below

ền Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017 .................................................0.00 10 Gardasil

本網站 Restricted
Maximum of three doses for patient meeting any of the following criteria:

1. Females aged under 20 years old; or
2. Patients aged under 26 years old with confirmed HIV infection; or
3. For use in transplant patients.

INFLUENZA VACCINE – Restricted see terms on the next page

ền Inj 45 mcg in 0.5 ml syringe .................................................................90.00 10 Fluarix

Influvac
VACCINES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Restricted**

Any of the following:

1. **All people 65 years of age and over; or**
2. **People under 65 years of age who:**
   1. **Have any of the following cardiovascular diseases:**
      1.1 Ischaemic heart disease; or
      1.2 Congestive heart disease; or
      1.3 Rheumatic heart disease; or
      1.4 Congenital heart disease; or
      1.5 Cerebro-vascular disease; or
   2. **Have any of the following chronic respiratory diseases:**
      2.1 Asthma, if on a regular preventative therapy; or
      2.2 Other chronic respiratory disease with impaired lung function; or
   3. **Have diabetes;**
   4. **Have chronic renal disease;**
   5. **Have any cancer, excluding basal and squamous skin cancers if not invasive;**
   6. **Have any of the following other conditions:**
      6.1 Autoimmune disease;
      6.2 Immune suppression;
      6.3 HIV;
      6.4 Transplant recipients;
      6.5 Neuromuscular and CNS diseases;
      6.6 Haemoglobinopathies;
      6.7 Are children on long term aspirin; or
   7. **Are pregnant,** or
   8. **Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or**
   9. **People under 18 years of age living within the boundaries of the Canterbury District Health Board.**

Note: The following conditions are excluded from funding:
- asthma not requiring regular preventative therapy; and
- hypertension and/or dyslipidaemia without evidence of end-organ disease.

MEASLES, MUMPS AND RUBELLA VACCINE – **Restricted**

see terms below

\[
\text{Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent – 1\% DV Jul-14 to 2017 }\]

\[
\text{................................................ } 0.00 \text{ 10 M-M-R-II }
\]

**Restricted**

A maximum of two doses for any patient meeting the following criteria:

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – **Restricted**

see terms below

\[
\text{Inj 80 D-antigen units in 0.5 ml syringe – 1\% DV Jul-14 to 2017 }\]

\[
\text{................................. } 0.00 \text{ 1 IPOL }
\]

**Restricted**

Up to three doses for patients meeting either of the following:

1. For partially vaccinated or previously unvaccinated individuals; or
2. For revaccination following immunosuppression.

Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE

\[
\text{Inj 2.5 IU vial with diluent}
\]
ROTA VIRUS LIVE REASSORTANT ORAL VACCINE – Restricted see terms below

- Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per 2 ml,
  - 1% DV Jul-14 to 2017 ................................................................. 0.00 10  RotaTeq

Restricted
Maximum of three doses for patients meeting the following:
1. First dose to be administered in infants aged under 15 weeks of age; and
2. No vaccination being administered to children aged 8 months or over.

VARICELLA VACCINE [CHICKEN POX VACCINE] – Restricted see terms below

- Inj 2,000 PFU vial with diluent – 1% DV Jul-14 to 2017 ..................................0.00 1  Varilrix

Restricted
Maximum of two doses for any of the following:
1. For non-immune patients:
   1.1 With chronic liver disease who may in future be candidates for transplantation; or
   1.2 With deteriorating renal function before transplantation; or
   1.3 Prior to solid organ transplant; or
   1.4 Prior to any elective immunosuppression*.
2. For patients at least 2 years after bone marrow transplantation, on advice of their specialist.
3. For patients at least 6 months after completion of chemotherapy, on advice of their specialist.
4. For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.
5. For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.
6. For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
7. For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days
### Optional Pharmaceuticals

**NOTE:**

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a number of additional Optional Pharmaceuticals, including some wound care products and disposable laparoscopic equipment, are listed in an addendum to Part III which is available at www.pharmac.govt.nz. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

#### BLOOD GLUCOSE DIAGNOSTIC TEST METER

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>20.00</td>
<td>Caresens II</td>
</tr>
<tr>
<td>9.00</td>
<td>FreeStyle Lite</td>
</tr>
<tr>
<td>19.00</td>
<td>On Call Advanced</td>
</tr>
<tr>
<td></td>
<td>Accu-Chek Performa</td>
</tr>
</tbody>
</table>

- 1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips
- Meter

#### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.56</td>
<td>CareSens</td>
</tr>
<tr>
<td>21.65</td>
<td>CareSens N</td>
</tr>
<tr>
<td>28.75</td>
<td>FreeStyle Lite</td>
</tr>
<tr>
<td>19.10</td>
<td>On Call Advanced</td>
</tr>
</tbody>
</table>

- Blood glucose test strips
- Blood glucose test strips × 50 and lancets × 5

#### BLOOD KETONE DIAGNOSTIC TEST METER

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>40.00</td>
<td>Freestyle Optium</td>
</tr>
</tbody>
</table>

#### INSULIN PEN NEEDLES

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.50</td>
<td>B-D Micro-Fine</td>
</tr>
<tr>
<td>11.75</td>
<td>B-D Micro-Fine</td>
</tr>
<tr>
<td>10.50</td>
<td>ABM</td>
</tr>
<tr>
<td>10.50</td>
<td>ABM</td>
</tr>
</tbody>
</table>

- 29 g × 12.7 mm
- 31 g × 5 mm
- 31 g × 6 mm
- 31 g × 8 mm
- 32 g × 4 mm

#### INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>13.00</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>13.00</td>
<td>B-D Ultra Fine</td>
</tr>
<tr>
<td>13.00</td>
<td>ABM</td>
</tr>
<tr>
<td>13.00</td>
<td>ABM</td>
</tr>
</tbody>
</table>

- Syringe 0.3 ml with 29 g × 12.7 mm needle
- Syringe 0.3 ml with 31 g × 8 mm needle
- Syringe 0.5 ml with 29 g × 12.7 mm needle
- Syringe 0.5 ml with 31 g × 8 mm needle
- Syringe 1 ml with 29 g × 12.7 mm needle
- Syringe 1 ml with 31 g × 8 mm needle

#### KETONE BLOOD BETA-KETONE ELECTRODES

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.50</td>
<td>Freestyle Optium Ketone</td>
</tr>
</tbody>
</table>

#### MASK FOR SPACER DEVICE

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.99</td>
<td>EZ-fit Paediatric Mask</td>
</tr>
</tbody>
</table>

#### PEAK FLOW METER

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.44</td>
<td>Breath-Alert</td>
</tr>
<tr>
<td>11.44</td>
<td>Breath-Alert</td>
</tr>
</tbody>
</table>

**e.g. Brand** indicates brand example only. It is not a contracted product.
### PART III - OPTIONAL PHARMACEUTICALS

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREGNANCY TEST - HCG URINE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassette</td>
<td>22.80</td>
<td>40 test</td>
<td>Innovacon hCG One Step Pregnancy Test</td>
</tr>
<tr>
<td>SODIUM NITROPRUSSIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test strip</td>
<td>6.00</td>
<td>50 strip</td>
<td>Accu-Chek Ketur-Test</td>
</tr>
<tr>
<td>SPACER DEVICE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>230 ml (single patient)</td>
<td>4.72</td>
<td>1</td>
<td>Space Chamber Plus</td>
</tr>
<tr>
<td>800 ml</td>
<td>8.50</td>
<td>1</td>
<td>Volumatic</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INDEX

Generic Chemicals and Brands

- Symbols -

8-methoxypsoralen ........................................... 55

- A -

A-Scabies ..................................................... 52
Abacavir sulphate ........................................ 86
Abacavir sulphate with lamivudine .................. 86
Abiximab ..................................................... 151
Abilify .......................................................... 121
ABM Hydrocortisone .................................... 25
Acarboside .................................................. 17
Acarb ............................................................ 17
Accu-Chek Ketur-Test .................................. 219
Accu-Chek Performa ...................................... 218
Accuretic 10 ............................................... 39
Accuretic 20 ............................................... 39
Acetadote .................................................... 187
Acetazolamide .............................................. 184
Acetic acid Extemporaneous ......................... 195
Genito-Urinary ............................................. 58
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid ........ 58
Acetic acid with propylene glycol ...................... 186
Acetylsalicylic acid ....................................... 185
Acetylcysteine .............................................. 187
Aciclovir
Infection ..................................................... 91
Sensory ....................................................... 181
Acid Citrate Dextrose A .................................. 32
Acidex .......................................................... 14
Acipimox ....................................................... 47
Acitretin ....................................................... 55
Aclasta ........................................................ 97
Act-HIB ......................................................... 213
Actavis ........................................................ 123
Actemra ........................................................ 170
Actinomycin D .............................................. 133
Adalimumab ............................................... 151
Adapalene .................................................... 52
Adenalin ......................................................... 43
Adefovir dipivoxil ......................................... 88
Adenosine ....................................................... 41
Adenuric ......................................................... 101
Adrenalin ......................................................... 47
ADT Booster .................................................. 212
Adult diphtheria and tetanus vaccine .................... 212
Advantan ....................................................... 54
Advate .......................................................... 31
Aerrane ........................................................ 106

Afinitor ......................................................... 173
Agents Affecting the Renin-Angiotensin System ........... 39
Agents for Parkinsonism and Related Disorders ............. 105
Agents Used in the Treatment of Poisonings .......... 187
Ajmaline ......................................................... 41
Alanase ......................................................... 175
Albendazole .................................................... 82
Aldara ......................................................... 56
Alendronate sodium ......................................... 95–96
Alendronate sodium with cholecalciferol ................. 96
Alfalfacitobil .................................................... 26
Alfentanil ...................................................... 110
Alinia .......................................................... 83
Alitraq ........................................................ 204
Alldersothe .................................................. 176
Allopurinol ..................................................... 100
Alpha tocopherol acetate .................................... 26
Alpha-Adrenoceptor Blockers ............................ 40
Alprazolam ...................................................... 127
Alprostadil hydrochloride ................................ 48
Alteplase ....................................................... 35
Alum ........................................................... 195
Aluminium hydroxide ...................................... 14
Aluminium hydroxide with magnesium hydroxide and simethicone .......... 14
Amantadine hydrochloride ................................ 105
AmBisome ...................................................... 79
Ambrisentan ................................................... 49
Amethocaine ............................................... 109, 183
Nervous ...................................................... 109
Sensory ....................................................... 183
Amikacin ........................................................ 72
Amiloride hydrochloride ................................... 45
Amiloride hydrochloride with furosemide ................. 45
Amiloride hydrochloride with hydrochlorothiazide .......... 45
Aminophylline .................................................. 179
Amiodarone hydrochloride ................................ 41
Amisulpride ................................................... 120
Amitrip ......................................................... 113
Amitriptyline .................................................. 113
Amlodipine ..................................................... 43
Amorolfine ..................................................... 51
Amoxicillin ................................................... 75
Amoxicillin Actavis ......................................... 75
Amoxicillin with clavulanic acid .......................... 75
Amphotericin B ............................................. 75
Amitriptyline ................................................... 48
Anabolics ...................................................... 62
Anaesthesia ................................................... 106
Anagrelide hydrochloride ................................ 135
Analesgesic .................................................... 109
Anastrozole ................................................... 145
Andriol Testocaps .......................................... 62
Androderm ..................................................... 62
Androgen Agonists and Antagonists ..................... 62
Anexate ....................................................... 187
Antabuse ....................................................... 131
Antihistamines and Antiflatulents ....................... 14
Anti-Infective Agents ....................................... 58
Anti-Infective Preparations Dermatological ............ 51
Sensory ....................................................... 181
Anti-Inflammatory Preparations ......................... 182
Antiacne Preparations ..................................... 52
Antianaemics .................................................. 28
Antivirals ....................................................... 72
Anticholinergic Agents ..................................... 176
Anticholinesterase .......................................... 95
Antidepressants ............................................. 113
Antidiarrhoeal and Intestinal Anti-Inflammatory Agents .......... 14
Antiepilepsy Drugs .......................................... 115
Antifibrinolytics, Haemostatics and Local Sclerosants .... 30
Antifungals ..................................................... 78
Antihypotensives ............................................ 42
Antimigraine Preparations ................................ 119
Antimycobacterial .......................................... 81
Antinast ......................................................... 120
Antinase and Vertigo Agents ............................... 119
Antiparasitics ................................................ 82
Antipruritic Preparations ................................... 52
Antipsychotic Agents ....................................... 120
Antiretrovirals ............................................... 84
Antirheumatoid Agents ...................................... 95
Antiseptics and Disinfectants ............................ 189
Antispasmodics and Other..................................
Agents Altering Gut
Motility ........................................ 16
Antithrombotics .............................. 32
Antithymocyte globulin
(rabbit) .......................................... 173
Antithymocyte globulin
(equine) .......................................... 173
Antilucrent ..................................... 16
Antivirals ........................................ 88
Anxiolytics ...................................... 127
Apipiprazole .................................... 121
Aripiprazole .................................... 121
Aristocort ........................................ 54
Aromasin ....................................... 145
Arrow - Clopid ................................ 34
Arrow - Amritryline ......................... 113
Arrow-Bendrofluzide ....................... 45
Arrow-Brimonodine ......................... 185
Arrow-Calcium ................................ 22
Arrow-Citalopram ........................... 114
Arrow-Diazepam ................................ 127
Arrow-Doxorubicin ......................... 133
Arrow-Etidronate ............................ 97
Arrow-Fluoxetine ............................ 115
Arrow-Gabapentin ........................... 116
Arrow-Lamotrigine ......................... 117
Arrow-Lisinopril .............................. 39
Arrow-Losartan & Hydrochlorothiazide 40
Arrow-Morphine LA ......................... 111
Arrow-Norflaxacin ........................... 76
Arrow-Ornidazoe ............................. 83
Arrow-Quinapril 10 ......................... 39
Arrow-Quinapril 20 ......................... 39
Arrow-Quinapril 5 ........................... 39
Arrow-Roxithromycin ....................... 75
Arrow-Sertraline ............................. 115
Arrow-Simva ................................... 46
Arrow-Sumatriptan ........................... 119
Arrow-Timolol ................................. 184
Arrow-Tolterodine ......................... 110
Arrow-Topiramate ......................... 118
Arrow-Tramadol ............................... 112
Arrow-Venlafaxine XR ..................... 114
Arsenic trioxide ............................... 135
Artemether with lumefantrine ............ 82
Artesunate ..................................... 82
Articaine hydrochloride .................... 107
Articaine hydrochloride with adrenaline 107
Asacol ............................................ 15
Asamin ........................................... 15
Ascorbic acid
Alimentary ....................................... 26
Extemporaneous ............................. 195
Aspen Adrenaline ............................. 47
Aspen Ciprofloxacin ......................... 76
Aspirin
Blood ........................................... 34
Nervous ......................................... 109
Asthalin ......................................... 177
Atazanavir sulphate ......................... 87
Atezolozole .................................... 42
Atezolozole-AFT ............................... 42
ATGAM ....................................... 173
Ativan .......................................... 127
Atomoxetine ................................... 129
Atorvastatin .................................. 46
Atovaqone with proguanil hydrochloride 82
Atracurium besylate ......................... 101
Atriplex ......................................... 86
Atropine sulphate
Cardiovascular ................................ 41
Sensory ......................................... 185
Atropl ........................................... 185
Augmentin ..................................... 75
Auranofin ...................................... 95
Avanex .......................................... 114
Avelox .......................................... 76
Avelox IV 400 .................................. 76
Avonex .......................................... 128
Avonex Pen ..................................... 128
Azacitidine .................................... 134
Azactan .......................................... 77
Azamun .......................................... 173
Azathioprine ................................... 173
Azithromycin ................................... 74
Azol ................................................. 64
AZT ............................................... 86
Aztreonam ....................................... 77

-A-
B-D Micro-Fine ...................... 218
B-D Ultra Fine ................... 218
B-D Ultra Fine II .................. 218
Bacillus calmette-guerin (BCG) ............. 173
Bacillus calmette-guerin vaccine .............. 212
Baclofen ....................................... 101
Bacterial and Viral Vaccines ........... 212
Bacterical Vaccines ........................ 212
Baraclude ...................................... 88
Barium sulphate ......................... 191
Barium sulphate with sodium bicarbonate 191
Barrier Creams and Emollients ............. 52
Basiliximab .................................... 158
BCG Vaccine .................................. 212
Beclazone 100 .................................. 177
Beclazone 250 ................................. 177
Beclazone 50 .................................. 177
Beclomethasone ............................. 192
INDEX
Generic Chemicals and Brands

dipropionate ..............................175, 177
Bee venom ..................................175
Bendrofluazide ............................45
Bendrofluamide............................45
Bendrofluamide [Bendrofluamide] ....45
BeneFIX ........................................31
Benzhathine benzylpenicillin ...........75
Benzbromaron AL 100 .................100
Benzbromaronone ..........................100
Benzoic acid ................................107
Benziol peroxide ..........................195
Benztrap ........................................105
Benztrona mesylate ........................105
Benzydmine hydrochloride ..............24
Benzydmine hydrochloride with cetylpyridinium chloride ..........24
Benzylenpenicillin sodium [Penicillin G] .... 75
Beractant ....................................180
Beta Scalp .....................................55
Beta-Adrenerceptor Agonists ..........177
Beta-Adrenerceptor Blockers ..........42
Betadine .....................................189
Betadine Skin Prep ......................189
Betagan .......................................184
Betalin dysthrohydrochloride ............119
Betaline .......................................21
Betamethahone ..............................62
Betamethahone dipropionate ..............54
Betamethahone dipropionate with calcitriol ..........55
Betamethahone sodium phosphate with betamethahone acetate ..........62
Betamethahone valerate ..................54–55
Betamethahone valerate with clicouinol ......55
Betamethahone valerate with fusidic acid ..........55
Betaxolol .....................................184
Betoptic .......................................184
Betoptic S .....................................184
Bevacizumab ................................158
Bezafibrate ...................................45
Bezalip ...........................................45
Bezalip Retard ...............................45
Bicalcical .................................144
Bicalutamide ................................144
Bicillin LA .....................................75
Bile and Liver Therapy ....................17
Biliscopin ....................................192
Bimatoprost ...................................185
Biodone .......................................110
Biodone Extra Forte ....................110
Biodone Forte ...............................110
Biotin ..........................................22
Bisacodyl .....................................21
Bismuth subgallate .......................195
Bismuth subinrate and iodoform paraffin ..........193
Bismuth trioxide ...........................17
Bisporol .......................................42
Bivalirudin ..................................32
Bleomycin sulphate .......................133
Blood glucose diagnostic test meter ..........218
Blood glucose diagnostic test strip ..........218
Blood ketone diagnostic test meter ..........218
Bocprevir ....................................91
Bonney’s blue dye .......................192
Bostrix .........................................213
Boric acid .....................................195
Bortezomib ..................................136
Bosentan .......................................49
Bosvate .......................................42
Botax ............................................101
Botulism antitoxin ........................187
Breath-Alert ..................................218
Bridion .........................................102
Brilinta .........................................34
Brimonidine tartrate .....................185
Brimonidine tartrate with timolol ..........185
Brinzolamide ...............................184
Bromocriptine ..............................105
Brufen SR ......................................103
Budesonide ...................................14
Alimentary ...................................175, 177
Budesonide with efomteroel ..........................179
Bumetanide ...................................44
Bupafarin ......................................108
Bupivacaine hydrochloride .............107
Bupivacaine hydrochloride with adrenaline ..........107
Bupivacaine hydrochloride with fentanyl ..........108
Bupivacaine hydrochloride with glucose ..........108
Buprenorphine with naloxone ...............131
Bupropion hydrochloride .................131
Burinex ....................................... 44
Buscopan ......................................16
Buserelin ..................................... 65
Buspirone hydrochloride .................127
Busulfan ......................................133
Butacort Aqueous .........................175
Cabergoline .................................. 64
Caffeine .......................................129
Caffeine citrate .........................179
Cal-d-Forte ...................................26
Calamine .......................................52
Calcitriol ......................................55
Calcitonin .....................................62
Calcitriol ......................................26
Calcitriol-AFT ...............................26
Calcium carbonate .......................14, 22
Calcium Channel Blockers .............. 43
Calcium chloride .......................... 35
Calcium chloride with magnesium chloride, potassium chloride, sodium acetate, sodium chloride and sodium citrate ..........183
Calcium folinate ............................143
Calcium Follate Ebeewe ....................143
Calcium gluconate
Blood ........................................... 35
Dermatological .............................57
Calcium Homeostasis .................... 62
Calcium polystyrene sulphonate .......... 38
Calcium Resonium ....................... 38
Calsource ......................................22
Cancidas ..................................... 80
Candesartan cilexetil .................... 40
Candestar .....................................40
Capecitabine ................................134
Capsaicin .....................................134
Capoten ....................................... 39
Capsaicin Musculoskeletal System ........ 104
Nervous .......................................109
Captopril .......................................39
Carbaccord ..................................138
Carbamazepine .............................115
Carbasorb-X .................................188
Carbimazole ..................................70
Carbomer .....................................186
Carboplatin ..................................138
Carboplatin Ebeewe .......................138

-C-
Caffeine .......................................129
Caffeine citrate .........................179
Cal-d-Forte ...................................26
Calamine .......................................52
Calcitriol ......................................55
Calcitonin .....................................62
Calcitriol-AFT ...............................26
Calcium carbonate .......................14, 22
Calcium Channel Blockers .............. 43
Calcium chloride .......................... 35
Calcium chloride with magnesium chloride, potassium chloride, sodium acetate, sodium chloride and sodium citrate ..........183
Calcium folinate ............................143
Calcium Follate Ebeewe ....................143
Calcium gluconate
Blood ........................................... 35
Dermatological .............................57
Calcium Homeostasis .................... 62
Calcium polystyrene sulphonate .......... 38
Calcium Resonium ....................... 38
Calsource ......................................22
Cancidas ..................................... 80
Candesartan cilexetil .................... 40
Candestar .....................................40
Capecitabine ................................134
Capsaicin .....................................134
Capoten ....................................... 39
Capsaicin Musculoskeletal System ........ 104
Nervous .......................................109
Captopril .......................................39
Carbaccord ..................................138
Carbamazepine .............................115
Carbasorb-X .................................188
Carbimazole ..................................70
Carbomer .....................................186
Carboplatin ..................................138
Carboplatin Ebeewe .......................138
<table>
<thead>
<tr>
<th>INDEX</th>
<th>223</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboprost trometamol</td>
<td>60</td>
</tr>
<tr>
<td>Carboxymethylcellulose</td>
<td>24</td>
</tr>
<tr>
<td>Alimentary</td>
<td>195</td>
</tr>
<tr>
<td>Cardinol LA</td>
<td>43</td>
</tr>
<tr>
<td>Cardizem CD</td>
<td>44</td>
</tr>
<tr>
<td>CareSens</td>
<td>218</td>
</tr>
<tr>
<td>CareSens II</td>
<td>218</td>
</tr>
<tr>
<td>CareSens N</td>
<td>218</td>
</tr>
<tr>
<td>CareSens N POP</td>
<td>218</td>
</tr>
<tr>
<td>Carmellose sodium</td>
<td>186</td>
</tr>
<tr>
<td>Carmustine</td>
<td>133</td>
</tr>
<tr>
<td>Carvediol</td>
<td>42</td>
</tr>
<tr>
<td>Caspofungin</td>
<td>80</td>
</tr>
<tr>
<td>Catapres</td>
<td>44</td>
</tr>
<tr>
<td>Catapres-TTS-1</td>
<td>44</td>
</tr>
<tr>
<td>Catapres-TTS-2</td>
<td>44</td>
</tr>
<tr>
<td>Catapres-TTS-3</td>
<td>44</td>
</tr>
<tr>
<td>Ceenu</td>
<td>133</td>
</tr>
<tr>
<td>Cefaclor</td>
<td>73</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>73</td>
</tr>
<tr>
<td>Cefalexin Sandoz</td>
<td>73</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>73</td>
</tr>
<tr>
<td>Cefepime</td>
<td>73</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>73</td>
</tr>
<tr>
<td>Cefotaxime Sandoz</td>
<td>73</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>73</td>
</tr>
<tr>
<td>Cefotarolone fosamil</td>
<td>74</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>73</td>
</tr>
<tr>
<td>Ceftiraxonol</td>
<td>73</td>
</tr>
<tr>
<td>Ceftiraxone-AFT</td>
<td>73</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>73</td>
</tr>
<tr>
<td>Ceflecob</td>
<td>102</td>
</tr>
<tr>
<td>Celiprolol</td>
<td>42</td>
</tr>
<tr>
<td>CellCept</td>
<td>174</td>
</tr>
<tr>
<td>Celol</td>
<td>42</td>
</tr>
<tr>
<td>Centrally-Acting Agents</td>
<td>44</td>
</tr>
<tr>
<td>Cephalexin ABM</td>
<td>73</td>
</tr>
<tr>
<td>Cetirizine - AFT</td>
<td>175</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>175</td>
</tr>
<tr>
<td>Cetomacrogol</td>
<td>53</td>
</tr>
<tr>
<td>Cetomacrogol with glycerol</td>
<td>53</td>
</tr>
<tr>
<td>Cetrimide</td>
<td>195</td>
</tr>
<tr>
<td>Champix</td>
<td>132</td>
</tr>
<tr>
<td>Charcoal</td>
<td>188</td>
</tr>
<tr>
<td>Chemotherapeutic Agents</td>
<td>133</td>
</tr>
<tr>
<td>Chickenpox vaccine</td>
<td>217</td>
</tr>
<tr>
<td>Chlorafast</td>
<td>181</td>
</tr>
<tr>
<td>Chlortalidone</td>
<td>181</td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>128</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>133</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>77</td>
</tr>
<tr>
<td>Infection</td>
<td>77</td>
</tr>
<tr>
<td>Sensory</td>
<td>181</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>58</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>189, 193</td>
</tr>
<tr>
<td>Various</td>
<td>189, 193</td>
</tr>
<tr>
<td>Chlorhexidine gluconate</td>
<td>24</td>
</tr>
<tr>
<td>Alimentary</td>
<td>195</td>
</tr>
<tr>
<td>Extemporaneous</td>
<td>58</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>189</td>
</tr>
<tr>
<td>Chlorhexidine with cetrimide</td>
<td>189, 193</td>
</tr>
<tr>
<td>Chlorhexidine with ethanol</td>
<td>189</td>
</tr>
<tr>
<td>Chloroform</td>
<td>195</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>82</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>45</td>
</tr>
<tr>
<td>Chlorpheniramine maleate</td>
<td>175</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>121</td>
</tr>
<tr>
<td>Chloriserg</td>
<td>181</td>
</tr>
<tr>
<td>Chloral hydrate</td>
<td>128</td>
</tr>
<tr>
<td>Citalopram hydrobromide</td>
<td>174</td>
</tr>
<tr>
<td>Cicleson</td>
<td>181</td>
</tr>
<tr>
<td>Choice TT380 Short</td>
<td>59</td>
</tr>
<tr>
<td>Choice TT380 Standard</td>
<td>59</td>
</tr>
<tr>
<td>Cholecalciferol</td>
<td>26</td>
</tr>
<tr>
<td>Cholesterylamine</td>
<td>46</td>
</tr>
<tr>
<td>Choline salicylate with cetalkonium chloride</td>
<td>24</td>
</tr>
<tr>
<td>Cholavastine</td>
<td>46</td>
</tr>
<tr>
<td>Choriongonadotropin alfa</td>
<td>65</td>
</tr>
<tr>
<td>Ciclopirox olamine</td>
<td>51</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>145</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>91</td>
</tr>
<tr>
<td>Cilazapril</td>
<td>39</td>
</tr>
<tr>
<td>Cilazapril with hydrochlorothiazide</td>
<td>39</td>
</tr>
<tr>
<td>Cilicaine</td>
<td>75</td>
</tr>
<tr>
<td>Cilicaine VK</td>
<td>75</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>16</td>
</tr>
<tr>
<td>Cinchocaine hydrochloride with hydrocortisone</td>
<td>15</td>
</tr>
<tr>
<td>Cipodox</td>
<td>76</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>76</td>
</tr>
<tr>
<td>Ciprofloxacin infection</td>
<td>76</td>
</tr>
<tr>
<td>Sensory</td>
<td>181</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>138</td>
</tr>
<tr>
<td>Cisplatin Ebeve</td>
<td>138</td>
</tr>
<tr>
<td>Citralopram hydrobromide</td>
<td>114</td>
</tr>
<tr>
<td>Citaxen</td>
<td>109</td>
</tr>
<tr>
<td>Citric acid</td>
<td>195</td>
</tr>
<tr>
<td>Citric acid with magnesium oxide and sodium picosulfate</td>
<td>20</td>
</tr>
<tr>
<td>Citric acid with sodium bicarbonate</td>
<td>191</td>
</tr>
<tr>
<td>Cladribine</td>
<td>135</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>74</td>
</tr>
<tr>
<td>Clidemycin</td>
<td>33</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>77</td>
</tr>
<tr>
<td>Clindamycin ABM</td>
<td>77</td>
</tr>
<tr>
<td>Clofazimine</td>
<td>81</td>
</tr>
<tr>
<td>Clomazol</td>
<td>51, 58</td>
</tr>
<tr>
<td>Clomiphene citrate</td>
<td>64</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>115, 127</td>
</tr>
<tr>
<td>Clonidine</td>
<td>44</td>
</tr>
<tr>
<td>Clonidine BNM</td>
<td>44</td>
</tr>
<tr>
<td>Clonidine hydrochloride</td>
<td>44</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>34</td>
</tr>
<tr>
<td>Clopine</td>
<td>121</td>
</tr>
<tr>
<td>Clopoxil</td>
<td>125, 127</td>
</tr>
<tr>
<td>Clostridium botulinum type A toxin</td>
<td>101</td>
</tr>
<tr>
<td>Clotrimazole</td>
<td>51</td>
</tr>
<tr>
<td>Dermatological</td>
<td>58</td>
</tr>
<tr>
<td>Clotrimazole</td>
<td>195</td>
</tr>
<tr>
<td>Clotrimazole</td>
<td>121</td>
</tr>
<tr>
<td>Clovaril</td>
<td>121</td>
</tr>
<tr>
<td>Clo-trimoxazole</td>
<td>78</td>
</tr>
<tr>
<td>Coal tar</td>
<td>195</td>
</tr>
<tr>
<td>Coal tar with salicylic acid and sulphur</td>
<td>55</td>
</tr>
<tr>
<td>Coal tar with triethanolamine</td>
<td>55</td>
</tr>
<tr>
<td>Lauryl sulphate and fluorescein</td>
<td>55</td>
</tr>
<tr>
<td>Cocaine hydrochloride</td>
<td>108</td>
</tr>
<tr>
<td>Cocaine hydrochloride with adrenaline</td>
<td>108</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>58</td>
</tr>
<tr>
<td>Extemporaneous</td>
<td>195</td>
</tr>
<tr>
<td>Nervous</td>
<td>110</td>
</tr>
<tr>
<td>Cogentin</td>
<td>105</td>
</tr>
<tr>
<td>Colaspace [L-asparaginase]</td>
<td>136</td>
</tr>
<tr>
<td>Colchicine</td>
<td>101</td>
</tr>
<tr>
<td>Colestipol</td>
<td>77</td>
</tr>
<tr>
<td>Colestipol hydrochloride</td>
<td>46</td>
</tr>
<tr>
<td>Colgout</td>
<td>101</td>
</tr>
<tr>
<td>Colilfoam</td>
<td>15</td>
</tr>
<tr>
<td>Colistin</td>
<td>16</td>
</tr>
<tr>
<td>Colon-Stimulating Factors</td>
<td>35</td>
</tr>
</tbody>
</table>
INDEX

Generic Chemicals and Brands

Coloxyl ........................................ 20
Compound electrolytes .................. 35, 38
Compound electrolytes with glucose ................... 35, 38
Compound ...........................................
hydroxybenzoate ............................. 195
Compound sodium lactate ...................
[Hartmann's solution] ......................... 36
Compound sodium lactate with glucose .................. 36
Concerta ......................................... 130
Condylone ........................................ 56
Contraceptives ................................. 58
Contrast Media ................................. 190
Cordarone-X .................................... 41
Corticosteroids
Dermatological .................................. 54
Hormone .......................................... 62
Corticotrorelin (ovine) ......................... 65
Cosopt ............................................. 184
Cough Suppressants ............................ 177
Crotamiton ....................................... 52
Crystaderm ....................................... 51
CT Plus+ .......................................... 191
Curosurf .......................................... 180
Cvite ............................................... 26
Cyclizine hydrochloride ....................... 119
Cyclizine lactate ............................... 119
Cyclogyl ........................................... 185
Cyclopentolate hydrochloride .............. 185
Cyclophosphamide ......................... 133
Cycloserine ...................................... 81
Cyklokapron .................................... 31
Cymevene ........................................ 91
Cyproheptadine ............................... 91
Cyproheptadine hydrochloride ............. 175
Cyproterone acetate ......................... 175
Cyproterone acetate with ethinylestroadiol .................. 58
Cysteamine hydrochloride .................. 195
Cytarabine ...................................... 135
D - .......................................................... 224
Danaparoid ..................................... 32
Danazol ............................................ 64
Danthron with poloxamer ................. 21
Dantrolene ...................................... 102
Dapta-Tabs ..................................... 45
Dapsone ............................................
Contracted ................................. 81
Infection ........................................ 81
Daptomycin ..................................... 77
Darunavir ....................................... 87
Dasatinib ......................................... 138
Daunorubicin .................................. 133
DBL Amikacin .................................. 72
DBL Aminophylline ........................... 179
DBL Cefepime .................................. 73
DBL Ceftazidime .............................. 73
DBL Docetaxel .................................. 143
DBL Epirubicin Hydrochloride ......... 134
DBL Ergometrine ............................. 60
DBL Leucovorin Calcium .................. 143
DBL Meropenem ................................ 72
DBL Morphine Sulphate ..................... 111
DBL Pethidine Hydrochloride ........... 112
DBL Rocuronium Bromide ................. 102
DBL Tobramycin ............................. 72
DDI .................................................. 86
De-Nol ............................................ 17
De-Worm .......................................... 82
Decongestants ................................. 177
Decongestants and Antiallergics ........ 182
Decolzol ......................................... 24
Deferasirox ............................. 188
Deferiprone ...................................... 188
Defibrotide ..................................... 32
Definity ......................................... 192
Demeclocycline ............................... 76
Deoxycoformycin ......................... 137
Depo-Medrol ..................................... 63
Depo-Medrol with Lidocaine ............. 63
Depo-Provera .................................. 59
Depo-Testosterone ......................... 62
Deprim .......................................... 78
Dermol ........................................... 54, 56
Desferroxamine mesilate .................. 188
Desflurane ...................................... 106
Desmopressin acetate ....................... 70
Desmopressin-PH&T ....................... 70
Dexamethasone
Hormone ........................................... 62
Sensory .......................................... 182
Dexamethasone phosphate ............... 62
Dexamethasone with framycetin and gramicidin ................. 181
Dexamethasone with neomycin sulphate and polymyxin B sulphate ................. 181
Dexamethasone with tolbramycin .......... 181
Dexamethasone-hamelin ............... 62
Dexametamide ............................... 129
Dexmedetomidine ......................... 106
Dextrose .................. 17, 36, 195
Alimentary ..................................... 17
Blood ............................................ 36
Extemporaneous ....................... 195
Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A] .................. 32
DHC Continus ................................ 110
Diabetes ........................................... 17
Diacemit ...................................... 118
Diagnostic Agents ......................... 192
Diagnostic and Surgical Preparations .................. 183
Diamide Relief ................................ 14
Diamox ......................................... 184
Diatriozoate meglumine with sodium amidotriazoate ................. 190
Diatrizoate sodium ......................... 190
Diazepam ....................................... 115, 127
Diazoxide
Alimentary ..................................... 17
Cardiovascular .............................. 48
Dichlorobenzyl alcohol with amylymetacresol .................. 24
Diclax SR ........................................ 103
Dilofenac sodium
Musculoskeletal System .................. 103
Sensory .......................................... 182
Dicobalt edetate ......................... 188
Didanosine [DDI] ............................. 86
Diflucan ........................................... 79
Diflucortolone valerate .................... 54
Digestives Including Enzymes ................. 19
Digoxin .......................................... 41
Digoxin immune Fab ....................... 187
Dihydrocodeine tartrate .................. 110
Dihydroergotamine mesylate ................. 119
<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinyloestradiol with levonorgestrel</td>
<td>58</td>
</tr>
<tr>
<td>Ethinyloestradiol with norethisterone</td>
<td>58</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>115</td>
</tr>
<tr>
<td>Ethyl chloride</td>
<td>108</td>
</tr>
<tr>
<td>Etidronic acid disodium</td>
<td>97</td>
</tr>
<tr>
<td>Etomoxirate</td>
<td>106</td>
</tr>
<tr>
<td>Etopophos</td>
<td>136</td>
</tr>
<tr>
<td>Etoposide</td>
<td>136</td>
</tr>
<tr>
<td>Etoposide (as phosphate)</td>
<td>136</td>
</tr>
<tr>
<td>Etoricoxib</td>
<td>103</td>
</tr>
<tr>
<td>Etravirine</td>
<td>85</td>
</tr>
<tr>
<td>Everolimus</td>
<td>173</td>
</tr>
<tr>
<td>Evixa</td>
<td>99</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>46</td>
</tr>
<tr>
<td>Ezetimibe with simvastatin</td>
<td>46</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>127</td>
</tr>
<tr>
<td>Finpro</td>
<td>61</td>
</tr>
<tr>
<td>Flagyl</td>
<td>83</td>
</tr>
<tr>
<td>Flagyl-S</td>
<td>83</td>
</tr>
<tr>
<td>Flamazine</td>
<td>51</td>
</tr>
<tr>
<td>Flecaïnide acétate</td>
<td>41</td>
</tr>
<tr>
<td>Fleet Phosphate Enema</td>
<td>21</td>
</tr>
<tr>
<td>Flioxase Hayfever &amp; Allergy</td>
<td>175</td>
</tr>
<tr>
<td>Flitoxide</td>
<td>178</td>
</tr>
<tr>
<td>Flitoxide Accuhaler</td>
<td>178</td>
</tr>
<tr>
<td>Florinef</td>
<td>63</td>
</tr>
<tr>
<td>Fluanxol</td>
<td>125</td>
</tr>
<tr>
<td>Fluorax</td>
<td>215</td>
</tr>
<tr>
<td>Flucloxacinil</td>
<td>75</td>
</tr>
<tr>
<td>Flucloxicin</td>
<td>75</td>
</tr>
<tr>
<td>Flucon</td>
<td>182</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>79</td>
</tr>
<tr>
<td>Fluconazole-Claris</td>
<td>79</td>
</tr>
<tr>
<td>Flucytosine</td>
<td>80</td>
</tr>
<tr>
<td>Fludara Oral</td>
<td>135</td>
</tr>
<tr>
<td>Fluorarabine Ebeve</td>
<td>135</td>
</tr>
<tr>
<td>Fluorarabine phosphate</td>
<td>135</td>
</tr>
<tr>
<td>Fluorocortisone acetate</td>
<td>63</td>
</tr>
<tr>
<td>Fluids and Electrolytes</td>
<td>35</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>187</td>
</tr>
<tr>
<td>Flurometase pivalate with cloquiol</td>
<td>181</td>
</tr>
<tr>
<td>Fluorocortolone caproate with fluocortolone pivalate and cinchocaine</td>
<td>15</td>
</tr>
<tr>
<td>Fluorescein sodium</td>
<td>183</td>
</tr>
<tr>
<td>Fluorescein sodium with lignocaine hydrochloride</td>
<td>183</td>
</tr>
<tr>
<td>Fluoresce its</td>
<td>183</td>
</tr>
<tr>
<td>Fluorometholone</td>
<td>182</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>135</td>
</tr>
<tr>
<td>Fluorouracil Ebeve</td>
<td>135</td>
</tr>
<tr>
<td>Fluorouracil sodium</td>
<td>56</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride</td>
<td>115</td>
</tr>
<tr>
<td>Flupenthixol decanoate</td>
<td>125</td>
</tr>
<tr>
<td>Fluphenazine decanoate</td>
<td>125</td>
</tr>
<tr>
<td>Flutamide</td>
<td>144</td>
</tr>
<tr>
<td>Flutamin</td>
<td>144</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>178</td>
</tr>
<tr>
<td>Fluciticasone propionate</td>
<td>175</td>
</tr>
<tr>
<td>Fluciticasone with salmeterol</td>
<td>179</td>
</tr>
<tr>
<td>Foban</td>
<td>51</td>
</tr>
<tr>
<td>Folic acid</td>
<td>30</td>
</tr>
<tr>
<td>Fondaparinux sodium</td>
<td>33</td>
</tr>
<tr>
<td>Food Modules</td>
<td>198</td>
</tr>
<tr>
<td>Food/Fluid Thickeners</td>
<td>199</td>
</tr>
<tr>
<td>Forteo</td>
<td>100</td>
</tr>
<tr>
<td>Fortisip (Vanilla)</td>
<td>211</td>
</tr>
<tr>
<td>Fortum</td>
<td>73</td>
</tr>
<tr>
<td>Fortum</td>
<td>95</td>
</tr>
<tr>
<td>Fortum Plus</td>
<td>96</td>
</tr>
<tr>
<td>Foscarnet sodium</td>
<td>91</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>77</td>
</tr>
<tr>
<td>Fragmin</td>
<td>32</td>
</tr>
<tr>
<td>Fracayal</td>
<td>181</td>
</tr>
<tr>
<td>Freeflex</td>
<td>37</td>
</tr>
<tr>
<td>FreeStyle Lite</td>
<td>218</td>
</tr>
<tr>
<td>Freestyle Optium</td>
<td>218</td>
</tr>
<tr>
<td>Freestyle Optium Ketone</td>
<td>218</td>
</tr>
<tr>
<td>Fresofol 1%</td>
<td>107</td>
</tr>
<tr>
<td>Frusemide-Claris</td>
<td>44</td>
</tr>
<tr>
<td>Fucilin</td>
<td>77</td>
</tr>
<tr>
<td>Fucithalmic</td>
<td>181</td>
</tr>
<tr>
<td>Fungulin</td>
<td>24</td>
</tr>
<tr>
<td>Furosemide (frusemide)</td>
<td>44</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td>51</td>
</tr>
<tr>
<td>Dermatological</td>
<td>51</td>
</tr>
<tr>
<td>Infection</td>
<td>77</td>
</tr>
<tr>
<td>Sensory</td>
<td>181</td>
</tr>
<tr>
<td>Fuzeon</td>
<td>84</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>116</td>
</tr>
<tr>
<td>Gadobenic acid</td>
<td>191</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>191</td>
</tr>
<tr>
<td>Gadodiamide</td>
<td>191</td>
</tr>
<tr>
<td>Gadoteric acid</td>
<td>191</td>
</tr>
<tr>
<td>Gadovist</td>
<td>191</td>
</tr>
<tr>
<td>Gadoxetate disodium</td>
<td>192</td>
</tr>
<tr>
<td>Gamma benzene hexachloride</td>
<td>51</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>91</td>
</tr>
<tr>
<td>Gardasil</td>
<td>215</td>
</tr>
<tr>
<td>Gastrografin</td>
<td>190</td>
</tr>
<tr>
<td>Gastrosothe</td>
<td>16</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>139</td>
</tr>
<tr>
<td>Gelafusal</td>
<td>38</td>
</tr>
<tr>
<td>Gelatine, succinylated</td>
<td>38</td>
</tr>
<tr>
<td>Gelofusine</td>
<td>38</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>135</td>
</tr>
<tr>
<td>Gemcitabine Ebeve</td>
<td>135</td>
</tr>
<tr>
<td>Gemfibrozil</td>
<td>46</td>
</tr>
<tr>
<td>Genoptic</td>
<td>181</td>
</tr>
<tr>
<td>Genox</td>
<td>145</td>
</tr>
<tr>
<td>Gentamicin sulphate</td>
<td>72</td>
</tr>
<tr>
<td>Infection</td>
<td>72</td>
</tr>
<tr>
<td>Sensory</td>
<td>181</td>
</tr>
<tr>
<td>Gestrinone</td>
<td>64</td>
</tr>
<tr>
<td>Gilentanyl</td>
<td>127</td>
</tr>
<tr>
<td>Ginet</td>
<td>58</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>128</td>
</tr>
</tbody>
</table>
INDEX

Generic Chemicals and Brands

Glaucoma Preparations .................................. 184
Gilbenclamide ........................................... 19
Glilazide .................................................. 19
Glipizide .................................................. 19
Glivec ...................................................... 139
Glixide ..................................................... 19
Glucagen Hypokit ...................................... 17
Glucagon hydrochloride .............................. 17
Glucerna Select (Vanilla) .......................... 203
Glucerna Select RTH (Vanilla) ....................... 203
Glucose [Dextrose]
   Alimentary ........................................... 17
   Blood .................................................. 36
   Extemporaneous ................................... 196
Glucose with potassium chloride .................. 36
Glucose with potassium chloride and sodium chloride .................. 36
Glucose with sodium chloride ..................... 36
Glucose with sucrose and fructose .................. 17
Glycerin with sodium saccharin .................... 196
Glycerin with sucrose ................................ 196
Glycerol
   Alimentary .......................................... 21
   Extemporaneous ................................... 196
Glycerol with paraffin .............................. 53
Glycerin trinitrate
   Alimentary .......................................... 16
   Cardiovascular .................................... 47
Glycine .................................................. 193
Glycopyrrolonium .................................... 176
Glycopyrrolonium bromide ......................... 16
Glypressin ............................................. 71
Glytrin .................................................. 47
Gonadorelin .......................................... 136
Goserelin ............................................. 65
Granirex ............................................... 119
Granisetron .......................................... 119

- H -
Hamilin ............................................... 110
Hartmann's solution ................................. 35
Havrix .................................................. 214
Havrix Junior ......................................... 214
HBvaxPRO ............................................. 215
Healon GV ............................................. 184
healthE Dimethicone 5% ......................... 52
healthE Fatty Cream .............................. 53
Heparin sodium ........................................ 33
Heparinised saline ................................... 33
Heparon Junior ........................................ 204
Hepatitis A vaccine ................................. 214
Hepatitis B recombinant vaccine .................. 215
Hepsera ............................................... 88
Herceptin ............................................. 172
Hexamine hippurate ................................. 78
Histidine acid phosphate ........................... 192
Holoxan ............................................... 133
Hormone Replacement Therapy ..................... 63
HPV .................................................... 215
Humalog Mix 25 ...................................... 18
Humalog Mix 50 ...................................... 18
Human papillomavirus (6, 11, 16 and 18) vaccine [HPV] .......... 215
Humatin .............................................. 72
Humira ............................................... 151
HumiraPen ........................................... 151
Hyaluronidase ....................................... 100
Hybloc ............................................... 42
Hydralazine hydrochloride ......................... 48
Hydrea ............................................... 136
Hydrocortisone
   Dermatological ................................... 54
   Extemporaneous .................................. 196
   Hormone .......................................... 63
Hydrocortisone acetate
   Alimentary ......................................... 15
   Dermatological ................................... 54
   Hydrocortisone butyrate ......................... 54, 56
   Hydrocortisone with ciprofloxacin ............. 182
   Hydrocortisone with miconazole ............... 55
   Hydrocortisone with natamycin and neomycin .. 55
   Hydrocortisone with paraffin and wool fat .... 54
   Hydrocortisone with wool fat and mineral oil .. 54
   Hydrogen peroxide ................................ 51
   Hydroxocobalamin ............................... 187
   Hydroxocobalamin acetate ...................... 25
   Hydroxychloroquine ............................. 95
   Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride .................. 98
   Hydroxyethyl starch 130/0.4 with sodium chloride .................. 38
   Hydroxyurea ....................................... 136
   Hygroton .......................................... 45
   Hylo-Fresh ........................................ 186
   Hyosine butylbromide ........................... 16
   Hyosine hydrobromide ........................... 120
   Hyperuricaemia and Antigout .................... 100
   Hypnol ............................................. 128
   Hypromellose ..................................... 183, 186
   Hypromellose with dextran ...................... 186
   Hysite ............................................. 185

- I -
Ibiamox .............................................. 75
Ibuprofen ............................................. 103
Idarubicin hydrochloride ......................... 134
Ifosamide ............................................ 133
Ikorel ............................................... 48
Ilomedin ............................................. 50
Iloprost .............................................. 50
Imatinib mesilate ................................. 139–140
Imatinib-AFT ........................................ 139
Imiglucerase ......................................... 22
Imipenem with cilastatin ......................... 72
Imipramine hydrochloride ......................... 113
Imiquimod ........................................... 56
Immune Modulators ................................. 93
Immunosuppressants .............................. 145
Impact Advanced Recovery
   (Chocolate) ....................................... 209
Impact Advanced Recovery
   (Vanilla) .......................................... 209
Imuran ............................................... 173
Indacaterol ......................................... 178
Indapamide .......................................... 45
Indigo carmine ...................................... 192
Indinavir ............................................. 87
Indocyanine green .................................. 192
Indomethacin ........................................ 103
Infanrix IPV ......................................... 212
Infanrix-hexa ....................................... 212
Infliximab ........................................... 158
Influenza vaccine ................................... 215
Influvac ............................................. 215
Inhaled Corticosteroids ......................... 177
Innovacon hCG One Step
Pregnancy Test ................. 219
Insulin aspart .......................... 18
Insulin aspart with insulin aspart
protamine .......................... 18
Insulin glargine ......................... 18
Insulin glulisine ......................... 18
Insulin isophane ......................... 18
Insulin isopro ........................ 18
Insulin lispro ......................... 18
Insulin lispro with insulin lispro
protamine .......................... 18
Insulin neutral ......................... 18
Insulin neutral with insulin
isophane ......................... 18
Insulin pen needles ................. 218
Insulin syringes, disposable with
attached needle .............. 218
Integrilin .............................. 34
Intelligence ............................. 85
Interferon alfa-2a ..................... 93
Interferon alfa-2b ..................... 93
Interferon beta-1-alpha ............. 128
Interferon beta-1-beta ............. 128
Interferon gamma ..................... 93
Intrauterine device ................. 59
Invanz ................................. 72
Invega Sustenna ....................... 126
Iodine .................................. 70
Iodine with ethanol ................. 189
Iodised oil ............................. 190
Iodixanol .............................. 190
Lohexol ............................... 190
Ioscan ................................. 190
IPOL ................................. 216
Ipratropium bromide .............. 175–176
Iressa ................................. 139
Irinotecan Actavis 100 ............... 136
Irinotecan Actavis 40 ............... 136
Irinotecan hydrochloride ........... 136
Iron polymaltose ..................... 23
Iron sucrose ........................... 23
Irrigation Solutions ................. 193
Isentress ............................. 88
Ismo 40 Retard ......................... 47
Isom-20 .................................. 47
Isosfuranate ......................... 106
Isoniazid .............................. 81
Isoniazid with rifampicin ........... 81
Isopenaline ......................... 48
Isopropyl alcohol ..................... 189
Isoprin .............................. 44
Isopto Carpine ....................... 185
Isosorbide mononitrate .......... 47
Isotretinoin ......................... 52
Ispaghula (psyllium) husk ........... 20
Isradipine ............................ 43
Itch-Sothe ............................ 52
Itraconazole ......................... 79
Itroazole ............................. 79
Ivermectin .......................... 82
Jadelle ............................... 59
Jevity ................................ 210
Jevity HiCal RTH ..................... 210
Jevity RTH ............................ 210
Kaletra ................................ 87
Kenacomb ......................... 136
Kenacort-A ......................... 63
Kenacort-A40 ......................... 63
Ketamine ............................. 106
Ketoc 3:1 (Unflavoured) .... 208
Ketocal 4:1 (Unflavoured) ...... 208
Ketocal 4:1 (Vanilla) .......... 208
Ketoconazole
Dermatological ..................... 51
Infection ............................. 78
Ketone blood beta-ketone
electrodes ...................... 218
Ketoprofen ......................... 103
Ketorolac trometamol .............. 182
Kivexa .............................. 86
Klacid ................................. 74
Klean Prep .......................... 20
Kogenate FS ......................... 31
Konakion MM ......................... 32
Konsyl-D .......................... 20
L-asparaginase ..................... 136
L-aspartate ......................... 17
Labetalol ............................. 42
Lacosamide ......................... 116
Lactose ............................. 196
Lactulose ............................ 21
Lavenol ............................. 21
Lamical .............................. 117
Lamivudine ....................... 86, 89
Lamotrigine ......................... 117
Lansoprazole ......................... 16
Lantus .............................. 18
Lantus SoloStar ...................... 18
Lapatinib ............................ 140
Lariam .............................. 83
Latanoprost ......................... 185
Lax-Sachets ......................... 21
Lax-Tabs ............................ 21
Laxatives ............................. 20
Laxose .............................. 20
Laxol .............................. 20
Leffunomide ......................... 95
Lenalidomide ....................... 136
Letrocet ............................. 145
Letrozole ............................. 145
Leukotriene Receptor
Antagonists ...................... 178
Leunase ............................. 136
Leuprolin acetate ................... 65
Leustatin ............................. 135
Levetiracetam ......................... 117
Levetiracetam-Rex ................... 117
Levobunolol hydrochloride ........ 184
Levocabastine ....................... 182
Levocarnitine ......................... 22
Levodopa with benserazide ...... 106
Levodopa with carbidopa ...... 106
Levomepromazine ................... 121
Levonorgestrel ....................... 59
Levomendan ......................... 47
Levotiroxine ......................... 70
Lidocaine [Lignocaine] hydrochloride ........ 108
Lidocaine [Lignocaine] hydrochloride with
adrenaline ...................... 108
Lidocaine [Lignocaine] hydrochloride with
adrenaline and
tetracaine ...................... 108
Lidocaine [Lignocaine] hydrochloride with
phentylephrine .................. 108
Lidocaine [Lignocaine] with
prilocaine ...................... 109
Lidocaine-Claris ..................... 108
Lignocaine ......................... 108
Lincomycin ......................... 78
Lindane [Gamma benzene
hexachloride] ................. 51
Linezolid ......................... 78
Lioresal Intrathelial .................. 101
Liothyronine sodium .............. 70
Lipazil ......................... 46
Lipid-Modifying Agents ........... 45
INDEX

Generic Chemicals and Brands

Lipiodol Ultra Fluid .......................... 190
Liquigen ........................................ 191
Liquifilm Forte ............................... 186
Liquifilm Tears ............................... 186
Lisinopril ........................................ 39
Lissamine green .............................. 183
Lisuride hydrogen maleate .............. 106
Lithicarb FC .................................... 121
Lithium carbonate ............................ 121
Local Preparations for Anal and
Rectal Disorders ............................. 15
Locoid .......................................... 54, 56
Locoid Crelo ..................................... 54
Locoid Lipocream ............................. 54
Lodoxamide ..................................... 182
Logem ............................................ 117
Lomide .......................................... 182
Lomustine ....................................... 133
Long-Acting Beta-Adrenoceptor
Agonists ..................................... 178
Loniten .......................................... 48
Loperamide hydrochloride ................ 14
Lopinavir with ritonavir ................. 87
Lopresor ........................................ 42
Lorafix .......................................... 176
LoraPaed ........................................ 176
Loratadine ..................................... 176
Lorazepam ...................................... 115, 127
Lormetazepam ................................. 128
Losartan Actavis .............................. 40
Losartan potassium ......................... 40
Losartan potassium with
hydrochlorothiazide ..................... 40
Lostaar ........................................... 40
Lovir ............................................. 91
Loxalate ......................................... 114
Loxamine ....................................... 115
Lucrin Depot PDS ......................... 65, 65
Lycicat .......................................... 47
Lyderm .......................................... 52

- M -

m-Amoxiclav ................................. 75
m-Esion ......................................... 111
M-M-R-II ........................................ 216
m-Mometasone ............................... 54
Mabthera ....................................... 164
Macrofol 3350 with ascorbic
acid, potassium chloride and
sodium chloride ......................... 20
Macrofol 3350 with potassium
chloride, sodium bicarbonate,
sodium chloride and sodium
sulphate .................................... 20
Macrofol 400 and propylene
glycol ........................................... 186
Madopar 125 ................................ 106
Madopar 250 ................................ 106
Madopar 62.5 ................................ 106
Madopar HBS ................................ 106
Madopar Rapid ................................ 106
Mafenide acetate ............................ 51
Magnesium hydroxide
Alimentary .................................... 23
Extemporaneous ......................... 196
Magnesium oxide ........................ 23
Magnesium sulphate .................... 23
Magnevist ..................................... 192
Malarone ........................................ 82
Malarone Junior ............................. 82
Malathion [Maldison] ................. 52
Malathion with permethrin and
piperylon butoxide .................. 52
Maldison ....................................... 51
Mannitol ....................................... 45
Maprotiline hydrochloride ....... 113
Marcain ........................................ 107
Marcain Heavy ............................. 108
Marcain Isobaric ......................... 107
Marcain with Adrenaline .......... 107
Marevan ........................................ 34
Marine Blue Lotion SPF 50+ ....... 56
Martindale Acetylcysteine ........ 187
Mask for spacer device .......... 218
Mast Cell Stabilisers ............... 179
Maxidex .................................... 182
Maxitol ........................................ 181
Measles, mumps and rubella
vaccine ........................................ 216
Mebendazole ................................ 82
Mebeverine hydrochloride .......... 16
Medrol ........................................ 63
Medroxyprogesterone .......... 65
Medroxyprogesterone acetate
Genito-Urinary ......................... 59
Hormone ....................................... 64
Mefenamic acid ......................... 103
Mefloquine ................................... 83
Megestrol acetate .................... 144
Meglumine gadopentetate .... 192
Meglumine iotroxate ............... 192
Melatonin ....................................... 128
Meloxicam ..................................... 103
Melphalan .................................... 133
Menactra ...................................... 213
Meningococcal (A, C, Y and
W-135) conjugate
vaccine ...................................... 213
Meningococcal C conjugate
vaccine ...................................... 213
Menthol ....................................... 196
Mepivacaine hydrochloride .... 109
Mercaptopurine ......................... 135
Meropenem ................................... 72
Mesalamine .................................. 15
Mesna .......................................... 143
Mestinon ....................................... 95
Metabolic Disorder Agents ........ 21
Metabolic Products .................... 200
Metadine ...................................... 120
Metamizol ................................... 48
Metformin .................................... 19
Methacholine chloride .......... 192
Methadone hydrochloride
Extemporaneous .................... 196
Nervous ........................................ 110
Methatabs ................................... 110
Methoxsalen ................................ 109
Methyl aminolevulinate
hydrochloride ......................... 56
Methyl hydroxybenzoate .......... 196
Methylcellulose ......................... 196
Methylcellulose with glycerin and
sodium saccharin .................... 196
Methylcellulose with glycerin and
sucrose .................................... 196
Methylprednisolone (as sodium
succinate) ................................. 63
Methylprednisolone aceponate .... 54
Methylprednisolone acetate .... 63
Methylprednisolone acetate with
lignocaine ............................. 63
Methylthioninium chloride
[Methylene blue] ...................... 192

229
INDEX
Generic Chemicals and Brands

Methylxanthines ........................................... 179
Metoclopramide ........................................... 120
  hydrochloride ............................................ 119
  with paracetamol ........................................ 119
Metolazone .............................................. 45
Metoprolol - AFT CR ....................................... 42
Metoprolol succinate ..................................... 42
Metoprolol tartrate ....................................... 42
Metronidazole
  Dermatological .......................................... 51
  Infection .................................................. 83
Metyrapone ............................................. 64
Mexiletine hydrochloride ................................ 42
Mexiletine Hydrochloride USP ............................ 42
Miacalcic .................................................. 62
Mianserin hydrochloride ................................ 113
Micolette ................................................. 21
Miconazole ................................................ 24
Miconazole nitrate
  Dermatological .......................................... 51
  Genito-Urinary ........................................... 58
Micreme .................................................... 58
Micreme H .................................................. 55
Microgynon 50 ED ........................................ 58
Midazolam .................................................. 128
Midodrine .................................................. 42
Mifepristone .............................................. 60
Milrinone ................................................... 48
Minerals ..................................................... 22
Minidial ..................................................... 19
Minirin ....................................................... 70
MiniTT380 Slimline ....................................... 59
Minocycline ............................................... 77
Minoxidil .................................................... 48
Mirtazapine ............................................... 114
Misoprostol ............................................... 16
Mitomycin C ............................................... 134
Mitozantrone ............................................. 134
Mitozantrone Ebewe ....................................... 134
Mivacron ................................................... 102
Mivacurium chloride ................................. 102
Moclobemide ............................................. 113
Modafinil ................................................... 130
Modecate .................................................... 125
Mogine ....................................................... 117
Mometasone furoate ..................................... 54
Monosodium glutamate with sodium aspartate .......... 194
  Monosodium L-aspartate ................................ 194
Montelukast ............................................... 178
Morocloog alfa [Recombinant factor VIII] ............... 31
  Morphine hydrochloride ................................ 111
  Morphine sulphate ...................................... 111
  Morphine tartrate ...................................... 111
  Motetis ................................................... 105
  Mouth and Throat ....................................... 24
  Moxifloxacin .......................................... 76
  Mucolytics and Expectorants ......................... 179
  Multithanace .............................. 191
  Multiple Sclerosis Treatments ....................... 127
  Multivitamins ......................................... 25
  Mupirocin ............................................... 51
  Muscle Relaxants and Related Agents ................. 101
  Myambutol .............................................. 81
  Mycobutin .............................................. 81
  MycoNail ................................................ 51
  MycoNail .............................................. 174
  Mydriacyl ............................................... 185
  Mydriatics and Cyclogepics ............................ 185
  Mylan Atenolol ........................................ 42
  Mylan Fentanyl Patch ................................ 110
  Myleran ................................................ 133

- N -

  Nadolol ................................................... 43
  Naloxone hydrochloride ................................ 187
  Natraccord .............................................. 131
  Naltrexone hydrochloride .............................. 131
  Naphazoline hydrochloride ............................. 182
  Naphcon Forte ........................................ 182
  Naprofen .............................................. 104
  Naropin ................................................ 109
  Natalizumab ........................................... 127
  Natamycin .............................................. 181
  Natulan ................................................ 137
  Nausicalm ............................................. 119
  Navelbine ............................................. 144
  Nedocromil ............................................ 179
  Nefopam hydrochloride ................................ 109
  Neisvac-C .............................................. 213
  Neocate Advance (Vanilla) ............................ 206
  Neocate Gold (Unflavoured) ............................ 206
  Neoral ................................................... 145
  NeoRecormon .......................................... 29
  Neostigmine metilsulfate .............................. 95
  Neostigmine metilsulfate with glycopeynron bromide 95
  Neosynephrine HCL .................................... 48
  Nepro HP (Strawberry) ................................. 209
  Nepro HP (Vanilla) .................................... 209
  Nepro HP RTH ............................................ 209
  Neulastim .............................................. 35
  Neupogen .............................................. 35
  NeuroTabs .............................................. 23
  Nevirapine ............................................. 85
  Nevirapine Alphapharm ................................ 85
  Nicorandil ............................................. 48
  Nicotine ................................................ 132
  Nicotinic acid ......................................... 47
  Nifedipine .............................................. 43
  Nilotinib ................................................. 140
  Nilstat ................................................... 24, 79
  Nimodipine ............................................. 43
  Nitazoxanide .......................................... 83
  Nitrados ............................................... 128
  Nitrates ................................................ 47
  Nizacipam .............................................. 128
  Nitroderm TTS 5 ....................................... 47
  Nitroderm TTS 10 ...................................... 47
  Nitrofuranoin .......................................... 78
  Nitronal ................................................ 47
  Noflam 250 ............................................. 104
  Noflam 500 ............................................. 104
  Non-Steroidal Anti-Inflammatory Drugs ................. 102
  Nonacog alfa [Recombinant factor IX] ................. 31
  Noradrenaline ......................................... 48
  Norethisterone Genito-Urinary ......................... 59
  Hormone ............................................... 65
  Norethisterone with mestranol ........................ 58
  Norfloxacin .......................................... 76
  Normison .............................................. 128
  Norpress ............................................... 113
  Nortriptyline hydrochloride ........................... 113
  Norvir ................................................... 87
  Novasource Renal (Vanilla) ............................ 209
  Novatretin ............................................. 55
  NovoMix 30 FlexPen ................................... 18
  NovoSeven RT .......................................... 31
  Novaxil ................................................ 79
  Nupentin ................................................ 116
  Nutrini Energy Multi Fibre ............................. 208
  Nutrini Low Energy Multi Fibre RTH ................. 208
  Nutrison Concentrated ................................ 204
  Nutrison Energy ........................................ 210
  Nwyfax Retard ......................................... 43
  Nystatin
    Alimentary ............................................ 24
    Dermatological ...................................... 51
<table>
<thead>
<tr>
<th>Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peteha .................................. 81</td>
</tr>
<tr>
<td>Pethidine hydrochloride ........... 112</td>
</tr>
<tr>
<td>Pexsig .................................. 44</td>
</tr>
<tr>
<td>Phenelzine sulphate .................. 113</td>
</tr>
<tr>
<td>Phenindione ............................. 33</td>
</tr>
<tr>
<td>Phenobarbital ......................... 117, 128</td>
</tr>
<tr>
<td>Phenobarbital sodium ............... 196</td>
</tr>
<tr>
<td>Phenol ................................... 193</td>
</tr>
<tr>
<td>Phenol oily ............................. 16</td>
</tr>
<tr>
<td>Phenol with ioxaglic acid .......... 193</td>
</tr>
<tr>
<td>Phenoxybenzamine hydrochloride ... 40</td>
</tr>
<tr>
<td>Phenoxymethylpenicillin [Penicillin V] ..... 75</td>
</tr>
<tr>
<td>Phentolamine mesylate .............. 40</td>
</tr>
<tr>
<td>Phenytoin ................................ 117</td>
</tr>
<tr>
<td>Phenytoin sodium ..................... 115, 117</td>
</tr>
<tr>
<td>Pholcodine .............................. 177</td>
</tr>
<tr>
<td>Phosphorus ................................ 38</td>
</tr>
<tr>
<td>Phytomenadione ......................... 32</td>
</tr>
<tr>
<td>Picibanil ................................. 35</td>
</tr>
<tr>
<td>Pilocarpine hydrochloride .......... 185</td>
</tr>
<tr>
<td>Pilocarpine nitrate .................... 196</td>
</tr>
<tr>
<td>Pimafucort ............................... 55</td>
</tr>
<tr>
<td>Pindolol .................................. 43</td>
</tr>
<tr>
<td>Pinetasol ................................ 55</td>
</tr>
<tr>
<td>Pinarax ................................... 21</td>
</tr>
<tr>
<td>Pinarax Forte ............................ 21</td>
</tr>
<tr>
<td>Pioglitazone ............................. 19</td>
</tr>
<tr>
<td>Piperacillin with tazobactam ....... 75</td>
</tr>
<tr>
<td>Pipithiazine palmitate ............... 126</td>
</tr>
<tr>
<td>Pituitary and Hypothalamic Hormones and Analogues ........................ 65</td>
</tr>
<tr>
<td>Pivmecillinam ........................... 78</td>
</tr>
<tr>
<td>Pizaccord ................................ 19</td>
</tr>
<tr>
<td>Pizotifen ................................ 119</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Berry) .......... 201</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Orange) ....... 201</td>
</tr>
<tr>
<td>PKU Anamix Junior LQ (Unflavoured) .... 201</td>
</tr>
<tr>
<td>Plaquinil .................................. 95</td>
</tr>
<tr>
<td>Plendi ER .................................. 43</td>
</tr>
<tr>
<td>Pms-Bosentan ............................ 49</td>
</tr>
<tr>
<td>Pneumococcal (PCV13) conjugate vaccine ........ 214</td>
</tr>
<tr>
<td>Pneumococcal (PPV23) ................... 214</td>
</tr>
<tr>
<td>Pneumococcal (PPV23) conjugate vaccine ........ 214</td>
</tr>
<tr>
<td>Polysaccharide vaccine .............. 214</td>
</tr>
<tr>
<td>Pneumovax 23 ........................... 214</td>
</tr>
<tr>
<td>Podophyllumtoxin ....................... 56</td>
</tr>
<tr>
<td>Polidocanol .............................. 30</td>
</tr>
<tr>
<td>Poliomyelitis vaccine ............... 216</td>
</tr>
<tr>
<td>Poloxamer ............................... 20</td>
</tr>
<tr>
<td>Poly Gel .................................... 186</td>
</tr>
<tr>
<td>Poly-Tears ............................... 186</td>
</tr>
<tr>
<td>Poly-Visc .................................. 186</td>
</tr>
<tr>
<td>Polyhexamethylene biguanide ........ 196</td>
</tr>
<tr>
<td>Polyvinyl alcohol ...................... 186</td>
</tr>
<tr>
<td>Polyvinyl alcohol with povidone .... 186</td>
</tr>
<tr>
<td>Poractant alfa ........................... 180</td>
</tr>
<tr>
<td>Posaconazole ............................ 79</td>
</tr>
<tr>
<td>Postinor-1 ................................ 59</td>
</tr>
<tr>
<td>Potassium chloride ..................... 36, 38</td>
</tr>
<tr>
<td>Potassium chloride with sodium chloride ...... 37</td>
</tr>
<tr>
<td>Potassium citrate ...................... 61</td>
</tr>
<tr>
<td>Potassium dihydrogen phosphate .... 37</td>
</tr>
<tr>
<td>Potassium iodate ....................... 23</td>
</tr>
<tr>
<td>Hormone ................................... 70</td>
</tr>
<tr>
<td>Potassium iodate with iodine ....... 23</td>
</tr>
<tr>
<td>Potassium perchlorate ................ 70</td>
</tr>
<tr>
<td>Potassium permanganate ............. 55</td>
</tr>
<tr>
<td>Povidone K30 ............................ 196</td>
</tr>
<tr>
<td>Povidone-Iodide ........ ............ 189</td>
</tr>
<tr>
<td>Povidone-Iodide with ethanol ....... 189</td>
</tr>
<tr>
<td>Pradaxa ................................... 32</td>
</tr>
<tr>
<td>Pralidoxime iodide .................... 187</td>
</tr>
<tr>
<td>Pramipexole hydrochloride .......... 106</td>
</tr>
<tr>
<td>Prasugrel .................................. 34</td>
</tr>
<tr>
<td>Pravastatin ............................. 46</td>
</tr>
<tr>
<td>Praziquantel ............................ 82</td>
</tr>
<tr>
<td>Prazosin ................................... 41</td>
</tr>
<tr>
<td>Precedex ..................................... 106</td>
</tr>
<tr>
<td>Prednisolone ............................ 63</td>
</tr>
<tr>
<td>Prednisolone acetate ............... 182</td>
</tr>
<tr>
<td>Prednisolone sulphate .............. 182</td>
</tr>
<tr>
<td>Pregnancy test - hCG urine .......... 219</td>
</tr>
<tr>
<td>Provera .................................... 64, 65</td>
</tr>
<tr>
<td>Propranolol .............................. 43</td>
</tr>
<tr>
<td>Propranolol hydrochloride .......... 196</td>
</tr>
<tr>
<td>Prazosin.................................. 41</td>
</tr>
<tr>
<td>Proxymetacaine hydrochloride ...... 183</td>
</tr>
<tr>
<td>Pseudoephedrine hydrochloride .... 177</td>
</tr>
<tr>
<td>Psorials and Eczema Preparations .... 55</td>
</tr>
<tr>
<td>PTU ........................................... 70</td>
</tr>
<tr>
<td>Pulmocare (Vanilla) ................. 209</td>
</tr>
<tr>
<td>Pulmonary Surfactants .............. 180</td>
</tr>
<tr>
<td>Pulmozyme ............................... 179</td>
</tr>
<tr>
<td>Puri-nethol .............................. 135</td>
</tr>
<tr>
<td>Pyrazinamide ............................ 81</td>
</tr>
<tr>
<td>Pyridostigmine bromide ............. 95</td>
</tr>
<tr>
<td>PyridoxADE ............................... 26</td>
</tr>
<tr>
<td>Pyridoxal-5-phosphate .............. 22</td>
</tr>
<tr>
<td>Pyridoxine hydrochloride .......... 26</td>
</tr>
<tr>
<td>Pyrimethamine ........................... 83</td>
</tr>
<tr>
<td>Pytazen SR ................................ 34</td>
</tr>
</tbody>
</table>

**Q** 300 ................................ 83
<table>
<thead>
<tr>
<th>Index</th>
<th>Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>chloride and potassium</td>
</tr>
<tr>
<td></td>
<td>chloride</td>
</tr>
<tr>
<td></td>
<td>Sodium citrate with sodium lauryl sulphoacetate</td>
</tr>
<tr>
<td></td>
<td>Sodium citro-tartrate</td>
</tr>
<tr>
<td></td>
<td>Sodium cromoglycate</td>
</tr>
<tr>
<td></td>
<td>Alimentary</td>
</tr>
<tr>
<td></td>
<td>Respiratory</td>
</tr>
<tr>
<td></td>
<td>Sodium dichloride</td>
</tr>
<tr>
<td></td>
<td>Sodium dihydrogen phosphate</td>
</tr>
<tr>
<td></td>
<td>Sodium fluoride</td>
</tr>
<tr>
<td></td>
<td>Sodium hyaluronate</td>
</tr>
<tr>
<td></td>
<td>Alimentary</td>
</tr>
<tr>
<td></td>
<td>Sensory</td>
</tr>
<tr>
<td></td>
<td>Sodium hyaluronate with chondroitin sulphate</td>
</tr>
<tr>
<td></td>
<td>Sodium hypochlorite</td>
</tr>
<tr>
<td></td>
<td>Sodium methasulfite</td>
</tr>
<tr>
<td></td>
<td>Sodium nitrate</td>
</tr>
<tr>
<td></td>
<td>Sodium nitroprusside</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular</td>
</tr>
<tr>
<td></td>
<td>Part III - OPTIONAL</td>
</tr>
<tr>
<td></td>
<td>PHARMACEUTICALS</td>
</tr>
<tr>
<td></td>
<td>Sodium phenylbutyrate</td>
</tr>
<tr>
<td></td>
<td>Sodium phosphate with phosphoric acid</td>
</tr>
<tr>
<td></td>
<td>Sodium polystyrene</td>
</tr>
<tr>
<td></td>
<td>sulphonate</td>
</tr>
<tr>
<td></td>
<td>Sodium stibogluconate</td>
</tr>
<tr>
<td></td>
<td>Sodium tetradecl sulphate</td>
</tr>
<tr>
<td></td>
<td>Sodium thiosulfate</td>
</tr>
<tr>
<td></td>
<td>Sodium valproate</td>
</tr>
<tr>
<td></td>
<td>Sodium with potassium</td>
</tr>
<tr>
<td></td>
<td>Solian</td>
</tr>
<tr>
<td></td>
<td>Solifenacin succinate</td>
</tr>
<tr>
<td></td>
<td>Solox</td>
</tr>
<tr>
<td></td>
<td>Solu-Cortef</td>
</tr>
<tr>
<td></td>
<td>Solu-Medrol</td>
</tr>
<tr>
<td></td>
<td>Somatropin</td>
</tr>
<tr>
<td></td>
<td>Sotacor</td>
</tr>
<tr>
<td></td>
<td>Sotalol</td>
</tr>
<tr>
<td></td>
<td>Soya oil</td>
</tr>
<tr>
<td></td>
<td>Space Chamber Plus</td>
</tr>
<tr>
<td></td>
<td>Spacer device</td>
</tr>
<tr>
<td></td>
<td>Span-K</td>
</tr>
<tr>
<td></td>
<td>Specialised Formulas</td>
</tr>
<tr>
<td></td>
<td>Spiractin</td>
</tr>
<tr>
<td></td>
<td>Spiramycin</td>
</tr>
<tr>
<td></td>
<td>Spiriva</td>
</tr>
<tr>
<td></td>
<td>Spironolactone</td>
</tr>
<tr>
<td></td>
<td>Sprycel</td>
</tr>
<tr>
<td></td>
<td>Standard Feeds</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Staphylococcus</td>
</tr>
<tr>
<td></td>
<td>Starch</td>
</tr>
<tr>
<td></td>
<td>Stavudine</td>
</tr>
<tr>
<td></td>
<td>Sterculia with frangula</td>
</tr>
<tr>
<td></td>
<td>Stesolid</td>
</tr>
<tr>
<td></td>
<td>Stimulants / ADHD</td>
</tr>
<tr>
<td></td>
<td>Striplentol</td>
</tr>
<tr>
<td></td>
<td>Stocrin</td>
</tr>
<tr>
<td></td>
<td>Strattera</td>
</tr>
<tr>
<td></td>
<td>Streptomyacin sulphate</td>
</tr>
<tr>
<td></td>
<td>Stromectol</td>
</tr>
<tr>
<td></td>
<td>Suboxone</td>
</tr>
<tr>
<td></td>
<td>Sucralfate</td>
</tr>
<tr>
<td></td>
<td>Sucrose</td>
</tr>
<tr>
<td></td>
<td>Sugammadex</td>
</tr>
<tr>
<td></td>
<td>Sulindac</td>
</tr>
<tr>
<td></td>
<td>Sulphonamide sulphatide</td>
</tr>
<tr>
<td></td>
<td>Sulphadiazine</td>
</tr>
<tr>
<td></td>
<td>Sulphadiazine silver</td>
</tr>
<tr>
<td></td>
<td>Sulphasalazine</td>
</tr>
<tr>
<td></td>
<td>Sulphur</td>
</tr>
<tr>
<td></td>
<td>Sumatriptan</td>
</tr>
<tr>
<td></td>
<td>Sunninitib</td>
</tr>
<tr>
<td></td>
<td>Sunscreen, proprietary</td>
</tr>
<tr>
<td></td>
<td>Suprane</td>
</tr>
<tr>
<td></td>
<td>Surgical Preparations</td>
</tr>
<tr>
<td></td>
<td>Survanta</td>
</tr>
<tr>
<td></td>
<td>Sustagen Diabetic (Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Sustagen Hospital Formula</td>
</tr>
<tr>
<td></td>
<td>(Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Sustagen Hospital Formula</td>
</tr>
<tr>
<td></td>
<td>(Vanilla)</td>
</tr>
<tr>
<td></td>
<td>Sutent</td>
</tr>
<tr>
<td></td>
<td>Suxamethonium chloride</td>
</tr>
<tr>
<td></td>
<td>Symmetrel</td>
</tr>
<tr>
<td></td>
<td>Sympathomimetics</td>
</tr>
<tr>
<td></td>
<td>Synacatn</td>
</tr>
<tr>
<td></td>
<td>Synacatn Depot</td>
</tr>
<tr>
<td></td>
<td>Syntometrine</td>
</tr>
<tr>
<td></td>
<td>Syrup</td>
</tr>
<tr>
<td></td>
<td>Systane Unit Dose</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus Sandoz</td>
</tr>
<tr>
<td></td>
<td>Tagitol V</td>
</tr>
<tr>
<td></td>
<td>Talc</td>
</tr>
<tr>
<td></td>
<td>Tambocor</td>
</tr>
<tr>
<td></td>
<td>Tambocor CR</td>
</tr>
<tr>
<td></td>
<td>Tamoxifen citrate</td>
</tr>
<tr>
<td></td>
<td>Tamsulosin</td>
</tr>
<tr>
<td></td>
<td>Tamsulosin-Rex</td>
</tr>
<tr>
<td></td>
<td>Tarceva</td>
</tr>
<tr>
<td></td>
<td>Tassigna</td>
</tr>
<tr>
<td></td>
<td>Tasmar</td>
</tr>
<tr>
<td></td>
<td>Tazocin EF</td>
</tr>
<tr>
<td></td>
<td>Teicoplanin</td>
</tr>
<tr>
<td></td>
<td>Temaccord</td>
</tr>
<tr>
<td></td>
<td>Temazepam</td>
</tr>
<tr>
<td></td>
<td>Temozolomide</td>
</tr>
<tr>
<td></td>
<td>Tenecteplase</td>
</tr>
<tr>
<td></td>
<td>Tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td></td>
<td>Tenoxicam</td>
</tr>
<tr>
<td></td>
<td>Terazosin</td>
</tr>
<tr>
<td></td>
<td>Terbinafine</td>
</tr>
<tr>
<td></td>
<td>Terbutaline</td>
</tr>
<tr>
<td></td>
<td>Terbutaline sulphate</td>
</tr>
<tr>
<td></td>
<td>Teriparatide</td>
</tr>
<tr>
<td></td>
<td>Terlipressin</td>
</tr>
<tr>
<td></td>
<td>Testosterone</td>
</tr>
<tr>
<td></td>
<td>Testosterone cyionate</td>
</tr>
<tr>
<td></td>
<td>Testosterone esters</td>
</tr>
<tr>
<td></td>
<td>Testosterone undecanoate</td>
</tr>
<tr>
<td></td>
<td>Tetrafenazine</td>
</tr>
<tr>
<td></td>
<td>Tetracaine [Amethocaine]</td>
</tr>
<tr>
<td></td>
<td>hydrochloride</td>
</tr>
<tr>
<td></td>
<td>Nervous</td>
</tr>
<tr>
<td></td>
<td>Sensory</td>
</tr>
<tr>
<td></td>
<td>Tetracosactide</td>
</tr>
<tr>
<td></td>
<td>[Tetracosactrin]</td>
</tr>
<tr>
<td></td>
<td>Tetracyclina</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
</tr>
<tr>
<td></td>
<td>Thalidomide</td>
</tr>
<tr>
<td></td>
<td>Thalomid</td>
</tr>
<tr>
<td></td>
<td>Theobroma oil</td>
</tr>
<tr>
<td></td>
<td>Theophylline</td>
</tr>
<tr>
<td></td>
<td>Thiamine hydrochloride</td>
</tr>
<tr>
<td></td>
<td>Thioguanine</td>
</tr>
<tr>
<td></td>
<td>Thiopenal [Thiopenone]</td>
</tr>
<tr>
<td></td>
<td>sodium</td>
</tr>
<tr>
<td></td>
<td>Thiopenone</td>
</tr>
<tr>
<td></td>
<td>Thiopeta</td>
</tr>
<tr>
<td></td>
<td>Thrombin</td>
</tr>
<tr>
<td></td>
<td>Thymol glycerin</td>
</tr>
<tr>
<td></td>
<td>Thyroid and Antithyroid</td>
</tr>
<tr>
<td></td>
<td>Preparations</td>
</tr>
<tr>
<td></td>
<td>Thyroidropin alfa</td>
</tr>
<tr>
<td></td>
<td>Ticagrelor</td>
</tr>
<tr>
<td></td>
<td>Ticarcillin with clavulanic acid</td>
</tr>
<tr>
<td></td>
<td>Ticlopidine</td>
</tr>
<tr>
<td></td>
<td>Tigecycline</td>
</tr>
<tr>
<td></td>
<td>Timolol</td>
</tr>
<tr>
<td></td>
<td>Timolol maleate</td>
</tr>
<tr>
<td></td>
<td>Timoptol XE</td>
</tr>
<tr>
<td></td>
<td>Tiotropium bromide</td>
</tr>
</tbody>
</table>
INDEX
Generic Chemicals and Brands

- X -
X-Opaque-HD ........................................ 191
Xanthan .................................................. 197
Xarelto .................................................... 33
Xifaxan ..................................................... 17
Xolair ....................................................... 163
Xylocaine ................................................... 108
Xylocaine Viscous ....................................... 108
Xylometazoline hydrochloride ......................... 177
Xynthia ....................................................... 31

- Y -
Yellow jacket wasp venom .................................. 175

- Z -
Zanamivir .................................................. 92
Zantac ....................................................... 16
Zapril ......................................................... 39
Zarator ....................................................... 46
Zarzio ......................................................... 35
Zavedos ...................................................... 134
Zeffix ........................................................ 89
Zeldox ....................................................... 125
Zetop ........................................................ 175
Ziagen ....................................................... 86
Zidovudine [AZT] ......................................... 86
Zidovudine [AZT] with lamivudine ....................... 86
Zinacef ...................................................... 73
Zinc
Alimentary ............................................... 23
Dermatological .......................................... 52
Zinc and castor oil ...................................... 52
Zinc chloride ............................................. 23
Zinc oxide ................................................. 197
Zinc sulphate ............................................ 24
Zinc with wool fat ...................................... 53
Zincaps ...................................................... 24
Zinforo ...................................................... 74
Zinnat ....................................................... 73
Ziprasidone ............................................... 125
Zithromax .................................................. 74
Zoladex ..................................................... 65
Zoledronic acid
Hormone .................................................. 62
Musculoskeletal System .................................. 97
Zometa ...................................................... 62
Zopiclone .................................................. 129
Zostrix ...................................................... 104
Zostrix HP .................................................. 109
Zovirax IV ................................................ 91
Zuclopenthixol acetate ................................. 125
Zuclopenthixol decanoate ............................ 127
Zuclopenthixol hydrochloride ......................... 125
Zyban ....................................................... 131
Zypine ...................................................... 122
Zypine ODT ................................................ 122
Zyprexa Relprevv ........................................ 126

236